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A B S T R A C T
RNA interference (RNAi) enables the silencing of gene expression demonstrating enormous clin-
ical potential. Systemic application of RNAi therapeutics, however, requires delivery strategies
evading enzymatic degradation in combination with stability in blood for long systemic circu-
lation. This thesis comprises the consecutive development of polypept(o)ide-based core-shell
carrier systems to fulfill this task.
Polypept(o)ides show great promise as a synthetic delivery platform in medical application
and allow for a controlled synthesis of well-defined materials with conformational and chemical
diversity. The presented work closes a relevant synthetic gap in polymerization of these mate-
rials with the development of S-alkylsulfonyl-L-cysteines. The established novel protective and
activating group for thiols, for the first time, mediates direct chemoselective disulfide forma-
tion in compatibility with the nucleophilic ring-opening polymerization strategy. (Multi)block
copolypept(o)ides with orthogonal thiol reactivity could thus be sequentially polymerized and
were implemented in secondary structure-modulated self-assembly of cross-linked nanoparti-
cles with control over size, morphology as well as functionality. In vivo application of the result-
ing cationic systems revealed outstandingly stable blood circulation in combination with pas-
sive tumor accumulation and a low systemic burden. Eventually, RNAi mediated knockdown
in solid tumors was realized upon systemic delivery by cationic, cross-linked polypept(o)ide-
based systems, concluding this journey towards gene delivery vectors in systemic application.
K U R Z D A R S T E L L U N G
RNA-Interferenz (RNAi) ermöglicht die Hemmung von Genexpression und zeigt ein enormes
klinisches Potential. Für systemische Anwendungen von RNAi-Therapeutika bedarf es jedoch
Transportstrategien, welche den enzymatischen Abbau verhindern sollen; dies in Kombination
mit Stabilität im Blut für eine lange systemische Zirkulation. Zu diesem Zweck unfasst die vor-
liegende Dissertation die fortwährende Entwicklung von Kern-Schale-Systemen auf Basis von
Polypept(o)iden.
Polypept(o)ide als synthetische Plattform sind hervorragend geeignet für medizinische An-
wendungen und erlauben die kontrollierte Synthese wohldefinierter Materialen von struktur-
eller und chemischer Vielfalt. Eine erhebliche synthetische Lücke in der Herstellung dieser Ma-
terialen wird durch die Entwicklung von S-Alkylsulfonyl-L-Cysteinen geschlossen. Die einge-
führte neuartige Aktivierungs- und Schutzgruppe für Thiole eröffnet erstmalig Möglichkeiten
für unmittelbare, chemoselektive Bildung von Disulfiden in Kompatibilität mit nucle-
ophiler Ring-öffnenden Polymerisation. (Multi)block Copolypept(o)ide mit orthogonaler Thiol-
Reaktivität konnten so sequenziell polymerisiert werden und bieten in der Sekundärstruktur-
modulierten Selbsassemblierung von vernetzten Nanopartikeln die Kontrolle über Partikel-
größe, Morphologie sowie Funktionalität. Der Einsatz in vivo zeigt eine außerordentlich sta-
bile Blutzirkulation von so hergestellten kationischen Systemen, sowie passive Tumoranreiche-
ung und geringe systemische Akkumulation. Schließlich wurde, dank systemischem Trans-
port durch kationische, vernetzte Systeme auf Polypept(o)id-Basis, ein RNAi-vermittelter Knock-
down von Genexpression im Tumor demonstriert, womit ein fundamentaler Abschnitt des
Weges zu Gentransfersystemen für systemische Anwendungen zurückgelegt wurde.
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Part I
I N T R O D U C T I O N

1
O B J E C T I V E S A N D O V E RV I E W
This thesis evolved around the subject of chemoselective disulfide
formation mediated by S-alkylsulfonyl-L-cysteines for stabilization of
polypept(o)ide-based core-shell carrier systems in systemic application
as nanomedicines. To fulfill this goal, protective and activating groups
are desired in compatibility with the ring-opening polymerization of
α-amino acid N- carboxyanhydrides for synthesis of di- and triblock
copolypept(o)ides with orthogonal thiol reactivity. By secondary
structure-modulated self-assembly, a versatile nanoparticle platform is
then accessible with control over size, morphology and functionality,
resulting in long circulating, disulfide stabilized nanocarriers which
were eventually employed in systemic gene delivery.
Polypept(o)ides, which feature hybrid blocks of a polypeptide and
polypeptoid, are employed in this work as a promising material for
nanoparticles in medical application. Synthesis is readily performed on
a large scale by ring-opening polymerization ring-opening polymeriza-
tion (ROP) of α-amino acid N- carboxyanhydride (NCA) monomers, if se-
quential control is expendable. The resulting polypept(o)ides combine
high stability in aqueous media with enzymatic degradability, provide
the option to form secondary structures and offer intrinsic multifunc-
tionality of amino acid side chains, marking it a distinguished bioma-
terial. Since reliable control over materials for medical applications is
critical, Chapter 8 elaborates on the impact of monomer purity on ROP
as evaluated by X-ray diffraction of numerous NCAs.
With focus on nanomedicines for systemic application, this thesis
tackles challenges and provides strategies in nanoparticle design, stress-
ing the importance of controlled carrier synthesis and stabilization. In
this context, disulfide mediated cross-linking is introduced and strate-
gies in different polymerization techniques towards directed formation
of asymmetric disulfides in synthetic peptides and polymers are dis-
cussed in Chapter 4. Thus, the implementation of thiol-reactive moieties
for disulfide-mediated stabilization of polypept(o)ide-based nanomedi-
cines was envisioned by use of the thiol side chain of the amino acid
cysteine. However, at the origin of investigation, strategies for chemose-
lective formation of asymmetric disulfides compatible with nucleophilic
conditions of the ROP of NCAs were completely lacking.
The desired balance between stability against amine initiators em-
ployed in NCA ROP and reactivity towards thiols is not a trivial task to
achieve, as portrayed in PART II. The synthetic effort on moieties combin-
ing properties of a protective and activating group is presented in Chap-
ter 6, peaking in the development of the novel S-alkylsulfonyl group in
Chapter 7. Stability towards N-nucleophiles, as well as immediate reac-
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tivity upon exposure to thiols is evaluated synthetically and by density
functional theory DFT calculations of the relevant frontier orbitals, for
validation on compatibility of the S-alkylsulfonyl group with NCA ROP,
paired with chemoselective disulfide formation.
Controlled polypept(o)ide synthesis is evaluated in PART III of this
thesis. As stability of the S-alkylsulfonyl group during ROP is ensured,
polymerization conditions are optimized in Chapter 9, as deduced by ki-
netic evaluation on poly(S-alkylsulfonyl-L-cysteines) (PCysSO2R), reveal-
ing an innate tendency to exhibit secondary structures. Orthogonal poly-
mer side chain reactivity of the PCysSO2R segment is further evaluated in
trifunctional PSar-block-PCysSO2Et diblock copolypept(o)ides in combina-
tion with chain end functionality for covalent end group modification
(Chapter 10). The versatile synthetic approach of sequential NCA poly-
merization employing PCysSO2Et for thiol reactivity, is also demonstrated
in the synthesis of triblock copolypept(o)ides upon sequence permuta-
tion (Chapter 11).
With amphiphilic PSar-block-PCysSO2Et block copolypept(o)ides at hand,
self-assembly and nanoparticle stabilization were investigated in PART IV.
The polycysteine segment drives nanostructure formation upon its hydro-
phobic nature, as well as by secondary structure stabilization, and pro-
vides thiol-reactive side chains for stabilization of the resulting core-
shell structures by core cross-linking. Independent control over parti-
cle size, morphology and core functionality is enabled by the unique
physico-chemical properties of PSar-block-PCysSO2Et, as will be introduced
for self-assembly structures in Chapter 12 and systematically optimized
in Chapter 13. The significance of covalent carrier modification for appli-
cations in vivo, as achieved for polypept(o)ide-based systems in this the-
sis by core cross-linking and covalent polymer end group modification,
is investigated by near-infrared fluorescence correlation spectroscopy
performed in full human blood (Chapter 14).
The final part of this thesis (PART V) combines findings on orthogonal
thiol-reactivity, block copolypept(o)ide synthesis and secondary struc-
ture stabilization, to accomplish polypept(o)ide-based systems for sys-
temic application as nanomedicines. In vivo studies of cross-linked par-
ticles varying in size, morphology and core polarity provide substantial
information on blood circulation and biodistribution (Chapter 15). Ex-
iting findings on stable circulation of polycationic systems in combina-
tion with passive tumor targeting and low systemic accumulation, drive
the investigation of polypept(o)ide-based carriers for systemic siRNA de-
livery (Chapter 16). With this rationale, triblock copolypept(o)ide are
employed featuring an outer shielding PSar block in conjunction with a
PCysSO2R segment, mediating bioreversible carrier stabilization by
disulfide cross-linking, and a PLys block for stable siRNA complexation.
The influence of block sequence on carrier microstructure and thus per-
formance is examined upon alteration of the triblock sequence.
Ultimately, lead candidates are implemented in a mammary carcinoma
animal model, for siRNA mediated knockdown of a reporter gene in the
tumor.
2
P O LY P E P T ( O ) I D E S I N N A N O M E D I C I N E
2.1 P O LY M E R - B A S E D N A N O M E D I C I N E S
Numerous, sometimes life-threatening, diseases arise from deviations in
biological processes on the molecular or nanoscale level. Critical defects
may originate from mutated genes, infections caused by viruses or bac-
teria or misfolded proteins to name some sources for malfunction. This
complexity of the underlying pathologies gave rise to a multitude of
therapeutic approaches rooted in nanotechnology, establishing the field
of nanomedicine.[1–3] The multidisciplinary nature of nanotechnologies
results, however, in a fairly stretched terminology of nano-dimensional
carrier systems (especially considering the discrete dimensions of the
materials). In general, a nanomaterial is defined as a "material having one
or more external dimensions in the nanoscale (1 - 100 nm)."[4] However,
by considering materials approximately up to 300 nm in diameter, many
applications with significant contribution in the field of nanomedicine
can be included.[5] In general, the physiological behavior on this scale
is definitely not dictated by size alone, but is also highly dependent on
material- and geometry-characteristics. The examination of nanoparticle
dimension serves here as a rough estimate to outline the term nanomedi-
cine. An overview of established nanotherapeutic platforms is given in
Figure 2.1, illustrating the manifold approaches in nanomedicine used
to address clinical relevant targets.
Figure 2.1: Schematic illustration of nanotherapeutic platforms such as drug
conjugates, lipid-based nanocarriers, polymer-based nanocarriers,
inorganic nanoparticles and viral nanoparticles.[3]
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Delivery strategies
based on polymers.
The majority of approved nanomedicines or under ongoing clinical in-
vestigation are already clinically approved drugs improved by nanofor-
mulation as summarized in Table 2.1. This approach servers to over-
come limitations of the therapeutic active agents such as poor solubil-
ity, premature degradation in plasma, poor biodistribution and severe
side effects. Thus, formulations of highly toxic or poorly soluble drugs
such as amphotericin B and paclitaxel, have shown the greatest clinical
success.[6]
Table 2.1: Approved nanotherapeutics.[6]
Along with successful delivery platforms such as liposomal formu-
lations, inorganic nanoparticles, antibody-drug conjugates and viral
vectors, approaches emloying polymer-based delivery strategies are of
great interest. Polymer-based technologies have influenced practically
every branch of medicine, including ophthalmology, pulmonary, pain
medicine, endocrinology, oncology, cardiology, orthopedics, immunol-
ogy, neurology and dentistry.[7,8] Examples of polymer-based products
currently in clinical practice are: Atridox (poly(D,L-lactide) (PLA) in N-
ethyl-2-pyrro-lidone (NMP) and doxycycline / chronic pariodontitis),[9]
Capronor (poly(-caprolactone and levonoregesrel / contraceptive),[10]
Genexol-PM (PEG-PLA micelles and paclitaxel / cancer (breast, lung,
prostate, and pancreatic)),[11] Gliadel (poly(bis(p-carboxyphenoxy))
propane : sebacic acid 20:80 and carmustine / brain cancer along with
surgery and irradiation therapy),[12] Nanoxel (PEGylated micelle of N-
isopropyl acrylamide (NIPAM) and vinylpyrrolidone (VP) copolymer and
paclitaxel / cancer (breast, lung, prostate, and pancreatic)),[13] Sando-
statin LAR (PLGA-glucose copolymer and octreotide / growth hormone
suppression),[14] Zoladex (D,L-lactide glycolide copolymer (PLGA) and
goserelin acetate / prostate cancer and endometrioses).[15]
As displayed in Figure 2.2, different designs of polymer-based nano-
medicines are available such as A) polymer–protein or B) polymer–drug
conjugates, C) polymeric micelles obtained by self-assembly of block
copolymers, D) core cross-linked nanogels with ability to swell in the
core, E) vesicle formation of block copolymers into polymersomes,
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F) branched dendrimers or G) polyplexes as non-viral vectors for de-
livery of negatively charged nucleic acids.[16]
Figure 2.2: Classes of polymer-based nanomedicines for pharmaceutical
applications.[16]
Polymeric materials offer variability on the structural level (e. g. lin-
ear, branched, grafted, star-shaped, homo- or block copolymer architec-
tures and their respective formulations as nanomedicines) as well as in
their chemical nature. In this context, additional functionalities in form
of stimuli-responsive moieties in the nanocarrier may be desired.[17] As
summarized in Figure 2.3, spatial- temporal- or dosage-controlled re-
lease of a therapeutic active agent from a polymeric nanocarrier can be
induced by various internal or external stimuli. Especially for systemic
application, delivery systems responding to endogenous stimuli such as
change in pH or redox potential are of eminent importance. Deviations
in pH, for example, are associated with pathological conditions in cancer
or inflammation. Further, redox-sensitive materials are of great interest
for delivery to intracellular compartments,[18] since materials featuring
e. g. disulfide stabilization are stable in mildly oxidizing extracellular
milieus such as the blood stream, but are rapidly cleaved once exposed
to the reducing environment of intracellular fluids.[19]
Figure 2.3: External and internal stimuli, which can be used to control the re-
lease of active agents from polymer-based nanomedicines (adapted
from[16]).
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NCAs as monomers.
This desired "smart" behavior requires highly functional and
biomimetic polymeric materials as often accomplished by natural sub-
stances. And while much has been realized with traditional synthetic
polymers, there is a need for bio-compatible and bio-degradable poly-
mers prepared by robust methods enabling precise control over chem-
ical composition, architecture and incorporation of readily functional-
ized building blocks. Such complex requirements can pose a challenge
for many synthetic polymer-based systems. Due to narrow possibilities
for modification, already balanced material properties can be negatively
altered by chemical modifications. With applications as nanomedicines
in mind, the incorporation of peptide and polypeptide domains allows
for introduction of intrinsic functionality of building blocks, moieties for
chemical modification, stimuli responsiveness and structural stability.
In addition, they combine stability against hydrolysis with enzymatic
degradability resulting in non toxic amino acids as metabolites. Hence,
the next section will elaborate on synthetic approaches to polypeptides
as well as polypept(o)ides as an extension of this material class.
2.2 O N T H E S Y N T H E S I S O F P O LY P E P T ( O ) I D E S
The chemical structure of polypeptides is based on α-amino acids as
building blocks. Covalent amide bond linkages dominate the chain
backbone, while the overall chemical properties are dictated by side
chains of the respective amino acid. Thus, highly versatile materials
can be obtained with diverse functionalities and the ability to respond
to various external stimuli. For example, acidic poly(aspartic acid),
poly(L-glutamic acid), neutral poly(histidine) or basic poly(L-lysine)
are relevant as pH sensitive entities in nanocarrier systems.[20] Further,
the redox pair of disulfides and thiols is extensively used to mediate
redox-sensitivity. For this purpose, poly(L-cysteine), poly(L-methionine)
as well as their derivatives are used.[21,22] Additionally, polypeptides
introduce the possibility of hydrogen bonding of the backbone and
hydrophobic interactions of side chains. This behavior enables hier-
archical inter- and intra-molecular organization such as secondary
structure formation, which has an impact on solubility properties of the
material.[23,24] Upon combination of polypeptides based on α-amino
acids and polypeptoids consisting of N-substituted amino acids, hybrid
materials defined as polypept(o)ides are obtained.[25] This introduces
the option to exploit the "stealth"-like properties of the polypeptoid
polysarcosine (poly(N-methylated glycine)),[26,27] which has the poten-
tial to surrogate the role of poly(ethylene glycol) (PEG) in biomedical
applications.[28–30]
The amine-initiated ring-opening polymerization (ROP) of α-amino
acid N-carboxyanhydrides (NCAs) was pioneered by Sigmund and
Wessely[31] Szwarc,[32] as well as Ballard and Bamford.[33,34] If sequence
control is expendable, it represents now the most commonly applied
technique for rapid and large-scale synthesis of both, polypeptides and
2.2 O N T H E S Y N T H E S I S O F P O LY P E P T ( O ) I D E S 9
Modes of
ring-opening NCA
polymerization.
polypeptoids.[35–38] The first report on NCA synthesis is dated back to
1906, as Leuchs observed methyl- or ethyl-chloride formation upon heat-
ing of N-ethoxycarbonyl and N-methoxycarbonyl amino acid chlorides
(Figure 2.4 A).[39] An alternative method commonly used today was pro-
posed by Fuchs in 1922[40] and improved by Farthing.[41,42] It utilizes
directly the amino acid which is reacted with phosgene or a phosgene
analogon for a more convenient synthesis (Figure 2.4 B).
Figure 2.4: A) First report of NCA synthesis[43] and B) NCA synthesis by the
FUCHS-FARTHING method.[40–42]
The ROP of NCAs can potentially follow two pathways as illustrated in
Figure 2.5. An attack by nucleophilic initiators on the C – 5 will follow the
normal amine mechanism (NAM), while deprotonation by initiators with
basic character will lead to the activated monomer mechanism (AMM).
Figure 2.5: Mechanistic pathways for the nucleophilic ring-opening NCA poly-
merization and frequent side reactions.[25]
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Controlled NCA
polymerization.
Ring-opening by primary or secondary amines following the NAM
is proceeded by subsequent decarboxylation. Thus, another terminal
amine is generated and is available for further chain propagation.
Polymerizations following the NAM are of living character, as indicated
by incorporation of initiator molecules into every polymer chain, linear
pseudofirst order reaction kinetics and faster initiation compared to
chain propagation.[44] This mechanism portrays the desired NCA poly-
merization pathway, offering control over molecular weights, polymer
dispersity and end-group integrity. In contrast, abstraction of the acidic
proton by initiators with basic character (e. g. tertiary amines, hydrox-
ides or alkoxides), initiates the undesired AMM.[45,46] The generated NCA-
anion is highly reactive and can initiate polymerization itself, leading to
oligomers with two reactive end groups. Ultimately, an overlap of ROP
and condensation processes occurs at the growing polypeptide chain,
leading to broad molecular weight distributions. Since NCAs based on
N-substituted amino acids like sarcosine do not feature a cleavable
proton, they follow exclusively the NAM. Thus, following characteristics
of living polymerization, high molecular weight polymers upon narrow
dispersities are readily available.[26,44,47]
Control over polymerization conditions proves a crucial element in
NCA polymerization to obtain well-defined materials with narrow dis-
persities and high molecular weights. The strategies cover variation
of initiators such as rare earth catalysts,[48] amine hydrochlorides,[49]
organo-nickel initiators,[50] ammonium salts with tetrafluoroborate
anions[51] as well as hexamethyldisilazane-mediated polymerization
approaches.[52] Further, high purity reagents employed in high vacuum
techniques,[53] variation in temperature[54,55] and the introduction of N2
flow[56] assure control over NCA polymerization. Purity of employed
solvents, initiators and especially NCA monomers is crucial for a con-
trolled ring-opening polymerization mechanism, since impurities may
act as chain-transfer agents, terminate growing species or catalyze side
reactions. Monomer purification by means of crystallization, or by sub-
limation (as introduced by Ballard et al. for sarcosine NCA[33,34]) is a rele-
vant measure to improve the outcome of the polymerization. All purifi-
cation procedures have to be performed upon exclusion from air (and
thus moisture) and employ absolute solvents to ensure the absence of
water.[53,57]
The benefit of ring-opening polymerizations of NCAs in a controlled
fashion is the possibility to construct highly defined, multi functional
polypept(o)idic materials as illustrated in Figure 2.6. Random copoly-
merizations are feasible as well as sequential polymerizations, leading
to various architectures such as multiblock copolypept(o)ides, star-like
(block co)polypept(o)ides and cylindrical brush polypept(o)ides (Fig-
ure 2.6 left). Apart from conformational diversity, a remarkably ver-
satile chemical toolbox is readily available for NCA ROP. A multitude
of reactive NCAs can be polymerized or accessed by post polymer-
ization modification reactions[21,58] and the choice of specialized ini-
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nanomedical
applications.
tiator molecules allows for end-group functionality[59,60] or backbone
degradation[61,62] (Figure 2.6 middle). This level of complexity, however,
should not compromise polymer definition, especially in light of appli-
cations in the field of nanomedicine. As illustrated exemplary in Fig-
ure 2.6 (right), controlled NCA polymerization yields highly multifunc-
tional polypept(o)idic materials with precise control over polymer dis-
persity, molecular architecture as well as end-group integrity.[25,63]
Figure 2.6: Synthetic approaches and architectures of block copolypept(o)ides:
A) sequential polymerization of multiblock copolypept(o)ides, B) bi-
functional initiator approach, C) star-like block copolypept(o)ides
and D) cylindrical core-shell brush pept(o)ides. To the right hand
side, available functionalities and exemplary characterization meth-
ods of block copolypept(o)ides (DOSY 1H NMR ,[61] GPC,[26] MALDI[27]).
To date, polypept(o)ide-based nanomedicines accomplish promising
performances in drug delivery applications as demonstrated for mi-
crocapsules based on PSar – PGlu(OMe),[64,65] – PLys(Z)[64,66] or – PAla[28,66]
block copolypept(o)ides and micelles based on PSar – b-PLLA[67,68] from
Kimura and coworkers. Further, PSar – PGlu(OBn) block copolypept(o)ides
were employed for drug formulations[26] and improved by mannose
ligands[59] in our group. Polypept(o)ide-based vehicles for gene therapy
based on PSar – PLys copolypept(o)ides were also recently explored in our
group. Architectures of core-shell cylindrical brush polymers[69] were
investigated for siRNA delivery as well as (multi)block copolypept(o)ide
based peptoplexes for delivery of pDNA[70,71] and improved by disulfide
cross-linking.[71]
Following up on the topic of delivery systems for gene therapies, the
next chapter will elaborate on the concept of RNA interference (RNAi)
therapeutics as well as the resulting structural and chemical require-
ments on delivery systems for systemic applications.

3RNA interference.
R AT I O N A L D E S I G N O F N A N O C A R R I E R S
3.1 D E L I V E R Y O F N U C L E I C A C I D S
Within the last decade, gene therapy has offered promising approaches
with a current overwhelming focus on cancer therapies (65.0% of clin-
ical trials, 1688 in total) and inherited monogenetic diseases (11.1% of
clinical trials, 287 in total).[72] Further, in the last five years an increased
focus on alternatives to gene-addition strategies was noted, especially in
dominant disease processes, where the mere introduction of a function-
ally intact gene prove insufficient.[72–75] In this context, approximately
20 clinical trials based on the mechanism of RNA interference (RNAi) have
been initiated,[76] emphasizing the relevance to pursue clinically viable
RNAi therapeutics.
The process of RNA interference (RNAi), first described by Mello and
Fire in 1998,[77] allows for control over gene expression by base-pairing
small interfering RNA (siRNA) with messenger RNA (mRNA) of comple-
mentary sequence[78,79] (see Figure 3.1).
Figure 3.1: Mechanism of RNA interference mediated by small interfering RNA
(siRNA) and the RNA-induced silencing complex (RISC). Cleavage of
complementary mRNA by the activated RISC–siRNA complex results
then in the desired silencing of the target gene.[80]
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strategies.
Upon cleavage of double-stranded RNA (dsRNA) by the RNase Dicer
or by direct introduction of siRNA into the cytosol, a protein complex
called the RNA-induced silencing complex (RISC) is formed. The protein
Argonaute 2 (AGO2) in the RISC was identified as the responsible factor
for mRNA cleavage,[81] which results in decreased expression of the cor-
responding protein. This nobel price winning discovery[82] on silencing
of endogenous genes has notably developed our understanding of eu-
karyotic gene regulation and introduced the possibility to exploit the
RNAi mechanism therapeutically.[80,83–85]
Most clinical trials employing siRNA based therapeutics are focused
on cancer therapies (e. g. pancreas, lung, liver or solid tumors in general)
but also on topical use, e. g. for ocular disorders, the respiratory tract or
dermal applications. The therapeutic relevant targets range from vari-
ous protein kinase types and growth factors, mutations of the p53 pro-
tein (which plays a crucial role in the cell cycle and tumor suppression)
and many more.[76,86] The progress of a selection of ongoing clinical tri-
als is summarized in Table 3.1.
In contrast to small molecule inhibitors (<500 Da), which can pas-
sively overcome cellular membranes by diffusion,[87] siRNA molecules
commonly prove too large (∼14 kDa) and too charged (∼40 charged phos-
phates) to enter cells on their own.[88] Further, naked siRNA is not stable
upon systemic administration due to rapid renal clearance and degrada-
tion by ribonucleases.[89] Some applications of naked siRNA molecules
exist e. g. for inhalative treatment of respiratory viral infections (ALN-
RSV01,[90] Alnylam Pharmaceuticals). Additionally, increased resistance
to enzymatic degradation by chemical modifications of siRNA is feasi-
ble, e. g. by O-methylation[91,92] or charge-neutralizing phosphotriester
backbone modifications.[93] Most systemic application strategies, how-
ever, rely on nanodimensional delivery systems based on lipid nanopar-
ticles, cyclodextrines or polymers.[85] Cyclodextrins (e. g. CALAA-1,[94]
Calando Pharmaceuticals) mediate efficient condensation due to strong
basicity of amidine groups, but depend on PEGylation to mediate
stabilization.[95] And while a wide variety of cationic and ionizable lipids
is available (e. g. Atu-027,[96] Silence Therapeutics or ApoB SNALPs,[97]
Tekmira), they suffer from an innate immune response which can be
compensated, again, by PEGylation to enhance circulation times.[98] Thus,
efficient delivery of siRNA molecules remains a crucial technological chal-
lenge in the development of RNAi therapeutics.[78,79,83,93]
Current strategies in siRNA delivery, e. g. to solid tumors, are grav-
itating towards polymer based core-shell systems featuring a polyca-
tionic core and a shielding corona.[100,101] Most prominently, core-shell
polyion-complexes (or polyplexes) of negatively charged nucleic acids
and positively charged polymers are employed for this purpose.[70,102,103]
Particle formation is driven by an entropic gain due to release of counter
ions following multivalent polyanion-polycation interaction. In this case,
dimensions are predominantly dictated by the polyanion and additional
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From intravenous
injection to systemic
circulation.
structural stabilization proves beneficial for delivery of relatively small
siRNAs, in contrast to much larger DNA molecules.[85]
As an alternative, cationic nanohydrogels[104] can be employed, which
are produced by self-assembly of amphiphiles and feature compartmen-
talization based on phase separation. Subsequent core cross-linking al-
lows for stabilization as well as inversion of the core-polarity upon intro-
duction of polycationic moieties. In this context, Siegward et al. prepared
a library of nucleic acid delivery systems based on block copolymers
of poly(diethyleneglycol) methacrylate) (PDEGMA) and acrylates with
epoxy side chains available for diamine cross-linking.[105] Further, Nuhn
and colleagues employed nanohydrogels based on poly(triethylene gly-
col methyl ether methacrylate) and poly(pentafluorophenyl methacry-
late) (P(MEO3MA) – b-P(PFPMA)) combined with oligoamine cross-linkers
for siRNA delivery.[106,107] Loading of siRNA sin the polycationic core is
performed after particle formation, ideally without affecting particle size
or shape.
Ultimately, the particular physico-chemical properties of gene deliv-
ery vectors (or of nanocarriers in general), will determine their pharma-
cokinetic and pharmacodynamic behavior. Thus, challenges of in vivo
applications, relevant factors on biodistribution and strategies to pro-
mote carrier stability will be discussed in the following section.
3.2 S Y S T E M I C A P P L I C AT I O N O F N A N O PA R T I C L E S
Since intravascular degradation of naked siRNA by ribonucleases has to
be avoided, nanoparticle carriers hold promise for effective intracellular
delivery of RNAi therapeutics. However, abundant challenges need to
be addressed by polymeric delivery vectors to promote clinical transla-
tion of RNAi-based therapeutics as illustrated in Figure 3.2.[79,108] When
administered intravenously, adsorption of opsonins (plasma proteins re-
sponsible for enhanced phagocytosis) is guided by the physico-chemical
properties of the particle surface. Opsonization, in turn, facilitates up-
take of nano-sized carriers from the blood stream by macrophages of the
mononuclear phagocyte system (MPS) in the liver, the lymph nodes and
the spleen. If premature degradation and clearance was avoided, pene-
tration of the target tissue, e. g. the tumor, and internalization poses the
next challenge. Following cellular uptake, particles are processed in en-
dosomolytical pathways and the siRNA cargo needs to be released into
the cytosol for effective initiation of the RNAi mechanism. Impacts of the
outlined barriers on nanoparticle-based siRNA delivery and strategies to
overcome those challenges are multifactorial as will be discussed subse-
quently in detail.
Upon systemic administration (see Figure 3.3), distribution of nano-
carriers in the blood stream follows initially the venous network to the
heart and passes then entirely to the pulmonary circulation. The lung
capillaries constitute some of the smallest blood vessels in the body and
are responsible for the first sieving of nanocarriers. Rigid or large mor-
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Figure 3.2: Biological barriers in intravenous delivery strategies for RNAi:
degradation of naked RNA by serum endonucleases, opsonization
and phagocytosis by e. g. macrophages, renal and hepatic clearance
as well as trafficking to tumors by the enhanced permeability and
retention effect (EPR) and receptor-mediated endocytosis. Once in-
side the cell, endosomal escape is the premise for interaction with
the RISC and effective gene silencing (adapted from[79]).
Renal filtration.
phologies ranging from several hundred nanometers up to tens of mi-
crons, especially upon positive surface charge, are sequestered in the
lungs.[109,110] Carrier instability or interaction with blood components
is often responsible for aggregate formation and accumulation in the
lung. However, all particles that avoid pulmonary retention, enter the
systemic circulation via the heart. Now they are subject to the filter or-
gans, most importantly the kidneys, the liver and the spleen (see Fig-
ure 3.4 for illustration of the functional structures).
The kidney (Figure 3.4 A) is separated in two areas, the cortex and the
medulla. The nephron is the basic functional unit and spans those two
parenchyma. It contains the glomerus, which is responsible for blood fil-
tration. The glomerular capillaries feature a highly-fenestrated endothe-
lium (60-80 nm in size) and are covered in a thick fibrous network con-
sisting of a glycocalyx layer, a hydrated collagen matrix and negatively
charged glycoproteins. Additionally, a layer of podocytes forms filtra-
tion slits of 4-6 nm, which are ultimately responsible for high permselec-
tivity of the filtration process in the glomerulum.[110]
Glomerular filtration, and thus accumulation in the kidneys, is a
pathway relevant only for small particle species such as quantum dots
or macromolecules resulting from biodegradable nanocarriers.[112,113]
In approximation, proteins with hydrodynamic diameter smaller
than 5-6 nm (corresponding molecular weight for globular proteins
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Figure 3.3: Distribution of blood flow in the pulmonary and systemic circula-
tion pathways and percentage of blood flow.[110,111].
Phagocytosis in the
liver.
is 60 kDa) are freely filtered, while particles larger than 6 nm are not
typically capable of glomerular filtration.[114] The molecular weight
limits of renal filtration is especially relevant for bio-compatible hydro-
philic polymers, which are not degraded into shorter fragments e. g.
linear poly(ethylene glycol) (PEG; 30 kDa), poly(vinyl alcohol) (PVA
30 kDa), poly-(N-isopropylacrylamide) (PNIPAM; 32 kDa) or poly(N-
(2-hydroxypropyl)methacrylamide) (PHPMA; 45 kDa).[110] However,
macromolecules close to the threshold have to distort and squeeze
through the pores. The necessary deformability is heavily affected by
parameters such as polymer architecture, general backbone flexibility
and hydration state.
For particles excluded from renal clearance, the hepatobiliary system
in the liver is the main pathway of excretion (Figure 3.4 B). Degradation
and excretion via the bile is mediated primarily by phagocytosis. The
liver is a highly perfused organ (fed by the hepatic artery and the por-
tal vein), while bile drains into the gall bladder. The functional units are
hexagonal liver lobules containing hepatocyte plates and the sinusoids.
The sinusoids, where the arterial and portal veins merge, do not exhibit
any basal membrane and are highly fenestrated (100-150 nm). This struc-
ture allows for almost unrestricted transfer to the perisinusoidal space
(space of Disse) and access to the hepatocytes. However, inside the sinu-
soid capilaries in direct contact with the blood flow is the location of the
Kupffer cells. These cells of the MPS are key to the phagocytic liver ac-
tivity and constitute 80-90 % of the total macrophage population in the
body.[110,114]
Kupffer cells ingest preferably opsonized particles, which are then
encapsulated in phagosomes and exposed rapidly to an acidified mi-
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Sieving through the
spleen.
lieu during maturation into phagolysosomes. Particle size and curva-
ture poses a considerable effect on cell contact and internalization. Par-
ticles smaller than 1 µm offer less efficient contacts with the ruffled cell
surface of the Kupffer cells and are mostly subject to pino- or endocyto-
sis. Diameters of 1-3 µm offer optimal conditions for phagocytosis, while
larger particles require severe remodeling of the cytoskeleton to achieve
internalization (upper size in vitro 20 µm or 3fold exceeding volume of
the macrophage).[110]
Figure 3.4: Blood filtration A) in the kidney, B) the liver and C) the spleen: (top)
illustration of the whole organ, (middle) structural composition and
blood flow and (bottom) structure of the functional units (adapted
from[110]).
The spleen acts as a blood filter system and participates in lympho-
cyte maturation and recycling. The whole organ is protected by a fibrous
capsule and is composed of white and red pulps (Figure 3.4 C). Its per-
fusing arteries empty into the splenic sinusoids (closed circulation) or
directly into the parenchyma (open circulation). While the white pulp is
engaged in proliferation of lymphocytes (B and T types), the red pulp
is dominated by a tangled architecture of reticular fibers where blood
components must pass the 200 nm fenestration of the sinusoids. In the fi-
brous network, aged red blood cells are filtered and pathogens are taken
up by marcophages.
In general, sequestration of nanocarriers in the spleen is not desired,
since immunogenic reactions can be induced such as the accelerated
blood clearance (ABC) phenomenon. It describes faster blood clearance
of a second administration compared to the first dose of a therapeutic
agent or nanocarrier. The underlying principle is the interaction of the
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Influence of particle
morphology...
nanocarrier with B cells in the spleen, which induces antibody secretion.
Upon injection of a second dose during this period of increased antibody
levels (usually within 2-4 days), particles in blood are readily opsonized
by circulating antibodies and subject to fast hepatic clearance.[110]
As outlined above for the most important filter organs, particle size
commonly dictates the in vivo fate of nanocarriers (Figure 3.5 A). Upon
increasing size beyond 150 nm, particles accumulate more and more in
the liver and spleen. Especially very large particles of several microns
are retained in the lung capillaries upon first passage. In contrast, small-
sized nanoparticles (<5 nm) are subject to rapid renal filtration.
Figure 3.5: Biodistribution in organs relevant for nanoparticle filtration includ-
ing lungs, liver, spleen and kidneys in relation to A) particle size, B)
geometry and C) surface charge.[115]
Different geometries of nanoparticles such as spherical, cylindrical or
discoidal morphology can also have an effect on pharmacokinetics and
biodistribution (Figure 3.5 B). Upon a difference in flow-characteristics
and circulation halftime, both cell membrane interactions and macro-
phage uptake are affected. In general, rigidity promotes sequestration
in the lungs, the liver as well as in the spleen in accordance to the in-
troduced hydrodynamic diameter ranges.[110] The factor contributed by
nanoparticle shape, however, not a topic commonly agreed on. For ex-
ample, particles of discoidal morphologies are discussed to exhibit tum-
bling dynamics that promote vessel wall interaction, while smaller, spher-
ical structures remain in a cell free layer closer to the endothelial ep-
ithel. Further, once particles come in contact with endothelial cells, cel-
lular adhesion is also dependent on the available surface area of the
nanoparticle.[115]
The validation of this perception is based on the hydrodynamic di-
mensions of nanoparticles in the blood and holds true only for strongly
shape anisotropic structures. Particularly rigid or short elongated struc-
tures will effectively exhibit a spherical hydrodynamic shape in the
blood flow due to rotation. As a consequence, they will not be affected
in the same manner by physical forces in flowing blood. On the size
scale of micrometers, however, filament-like micelles can align with the
blood flow, which extends circulation time in comparison to spherical
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Targeting strategies.
counterparts as demonstrated by Discher and co-workers.[116] Further,
particle curvature affects the speed of phagocytosis by macrophages,
since optimal membrane spreading of macrophages is hindered by
particles with high aspect ratios. Thus, spherical particles are commonly
internalized faster as investigated by Mitragotri and co-workers.[117] In
agreement to these findings, decreased clearance by the MPS allowed
for prolonged circulation of fillomicelles which showed higher accumu-
lation rates in tumors in contrast to spherical micelles.[118]
Further, the surface charge of nanoparticles poses a critical parameter
on biodistribution (Figure 3.5 C). In general, high surface charges will re-
sult in promoted deposition of opsonins on the particle surface and thus
result in accelerated blood clearance by the MPS.[110] Most cellular mem-
branes bear a negative charge due to composition of the lipid bilayer[119].
Thus, toxicity associated with cell wall disruption is mostly associated
by cationic particles[120] along with poor systemic circulation.[109] Neu-
tral or slightly negatively charged nanoparticles, on the other hand, show
a reduced adsorption of serum proteins leading to longer circulation
times.[109,112] As demonstrated by Kataoka and co-workers, neutral (1.3
mV) and anionic (–10.6 mV) surfaces prolonged circulation of PEGylated
polymeric micelles with lower accumulation in liver and spleen.[121]
Ultimately, nanocarrier systems are supposed to enhance specific de-
livery to certain cell types or tissues. Apart from excretion or accumu-
lation in the presented filtration organs, options to enhance specificity
need to be taken into account (Figure 3.6). One targeting strategy fol-
lows a passive accumulation mechanism and exploits pathophysiologi-
cal characteristics of cancerous or inflamed tissue (see Figure 3.6 A). Ac-
cumulation of particles is achieved by promoted extravasation trough ir-
regular fenestrated vasculature and retention due to defective lymphatic
drainage in those tissues, which coined the term enhanced permeability
and retention (EPR) effect[122].
Figure 3.6: Illustration of targeting strategies: A) Passive accumulation of nano-
materials in tumor tissues by extravasation through fenestrated vas-
culature (EPR effect). B) Active targeting of (1) cancer cells or (2)
tumor endothelium by nanocarriers modified with appropriate lig-
ands. C) An external trigger (e. g. acidification due to hypoxia of fast
growing, poorly vascularized cancerous tissue) induces payload re-
lease from stimuli-responsive nanocarriers.[3]
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This passive targeting strategy is relevant for nanoparticles sized
roughly between several tens to 100 nm and profits heavily from long
systemic circulation for sufficient accumulation at the tumor site.[123]
Further, methods which increase fenestrations in tumor vasculature even
further e. g. administration of vascular endothelial growth factor (VEGF)
or nitric oxide prove beneficial. Additionally, most solid tumors exhibit
a dense extracellular matrix (ECM) which impedes successful penetra-
tion by nanomaterials. Thus, administration of collagen-degrading en-
zymes such as matrix metalloproteinases promote vascular permeabil-
ity and particle accumulation.[115] As demonstrated by Cabral et al., ac-
cumulation and tumor penetration depth of nanocarriers profits from a
decrease in size (30 nm outperformed sub 100 nm particles).[124] Again,
an increase in permeability (e. g. by andministration of a TGF-β inhibitor
(transforming growth factor) which decreases pericyte coverage in the
endothelium) enhanced tumor accumulation for larger structures (50, 70
and 100 nm hydrodynamic diameter).
Active targeting can be achieved upon interaction of ligands pre-
sented on the particle surface with receptors on specific cells e. g. cancer
cells or the tumor endothelium as illustrated in Figure 3.6 B. Multiple
ligands have been employed for this purpose such as small molecules
e. g. folic acid and carbohydrates or complex molecules such as peptides,
proteins or antibodies.[3] For delivery of RNAi therapeutic platforms to
tumors the most prominent example is the cyclic RGD peptide.[125] Cyclic
RGD binds to integrins, which are highly expressed on endothelial cells
of tumors and on a number of tumor cells (about 10–15 %). It has been
first exploited as a targeting stragegy in antiangiogenic siRNA therapy us-
ing poly(ethyleneimine) (PEI) particles targeting the vascular endothelial
growth factor (VEGF) by Woodle an co-workers.[125] A bottom-up con-
struction of siRNA carriers employing cyclic RGD was recently demon-
strated by Kataoka and co-workers. They used unimer polyion complex-
assembled gold nanoparticles (poly(ethylene glycol)-block-poly(L-
lysine) modified with lipoic acid as the unimer) for delivery to a sub-
cutaneous cervical cancer (HeLa) model.[126] In general, active targeting
relies on the availability of a specific ligand and a physiologically reason-
able target. The choice of the ligand must allow for specific binding to
target cells, while avoid or minimize binding to healthy tissue. Further,
the density of the targeting ligand need to be tailored carefully to ensure
the desired binding characteristics while maintaining low opsonization
by plasma proteins.
Another approach to augment specific delivery is the release at the
desired site of action upon a stimulus (Figure 3.6 C). As outlined in
Chapter 2, stimuli can be categorized into internal (patho-physiological
or patho-chemical conditions) or external stimuli (physical stimuli such
as light, temperature, magnetic force, ultrasound or electric field). Espe-
cially for systemic application, delivery systems responding to endoge-
nous stimuli such as change in pH, redox potential, ionic strength or
shear stress in the target tissues can be harnessed.[3] For delivery to solid
tumors, the extracellular acidic milieu in contrast to systemic pH can be
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used or the decreasing pH of intracellular organelles.[127] Further, most
tumors exhibit hypoxic areas due to poor vascularization. This environ-
ment is thus rich in reductive agents, which can be exploited for trig-
gered release from redox-responsive nanocarriers.[128]
Once nanocarriers are located at the therapeutic relevant site in the tis-
sue, cellular uptake is the next challenge. As illustrated in Figure 3.7, sev-
eral endocytic pathways can be accessed, each regulated in a mechanis-
tically distinct manner. Cellular uptake can occur by phagocytosis (espe-
cially in macrophages, not illustrated), macropinocytosis, receptor medi-
ated endocytosis (which depends on recruitment of clatrin or caveolin)
or other pathways.[129] In nonspecialized mammalian cells, clathrin-
mediated endocytosis in particular represents the typical uptake mech-
anism for nanoparticles.[130] Upon ligand interaction, clathrins are re-
cruited from the cytosolic side and mediate the engulfment of the cel-
lular membrane. After constriction of the membrane by the enzyme dy-
namin, internalized particles are confined to intracellular vesicles called
endosomes.
Figure 3.7: Pathways of endocytic internalization of nanocarriers and endoso-
mal trafficking in the cell including the following stages: Vesicular
transport of internalized contents into sorting endosomes followed
by possible excretion to the cell surface by fusion with the plasma
membrane, or alternatively maturation into lysosomes by lumi-
nal acidification and recruitment of degradative enzymes (adapted
from[129]).
Endosomes, however, are subject to manifold trafficking and sorting
pathways. Most relevant for intracellular delivery is the maturation to
late endosomes and ultimately to lysosomes. This process is character-
ized by acidification of the endosomal compartment by an ATPase medi-
ated proton influx and recruitment of digestive enzymes.[129] The result-
ing highly degradative environment, however, is preferably avoided in
order to preserve the structure of the delivered siRNA. Further, initiation
of the RNAi mechanism by formation of the RISC can only be achieved
upon presence of siRNA in the cytoplasm. Thus, exit strategies from en-
dosomes are essential for successful siRNA delivery.
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In light of the discussed challenges for systemic application of RNAi ther-
apeutics, concepts for polymer-based gene delivery systems addressing
those issues will be discussed in this section. A selection of synthetic
strategies resulting in favorable carrier functionalities is summarized in
Figure 3.8.
Figure 3.8: Strategies towards polymer-based vectors for delivery of therapeu-
tic nucleic acids.[84]
All approaches provide a polyelectrolyte mediating complexation of
negatively charged siRNA. Commonly, polycations are employed for
siRNA complexation, e. g. poly(ethyleneimine) (PEI), which performs
excellent in regard to transfection efficiency.[131] However, due to its
high charge-mediated toxicity the need for alternatives for systemic
applications is apparent. Various approaches address this issue such
as improved shielding,[132] degradability of PEI as demonstrated in the
group of Park[133] or the use of polyethyleneimine motifs in polymeric
side chains as shown in the group of Kataoka.[102] Further, Wagner and
co-workers employ polycationic polymers prepared by solid phase
synthesis.[103] This approach enables control over the exact sequence,
length as well as order of functional elements such as charge mediating
cationic building blocks (e. g. lysine or oligoamine sequences),[134]
endosomolytically active motifs (e. g. polyhistidines) or moieties for
bio-degradation (e. g. disulfides).[135] However, due to the poor sys-
temic performance of positively charged delivery vectors, polycationic
moieties are preferrably restricted to the nanocarrier core.
For passive accumulation mediated by the EPR effect, long circu-
lating particles in the range of several tens to 100 nm, are required,
with focus on smaller particles for better tumor penetration.[136]
Additionally, in order to extend blood circulation of the nanocarrier,
stealth properties of the particle surface are required to decrease
opsonization through steric repulsion.[137] Also efficient charge
shielding of negatively charged siRNA and the polycationic com-
ponents is desired, since it reduces adsorption of plasma proteins
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and ultimately avoids rapid clearance by the MPS. For this purpose,
various materials can be employed as a hydrophilic, non-charged
carrier-shell such as poly(ethylene glycol) (PEG),[138–140] poly(N-(2-
hydroxypropyl) methacryl-amide) (PHPMA),[107,141,142] poly(sarcosine)
(PSar),[70,143,144] polyoxazoline (POx),[145] poly(oligo(etylene glycol) metyl
ether methacrylate) (POEGMA),[146] or poly(phosphoester) (PPE).[147]
Strategies to exit the endosomal network prior to full maturation into
lysosomes need to be employed in order to deliver the siRNA into the cy-
tosol. This endosomal escape can be mediated by membrane destabiliz-
ing peptides e. g. INF7, H5WYG or GALA.[148] Further, cationic polymers
can destabilize the endosome by interaction with the outer negatively
charged membrane leading to membrane flipping.[149] Polymers such
as PEI and poly(L-lysine) can be employed for this purpose or neutrally
charged but ionizable lipids, which turn cationic upon acidification. Ad-
ditionally, protonation of secondary or tertiary amine groups leads to an
influx of water following the adsorbed protons, which can eventually
lead to rupture of the membrane. This proton sponge effect can be me-
diated by e. g. PEI or histidine moieties.[129] Again, in order to minimize
negative effects associated with high surface charge, these functionali-
ties need to be located in the particle core. If ligands for specific receptor
interactions are required, they need to be presented on the outer surface
of the nanocarrier without impeding the overall stealth properties of the
shell. Stimuli-responsive moieties, such as reversible disulfide linkages,
can be implemented in the particle core or as a linker between polymer
blocks constituting the core and shell.[61,103,150]
In addition to effective shielding, stabilization of carrier systems by
cross-linking proves beneficial on blood circulation compared to non
cross-linked systems[151–153] and can increase stability of siRNA com-
plexes.[135,154] As illustrated in Figure 3.9 for the self-assembly of am-
phiphiles into polymeric micelles, formulations remain in an equilib-
rium with individual polymer chains (unimers). Thus, the critical mi-
celle concentration (CMC) of the respective amphiphile also determines
the maximal concentration of free unimer.
Figure 3.9: Micelle formation by self-assembly of amphiphilic block copoly-
mers above their critical micelle concentration (CMC) (adapted
from[153]).
As a result, non stabilized core-shell systems obtained by self-
assembly of amphiphiles e. g. polymeric micelles or core-shell poly-
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plexes generated by electrostatic interactions are prone to destabiliza-
tion upon introduction into biological environments. Injection stress
due to dilution as well as adsorption of unimers to protein surfaces[152]
shifts the equilibrium towards free unimers. Ultimately, deviating
physico-chemical properties of nanocarriers are observed when aque-
ous solution behavior is compared to biological relevant environments.
Loss of the cargo, aggregation with plasma proteins and accelerated
blood clearance are possible consequences which need to be avoided.
To bypass those issues, polymeric micelles as well as core-shell poly-
ion complexes can be stabilized by covalent cross-linking.[153,155] Core
cross-linking is so far the most successful method, since e. g. shell cross-
linking might alter surface properties and increases probability of inter-
particle cross-linking and aggregation. Further, covalent core stabiliza-
tion offers means for covalent attachment of the therapeutic relevant
cargo.[151] Chemical approaches to increase stability of core-shell carri-
ers are illustrated in Figure 3.10.
Figure 3.10: Strategies for stabilization of polymeric micelles by core cross-
linking (adapted from[153]).
Free radical polymerization can be used with polymerizable groups
present in the hydrophobic core-forming block (Figure 3.10 top). After
micelle formation, cross-linking can be performed e. g. by photo-initiated
polymerization or by the addition of free radical initiators.[156,157] How-
ever, the resulting C – C bonds are not reversible, which might impede
release of the therapeutic cargo and does not promote bio-degradability
of the carrier system.
In this context, cross-linking by disulfide formation is an especially
attractive option to achieve stabilization in a bio-reversible fashion (Fig-
ure 3.10 middle). Nanocarriers in vivo are typically exposed to different
redox potentials when in systemic circulation in contrast to intracellular
compartments.[158] A protein disulfide isomerase is available for catal-
ysis of formation, reduction or isomerization of disulfide bonds inside
cells.[159] The main impact, however, has the tripeptide glutathione (γ-
L-glutamyl-L-cysteinyl-glycine or GSH), since it is the most abundant
low-molecular-weight biological thiol. Disulfide bonds are physiologi-
3.3 R E Q U I R E M E N T S F O R C O R E - S H E L L siR N A D E L I V E R Y S Y S T E M S 27
... or incorporation
of bifunctional
cross-linkers.
cally stable in the blood stream due to a weak reduction potential me-
diated by low GSH concentrations of 2-20 µM. In contrast, intracellular
levels of glutathione are much higher and range dependent on the cell-
cycle between 0.5 and 10 mM.[160,161] Thus, carrier systems featuring
disulfides are stable in the blood, but are rapidly cleaved once inside
cells.[19] With view on the development of vaccines, drug or gene deliv-
ery systems, the bio-reversibility of disulfides provides enormous bene-
fits for the design of drug delivery systems.[103,138,162,163] Stabilization of
nucleic acid carriers by disulfide bridging can be achieved by O2 oxida-
tion of thiol residues as employed in the Kataoka group with regard to
polyion complex micelles[164,165] and in the Wagner group for stabiliza-
tion of lipopolyplexes[166] or polyplexes based on oligoethyleneimine
building blocks.[135] Functionalization of the polymer material itself can
be achieved by polymerization of disulfide bearing monomers[167,168] or
by introduction of thiol-reactive moieties in a post-polymerization mod-
ification reaction. As demonstrated in the group of Kataoka, amine side
chains of a PLys segment were modified upon reaction with N-succin-
imidyl 3-(2-pyridyldithio)propionate (SPDP) to yield free thiols after re-
duction with dithiothreitol (DTT).[169]
An alternative pose bi-functional cross-linkers, which can be used
with reactive groups in the hydrophobic block (Figure 3.10 bottom).
For succesfull implementation of this approach, the reactive groups
have to remain stable upon polymerization and must not interfere with
the self-assembly or complexation process. In contrast to the radical
polymerization approach, side or end groups already present in the
polymer can be used without previous modification.[153] Additionally,
cross-linkers can introduce stimuli-responsive functionalities e. g. pH
sensitive moieties such as Schiff’s base, hydrazone esters, cis-aconityl
or acetal groups.[16,18,107] Also redox-sensitive disulfides can be in-
corporated into nucleic acid carriers by amine reactive reagents such
as dimethyl-3,3’-dithio-bis-propionimidate (DTBP)[170,171] or dithio-
bis(succinimidyl propionate) (DSP).[172] Recent developments in our
group on disulfide stabilization in α-amino acid N-carboxyanhydride
ring-opening polymerization follow a post polymerization approach
and the use of thiol-reactive building blocks. The former strategy uses
a post polymerization reaction with SPDP yielding a S-pyridyl group
as thiol reactive moiety. Cross-linking with various bifunctional thiol
cross-linkers results in libraries of functional multiblock polyplexes.[154]
The other strategy relies on the thiol-reactive S-alkylsulfonyl group
incorporated in poly(L-cysteines).[173] This approach enables the forma-
tion of cationic hydrogels by core cross-linking of polymeric micelles,
entirely bypassing additional post polymerization modification and
activation steps.[22]
In light of the advantages of disulfide stabilization of nanocarriers, de-
sire for chemical control over the employed material is eminent. Thus,
the following chapter will elaborate on strategies for chemoselective for-
mation of asymmetric disulfides in synthetic peptides and polymers.
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A B S T R A C T : With regard to protein- or peptide chemistry, thiols are
frequently chosen as a chemical entity for chemoselective modification
reactions. And while it is a well established methodology to address cys-
teines and homocysteines in aqueous media to form S – C bonds, possi-
bilities for the chemoselective formation of asymmetric disulfide bonds
are much less approached. Focusing on bioreversibility in conjugation
chemistry, the formation of disulfide bonds is highly desirable for the at-
tachment of thiol-bearing bioactive agents to proteins or in cross-linking
reactions, since disulfide bonds can combine stability in blood with
degradability inside cells. In this concept article recent approaches in
the field of activating groups for thiol moieties incorporated in poly-
meric and polypeptide materials are highlighted. Advantageous combi-
nations of stability during synthesis of the material with high reactivity
towards thiols are explored focusing on simplification and prevention
of side reactions as well as additional deprotection and activation steps
prior to disulfide formation. Moreover, applications of this chemistry
are highlighted and future perspectives are envisioned.
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Conjugating to
thiol-moieties e. g. in
cysteine ...
... for chemoselective
disulfide formation?
4.1 I N T R O D U C T I O N
A thiol moiety in natural peptides as well as in chemically or recom-
binant engineered peptide materials offers a wide range of options for
site specific chemical modification.[174] The reactivity profile of thiols is
mainly directed by their relatively low pKa, which distinguishes them
as excellent nucleophiles under physiological conditions,[175,176] as well
as their ability to participate in redox processes to form disulfide bonds
upon oxidation.[177] This high chemical reactivity of thiols, their abun-
dance in biological systems and the ease of modification gives reason
for the significance of reactions addressing thiols in organic chemistry
as well as in the life sciences.[178–180]
In this context, the only thiol bearing proteinogenic amino acid cys-
teine is of great importance. The cysteine moiety offers a gateway to
a broad range of bioconjugation techniques[181] as well as the possi-
bility to introduce disulfide bonds, both in natural peptides[182] and
in peptide-based materials.[183,184] Bioconjucation, defined as the cova-
lent attachment of biological and synthetic macromolecules, is a grow-
ing area of interest in biological as well as material sciences.[185–187]
Central to this field is the site selective conjunction of macro-
molecules based on two moieties with distinct directed reactivity.
This growing toolbox includes chemoselective reactions at cysteine
residues such as disulfide exchanges, alkylation, native chemical liga-
tion (NCL) with thioester reagents, Michael addition with maleimides
or thiol–ene components following a free radical or Michael addi-
tion mechanism.[181,188] NCL[189,190] and thiol–ene[191] coupling strate-
gies operate efficiently, however, they result in irreversible bonds, and
maleimide-thiol conjugates[192–194] are widely implemented in bioconju-
gation settings[192,193] yielding succinimide thioethers, which may un-
dergo hydrolysis and thiol scrambling. In contrast to the outlined bio-
conjugation strategies, disulfides are classified as a dynamic covalent
bond, a term covering a multitude of bond-types combining the advan-
tages of non-covalent and covalent bonds.[165,195,196] Upon a redox en-
vironment present in an extracellular setting, disulfide bonds are sta-
ble, unless subject to disulfide exchange, and are cleaved intracellu-
larly due to the more potent redox environment.[158,159] Especially in
the development of vaccines, drug or gene delivery systems this biore-
versibility of disulfides provides enormous benefits for the design of
nanomedicines.[103,138,162,163]
While there are numerous pathways which are encountered upon in-
troduction of a disulfide containing component in a biological environ-
ment,[197] creating materials for biomedical applications with the option
of chemoselective disulfide formation is a demanding task on its own.
One challenge is the mandatory use of protective groups in the synthe-
sis of reactive polythiol containing polymers, since free thiols interfere
with most polymerization techniques according to their nucleophilic
and redox-active nature (radical transfer).[198] Further, disulfide forma-
tion can be directly achieved by a nucleophilic attack of thiol or thiolate
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bearing target molecules at nucleophilic sulfur atoms in the synthesized
polymer. To ensure a chemoselective formation of disulfides, this pro-
cess requires soft, often sulfur based leaving groups structurally based
on thiosulfonates or disulfides (Scheme 4.1 and Table 4.1).
Scheme 4.1: Synthesis strategy for the chemoselective formation of asymmetric
disulfides (EWG = electron withdrawing group).
Paired with these activating group techniques, this article will focus
on the synthetic strategies for the incorporation of reactive thiols for
chemoselective disulfide formation by post-polymerization modification
reactions. In the next chapters we describe the synthesis of such poly-
mers obtained by either controlled radical polymerization (CRP), solid
phase peptide synthesis (SPPS) and ring-opening polymerization of α-
amino acid N-carboxyanhydride (NCA). Since other polymerization tech-
niques are seldom exploited in the context of chemoselective disulfide
formation, these approaches are briefly outlined before introducing the
main areas of chemoselective disulfide formation in polymer synthesis.
Aside from the illustrated approaches in Scheme 4.1 for chemoselec-
tive disulfide formation, incorporation of disulfides in the main chain
is also possible and it is an attractive motif for polymer networks
with self-healing properties such as polysulfides obtained by disulfide
metathesis under alkaline catalysis,[199] as well as polyurethane[200] or
poly(urea-urethane)[201] networks obtained by polyaddition reaction.
Further, polycondensation reactions yield polyesters as well as cysteine
based poly(disulfide-amides)[202] for applications in the field of self-
healing materials[203] or drug delivery systems.[204] Thiol reactivity in
the side chain of polyesters can be introduced for example by ring-
opening co-polymerization of lactides, followed a post-polymerization
conversion of a trityl-thiol protective group into a thiol reactive pyridyl
disulfide (PDS) groups.[205]
4.2 C O N T R O L L E D R A D I C A L P O LY M E R I Z AT I O N ( C R P )
Controlled radical polymerization techniques such as atom transfer
radical polymerization (ATRP),[226] nitroxide-mediated polymerization
(NMP),[227] and reversible addition–fragmentation chain transfer (RAFT)
polymerization[228] provide versatile tools for the preparation of well-
defined polymers and offer the great possibility to introduce a multi-
tude of different functionalities into polymers.[229] Directed disulfide for-
mation is known for ATRP and RAFT polymerizations and is achieved
by thiol transformation processes following two main strategies: the
thiol-alkanethiosulfonate reaction and the thiol-disufide reaction medi-
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Table 4.1: Activating groups for chemoselective disulfide formation.
structure group synthesis
strategy
alkane thiosulfonate-
R = Me (MTS)
= Et, iPr
= ONa thiosulfate-
(Bunte salts)[206]
ATRP[207]
RAFT[208]
SPPS[173]
NCA[173,209]
2- or 4-pyridyl-
(S-Pyr or PDS)
ATRP[210]
RAFT[211]
SPPS[212–214]
NCA[154]
2- or 4-nitrophenyl-
(S-Nps)
SPPS[215–217]
alkoxycarbonyl
sulfenyl-
(R= Me Scm)
(N’-methyl-N’-
phenylcarbamoyl)
sulfenyl- (Snm)
SPPS[218–220]
5-thio-2-nitrobenzoic
acid-
(Ellmans reagent)
RAFT[221]
SPPS[222]
3-nitro-2-pyridyl-
(S-Npys)
SPPS[223]
tert-butylthio-
(S-tBu)
SPPS[224]
trimethoxyphenylthio-
(S-Tmp)
SPPS[225]
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In controlled radical
polymerization, e. g.
ATRP ...
ated by activated disulfides with electron withdrawing groups (com-
pare Scheme 4.1).[230]
An initial protection step, however, is mandatory for the use of redox
sensitive functional groups such as thiols, since they interfere severely
with the controlled radical polymerization process. Thus, the chemical
strategies surrounding the thiol moiety are numerous and in the fol-
lowing section disulfide reactivity in ATRP and RAFT techniques will be
examined with focus on chemoselective disulfide formation. Thiol end-
functionalized polymers synthesized by ATRP are realized either by a
post-polymerization conversion of the bromo end-group or by protected
initiator pathways (Scheme 4.2 A). An end-group conversion can yield
the free thiol upon reaction with thiourea and NaOH,[231] or a thiol re-
active methane thiosulfonate (MTS) group upon reaction with sodium
methanethiosulfonate for directed disulfide formation.[207] Polymeriza-
tion routes by functional initiators employs either disulfide initiators
which yield bioreducible disulfides in the main chain,[232,233] or a
2,4-dinitrophenyl group in the initiator, which gives the free thiol upon
base mediated thiolysis.[234] Directed disulfide formation is achieved
by incorporating a pyridyl disulfide group (PDS) in the initiator, which
gives asymmetric disulfides upon reaction with thiols.[210,235]
Scheme 4.2: Entries for directed disulfide formation in ATRP and RAFT polymer-
ization techniques.
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( – SSO2 – R) and
PDS ( – SS – R) are
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disulfide formation.
RAFT polymerization is another versatile technique yielding well-
defined polymers and offers several routes for introduction of disulfide
bonds and thiol reactive moieties.[230,236,237] Disulfide bonds can be
incorporated by self-condensing vinyl polymerization of RAFT disulfide
monomers, yielding hyperbrasnched architectures with bioreducible
moieties.[238–240] Further, cross-linking monomers containing disulfide
bonds can be implemented in numerous RAFT crosslinking polymer-
ization strategies[241] e. g. in arm-first nanogel fromation[242–244] or
core-first approaches.[245] Synthetic strategies for a bioreducible, detach-
able corona of nanoparticles for biomedical applications[246,247] also rely
on the incorporation of disulfide bonds between two blocks during
RAFT polymerization. In terms of end-group functionality, materials
synthesized by RAFT polymerization have the advantage of the thio-
carbonylthio end-group, which can already be considered a protected
thiol group. Thus, many end-group transformation methods involve
the free thiol, which is obtained by reduction or through reaction with
nucleophiles e. g. aminolysis.[230,248] Functionality is then introduced
by thiol–ene, thiol–yne, Michael and maleimide reactions either as a
separate reaction step or in a one-pot process.[249–252]
In analogy to ATRP, strategies for directed thiol transformations
in RAFT polymerization are mediated by the MTS[208] and PDS group
(Scheme 4.2 B).[211] Both moieties can be introduced by aminolysis of
the thiocarbonylthio end-group as a post-polymerization modification
and, after directed disulfide formation, were utilized in encapsulation
of gold nanoparticles,[253] protein-polymer conjugates[254] and drug
attachment by disulfides.[255] Reaction with Ellman’s reagent (5,5’-
dithiobis-2-nitrobenzoic acid)[221,256] also yields activated thiols after
removal of the thiocarbonylthio moiety.[257] Further, thiol reactivity
by a PDS group can be introduced during the RAFT polymerization as
an end-group by mono- or bifunctional chain transfer agents[258–260]
or in the side chain. In the latter strategy, polymerization of PDS
modified monomers allowed for particle formation and stabilization
by disulfide cross-linking.[261–263] In addition, side chains can also be
functionalized in a post-polymerization reaction with N-succinimidyl
3-(2-pyridyldithio)-propionate (SPDP).[264]
Concluding, ATRP and RAFT as controlled radical polymerization tech-
niques allow for directed disulfide formation by conversion of thiol moi-
eties into thiol reactive methane thiosulfonates or into activated disul-
fides. However, since the thiol-reactive compounds are often amine in-
compatible, a separate step may be required during end-group conver-
sion. Further, upon generating free thiol end-groups, undesired disul-
fide formation and thiol exchange can pose a synthetic challenge.[265]
Alternatively, the PDS moiety, which proves to be stable during the con-
trolled radical polymerization process[266], can be introduced upon poly-
merization via the initiator in ATRP and RAFT or as a functionalized RAFT-
monomer.
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While the incorporation of activated thiols into polymers was es-
tablished over the last decade for controlled radical polymerization
techniques, their use in polypeptide synthesis was mainly limited to
postpolymerization modification techniques in synthetic or natural
polypeptides. Researchers encountered complex requirements for
protective groups and needed to choose between options in multistep
procedures of protection, deprotection, activation and conjugation
reactions. A suitable protective group avoiding this complexity, should
allow direct conversion into a disulfide and needs to provide the deli-
cate balance of stability towards amines and other hard nucleophiles
with reactivity towards thiols as soft nucleophiles.
4.3.1 Solid Phase Peptide Synthesis (SPPS)
Chemical design of peptide materials is a substantial goal in SPPS and
enables the formation of sequence defined peptides containing one or
several disulfide bridges, as well as peptide materials with disulfides for
stabilization of drug[267,268] and gene delivery systems[269,270] or peptide
based molecular transporters.[271] Disulfides are commonly introduced
via the amino acid cysteine. However, side-chain protection is essential,
since the nucleophilic thiol interferes with the peptide coupling reac-
tion and free thiols are generally incompatible with hydrolytic protec-
tive groups, as it poisons the catalyst.[272] And while a broad spectrum
of protective groups for cysteine in SPPS is available, strategies for disul-
fide formation rely either on (I) orthogonal reactive protective groups,
symmetrical removal and formation of disulfide by oxidation, (II) di-
rect oxidative symmetrical removal of protective groups mostly by I2 or
(III) asymmetric activation and disulfide formation in a displacement
reaction.[183,273]
Oxidation of free thiols after peptide synthesis and removal of protec-
tive group will yield symmetrical disulfides when (homo)cysteines react
with each other. Various oxidants are known from aerial oxygen,[164]
dimethylsulfoxide (DMSO)[274] and supported methionine sulfoxide in
analogy to DMSO oxidation with the advantage of simple removal of
the oxidizing agent,[275] chlorotrimethylsilane-nitrate salts[276] and oxi-
dation of free SH groups by immobilized metal complexes.[277] Further
selective oxidants are trans-3,4-dihydroxyselenolaneoxide (DHS)[278,279]
and N-Chlorosuccinimide (NCS), enabling on resin oxidation with good
compatibility to other protective groups.[280] Direct oxidation from
the protected cysteine is also a popular pathway, employed with the
S-acetamidomethyl group (S – Acm) which is removed by I2 forming
disulfide bonds,[281,282] or (microwave-assisted) disulfide formation
from S-triphenylmethyl protected cysteine (S – Trt) by I2 oxidation.[283]
Other strategies include reduction the of p-nitrobenzyl protective group
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(S – pNB) to a p-aminobenzyl group (S – pAB) prior to oxidation by I2,[284]
oxidation of the S – tBu group by O2 in a large excess of cysteine and a
chaotropic salt[285] and enzymatic cleavage of phenylacetamidomethyl
groups (S – Phacm) followed oxidation in the presence of DMSO in
aqueous conditions.[286] However, disulfide formation by oxidation
allows only the formation of symmetrical disulfides and suffers from
drawbacks such as removal of the oxidizing agent, low yield, long
reaction time, and the formation of side products.[287,288]
Directed asymmetrical disulfide formation, as required for bioconju-
gation, remains chemically challenging terrain since a displacement re-
action of a free, nucleophilic thiol with a second, activated thiol to form
a disulfide needs to be coordinated. Especially in intermolecular disul-
fide bridging, as in bioconjugation techniques employing native cys-
teine residues,[289,290] formation of homodimers has to be avoided in
favor of the desired heterodimer. An approach employing N-terminal
cysteine enables coupling forming a cleavable thiazolidine heterocycle
upon reaction with an aldehyde moiety.[291] Additionally, free thiols can
be activated by an electron withdrawing group e. g. by chlorination[292]
or as nitroso-thiols,[293,294] yielding, highly electrophilic species prone to
side reactions.
A strategy involving mixed aliphatic disulfides relies on the S – tBu pro-
tective group,[224] which is cleaved by thiol containing compounds such
as benzenethiol, β-mercaptoethanol or dthiothreitol (DTT) yielding the
free thiol.[295] The trimethoxyphenylthio group (S – Tmp)[225] is another
thiol labile alternative, since S – tBu removal proves to be occasionally
difficult[296] (Scheme 4.3 A). A similar approach relies on thiol free reduc-
ing agents such as tris(2-carboxyethyl)phosphine (TCEP) which liberates
the free cysteine thiol for further coupling reactions from an S – iPr protec-
tive group.[297] The advantage of the pathways outlined
above is the orthogonal reactivity to most cysteine protective groups,
the compatibility with the N-(9-Fluorenylmethoxycarbonyl) (Fmoc) strat-
egy and relatively mild deprotection procedures. However, the thiol re-
activity of these groups is limited to the thiol moieties employed in the
deprotection and they do not mediate a directed disulfide formation.
Mixed acyl and aryl disulfides are suitable for regiospecific displace-
ment by free thiol groups and yield ultimately unsymmetrical disulfides.
Activation by electron-withdrawing S-alkoxycarbonyl sulfenyl groups
e. g. the S-methoxycarbonylsulfenyl group (Scm),[218,298,299] ethyl-
(Sce), benzyl- (Sz), tert-butyl- (Scb) derivatives[219] or S-([N’-methyl-
N’-phenylcarbamoyl]sulfenyl) (Snm),[220] is accomplished by reaction
of the free or protected thiol with alkoxycarbonyl sulfenyl chloride
(Scheme 4.3 B). Upon reaction with DTT the free thiol is obtained and
mixed disulfides with a thiol component upon a mild base catalysis.[300]
The driving force for disulfide formation is the irreversible decompo-
sition of the Scm group in carbonyl sulfide and the respective alcohol.
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Scheme 4.3: Approaches for directed disulfide formation in SPPS: A) the free
thiol is obtained upon cleavage with thiol containing compounds,
B-C) protective group interconversion and disulfide formation and
D) direct disulfide formation from a protective and activating
group.
Electron-deficient
disulfides are
possible in terminal
position (C).
S – Npys avoids
deprotection
and activation,
but shows low
compatibility in
Fmoc-strategies (D).
Limiting factors are, however, a possible reaction with the N-terminus
and the base sensitivity of this class of activating groups.[220] Further
electron-withdrawing activating group such as 2- and 4-nitrophenyl
(S-Nps)[215–217] and 2- and 4-pyridyl groups (S-Pyr)[212–214] have been
used, since the disulfide formation is promoted by the low pKa of the
aromatic thiol leaving group (Scheme 4.3 C). The introduction of thiol
reactive moieties by 2-pyridinesulfenyl chloride is however susceptible
to hydrolysis.[273,301] An alternative strategy includes N-terminal thiol
deprotection followed by activation with excess 2,2’-dipyridyldisulfide
and coupling with a free thiol in the presence of DTT at pH 7.[302]
In analogy, reaction with 5,5’-dithiobis-2-nitrobenzoic acid (Ellman’s
reagent) gives also a suitable activated disulfide.
Although the performance of the above specified activating reagents
is efficient in terms of disulfide formation, the additional deprotection
and activation step complicates the overall synthetic strategy. An al-
ternative approach operates with the 3-nitro-2-pydidyl group (S-Npys)
combining characteristics of both, an activation and protective group
(Scheme 4.3 D left).[223] Introduction of the Npys group is performed by
38 D I R E C T E D F O R M AT I O N O F A S Y M M E T R I C D I S U L F I D E S
The S-alkylsulfonyl
group combines
thiol reactivity with
amine stability
for use in Fmoc-
strategies (D).
reaction of either the protected cysteine[303] or conversion of the free
thiol with Npys halides.[304] An alternative pathway includes conver-
sion with 2,2’-dithiobis(5-nitropyridine) (DTNP) into Npys and quanti-
tative disulfide formation upon addition of DTT (with and without ad-
dition of thioanisole).[305] Limiting factors are the high stability which
complicates removal and requires enhanced temperatures and an ac-
cess of DTNP. Further studies include Npys disulfide coupling assisted
by microwave irradiation[306] and immobilized Npys on resin enabling
disulfide formation and facilitated work-up.[307] The chemical stability
of the Npys group allows for Boc/benzyl synthesis conditions, but can-
not be applied to “low-high” cleavage protocols or to bases employed in
the Fmoc-strategy.[308] Thus, in the Fmoc-strategy, the Npys group can ei-
ther be incorporated at N-terminal position, introduced after solid phase
peptide synthesis or by conversion of other protective
groups.[309]
The S-alkylsulfonyl group is an alternative protective and activating
group for directed disulfide formation and is based on the thiosulfonate
motif (Scheme 4.3 D right).[173] Ethyl and isopropyl derivatives have
shown outstanding chemoselective thiol reactivity, while remaining
thermodynamic inert towards various amines, allowing standard Fmoc
solid phase peptide synthesis protocols. Thus the site of the cysteine
with a thiol-reactive protective group is not limited to a terminal
position. The thiosulfonyl groups remained intact during conversion
into the corresponding Fmoc derivatives, coupling by N,N-diisopropyl-
carbodiimide (DIC) with OtBu-alanine to give the dipeptide and cleavage
protocolls of the C- and N-terminal protective group. However, cou-
pling protocols employing 1-hydroxybenzotriazole (HOBt) or related
O-nucleophiles pose a challenge, since partial cleavage of the activating
group resulted in free thiols.
In summary, SPPS offers a well-supplied toolbox for disulfide forma-
tion. However, deprotection steps or interconversion to suitable acti-
vating groups can increase the synthetic effort. The Npys and S-alkyl-
sulfonyl group fall in the advantageous category of protective and ac-
tivating groups, which enables asymmetric disulfide formation with-
out further modifications, thus simplifying the overall peptide synthe-
sis procedure. In this context, O- and N-nucleophiles can pose a chal-
lenge when present besides thiol activating groups, since the reactiv-
ity towards the activated electrophilic sulfur is often high enough to
cause side reactions. Strategies in SPPS rely on amine mediated Fmoc-
deprotection, which is compatible with the S-alkylsulfonyl group but
not the Npys group. However, most activating routes also employ O-
nucleophiles derived from triazoles, rather than sole carbodiimides due
to the risk of racemization,[310] which results in partial cleavage of the
S-alkylsulfonyl group due to the oxophilic character of sulfur.
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4.3.2 NCA Polymerization
The ring-opening polymerization of α-amino acid N-carboxyanhy-
drides (NCAs) is a well-established methodology for rapid and large
scale preparation of synthetic polypeptides.[35,49–53,55,56,58,311–317] In con-
trast to SPPS, NCA polymerization techniques lack the possibility for
sequence-defined polypeptides, provides, however, the possibility of
(multi) block copolymer synthesis, graft copolymers and high molecu-
lar weight polypeptides. In addition, O-nucleophiles are absent during
polypeptide synthesis. Polypeptides synthesized by this method have
already entered clinical trails or, as in the case of copaxone, became
multi-billion dollar drugs.[315,316]
The high demand for reactive thiols enabling bioreversible conju-
gation to polypeptides by disulfide bonds is eminent, as illustrated
by the well established incorporation of disulfide bonds in initiators,
in the main or side chain of polypeptides[61,62,318,319] In addition, re-
active polypeptides enable a variety of post-polymerization modifica-
tion techniques.[21,58] A multitude of chemoselective modifications, e. g.
alkylation,[312] azide–alkyne,[314] thiol–ene and –yne reactions[311,313,317]
is available. However, in analogy to controlled radical polymerization
and solid phase peptide synthesis, most post-polymerization modi-
fications in NCA polymerization result in irreversible bonds.[320] Im-
plementations of reactive thiols in nucleophilic ring-opening polymer-
ization are scarce, since most activated disulfide moieties are prone
to nucleophilic initiators as a consequence of their pronounced re-
activity required for disulfide formation. A sequential NCA polymer-
ization followed by sequential deprotection procedures allows for a
post-polymerization modification approach and enables chemoselective
cross-linking by dithiols (Scheme 4.4 A).[154] Here, activated pyridyl
disulfide moieties were introduced into a poly-L-lysine segment in a tri-
block polypeptide-block-polypeptoid copolymer (polypept(o)id)[25,26]
employing N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP).[154]
However, to bypass the required deprotection and activation steps
after polymerization, a protective group for thiols, which combines sta-
bility during NCA peptide synthesis with the ability to form disulfide
bonds in a chemoselective reaction, appears highly desirable. Thus, acti-
vated cysteines were employed in NCA synthesis and polymerization,
first equipped with protective groups of varying potency as electron
withdrawing groups (Scheme 4.4 B).[321] The findings were, however,
humbling, since the protective groups in question are highly reactive
like most activated thiols and disulfides and were prone to hydroly-
sis and aminolysis during NCA synthesis as well as during polymer-
ization. At this point, a related class of sulfur–sulfur containing bonds
known for its potency in thiol activation was explored: the thiosul-
fonyl group.[206,322,323] Starting with S-pheylsulfonyl-L-cysteine[321] and
followed by S-alkylsulfonyl-L-cysteines[173] (Scheme 4.4 C), thiosulfonyl
protective groups were first explored in NCA polymerization to success-
fully bridge the gap between stability and reactivity.
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Scheme 4.4: A) Post-polymerization strategy for incorporation of pyridyl disul-
fide moieties in polypeptide side chains. B) L-Cysteine NCA
with disulfide-based side chains of decreasing electron deficiency.
C) S-phenylsulfonyl- S-ethylsulfonyl- and S-isopropylsulfonyl-L-
cysteine NCA. Reproduced with permission from refs.[154,321] copy-
right 2016 and 2017 Elsevier.
The synthesis of S-alkylsulfonyl-L-cysteines is straightforward and
involves the in situ formation of the S-nitrosocysteine followed
by conversion with either ethanesulfinic or isopropanesulfinic acid
sodium salt forming the corresponding thiosulfonate with retained
stereochemistry.[173] The desired asymmetric disulfides are obtained
upon reaction with soft nucleophiles, like thiols, exhibiting exceedingly
fast reaction rates, while hard nucleophiles like amines result in low re-
action rates so that a conversion is virtually inhibited[324] (Figure 4.1 A).
Thus, both protective groups are stable against aminolysis by primary
and secondary amines in a low temperature regime, which enables their
use in amine-initiated NCA polymerization (Figure 4.1 B). In aqueous
conditions, base-mediated hydrolysis needs to be taken into account
due to the the oxophilic character of sulfur, as reflected in increasing
rate constants upon higher pH levels. As a result, mildly acidic condi-
tions are preferred when in aqueous media.
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Figure 4.1: A) Synthesis of S-alkylsulfonyl-L-cysteines (Cys(SO2R)) and reactivity
profile towards hard N- and soft S-nucleophiles. B) Plot of log (kNu)
for Cys(SO2R) under alkaline hydrolysis (red) and aminolysis condi-
tions (blue) at different temperatures. C) DFT calculations of HOMO
and LUMO of Cys(SO2Et) and D) Cys(SO2iPr) each in relation to HOMOs
of butylamine and hexanethiol in a nucleophilic attack. Reproduced
with permission from ref.[173] copyright 2016 Wiley-VCH.
In the case of a nucleophilic attack, the reactivity profile of the S-alkyl-
sulfonyl group is directed by the difference between the energy level
of the lowest unoccupied molecular orbital (LUMO) of the electrophile
and the highest occupied molecular orbital (HOMO) of the nucleophile.
Figure 4.1 C and D show density functional theory (DFT) calculations of
the frontier orbitals of S-ethylsulfonyl- as well as S-isopropylsulfonyl-
L-cysteine in relation to hexanethiolate as a soft nucleophile and buty-
lamine as a hard nucleophile.[325,326] For both protective groups the en-
ergy gap between the LUMO and the HOMO of the amine (left) signifi-
cantly exceeds the gap to the HOMO of the thiol (right). A smaller energy
gap, however, facilitates an orbital controlled nucleophilic reaction and
the DFT calculations are well in line with the observed reactivity of the
S-alkylsulfonyl group towards thiols and the hindered aminolysis.
After ensuring the stability of the S-alkylsulfonyl group under amine-
initiated controlled ring-opening polymerization conditions, both pro-
tected L-cysteine derivatives were converted into the corresponding
NCAs and polymerized with neopentylamine as initiator (Figure 4.2
A). The resulting poly(S-alkylsulfonyl-L-cysteine) (PCys(SO2R)) display
a narrow, symmetrical molecular weight distribution with low poly-
mer dispersity (Ð < 1.2) (Figure 4.2 B). Further, matrix assisted laser
desorption/ionization-time of flight (MALDI-TOF) mass spectrometry
studies of homopolymers verified the integrity of the protective group
during the NCA polymerization and absence of side reaction.[209] Full
agreement between simulated and measured molecular weights clearly
confirms the absence of chemical chain termination or other side reac-
tions due to protective group cleavage and emphasize the highly con-
trolled polymerization of Cys(SO2R) NCAs.
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Figure 4.2: A) Polymerization of Cys(SO2R) NCA with neopentylamine as initia-
tor, B) HFIP GPC traces of PCys(SO2R) and C) MALDI-TOF spectrum of
PCys(SO2Et) . Reproduced with permission from refs.[173,209] copy-
right 2016 Wiley-VCH and American Chemical Society.
The chemoselective formation of asymmetric disulfides as mediated
by the S-alkylsulfonyl group in the polymer was carefully verified by
conversion with a thiol moiety (Figure 4.3 A). As evaluated by 1H NMR
full chemoselective conversion into the disulfide is achieved with high
reaction rates and without detectable side products (Figure 4.3 B).[209]
Subsequently, block copolypept(o)ides incorporating PCys(SO2R) as a
cross-linkable segment were realized by sequential polymerization. The
orthogonality of the thiol-reactive moiety of the S-alkylsulfonyl group
towards strain–promoted azide–alkyne cycloadditionn (SPAAC) and ac-
tivated ester-mediated amidation was investigated in amphiphilic poly-
sarcosine-block-poly(S-alkylsulfonyl-L-cysteine) block copolypept(o)ides
(Figure 4.3 C). All three functionalities can be addressed independently,
thus allowing for functional group interconversion of chain ends, as
well as directed disulfide formation in the side chain of the PCys(SO2R)
block in one step.[327]
A combination of this orthogonal direct disulfide formation with fur-
ther functional polypeptidic segments, such as a cationic poly-L-lysine
block as mentioned above in the strategy for post-polymerization modi-
fication for disulfide stabilized-polyplexes,[154] adumbrates a gateway to
numerous multifunctional polypept(o)idic systems and envisions their
use as material platform for biomedical applications.
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Figure 4.3: A) Reaction of PCys(SO2Et) with benzylmercaptan. B) 1H NMR spec-
trum of PCys(SO2Et) prior to conversion (red) and after conversion
with benzylmercaptan (blue). Enlarged comparison of both 1H NMR
spectra emphasizing the quantitative conversion (disappearance
of polymer associated protective group signal at 1.30 ppm (e) and
emerging signal at 1.08 ppm (5) of the fully converted protective
group). C) Scheme of PSar-b-PCys(SO2Et) end-group conversion with
NHS-ester and DBCO moieties, respectively, and thiol reactivity of the
S-ethylsulfonyl group in the side chain. Reproduced with permis-
sion from ref.[209,327] copyright 2016 and 2017 American Chemical
Society.
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The incorporation of activated thiols into polypeptides provides access
to reactive copolymers, which can be applied to postpolymerization
modification reactions[21,320,328,329] leading to the formation of disulfides.
Since these bonds are intrinsically reversible and possess a certain dy-
namic nature, the formation of disulfide bonds is used for bioreversible
cross-linking of micelles, polyplexes or protein polymer conjugates or
for the attachment of bioactive agents, e. g. antibody or protein drug
conjugates[103,153,330–332] In another recent example multiple functionali-
ties were introduced into polypept(o)ides bearing PCys(SO2R) segments
for the formation of asymmetric disulfides.
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In addition, self-assembly of polypeptides in solution and of
PCys(SO2R) containing block copolymers in particular, provides access to
compelling micellar morphologies (see Figure 4.4). The Cys(SO2R) block
adapts a β-sheet conformation (Figure 4.4 A), adding cooperative effects
to the self-assembly process. Thus, control over self-assembly in solution
is not longer solely directed by block length ratios of the hydrophilic to
the hydrophobic block, but can be modulated by hydrogen bond forma-
tion between polypeptides of a certain secondary structure.
Figure 4.4: A) CD spectrum of PCys(SO2Et) of varying degrees of polymerization
in HFIP confirming β-sheets in solution. B) Size range of core-cross-
linked nanohydrogels as shown in dynamic light scattering exper-
iments. C) Properties of core-cross-linked nanohydrogels in the ab-
sence of a chaotropic agent: I) intermolecular hydrogen bond for-
mation resulting in β-sheets and thus rod–coil polymers, II) elon-
gated shapes due to secondary structure stabilization (visualized
by AFM/TEM), III) illustration of the core framework of worm-like
particles with twisted β-sheets. D) Properties of core-cross-linked
nanohydrogels in the presence of a chaotropic agent such as thio-
urea: I) intermolecular hydrogen bond formation is repressed re-
sulting in coil–coil polymers, II) spherical structures as modulated
by the absence of secondary structure stabilization (visualized by
AFM/TEM), III) illustration of the core framework of spherical parti-
cles with intertwined polymer chains in random coil conformation.
Reproduced with permission from refs.[22,209] copyright 2016 Amer-
ican Chemical Society and 2017 Wiley-VCH.
Keeping in mind that the secondary structure of proteins can be
denatured by different external stimuli,[333] the self-assembly of such
polypeptides can coherently be controlled by modulation of hydrogen
bond formation. In the most prominent case, a rod–coil block copoly-
mer (intact β-sheet conformation, Figure 4.4 C I) can be converted to
a coil–coil polymer with help of a chaotropic agent (disturbed β-sheet
conformation, Figure 4.4 D). While rod–coil block copolymers (PSar407-
b-PCys(SO2Et)28) form worm-like micelles in aqueous solution (without
thiourea, Figure 4.4 C II) the same polymer can lead to the formation of
spherical micelles in the presence of a chaotropic agent (with thiourea,
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Figure 4.4 D II). Disturbing the formation of inter chain hydrogen bonds,
the chaotropic agent converts the rod–coil conformation of the block
copolymer to an rod–coil block copolymer and subsequently alters the
resulting nanoparticle morphology.
Moreover, the reactive poly(S-alkylsulfonyl-L-cysteine) block ensures
stabilization of the formed morphologies and the introduction of func-
tionality in the micellar core. The formation of disulfide linkages pro-
ceeds at the core-forming block in a chemoselective fashion, whenever
the cross-linking is realized by the reaction of di- or oligothiols in aque-
ous solution (Figure 4.5 A). Interestingly, the size and morphology of
the previously assembled micellar structures are not affected by this
cross-linking reaction even if the core polarity is inverted by hydrophilic
dithiols. Therefore, a complex goal, the complete decoupling of aggre-
gate formation and core functionalization as well as stabilization, is re-
alized. As a consequence, core functionality as well as polarity can be
easily adjusted according to the implemented dithiol in one single step
(Figure 4.5 B). Here, the lipoic acid derivatives are implemented after
equimolar reduction with TCEP.
Figure 4.5: A) Illustration of the cross-linking reaction mediated by the thiol re-
activity of the S-ethylsulfonyl group with various dithiols B) such
as hexanedithiol, triethylenetetramine α,ω-di(cysteine)diamide
(TETA), lipoic acid and lipoic acid derived cross-linkers prior to re-
duction with side chains of varying polarity. Reproduced with per-
mission from ref.[22] copyright 2017 Wiley-VCH
In summary, the implementation of the S-alkylsulfonyl group in the
core-forming block block leads to adjustable size- and morphology
regimes in nanoparticle formation by self-assembly. Further, indepen-
dent core functionalization in respect to the desired biomedical appli-
cation is achieved as well as bioreversible core stabilization and thus
creating a highly versatile nanoparticle platform.
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4.5 C O N C L U D I N G C O M M E N T S
Activated thiols moieties have already drawn the attention of research-
ers in the fields of organic chemistry and polymer science as a possi-
bility to introduce functionalities into macromolecules by bioreversible
disulfide formation. However, a lack of chemoselectivity in complex pro-
teins for side specific disulfide formation in the presence of amines or
other nucleophiles is limiting the use of activated disulfides. In contrast,
S-alkylsulfonyl protected thiols can overcome these limitations since
they enable the desired chemoselective formation of disulfide linkages
between macromolecules and peptides or other low molecular weight
compounds. We believe that in poly(S-alkylsulfonyl-L-cysteines) in par-
ticular, an exciting combination of properties is merged to enable asym-
metric disulfide formation in a chemoselective manner, while promot-
ing directed self-assembly in solution by β-sheet formation. These prop-
erties allow the straightforward synthesis of core–shell nanoparticles
with decoupled control over morphology and functionality. Therefore,
we anticipate that the S-alkylsulfonyl group for thiol-activation will de-
velop into a useful tool in the synthesis of functional nanoparticles and
in bioconjugation chemistry.
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Characterization of
single molecules...
... of
macromolecules...
... and of
nanodimensional
carrier-systems.
C H A R A C T E R I Z AT I O N M E T H O D S
5.1 I N T R O D U C T O R Y R E M A R K S
Single molecules, e. g. building blocks based on functional protected
amino acids or corresponding α-amino acid N-carboxyanhydrides
(NCAs), can be characterized by nuclear magnetic resonance (NMR) and
infrared (IR) spectroscopy as well as electrospray ionization (ESI-MS) or
field desorption mass spectrometry (FD-MS). Further, molecular orbitals
can be calculated by density functional theory (DFT). Here, a computed
quantum mechanical modeling provides information of the electronic
structure of a many-electron system for a better understanding of re-
activity profiles. X-ray diffraction can be used to evaluate the absolute
conformation of a crystalline compound, which proved to be an essen-
tial characterization tool, since the polymeric materials used in this work
are derived from NCAs of L-amino acids.
As most polymeric materials, polypept(o)ides (polypeptides-block-
polypeptoids) are commonly characterized by NMR spectroscopy to
evaluate the composition of the (block co-) polypept(o)ide. Further,
the presence of secondary structures in polypeptides can be evaluated
by means of NMR, IR or circular dichroism (CD) spectroscopy. By gel
permeation chromatography (GPC), relative average molecular weights
are determined (based on a calibration by polymer standards) as well as
polymer dispersity, which is a value for the molecular weight distribu-
tion. Further, matrix assisted laser desorption/ionization-time of flight
(MALDI-TOF) mass spectrometry can be applied to macromolecules since
it is a relatively gentle method avoiding fragmentation. No external
calibration is necessary, thus absolute average molecular weights and
dispersities are obtained. Additionally, end-group analysis of initiating
or terminating species is possible by comparing experimental values
with theoretically calculated molecular weights.
For polymers and nanoparticles in solution, light scattering tech-
niques such as dynamic light scattering (DLS) and static light scatter-
ing (SLS) exploit the interaction of the solute with light of a defined
wavelength (monochromatic laser), which induces oscillation of electro-
magnetic dipoles. The constructive or destructive interference between
the emitted light waves results in characteristic interference patterns,
which contains information on size and shape of the scattering species.
Upon introduction of a fluorescent label, polymers and particles can be
analyzed by fluorescence correlation spectroscopy (FCS) or UV-Vis spec-
troscopy. Visualization of nanoparticles can be achieved by means of
atomic force microscopy (AFM). Upon the measurement of forces be-
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tween a cantilever tip and the specimen, height micrographs are gener-
ated which depict the overall particle surface. In contrast, transmission
electron microscopy (TEM) visualization is based on interactions of an
electron beam with a thin sample, yielding a contrast image. Specimen
with an overall low electron density, as most carbon-based synthetic
polymers and peptides, can be stained by uranylacetate or osmiumten-
troxide to increase electron density and thus contrast. A valuable ex-
tension is cryogenic transmission electron microscopy (cryoTEM), since
visualization is based on transmitted electrons from a vitrified sample,
allowing the imaging of specimen in aqueous solution.
The biological evaluation of nanoparticles for nucleic acid delivery in-
cludes agarose gel electrophoresis to estimate complexation efficiency of
cationic carrier systems with negatively charged nucleic acids. Further,
cell viability assays evaluate the exposure of cells to empty or loaded
carrier systems. The functional knockdown mediated by transfection
with nucleic acids can be evaluated in vitro as well as in vivo by moni-
toring bioluminescence in luciferase-expressing cell lines. Ultimately, bi-
oluminescence as well as fluorescence signals can be evaluated in the
living organism by an in vivo imaging system (IVIS), allowing to track
fluorescent-labeled particles and their systemic distribution as well as
ex vivo imaging of organ and tissue samples.
A broad methodological approach is unmistakably necessary to per-
petually monitor the development from single molecule building blocks
such as protected amino-acids and α-amino acid N-carboxyanhydrides
(NCAs), to (multi)block copolypept(o)ides, towards self-assembly of
nanocarriers and their biological application. Thus, only several char-
acterization techniques and underlying theoretical background are de-
scribed in detail in the following sections. The selection is based on the
attempt to elaborate on characterization methods not widely used in the
field of organic chemistry as well as the impact of the respective charac-
terization technique on the scope of this thesis.
5.2 P H Y S I C O C H E M I C A L C H A R A C T E R I Z AT I O N
5.2.1 X-ray Diffraction
Based on the discoveries of Max von Laue et al.[334] showing that crys-
talline substances act as three-dimensional diffraction gratings for X-ray
wavelengths similar to the spacing of planes in a crystal lattice (≈10-10m),
X-ray diffraction (XRD) evolved into a popular technique for analysis of
crystalline materials. A typical setup is shown in Figure 5.1 based on
the elements of the X-ray tube, a rotating sample holder and an X-ray
detector.
5.2 P H Y S I C O C H E M I C A L C H A R A C T E R I Z AT I O N 49
Generation of
X-rays.
Premise of
constructive
interference.
Figure 5.1: Schematic representation of basic principles of X-ray diffraction.[335]
The incident beam is a monochromatic X-ray beam which is focused
on the sample. Polychromatic X-rays are generated in a cathode-ray
tube, where a filament is heated to produce electrons, which are acceler-
ated by applying a voltage. The impact of accelerated electrons on the
target material (most commonly molybdenum) results in dislocation of
inner shell electrons of the target material which generate a characteris-
tic X-ray spectrum (e. g. Kα and Kβ named for the K-shell). Filtering by
foils or crystal monochrometers results in the required monochromatic
X-ray beam.
Interaction of the incident beam with the sample atomic planes cre-
ate a multitude of events such as diffracted, transmitted, refracted, scat-
tered and absorbed beams. The geometry of incident rays, the orienta-
tion of the crystal and the detector can be changed to attain all possible
diffraction directions of the lattice. When the geometry of the incident
X-rays diffracted off the sample results in constructive interference of
the scattered X-rays, a peak in intensity is detected and converted to a
count rate by the detector. The necessary constructive interference oc-
curs when conditions satisfy BRAGG’s law:
nλ = 2dsinθ (1)
with n as an integer, λ the wavelength of the X-rays, d the interplanar
spacing of the atomic planes of the material and θ the diffraction angle.
Thus a relation of wavelength to the diffraction angle and lattice prop-
erties is established. Two methods can be applied to X-ray diffraction in
terms of the specimen under investigation: single-crystal X-ray diffrac-
tion or powder X-ray diffraction as portrayed in the following sections.
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Single-Crystal X-ray Diffraction[336]
Single-crystal X-ray diffraction is a non-destructive method and pro-
vides information on the internal lattice of crystalline materials. A pre-
quisite for this method is a stable crystal of relatively large size (50-
250 µm) and purity, which can not always be accessed. A relatively ex-
tensive data collection period of 24-72 h and the acquisition of an ade-
quate crystal are the drawbacks of this analytical technique. Its strengths
are the non-destructive manner of analysis as well as details available on
the internal crystal structure such as unit cell dimensions, bond-lengths,
bond-angles and details of site-ordering.
For single-crystal diffraction, molybdenum is the most common tar-
get material with Mo Kα radiation (λ= 0.71069 Å). The crystalline sam-
ple is mounted on thin glass fibers fixed to goniometer heads (three-
or four-circle) enabling precise movement of the sample and position-
ing in the center within the X-ray beam. A preliminary rotational image
is often obtained for sample screening and parameter selection. Detec-
tion and identification of intensity peaks is commonly performed by a
charge-coupled device (CCD), which transforms the X-ray photons into
an electrical signal ready for computational processing. After data col-
lection several corrections for instrumental factors, polarization effects,
X-ray absorption and (potentially) crystal decomposition are applied.
Based on the obtained data with help of complementary chemical in-
formation, a model of the arrangement on the atomar level in the lattice
is computationally produced and refined.
Powder X-ray Diffraction[335]
Powder X-ray diffraction utilizes a sample in form of very small crystal-
lites and can give insights on phase identification of a crystalline mate-
rial as well as unit cell dimensions. Analysis is performed by scanning
through a range of 2θ angles, which enables the detection of all possible
diffraction directions of the lattice in the random orientation of a pow-
dered state. The resulting powder diffraction profile exhibits character-
istic sharp peaks. Thus, powder diffraction is commonly implemented
for material identification of pure and mixed samples. Comparison of
peak patterns and intensities with databases of characteristic diffraction
profiles allows for identifications. Further, different phases and their per-
centage in the solid state of a material can be classified.
Limitations of powder X-ray diffraction are mostly associated with
the sample itself such as the necessity a single phase material of suffi-
cient homogeneity as well as a relatively large sample size of tenths of a
gram. Further, for mixed materials the detection limit is≈2 % and a stan-
dard reference of the compound with known d-spacing is mandatory.
Cell determination for non-isometric crystal systems is challenging and
interpretation may be further complicated by peak overlay. However,
powder X-ray diffraction is a powerful and rapid material identification
technique with minimal sample preparation.
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5.2.2 Light Scattering
The foundation of light scattering techniques evaluating properties of
polymers and nanoparticles in solution is based on the interaction of the
solute with light of a defined wavelength (monochromatic laser). Light
of a wavelength λ propagating in space (x) and time (t) can be described
as an electromagnetic wave by the following equation:
E(x, t) = E0
sin(2pix
λ
)
+ sin
2picλ
t
 (2)
The interaction of light as an electromagnetic wave with the observed
species in solution induces a modulation of charge distribution. This
results in an oscillating electromagnetic dipole, which emits light of the
same wavelength as the incoming wave all directions perpendicular to
the axis of oscillation (elastic scattering, see Figure 5.2).
Figure 5.2: Elastic light scattering as the underlying principle of light scattering
techniques.[337]
In particles or molecules larger than λ/20, several oscillating dipoles
are induced simultaneously, which results in a phase difference and a
non-isotropic angular dependence of the scattered light intensity. The
scattering angle (or scattering vector q) is given as the angle of observa-
tion towards the incident light beam. Since several dipoles are induced
in one particle, the constructive or destructive interference between the
emitted light waves results in characteristic interference patterns giv-
ing information on the shape of the scattering species. Light scattering
experiments of particles < λ/20 however, result in scattering intensity
independent from the scattering angle.
Figure 5.3: Influence of particle size on interference pattern: small < λ/20 (left)
and large > λ/20 (right) particles.[337]
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Principle of
auto-correlation.
Dynamic Light Scattering (DLS)[337,338]
Since particles in solution are in perpetual motion (BROWNIAN motion),
scattering intensity is subject to temporal fluctuation (Figure 5.4), which
is exploited in dynamic light scattering.
Figure 5.4: Influence of Brownian motion on interference pattern and scattering
intensity.[337]
A typical DLS setup is shown in Figure 5.5: the sample is illuminated
by a laser beam of a known wavelength λ and time-dependent fluctu-
ations of the light scattered from a spatially limited volume within the
sample are detected at a known scattering angle θ by a photon detector.
Figure 5.5: Schematic representation of a typical DLS setup.[339]
A quantitative analysis of the scattering intensity (Is(q, t)) fluctuation
is possible by correlating the signal with itself over time in an auto-
correlation function (Is(q, t)Is(q, t + τ)). Normalization results in the
following equation with τ as the lag time and q as the scattering vec-
tor:
g2(q, τ) =
〈Is(q, t)Is(q, t+ τ)〉
〈|Is(q, t)|2〉 (3)
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Figure 5.6: Detector signal of fluctuating scattering intensity at a fixed angle
and the computed intensity correlation function.[339]
Since polydisperse samples result in q-dependency of the amplitude
of the auto-correlation function, the observed decaying function (see Fig-
ure 5.6 left) is a superposition of several single exponential functions.
This intensity correlation function can be analyzed by the cumulant
method: by fitting a polynomial of third degree to the logarithm of the
intensity correlation function, the decay rate Γ (1st cumulant) is obtained
and related to the self-diffusion coefficient. Higher orders of the fitting
result (2nd cumulant) give quantitative information on the polydisper-
sity of the self-diffusion coefficient.
By means of the SIEGERT relation based on the principles of GAUS-
SIAN random processes (which applies to scattered light), a relation of
the auto-correlation function to the electric field correlation function is
established:
g2(q, τ) = 1+β|g1((q, τ))|2
g1(q, τ) =
〈Es(q, t)Es(q, t+ τ)〉
〈|Es(q, t)|2〉
(4)
Fitting to an exponential function gives the decay rate Γ
g1(q, τ) = exp(−Γτ) (5)
which is defined as
Γ = Dsq
2 (6)
establishing ultimately a relation to the self-diffusion coefficient.
Ultimately, by means of the STOKES-EINSTEIN equation a relation to
the hydrodynamic radius Rh is achieved, however, with the approxima-
tion of an equally sized, solid spheres (kB is the BOLTZMANN-constant,
T the temperature and η the viscosity of the suspending medium).
D =
kBT
6piηRh
(7)
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Zeta-Potential Measurment[120,340]
The zeta-potential (commonly abbreviated as ζ-potential) is a measure
for the electro kinetic potential at the electrical double layer encircling a
nanoparticle in solution. Since most cellular membranes bear a negative
charge due to composition of the lipid bilayer,[119] the ζ-potential is a
critical parameter when biological applications are considered. Toxicity
associated with cell wall disruption is mostly displayed by cationic par-
ticles, thus, the tendency to permeate membranes can be anticipated by
measurement of the ζ-potential.[120]
Figure 5.7: Illustration of ionic concentration surrounding a negatively charged
particle in solution and the resulting differences in potential relative
to distance from the particle surface.[341]
For measurement of the ζ-potential, DOPPLER electrophoresis mea-
sures the net velocity of the nanoparticle in solution upon application
of an electric field.[342] Most commonly, ζ-potential is measured in a DLS
setup using a capillary cell equipped with electrodes. Hence, upon an
applied electric field, displacement of the particles can be monitored
by DLS principles outlined above. The measured parameter is the net
electrophoretic mobility (µ), which is converted to the ζ-potential upon
HENRYs approximation:[343]
µ =
2ζ
3η0
f(κr) (8)
with  as the dielectric constant, κr the ratio of particle radius to the
DEBYE double layer thickness and η0 the solute viscosity. Generally, a
nanoparticle is considered approximately neutral with a ζ-potential be-
tween –10 and +10 mV, whereas ζ-potential of greater than +30 mV or
less than –30 mV are recognized as strongly cationic and strongly an-
ionic, respectively.[120] However, particle concentration, pH as well as
ionic strength of the solute play a role during the measurement and
need to be maintained constant for reproducibility of ζ-potential mea-
surements.
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Static Light Scattering (SLS)[337]
In contrast to dynamic light scattering, which is based on the temporal
motion of scattering particles, static light scattering measures the inten-
sity of scattered light itself. The obtained data can be analyzed by means
of the ZIMM-equation:
K · c
Rθ
=
1
Mw
(
1+
1
3
R2gq
2
)
+ 2A2c (9)
with K as the optical constant of the experimental setup, c the poly-
mer concentration, Rθ the reduced scattering intensity, Mw the mass
weighted molecular weight, q = 4pinsin(θ2 )/λ (n the refractive index,
θ the scattering angle and λ the wavelength of the beam) and A2 the
second VIRIAL coefficient, which gives information on solvent-solute-
interactions.
In a SLS setup scattering intensity is measured at various angles and
different concentrations (Figure 5.8).
Figure 5.8: Schematic representation of a typical SLS setup.[339]
Then,
K · c
Rθ
is plotted against q2 + kc, with k as a scaling factor in a
ZIMM-plot, followed by extrapolation of all concentrations c to an an-
gle of 0° and all scattering angles θ to a concentration of zero (see Fig-
ure 5.9).
Figure 5.9: Zimm plot analysis resulting in Mw, Rg and A2.[339]
The radius of gyration (Rg) is ultimately calculated from the slope of
c = 0, the second VIRIAL coefficient A2 from the slope of θ = 0 and the
absolute average molecular weight (Mw) from the intercept of both.
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Principles of FCS...
5.2.3 Fluorescence Correlation Spectroscopy (FCS)[344]
Fluorescence correlation spectroscopy relies on a setup related to that
of a confocal microscope. In the observed confocal volume, fluorescent
probes in solution such as small molecules, macromolecules or nanopar-
ticles are subject to random diffusion patterns and temporal fluctua-
tions in the detected fluorescence intensity are detected (compare Fig-
ure 5.2.2) As illustrated in Figure 5.10, the laser beam is focused to a
diffraction limited spot in the sample by an objective, which also col-
lects the emitted fluorescence light. Fluorescent light originated from
other regions than the focal region is blocked by a confocal pinhole after
passing through a dichroic mirror and emission filters. Thus a narrow
observation volume of less than 1 µm3 is obtained.
Figure 5.10: Schematic illustration of setup and principles of confocal fluores-
cence correlation spectroscopy.[345]
The fluctuating fluorescence intensity signal can be auto-correlated
(self-similarity of a time signal). Thus a fluorescence signal at a certain
time (F(t)) is measures against its time-average over time (〈F(t)〉) and
gives the time-dependent fluctuation as:
δF(t) = F(t) − 〈F(t)〉 (10)
In a confocal setup, this fluctuation from the temporal average can be
related in an autocorrelation curve G(τ) (see Figure 5.10)with τ as lag
time and F(t) the detected fluorescence intensity:
G(τ) = 1+
〈δF(t)δF(t+ τ)〉
〈δF(t)〉2 (11)
Parameters such as diffusion time (τD), number of molecules in the ob-
served volume (〈N〉), diffusion coefficient (D) and molecular brightness
(η) can be determined by fitting the autocorrelation curve with suitable
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... and FCCS.
mathematical models. The information on the diffusion coefficient fur-
ther gives the hydrodynamic radius (Rh) of the solute by means of the
STOKES-EINSTEIN equation (see Equation 7 in Figure 5.2.2).
An extension of the FCS technique is the fluorescence cross-cor-
relation spectroscopy (FCCS) or dual-color FCCS, which analyses two de-
tection regions simultaneously and thus monitors the interaction of bi-
molecular processes (Figure 5.11). If the perquisite of two fluorophores
of separated and thus independent emission wavelengths is met, their
conjoined or separate movement can be detected by fluorescence cross--
correlation spectroscopy (FCCS). The cross-correlation function includes
two coordinates (each for one of the two observed volumes) and fluc-
tuations from one volume (F1(t)) and the other (F2(t)) are related. In
the event that one molecule moves from one volume to the other, the
correlation curve will reach its maximum, otherwise it remains at zero.
The amplitude of the cross-correlation function is thus proportional to
diffusing species containing both fluorophores.
Figure 5.11: Schematic illustration of setup and principles of dual-color fluores-
cence cross-correlation spectroscopy.[346]
58 C H A R A C T E R I Z AT I O N M E T H O D S
Advantages of CCK-8
over MTT or related
assays.
5.3 B I O L O G I C A L E VA L U AT I O N
5.3.1 Cell Viability Assay[347]
The effect of exposure of cells to polymers, loaded and empty poly-
pept(o)idic carrier systems can be evaluated by colorimetric viability
assays e. g. cell counting kit-8 (CCK-8). Information on cell viability and
cell proliferation is obtained by evaluating the activity of NADH/NADPH
dehydrogenases. If active, they will produce the reduction equivalents
NADH and NADPH, which are essential in a normal functioning, viable
cell. The assay includes a water-soluble, slightly yellow tetrazolium salt
(WST-8: 5-(2,4-disulfophenyl)-3-(2-methoxy-4-nitrophenyl)-2-(4-nitro-
phenyl)-2H-tetrazolium monosodium salt) and an electron mediator
(here 1-methoxy-PMS). Upon reduction by NADH and NADPH, a bright
orange formazan dye (WST-8 Formazan) is formed (see Figure 5.12).
The absorbance of the formazan dye at 450 nm (measured e. g. in a plate
reader) is then directly proportional to the number of viable cells.
Figure 5.12: Cell viability detection mechanism with CCK-8.[347]
In contrast, in the MTT assay, MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide)) is reduced to a purple formazan dye,
which is water insoluble and form (cytotoxic) crystalline needles. Thus
for measurement it is required to solubilize the formazan needles and
remove floating cells along with cell culture media. Further, this assay
involves only the mitochondrial dehydrogenase (thus relies only on mi-
tochondrial activity, not the cell itself). The water-soluble tetrazolium
salts as well as the formazan derivatives used in the CCK-8 are not cyto-
toxic, which allows for continuous cell culture and the reduction mech-
anism involves most of the dehydrogenases in a cell.
5.3.2 Luciferase Assay[348]
A luciferase assay is based on activity of genes encoding the luciferase
enzymes from Renilla reniformis (sea pansy) or Photinus pyralis (firefly).
It can be performed with regular cells evaluating transfection with re-
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porter genes encoding luciferase enzymes, or with transgenic cells with
the corresponding luciferase gene in their genome, evaluating its knock-
down e. g. by transfection with corresponding anti-siRNA. When
D-luciferin is added to the cell culture or the respective organism (e. g.
i.v.), oxidative decarboxylation of D-luciferin is catalyzed by the firefly
luciferase and results in oxyluciferin and light emission (see Figure 5.13).
Conveniently, D-luciferin is not a substrate for any mammalian enzymes,
thus the readout is extremely specific and highly sensitive.
Figure 5.13: Oxidative decarboxylation of D-luciferin and resulting light-
emission.
The emitted light at 480 nm is called bioluminescence and can be
quantified in vitro by a luminometer or an in vivo imaging system (IVIS).
The light intensity is directly correlated to activity of luciferase and is
evaluated depending to the setup (evaluation of transfection or knock-
down): increase in bioluminescence indicating successful transfection or
decrease in bioluminescence demonstrating successful knock-down.
5.3.3 In Vivo Imaging System (IVIS)[349,350]
To determine the time dependent fate of an agent or its therapeutic po-
tential over time in an specific pathophysiological context in vivo, tra-
ditional approaches would require large cohorts of laboratory animals.
The readout would include sacrifice of the animals at different time
points, dissection and tissue histology. Apart from being costly and eth-
ically questionable, this approach decreases its statistical integrity, since
each animal is only measured once, and cannot be its own control over
time. Traditional clinical techniques such as magnetic resonance imag-
ing (MRI) and X-ray computed tomography (X-ray CT) are an option,
but are often expensive, difficult to accommodate and extensive studies
with large animal throughput prove to be demanding.
Noninvasive in vivo imaging with light photons enables to measure
the state of an animal at multiple time points and is an attractive option
to gain biological information fast and non-destructively in the living
organism.[349] However, tissue penetration of photons is highly depen-
dent on the absorption and scattering properties of tissue components.
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Certain advantages can be exploited in the near-infrared region of the
spectrum, since the absorption coefficients of hemoglobin and water
(the major absorbers of visible and infrared light) are lowest in the near-
infrared (NIR) region between 650-900 nm[350] (see Figure 5.14).
Figure 5.14: The NIR window is ideally suited for in vivo imaging due of
minimal light absorption by hemoglobin (<650 nm) and water
(>900 nm).[350]
In addition to absorption and scattering of fluorescence intensity, the
autofluorescence of tissue has an influence on signal to background ratio
as demonstrated in Figure 5.15.
Figure 5.15: Wavelength-dependent autofluorescence of vital organs and bod-
ily fluids. For orientation, the white light color image of the an-
imal is shown in A). Arrows mark the location of the gallblad-
der (GB), small intestine (SI) and bladder (Bl). Tissue autofluo-
rescence was imaged using three different excitation/emission fil-
ter sets: B) blue/green (460–500 nm/505–560 nm); C) green/red
(525–555 nm/590–650 nm); and D) NIR (725–775 nm/790–830 nm).
Fluorescence images have identical normalization.[351]
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The relation of excitation and emission wavelengths to tissue autoflu-
orescence is least favorable in Figure 5.15 B, due to green autofluores-
cence of skin, viscera and especially the gallbladder, bladder and urine.
This autofluorescence is substantially reduced by a red filter set under
green light excitation (Figure 5.15 C), however, with still high intestinal
autofluorescence. The use of a NIR filter set in Figure 5.15 D basically
eradicates autofluorescence. Thus, NIR dyes are an ideal choice in terms
of tissue penetration as well as signal to background ratio in in vivo imag-
ing applications.[351]
With an in vivo imaging system (IVIS), imaging of bioluminescence
and fluorescence is enabled in the living organism. Luciferase-based bi-
oluminescence imaging (see Section 5.3.2) depends solely on the energy
stored chemically in the substrate D-luciferin. During oxidation only by
the enzyme luciferase expressed in distinct cells this energy is released
as light of a certain wavelength. Thus emission is detected without an
external light source. In contrast, fluorescence imaging depends on ex-
ternal light of a specific wavelength as the energy source for fluorophore
activation (Figure 5.16). The fate of exogenous NIR imaging agents can
thus be followed in vivo.
Figure 5.16: Difference between bioluminescence or fluorescence mode.[352]
In IVIS the animal is anesthetized (usually 2–3% isoflurane) to reduce
movement and thus ensuring focus. Then, a photographic image is
recorded for orientation along with the analytical image in the respec-
tive mode (bioluminescence or fluorescence). Filters can be applied to
adjust excitation to the particular fluorophore as well as its emission.
Ultimately, both images are superimposed to create the typical visual
outcome of an IVIS experiment as illustrated in Figure 5.17. The actual
quantitative information is independent from the visualization (which
can be adjusted accordingly by definition of the scale bar limits). An ap-
propriate software enables the selection of regions of interest (ROIs) or
the whole image for quantification and the readout gives the light inten-
sity as total radiant efficiency in [p/s]/[µW/cm].[352]
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Figure 5.17: Construction of a typical IVIS image by superimposing a photo-
graphic image with the bioluminescent (or fluorescent) image.[353]
Factors for
consideration.
In superficial tissues, absorbing and fluorescent contrast is measured
by illuminating the tissue and recording emerging diffusely reflected
light. Cellular resolution is not possible, since the average path length of
the detected light is increased due to tissue absorption. Thus obtained
images are strongly weighted by the most superficial layer of the tissue,
although hey still contain some information on absorption contrast in
deeper layers. Evaluation need to consider different aspects related to
depth-sensitivity: If a fluorophore is present only in one organ, few mm
below the surface of the skin, it is likely to be detectable due to lack of a
larger signal from superficial layers. Detection is possible if fluorescence
quantum yield is high enough for the detector and if both excitation and
emission light are not excessively attenuated. Tissue autofluorescence
with similar spectral properties or fluorophore in overlying tissue may
overpower the detector or be indistinguishable from the fluorescence
signal of the desired probe. As a result, isolated fluorescent regions can
commonly be detected, interpretation and quantification, however, are
often far more challenging.
Also factors of the biological model need to be taken into account. If
a fluorescent tagged tumor is growing in an axial position, the contribu-
tions to the fluorescence signal from superficial and deeper parts vary
strongly. Thus, a growth rate to the double tumor volume might not re-
late to the detected signal over time. Xenograft models of tumors grown
subcutaneously reduce the impact of depth on quantification, however,
for some tumors this results in loss of their anatomical location (e.g. in
the colon, lung or liver) and thus altering the model severely from the
native disease. Ultimately, ex vivo imaging of the organs and tissues of
interest after conclusion of the biological study is necessary to confirm,
or critically discuss results gained during the in vivo setup.[349]
In summary, IVIS is a powerful tool for optical imaging related to in
vivo applications. For optimal results, different types of optical contrast
need to be taken into consideration, starting with the adequacy of the
biological animal model for the particular question as well as the choice
of operating mode (bioluminescence or fluorescence) and choice of the
fluorophore (preferably in the NIR region).
Part II
T H I O L A C T I VAT I O N I N
α - A M I N O A C I D N - C A R B O X YA N H Y D R I D E S

This PhD thesis was initiated by the need for moieties mediating
chemoselective formation of asymmetric disulfide bonds, e. g. for biore-
versible stabilization in systemic application of nanomedicines, such
as gene delivery vectors. Thus, thiol modifications were investigated,
which combine characteristics of an activating group to mediate reactiv-
ity towards thiols for directed formation of S – S bonds, with properties
of a protective group to ensure chemical stability in presence of amine
nucleophiles. The S-alkylsulfonyl group was introduced for immediate
thiol-reactivity, yielding asymmetric disulfides in unique compatibility
with nucleophilic ring-opening polymerization of respective L-cysteine
N-carboxyanhydride derivates.
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A B S T R A C T : Due to its ability to reversibly crosslink proteins, cys-
teine has a unique role as an amino acid in nature. For controlled, asym-
metric formation of disulfides from two thiols, one thiol needs to be
activated. While few activating groups for cysteine have been proposed,
they are usually not stable against amines making them unsuitable for
solid phase peptide synthesis or amine initiated polymerization of α-
amino acid N-carboxyanhydrides (NCAs). In this Letter we describe a
series of new thiol activated cysteines, as well as their NCAs and explore
the link between electron deficiency of the leaving group and control
over NCA polymerization.
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Cysteine-based
strategies for
disulfide formation.
6.1 I N T R O D U C T I O N
Since their discovery in 1906 Leuchs’ anhydrides,[39] also known as α-
amino acid N-carboxyanhydrides (NCAs), have attracted considerable
attention.[37,38] NCAs are mostly used as monomers for the prepara-
tion of poly(amino acid)s through ring-opening polymerization (ROP),
but they were also applied as synthons for the stepwise synthesis of
peptides.[36,354] In recent years, poly(amino acids) proved to be very
successful as carriers or polymeric drugs in the field of nanomedicine.
While copaxone is an approved drug with 4.7 billion $ sales in 2013 clin-
ical studies on multiple polypeptide based polymer drug conjugates or
drug formulations (OPAXIO, NC-6004, NK 105) are underway.[355] Ad-
ditionally, polypetide based polymers for drug delivery applications are
emerging.[25,26,59,355]
However, while disulfides are already widely used in nanomedi-
cine to reversibly attach drugs to carriers or to stabilize nanoparti-
cles, to our knowledge, poly(cysteine) has not been used for this pur-
pose. Neither protected or activated cysteine derivatives have been ex-
plored. The reasons for this fact are on the one hand the tendency of
poly(cysteine) to adopt a β-sheet conformation which leads to solubil-
ity issues and on the other hand the lack of reactive cysteine protective
groups itself. While derivates of 3-nitro-2-pyridinesulfenyl cysteine[223]
and 3-(2-pyridyldithio)propionate[212] are frequently employed as thiol-
reactive moieties, both protective groups can only be utilized for end-
group modification in Fmoc solid phase peptide coupling[356] or as bi-
functional linkers. Further, a series of cysteine NCAs (S-allyl-cysteine,
S-benzyl-cysteine, S-benzyloxycarbonyl-cysteine, S-benzyloxycarbonyl-
methylene- cysteine, S-butyl-cysteine, S-tert-butylmecapto-cysteine, a
range of S-alkyl-cysteines (dodecyl, hexyl, methyl, ethyl, prolyl, iso-
propyl), S-(2-trimethylsilylbenzyl)-cysteine, S-(4-trimethylsilyl benzyl)-
cysteine, cystine (bis-NCA), S-thiophenyl-cysteine) from the early years
of NCA polymerization have been collected.[45] However none of
them bear thiol-reactive protective groups, which can be directly ad-
dressed after polymerization. Newer cysteine NCAs have either not fo-
cused on post-polymerization modification of polymers at all[312,357,358]
or have worked with deprotection and modification using thiol-ene
chemistry, which leads to the formation of biological non-reversible
thioethers.[311,359,360] Approaches of crosslinking peptidic nanoparti-
cles with disulfides have so far been focused on oxidative disul-
fide formation[153,164,169,361,362] or polymerization of cystine biSNCA,[363]
while the first method is time-consuming and incomplete the latter hin-
ders control over polymerization and particle formation.
A protective group stable during ROP or standard Fmoc solid phase
synthesis of peptides but selectively addressable in post-polymerization
modification reactions leading to the formation of a bio-reversible
disulfide bond in one step is simply absent. In our search for a reac-
tive cysteine-protective group that is stable under NCA polymerization
conditions[364] we have come across a range of novel reactive cysteine
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NCAs, more or less suitable for NCA polymerization. In this Letter we
report the synthesis and analysis of these NCAs.
6.2 R E S U LT S A N D D I S C U S S I O N
As starting point for the synthesis of cysteine NCAs with a thiol-reactive
protective group we synthesized thiol-reactive groups known in the lit-
erature starting with ortho-nitrothiophenol.[365] The strong electron with-
drawing effect from the nitro group favors a thiol exchange with a more
electron rich thiol. According to Phocas et al.o-nitrothiophenol sulfenic
acid chloride (1 a), was reacted with cysteine hydrochloride.[365] The
product (1 b) was transformed into the NCA by reaction with diphosgene
in the absence of water (1 c, Scheme 6.1).
Scheme 6.1: Synthesis of disulfide-based NCAs.
This reaction scheme was used for all disulfide based NCAs. When the
sulfenyl chloride was not commercially available, it was synthesized
from the thiophenol by chlorination with sulfuryl chloride according
to Shang et al.[366] The modified cysteines 1–5 b were synthesized with
yields ranging from 13 % to 98 %, while the NCAs 1 c, 3–4 c were synthe-
sized with 22–65 % yields after 3 recrystallization steps. The NCA of ((p-
nitrophenyl)disulfanyl)cysteine (2 c) as well as S-(o-thiopyridinyl) cys-
teine (5 c) could not be purified. While in the case of 2 c cystine impuri-
ties could not be removed, 5 c is not even stable, since the pyridine can
act as an initiator in the NCA polymerization[37] which was additionally
confirmed by polymerizing Lys(Z)NCA with pyridine under the polymer-
ization conditions applied in this study. The suitability of the NCA 1 c
for amine initiated NCA polymerization was investigated by polymer-
ization with neopentylamine in absolute N,N-dimethyl formamide (see
Supplementary data).[24,367] The gel permeation chromatography plots
corresponding to the molecular weight distribution of polymers were
multimodal or broad indicating the existence of multiple side reactions.
These side reactions can be attributed to protective group cleavage by
the amine chain end and reinitiation by the free thiol (see Figure 6.1).
After 1 c failed to yield defined polymers we lowered the strength of
the electron-withdrawing group (EWG) to decrease the reactivity of the
disulfide and prevent a reaction of the disulfide with the primary amine
initiator (neopentylamine) or the polymer chain end. The reactivity was
reduced to pentafluoro thiophenol and ortho-Fluoro thiophenol. With
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decreasing electron deficiency of the thiol, the quality of the polymers
increased (Ð= 2.1, 1.8 and 1.6 for 1 c, 3 c, and 4 c respectively, see Figures
6.2, 6.3 and 6.4) but not to a point which we considered satisfying.
Realizing, that weakening of the EWG would not be enough to facil-
itate successful NCA polymerization and keep reactivity high enough
for postpolymerization modification reactions, we turned our attention
to different thiol activating groups. A group that has been used to
form asymmetrical disulfides are thiosulfonates.[368,369] Of this class S-
phenylsulfonates are known to react readily with free thiols achieving
complete conversions upon minutes,[290,370] thus a cysteine NCA based
on phenylthiosulfonate was synthesized. To achieve this, cysteine was
activated by transforming it into S-nitroso cysteine, which was reacted
with the corresponding sulfinate without purification. The synthesis
of thiosulfonates was based on work of Hart et al.,[371,372] which was
chosen over the more complex route of Weidner et al.[373] After purifi-
cation the S-phenylsulfonyl-L-cysteine was transformed into the corre-
sponding NCA using diphosgene (Scheme 6.2). The S-phenylsulfonyl-L-
cysteine 6 b was successfully synthesized with 48 % yield, while its NCA
(6 c) was synthesized with 77 % yield after 3 recrystallization steps to
achieve very high purity.
Scheme 6.2: Synthesis of a thiosulfonyl-based NCAs.
This NCA performed better than the disulfide based NCAs in the amine-
initiated polymerization yielding polymers with narrower molecular
weight distribution (Ð= 1.16 for 6 e, see Figure 6.5). The gel permeation
chromatography (GPC) plots however display the presence of low molec-
ular weight oligomers, which indicates partial protective group cleav-
age. Although we have developed new reactive cysteine NCA deriva-
tives, further investigation of the influence of the electron deficiency of
the substituent with even less electron-deficient S-alkylsulfonyl-L-cys-
teine NCAs seems necessary to achieve protective groups with high sta-
bility against amines and combine it with high reactivity toward thiols.
Since the thiosulfonate group does only partially engage in side reac-
tions toward amines this class of protective groups needs to be further
investigated in future. The next generation of derivatives, however, can
be synthesized using the herein reported synthetic pathway.
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We have reported the syntheses of a range of new, activated cysteine
amino acids and NCAs based on electron deficient disulfides and thio-
sulfonates. While especially the more reactive disulfides cannot be
polymerized in a controlled manner using primary amines as initia-
tors, they might be polymerized more controlled using organometallic
catalyst[48,50,374] or trimethylsilyl initiators.[52,375] In contrast, the thiosul-
fonate based monomer can be polymerized in a controlled fashion using
primary amines, leading to a new class of reactive polypeptides, show-
ing that higher electron density leads to higher stability against primary
amines and thus decreases side reactions during NCA polymerization.
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6.5 E X P E R I M E N TA L S E C T I O N
6.5.1 Materials and Instrumentation
All chemicals were purchased from Sigma Aldrich and used as re-
ceived unless otherwise noted. Tetrahydrofurane THF and hexane were
distilled from Na/K and ethyl acetate from CαH2. Cysteine was pur-
chased from OPREGEN and diphosgene from Alfa Aesar. Deuterated
solvents were purchased from Deutero. 1H, 19F and 13C nuclear magnetic
resonance (NMR) spectra were recorded on a Bruker AC 400 at a fre-
quency of 400, 376 and 101 MHz, respectively. 1H and 19F NMR spectra
were also recorded on a Bruker Avance III HD 300 at 300 and 282 MHz,
respectively. The spectra were recorded at room temperature (25 ◦C) and
calibrated using the solvent signals.[376] Field desorption mass spectrom-
etry FD – MS was performed on a FD Finnigan MAT90 spectrometer. Melt-
ing points were measured using a Mettler FP62 melting point apparatus
at a heating rate of 0.5 ◦C min−1. Preparative reverse phase-HPLC was
performed with a Knauer HPLC-System (Berlin, Germany), consisting
of two HPLC pumps (Smartline 1000), an UV/viSdetector (Smartline
2500), a RI-detector (Smartline 2400) and a Phenomenex (Torrance, U.S.
A.) Luna-column (10 lm, C18(2), 100A, 250 × 30 mm) run at a flow of
10.0 mL/min and loaded with a 2 mL injection loop. The system was op-
erated and samples analyzed with D-7000 HPLC-System-Manager soft-
ware (version 4.1). The detector was run at a wavelength of 214 nm.
6.5.2 Synthetic Procedures
(o-Nitrophenyl)disulfanyl-L-cysteine (Cys(oNTP)) 1 b
To a suspension of 5.86 g (37.18 mmol) cysteine hydrochloride in
150 mL acetic acid 10 g (52.74 mmol) (commercial) 2-nitrobenzene-
sulfenyl chloride was added. The suspension was stirred until it got
solid, then 100 mL acetic acid was added and the mixture was heated
to 70°C for 3.5 h. The solvent was removed in vacuo, the residue was
dissolved in 20 mL DMSO and precipitated with 250 mL CHCl3. After fil-
tration the precipitate was suspended in 200 mL CHCl3, stirred for 30
min, and collected by filtration twice. The product was dried in vacuo
yielding 8.63 g (31.45 mmol, 85 %) of a yellow solid.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 8.85 (s, 3H, NH3+), 8.28 (dd, JH,H =
9.6, 8.2 Hz, 2H, HAr), 7.89 (dd, JH,H = 8.3, 7.2 Hz, 1H, HAr), 7.55 (dd, JH,H
= 8.3, 7.2 Hz, 1H, HAr), 4.20 (t, JH,H = 5.8 Hz, 1H, CHNH3), 3.43– 3.26 (m,
2H, CHCH2S).
13C NMR (101 MHz, DMSO – d6) δ [ppm] = 169.09 (COO), 145.26 (CArNO2),
135.31 (CArS, CAr), 127.42 (CAr), 127.36 (CAr), 126.44 (CAr), 51.22 (Cα), 37.14
(Cβ).
FD – MS: 274.3 [M+H]+.
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(o-Nitrophenyl)disulfanyl-L-cysteine NCA (Cys(oNTP) NCA) 1 c
A suspension of 2.015 g (7.35 mmol) of ((2-nitrophenyl)disulfanyl)-
cysteine and 1.55 mL (9.56 mmol) limonene in 40 mL dry THF was
heated to 70 °C. 0.8 mL (4.59 mmol) diphosgene was added in 3 steps
every 20 min. The yellow solution was heated for 4 h. Nitrogen was
bubbled though the solution for 2 h to remove excess HCl and diphos-
gene and most of the solvent was removed. The residue was redis-
solved in 11 mL THF and precipitated by adding 100 mL of cyclohexane
very slowly. The precipitate was redissolved in 14 mL THF and insolu-
ble solids were removed by filtration. The product was recrystallized
two more times from THF/cyclohexane avoiding contact to air yielding
1.437g (4.78 mmol; 65 %) of a pale yellow powder.
1H NMR (300 MHz, DMSO-d6) δ [ppm] = 9.33 (s, 1H, NH), 8.31 (dd, JH,H =
8.2, 1.4 Hz, 1H, HAr), 8.23 (dd, JH,H = 8.2, 1.2 Hz, 1H, HAr), 7.90 (ddd, JH,H
= 8.4, 7.2, 1.4 Hz, 1H, HAr), 7.56 (ddd, JH,H = 8.4, 7.3, 1.3 Hz, 1H, HAr), 4.77
(ddd, JH,H = 6.0, 4.8, 1.3 Hz, 1H, CαH), 3.38–3.16 (m, 2H, CH2).
1H NMR (400 MHz, THF-d8) δ [ppm] = 8.47 (s, 1H, NH), 8.30 (td, JH,H = 8.0,
1.2 Hz, 2H, HAr), 7.81 (ddd, JH,H = 8.4, 7.2, 1.4 Hz, 1H, HAr), 7.47 (ddd,
JH,H = 8.1, 7.1, 1.1 Hz, 1H, HAr), 4.68 (dd, JH,H = 7.8, 3.7 Hz, 1H, CαH),
3.26 (dd, JH,H = 14.0, 3.9 Hz, 2H, CH2), 3.17 (dd, JH,H = 14.0, 7.8 Hz, 1H,
CH2).
13C NMR (101 MHz, THF-d8) δ [ppm] = 170.27 (Cα(CO)O), 152.57
(NH(CO)O), 146.98 (CArNO2), 136.85 (CArS), 135.53 (CAr), 128.21 (CAr),
127.88 (CAr), 127.14 (CAr), 57.77 (Cα), 40.34 (CH2).
(p-Nitrophenyl)disulfanyl-L-cysteine (Cys(pNTP)) 2 b
To a suspension of 277 mg (1.76 mmol) cysteine hydrochloride in 2 mL
DMF was added 6 mL acetic acid followed by 500 mg (2.64 mmol) com-
mercial 4-nitrobenzenesulfenyl chloride. The suspension was stirred at
room temperature for 2 days during which it lost most of its yellow color.
The AcOH was removed in vacuo. Then 30 mL CHCl3 was added slowly
to precipitate the product. After filtration the precipitate was suspended
in 30 mL CHCl3, stirred for 30 min, and collected by filtration three times.
The product was dried in vacuo yielding 394 mg (1.44 mmol, 82 %) of a
pale yellow solid.
1H NMR (300 MHz, DMSO-d6) δ [ppm] = 10.02–8.36 (br, 3H, NH3+), 8.24 (d,
JH,H = 8.9 Hz, 2H, HAr), 7.84 (d, JH,H = 9.0 Hz, 2H, HAr), 4.15 (t, JH,H = 5.9
Hz, 1H, CαH), 3.36 (dd, JH,H = 6.0, 2.4 Hz, 2H, CH2).
Pentafluorophenylsulfenyl chloride (PFTPCl) 3 a
A solution of 5 mL pentafluorothiophenol (7.505 g, 37.5 mmol) in 75 mL
DCM was cooled to 0 °C. 4.56 mL sulfuryl chloride (7.59 g, 56.3 mmol)
was added and the solution was stirred overnight. DCM and excess sul-
furyl chloride were removed in vacuo at 40 °C yielding 8.35 g (4.97 mL,
35 mmol, 93 %) of an orange liquid.
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19F NMR (400 MHz, CDCl3) δ [ppm] = 128.57 (m, 2F, o-F), 145.49 (tt, 1F, p-F),
160.17 (m, 2F, m-F).
S-(Pentafluorophenyl)-L-cysteine (Cys(PFTP)) 3 b
To a suspension of 1.35 g (8.59 mmol) cysteine hydrochloride in 35 mL
acetic acid, 3.02 g (13 mmol) pentafluorophenylsulfenyl chloride was
added. The suspension solidified after 5 min and another 23 mL of acetic
acid was added, yielding a yellow solution, which was stirred at 70 °C
for 3.5 h. During the reaction the yellow color of the solution got weaker.
The solvent was removed in vacuo and the slightly yellow residue was
extracted twice with 58 mL CHCl3, yielding 2.7 g (8.46 mmol, 98 %) of a
colorless solid.
1H NMR (400 MHz, CD3CN/TFA-d) δ [ppm] = 4.43 (dd, JH,H = 8.5, 4.3 Hz,
1H, CαH), 3.51 (dd, JH,H = 15.3, 4.3 Hz, 1H,CH2), 3.35 (dd, JH,H = 15.3, 8.6
Hz, 1H, CH2).
19F NMR (400 MHz, CD3CN/TFA-d) δ [ppm] = 134.66 (m, 2F, o-F), 153.01 (tt,
JH,H = 20.0, 3.9 Hz, 1F, p-F), 163.35 (m, 2F, m-F).
13C NMR (101 MHz, CD3CN/TFA-d) δ [ppm] = 168.95 (COO), 147.61 (ddd,
JH,H = 246.4, 11.6, 4.4 Hz, o-CAr), 144.73–140.78 (m, p-CAr), 139.72–135.61
(m, m-CAr), 110.06 (t, JH,H = 20.6 Hz, CArS), 53.23 (CH2), 39.31 (Cα).
FD – MS: 319.1 [M+H]+.
S-(Pentafluorophenyl)-L-cysteine NCA (Cys(PFTP) NCA) 3 c
2.35 g (7.35 mmol) S-(pentafluorphenyl)cysteine was suspended in
40 mL abs. THF and the suspension was heated to 70 °C. Then 0.8 mL
(6.63 mmol) of diphosgene was added over 1 h in which the solid dis-
solved. The solution was stirred for 1.5 more hours. Nitrogen was bub-
bled through the solution overnight to remove HCl and diphosgene. The
slightly yellow solid was then dissolved in 11 mL abs. THF and pre-
cipitated by slowly adding 130 mL abs. hexane. The precipitate was
collected by filtration without contact to air and recrystallized 3 times
from THF/hexane yielding 568 mg (1.64 mmol, 22 %) of the S(pentafluor-
phenyl)cysteine NCA.
1H NMR (400 MHz, THF-d8) δ [ppm] = 4.77 (dd, JH,H = 7.8, 3.6 Hz, 1H,
CαH), 3.41 (dd, JH,H = 14.4, 3.6 Hz, 1H, CH2), 3.22 (dd, JH,H = 14.3, 7.6 Hz,
1H, CH2).
19F NMR (400 MHz, THF-d8) δ [ppm] = 134.64 (m, 2F, o-F), 152.94 (tt, JH,H
= 20.7, 3.5 Hz, 1F, p-F), 163.28 (m, 2F, m-F).
13C NMR (101 MHz, THF-d8) δ [ppm] = 168.99 (Cα(CO)O), 151.50
(NH(CO)O), 147.47 (ddq, JH,H = 247.0, 11.8, 4.2 Hz, o-CAr), 142.75 (dtt,
JH,H = 256.2, 13.8, 5.3 Hz, p-CAr),139.08–136.55 (m-CAr), 111.68–110.23 (m,
CArS), 56.59 (CH2), 40.94 (Cα).
o-Fluorophenylsulfenyl chloride (oFTPCl) 4 a
5mL (46mmol) o-fluorothiophenol was dissolved in 92mL DCM and
cooled to 0 °C. 5.65 mL (70 mmol) sulfurylchloride was added and the
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solution was stirred for 16 h at room temperature. DCM and excess sul-
furyl chloride were removed in vacuo, yielding 7.39 g (45 mmol, 98 %) of
an orange–red liquid. That was used without further purification.
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.74 (td, 1H, JH,H = 1.7, 5.8 Hz, 1H,
HAr), 7.51–7.46 (m, 1H, HAr), 7.26–7.17 (m, 2H, HAr).
19F NMR (400 MHz, CDCl3) δ [ppm] = 105.82 (m, 1F, FAr).
S-(o-Fluorophenyl)-L-cysteine (Cys(oFTP)) 4 b
7.94 g (49 mmol) o-fluorophenylsulfenyl chloride was mixed with 3 mL
TFA and cooled in an ice-bath. 3.68 g (23 mmol) cysteine hydrochlo-
ride was dissolved in 40 mL TFA and added to the solution at a rate of
15 mL/h under constant stirring. The TFA was removed in vacuo at 45 °C
and 100 mL CHCl3/MeOH (1:1) was added to the resulting solid to extract
the product (residue: cystine, side product). The residue was filtered off
and the filtrate was concentrated in vacuo. 150 mL Et2O was added und
the product was collected by filtration. This was repeated one more time
yielding 0.99g (2.88 mmol, 13 %) a slightly yellow/brownish solid (TFA
salt).
1H NMR (400 MHz, MeOD) δ [ppm] = 7.73 (td, JH,H = 7.6, 1.7 Hz, 1H, HAr),
7.50–7.38 (m, 1H, HAr), 7.3–7.13 (m, 2H, HAr), 4.40 (dd, JH,H = 8.3, 4.2 Hz,
1H, CαH), 3.39 (dd, JH,H = 14.9, 4.2 Hz, 1H, CH2), 3.21 (dd, JH,H = 14.8, 8.3
Hz, 1H, CH2).
19F NMR (400 MHz, MeOD) δ [ppm] = 112.16 (ddd, JH,H = 9.4, 7.5, 5.1 Hz,
1F, FAr).
S-(o-Fluorophenyl)-L-cysteine NCA (Cys(oFTP) NCA) 4 c
0.99 g (2.88 mmol) S(o-fluorphenyl)cysteine was suspended in 30 mL
abs. THF and the suspension was heated to 70 °C. Then 0.35 mL
(2.88 mmol) of diphosgene was added over 1 h in which the solid dis-
solved. The solution was stirred for 1.5 more hours. Nitrogen was bub-
bled through the solution overnight to remove HCl and diphosgene. The
slightly yellow solid was then dissolved in 11mL abs. AcOEt and pre-
cipitated by slowly adding 60 mL abs. hexane. The precipitate was col-
lected by filtration without contact to air and recrystallized 3 times from
AcOEt/hexane yielding 332 mg (1.21 mmol, 42 %) of the S(o-fluorphenyl)-
cysteine NCA.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.31 (s, 1H, NH), 7.73 (td, JH,H
= 7.8, 1.8 Hz, 1H, HAr), 7.45 (dddd, JH,H = 8.7, 7.2, 5.3, 1.7 Hz, 1H,
HAr), 7.37–7.21 (m, 2H, HAr), 4.82 (ddd, JH,H = 6.0, 4.6, 1.3 Hz, 1H, CαH),
3.32–3.15 (m, 2H, CH2).
19F NMR (376 MHz, DMSO-d6) δ [ppm] = 111.70 (ddd, JH,H = 10.2, 7.8, 5.2
Hz, 1F, FAr).
13C NMR (101 MHz, DMSO-d6) δ [ppm] = 170.48 (Cα(CO)O), 160.53 (d, JH,H
= 244.3 Hz, CArF), 152.21 (NH(CO)O), 131.93 (CAr), 131.16 (d, JH,H = 7.9 Hz,
CAr), 125.95 (d, JH,H = 3.5 Hz, CAr), 122.96 (d, JH,H = 17.0 Hz, CAr), 116.62
(d, JH,H = 21.5 Hz, CAr), 57.14 (Cα), 39.51 (CH2).
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o-Pyridinylsulfenyl chloride hydrochloride (oTPCl) 5 a
See o-fluorophenylsulfenyl chloride. Yield: 97%.
1H NMR (300 MHz, DMSO-d6) δ [ppm] = 14.50 (s, 1H, CArH+), 8.49 (ddd,
J=4.9, 1.9, 0.9Hz, 1H, HAr), 7.84 (ddd, J=8.1, 7.5, 1.8 Hz, 1H, HAr), 7.65 (dt,
JH,H = 8.1, 1.0 Hz, 1H, HAr), 7.31 (ddd, JH,H = 7.5, 4.9, 1.0 Hz, 1H, HAr).
S-(o-Pyridinylsulfenyl)-L-cysteine (Cys(oTP)) 5 b
7.90 g (54.25 mmol) o-pyridinylsulfenyl chloride and 5.70 g
(36.17 mmol) cysteine hydrochloride were heated in 50 mL acetic
acid for 30 min. The solution turned bright yellow. The reaction
mixture was kept in the fridge overnight. The solid was collected by
filtration and washed with acetic acid. The solid was further washed
by suspending it in chloroform, stirring for 1 h and filtering of the
chloroform 3 times, yielding a bright yellow powder. The powder was
further purified by HPLC yielding 4.01 g (17.41 mmol, 48 %) of a yellow
powder.
1H NMR (300 MHz, DMSO-d6) δ [ppm] = 8.52 (ddd, JH,H = 4.8, 1.8, 0.9 Hz,
1H, HAr), 7.84 (ddd, JH,H = 8.1, 7.4, 1.9 Hz, 1H, HAr), 7.73 (dt, JH,H = 8.1,
1.0 Hz, 1H, HAr), 7.32 (ddd, JH,H = 7.4, 4.9, 1.1 Hz, 1H, HAr), 4.21 (dd, JH,H
= 7.5, 5.0 Hz, 1H, CαH), 3.48–3.22 (m, 2H, CH2).
ESI – MS: 231.0 [M+H]+.
The S(o-thiopyridinyl)cysteine NCA (5 c) could not be completely pu-
rified. It is not stable, as the pyridine can act as an initiator in the NCA
polymerization, which was confirmed by polymerizing Lys(Z)NCA with
pyridine.
S-Phenylsulfonyl-L-cysteine (Cys(SO2Ph)) 6 b
3 g (17.08 mmol) cysteine hydrochloride monohydrate was dissolved
in 17 mL 2 M hydrochloric acid and cooled to 5 °C in an ice bath.
1.18 g (17.08 mmol) Sodium nitrite was dissolved in 10 mL milli-Q water,
cooled and added to the cysteine solution via a dropping funnel. The so-
lution turned red. After stirring for 80 min at 5 °C, 5.61 g (34.16 mmol)
sodium benzylsulfinate was added. After 2 h discoloration of the solu-
tion was observed and a precipitate formed. Another 1.40 g (8.54 mmol)
sodium benzylsulfinate was added and the mixture was stirred for 2
more hours and stored at 4 °C overnight. The solid was collected by fil-
tration and washed two times with ice-cold milli-Q water. The brown
solid was recrystallized from water, washed with ethanol and diethyl
ether and dried in vacuo to yield 2.14 g (8.20 mmol, 48 %) of a slightly
yellowish solid.
1H NMR (400 MHz, D2O/TFA-d) δ [ppm] = 7.90 - 7.81 (m, 2H, HAr), 7.69
- 7.61 (m, 1H), 7.58 - 7.48 (m, 2H, HAr), 4.27 (dd, JH,H = 7.3, 4.6 Hz, 1H,
CαH), 3.48 (dd, JH,H = 15.8, 4.6 Hz, 1H, CH2), 3.39 (dd, JH,H = 15.8, 7.3 Hz,
1H, CH2).
13C NMR (101 MHz, D2O) δ [ppm] = 171.52 (COOH), 144.52 (CArS), 137.88
(CAr), 132.51 (CAr), 129.69 (CAr), 54.71 (CH2), 36.97 (Cα).
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S-Phenylsulfonyl-L-cysteine NCA (Cys(SO2Ph) NCA) 6 c
In an inert gas atmosphere 5 g (19.13 mmol) phenyl cysteine thiosul-
fonate was suspended in 50 mL abs. THF and heated to 70 °C. Diphos-
gene (2.08 mL, 17.22 mmol) was added in three steps every 20 min and
the suspension was stirred for another 2 h, in which all solid dissolved.
The solution was allowed to cool down and THF was removed, by pass-
ing dry nitrogen through the solution overnight. The crude product was
dried in vacuo and recrystallized 3 times by dissolving in THF and pre-
cipitating with hexane, yielding 4.20 g (14.73 mmol, 77 %) of a slightly
yellow powder.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.23 (s, 1H, NH), 7.95 (d, JH,H =
7.6 Hz, 2H, HAr), 7.81 (t, JH,H = 7.4 Hz, 1H, HAr), 7.71 (t, J=7.7Hz, 2H, HAr),
4.73 (t, J=5.6Hz, 1H, CαH), 3.49 (d, J=5.6Hz, 2H, CH2).
13C NMR (101 MHz, DMSO-d6) δ [ppm] = 169.29 (Cα(CO)O), 151.47
(NH(CO)O), 143.59 (CArS), 134.69 (CAr), 130.02 (CAr), 126.69 (CAr), 56.52
(CH2), 36.04 (Cα).
FD – MS: 287.0 [M]+.
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6.6 S U P P O R T I N G I N F O R M AT I O N
6.6.1 Polymerization of Activated Cysteine NCAs
DMF was purchased dry over molecular sieve. It was further purified
by stirring over molecular sieve (3 Å) and BaO. It was then distilled and
stored at −80 ◦C. Neopentylamine was dried over CαH2 and fractionally
distilled. GPC in hexafluoro 2-propanol (HFIP) was performed with 3 g l−1
potassium trifluoroacetate (KTFA) at 40 °C. The columns were packed
with modified silica (PFG columns, particle size: 7 µm, porosity: 100 Å
and 1000 Å). A refractive index detector (G 1362A RID, Jasco) was used
to detect the polymer. Molecular weights were calculated using a calibra-
tion performed with Polymethly methacrylate PMMA standards (Poly-
mer Standards Services GmbH).
6.6.2 Typical Polymerization Procedure
500 mg (1.74 mmol) Cys(SO2Ph) NCA were transferred in a Schlenk tube
under nitrogen counterflow. 4 ml dry DMF were added. A stock solution
of the initiator was prepared immediately prior to use: 1 ml dry DMF and
8.20 µL (6.07 mg, 0.07 mmol) neopentylamine were added in a glass vial.
0.5 ml of this solution was added via syringe to initiate the polymer-
ization. A steady flow of dry nitrogen was sustained during the poly-
merization, preventing any impurities from entering the Schlenk tube,
while ensuring the escape of produced CO2. The progress of the poly-
merization was monitored via infrared (IR) spectroscopy by the disap-
pearing NCA carbonyl peaks at 1858 cm−1 and 1788 cm−1. Samples were
taken using a nitrogen flushed syringe trough a septum. The polymer
was precipitated after 3 days in a mixture of cold diethylether. The sus-
pension was centrifuged (4500 rpm, 15 min, 0-10 °C) and decanted. This
procedure was repeated twice yielding 134 mg of a colorless to slightly
yellow solid.
Table 6.1: Analytical data of cysteine homopolymers.
polymer Mn/g mol−1 Ð
PCys(oNTP) 8000 2.10
PCys(PFTP) 1800 1.84
PCys(oFTP) 6700 1.59
PCys(SO2Ph) 6600 1.16
The broad distribution of the disulfide-based polymers can be
explained by chain termination due to attack of the amine chain end
with the activated disulfide. The resulting thiol can initiate further poly-
merization. This leads to broad molecular weight distributions. Less ac-
tivated disulfides (i.e. more electron rich aromates) lead to a decrease of
the termination reaction and more defined polymers.
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Figure 6.1: Side reaction resulting in chain termination.
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Figure 6.2: GPC plot of PCys(oNTP).
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Figure 6.3: GPC plot of PCys(PFTP).
80 E X P L O R I N G R E A C T I V E C Y S T E I N E N C As
Toluene
N
H
S
S
O
F
F
F
F
F
N
H O
S
S
NO2
Toluene
Toluene
N
H
S
S
O
F
Figure 6.4: GPC plot of PCys(oFTP).
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Figure 6.5: GPC plot of PCys(SO2Ph).
7
R E T H I N K I N G C Y S T E I N E P R O T E C T I V E G R O U P S :
S - A L K Y L S U L F O N Y L - L - C Y S T E I N E S F O R
C H E M O S E L E C T I V E D I S U L F I D E F O R M AT I O N
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A B S T R A C T : The ability to reversibly cross-link proteins and peptides
grants the amino acid cysteine its unique role in nature as well as in pep-
tide chemistry. We report a novel class of S-alkylsulfonyl-L-cysteines
and corresponding α-amino acid N-carboxyanhydrides (NCAs) thereof
for peptide synthesis. The S-alkylsulfonyl group is stable against
amines and thus enables its use under Fmoc chemistry conditions and
the controlled polymerization of the corresponding NCAs yielding well-
defined homo- as well as block co-polymers. Yet, thiols react immedi-
ately with the S-alkylsulfonyl group forming asymmetric disulfides.
Therefore, we introduce the first reactive cysteine derivative for efficient
and chemoselective disulfide formation in synthetic polypeptides, thus
bypassing additional protective group cleavage steps.
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7.1 I N T R O D U C T I O N
The incorporation of cysteines into peptides by solid phase peptide syn-
thesis (SPPS) or during polymerization of α-amino acid N-carboxyanhy-
drides (NCAs) commonly relies on the protection of the thiol group in
order to avoid side reactions. Numerous protective groups enable pep-
tide synthesis or NCA polymerization (e.g., benzyl, trityl or acetamido-
methyl thioethers along with tert-butyl disulfides),[179] but in order to
retain the free thiol group for further peptide modification, a cleavage
step is mandatory.
For rapid and large-scale synthesis of synthetic polypeptides in
the field of NCA polymerization,[35,49–53,55] a variety of reactive amino
acid derivatives as well as the corresponding NCAs have been es-
tablished and implemented in functional polypeptides, providing a
remarkable chemical diversity using post polymerization modifica-
tion reactions.[21,58] This chemical toolbox covers multiple functional
groups for chemoselective modification, for example, alkylation,[312]
azide–alkyne,[314] thiol-ene and -yne reactions.[311,313,317] However,
none of them can be applied to direct chemoselective disulfide bond
formation. Regarding the conjugation of synthetic peptides to proteins
or synthetic polymers,[188,377] a protective group for thiols combining
stability during peptide synthesis with the ability to form disulfide
bonds by a chemoselective reaction[181,378] appears favorable. Disulfide
bond formation is particularly attractive for a variety of biological
and medical applications since disulfides are stable extracellularly
but cleavable inside cells.[159] Although this characteristic may not be
required in all cases, the bioreversibility of disulfide bonds appears
to be highly desirable in the development of vaccines, drug or gene
delivery systems.[103,138,163]
Until now, disulfide formation is accomplished either by oxidation
of thiols,[164,274,276] which is time consuming, incomplete and does
not allow the formation of asymmetric disulfides, or by the forma-
tion of reactive thiols (chlorinated thiol and nitrosothiols),[292,294] disul-
fides like 2- or 4-nitrophenyl (Nps),[215,379] 2- or 4-pyridyl ([212,214]
and 3-nitro-2-pydidyl (Npys)[223,308]) or S-phenylsulfonates in the fi-
nal polypeptide.[290,322] Activated thiols or disulfides, however, share
a drawback, consisting of their limited stability against hydroly-
sis and aminolysis which prohibits their use in peptide synthesis
and NCA polymerization. Therefore, a protective group for thiols,
which combines stability during peptide synthesis with the ability to
form disulfide bonds by a chemoselective reaction, appears highly
desirable.[181,378] We have recently reported that S-phenylsulfonyl cys-
teines show better, but insufficient, stability towards amines com-
pared to activated disulfides in NCA polymerization.[321] The crit-
ical challenge is to achieve the delicate balance between stability
against amine and hydroxyl nucleophiles and reactivity towards thiols.
7.2 R E S U LT S A N D D I S C U S S I O N 83
7.2 R E S U LT S A N D D I S C U S S I O N
In this work we introduce the use of a novel class of S-alkylsulfonyl-
L-cysteines (Cys(SO2R)) (Figure 7.1) to address this issue. The S-alkyl-
sulfonyl groups provide steric hindrance in conjunction with a + I effect,
which enhances electron density at the S-alkylsulfonyl group ensuring
stability in contrast to other activated disulfides, while remaining highly
reactive towards thiols as demonstrated in this work.
Figure 7.1: S-ethylsulfonyl-L-cysteine (Cys(SO2Et)) 2 a and S-isopropylsulfonyl-
L-cysteine (Cys(SO2iPr)) 2 b.
The synthesis of the thiosulfonates 2 a and 2 b was adapted from the
work of Hart et al.[371,372] (Scheme 7.1) where the S-nitrosocysteine 1 is
generated in situ and reacts with either ethanesulfinic or isopropane-
sulfinic acid sodium salt forming the corresponding thiosulfonate 2 and
N-hydroxyalkylsulfonamide in a 1:1 ratio.[290,323] The stereochemistry is
fully preserved during the process as confirmed by X-ray crystallogra-
phy.
Scheme 7.1: Synthesis of Cys(SO2R) 2.
7.2.1 Evaluation of the S-Alkylsulfonyl Group towards Nucleophiles
The reactions of the S-alkylsulfonates in the presence of various nucle-
ophiles were evaluated in detail. From a mechanistic point of view, the
sulfenyl sulfur is the relevant moiety in a nucleophilic attack[380,381] (Fig-
ure 7.2 A) while the protective group is removed as a sulfinate. Deviating
reactivity is only relevant in electron-deficient halogenated derivatives,
in an attack on the sulfinyl sulfur atom.[380] Both amino acids were sub-
jected to buffers of varying pH and amine containing organic solutions
(see Supporting Information for details). The apparent rate constants[370]
for hydrolysis were found to be in the range of 10−3 s−1 under alkaline
conditions and in the range of 10−9 s−1 in mildly acidic media (Table 7.2).
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Stability against
N-nucleophiles...
... in combination
with reactivity
towards
S-nucleophiles
The stability towards aminolysis was investigated by using nucle-
ophiles such as neopentylamine (pKa 10.2)[382,383] and hexylmethy-
lamine (pKa 10.5)[384] as potential initiators in NCA ring-opening poly-
merization (ROP), along with morpholine (pKa 8.5)[383] and piperidine
(pKa 11.1)[383] as possible deprotection reagents in peptide synthesis.
The apparent rate constants were found to be temperature dependent
ranging between 10−6 s−1 to 10−7 s−1 (20 ◦C) and 10−8 s−1 to 10−9 s−1 at
(−10 ◦C, Table 7.3). As displayed in Figure 7.2 B, the plot of the rate con-
stants for all examined nucleophiles (kEtNu vs. k
iPr
Nu) shows good corre-
lation of the kinetic data, the slope of the correlation line being slightly
below one (0.73). This result confirms that both protective groups be-
have alike when exposed to O- and N-nucleophiles, with the S-isopro-
pylsulfonyl group providing enhanced stability. Ultimately, both protec-
tive groups are stable against primary and secondary amines; this en-
ables their use in NCA polymerization.
Figure 7.2: Reactivity of Cys(SO2R) 2 towards nucleophiles: A) Attack of
hard and soft nucleophiles on 2 with R’ = neopentylamine,
hexylmethylamine, morpholine, piperidine, 1-butanamine; R” = d-
penicillamine, cysteamine, glutathione, 1-hexanethiol. B) Plot of
log(kNu) for 2 under alkaline hydrolysis (red) and aminolysis (blue)
conditions at different temperatures.
In contrast, reaction rates for thiol nucleophiles are known to surpass
the rates for OH– ions and nitrogen bases by several orders of
magnitude.[324] To confirm the superior thiol-reactivity of 2, reactions in
water with a series of thiol-containing biomolecules (resulting in com-
pounds 3 I–III, see Scheme 7.2) were monitored by 1H nuclear magnetic
resonance (NMR) spectroscopy as illustrated in Figure 7.3.
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Scheme 7.2: Reactions of Cys(SO2R) 2 with thiols of varying pKa[385–387] yielding
asymmetric disulfides 3 I–III, annotations of 1H NMR spectra in Fig-
ures 7.3, 7.4 and 7.9 in the Supporting Information (grey).
Figure 7.3: 1H NMR spectra after reaction of: A) Cys(SO2Et) 2 a, and B) Cys(SO2iPr)
2 b with various thiols (I d-penicillamine, II: cysteamine, III: glu-
tathione) forming the corresponding asymmetric disulfide 3. The
fully reacted protective group is highlighted and annotations are
given in Scheme 7.2.
The conversions of 2 a (Figure 7.3 A) and 2 b (Figure 7.3 B) yield the
same mixed disulfide for each thiol compound I–III. The signals of the
S-alkylsulfonyl group of the intact, protected cysteine (c–f ) fully van-
ished after 60 s (minimum time to perform the 1H NMR spectroscopy
experiment), while signals corresponding to the converted protective
group (c’–f’) are present, along with the signals corresponding to the
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S-nucleophiles
mediates reactivity.
asymmetric disulfides 3I–III. Differences in reactivity of the individual
thiols can be expected, but could not be resolved at this time frame. Ul-
timately, mass spectrometry confirmed the sole presence of the mixed
disulfides in the absence of traceable side products. The observed rapid
and quantitative conversion of 2 with thiols is in line with reported rate
constants of thiosulfonates (e.g., phenylthiosulfonate)[370] in the range
of 105 mol−1 s−1 to 107 mol−1 s−1. The selective reactivity of the S-alkyl-
sulfonyl group towards thiols (1-hexanethiol, pKa 10.7)[388] was evalu-
ated in the presence of a competing N-nucleophile (1-butanamine, pKa
10.6)[389] see Figure 7.4 A and Figure 7.9 A in the Supporting Informa-
tion). The sole presence of an amine does not result in a conversion as
discussed above, though the cysteine sulfur atom is readily attacked by
the thiol to yield S-hexane-L-cysteine (4). This effect is consistently ob-
served, even if the amino acid 2 is exposed to both nucleophiles simul-
taneously with excess amine.
7.2.2 DFT Calculations
For a deeper understanding of the experimental data, density func-
tional theory (DFT) calculations were carried out to estimate the rele-
vant frontier orbitals in a nucleophilic attack (Table 7.4 in the Support-
ing Information). According to the principles outlined by Pearson and
Songstad[325,326,390] soft nucleophiles exhibit highest occupied molecu-
lar orbitals (HOMOs) of higher energy levels compared to hard nucle-
ophiles, with the reciprocal trend for lowest unoccupied molecular or-
bitals (LUMOs) of electrophiles. This classifies hexanethiolate as a soft
nucleophile and butaneamine as a hard nucleophile.
The LUMO of the S-alkylsulfonyl-L-cysteines is located at the S-alkyl-
sulfonyl group (ELUMO = 1.3538 eV for 2 a and ELUMO = 1.5453 eV for
2 b). However, the accessibility of the sulfonyl sulfur is highly hindered
by the steric demand of the oxygen atoms and the alkyl chain, there-
fore the soft cysteine sulfur engages in a nucleophilic attack.[380,381,391]
The HOMOs of both nucleophiles are located on the heteroatoms of the
nucleophiles. The active S-nucleophile in question is the dissociated
thiol, although considering the pKa and the aprotic conditions only a
small fraction is present as the anion. However, thiolates are discussed
as the relevant nucleophiles compared to thiols[390,392] and fast reaction
rates are sufficient to drive the reaction.[370] Further the non-protonated
amine is taken into consideration, since protonated amines react as weak
acids rather than as nucleophiles. As illustrated in Figure 7.4 B and Fig-
ure 7.9 B in the Supporting Information, the energy gap between the
LUMO and the HOMO of the amine significantly exceeds the gap to the
HOMO of the thiol. A smaller energy gap, however, facilitates an or-
bital controlled nucleophilic reaction, thus the DFT calculations are in
line with the stated conversion rates. In conclusion, under the reported
conditions, the S-alkylsulfonyl group rapidly engages in reactions with
thiol nucleophiles,[370] while competing hydrolysis and aminolysis are
suppressed.
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Figure 7.4: A) Detail on the 1H NMR spectra of the reaction of Cys(SO2iPr) 2 b with
1-butanamine and 1-hexanethiol forming exclusively S-hexane-L-
cysteine 4. B) DFT calculations of HOMO and LUMO of Cys(SO2iPr) 2 b
and HOMOs of butylamine (left) and hexanethiol (right).
7.2.3 Polypeptide Synthesis
The main need for protected amino acids is in peptide synthesis as well
as ring-opening polymerization of NCAs. Employing Cys(SO2R) s in pep-
tide synthesis according to the N-(9-Fluorenylmethoxycarbonyl) (Fmoc)
strategy requires only short deprotection times with N-nucleophiles,
Scheme 7.3: Synthesis of Cys(SO2R) NCA 5 and polymerization with neopenty-
lamine as initiator 6 (left) and synthesis of Fmoc-Cys(SO2R) 7 and the
resulting dipeptide 8 (right).
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the nucleophilic
ring-opening
polymerization...
on the range of hours. Thus, the S-alkylsulfonyl group can be handled
at room temperature. In contrast, controlled polymerization of NCAs re-
quires several days to reach high yields for well-defined polypeptides,
which are obtained at low temperatures. Those two major pathways em-
ployed with the novel protected cysteines are shown in Scheme 7.3
The amine-initiated-controlled ROP of NCAs[37–39] derived from S-alkyl-
sulfonyl-L-cysteines is depicted in the left part of Scheme 7.3. First, the
protected amino acids 2 were transferred into the corresponding NCAs 5
by the Fuchs–Farthing method using diphosgene.[40–42] Both NCAs were
successfully polymerized with neopentylamine as initiator,[24] yielding
Cys(SO2R) homopolymers 6. The 9 equivalent methyl-protons of the
neopentylamine allow a reliable end group analysis and thus determi-
nation of repeating units by 1H NMR spectroscopy. All polymers dis-
play a narrow, symmetrical molecular weight distribution with low dis-
persity indices (Figure 7.5 and Table 7.1). To verify the integrity of the
protective group during the NCA polymerization, matrix assisted laser
desorption/ionization-time of flight (MALDI-TOF) mass spectrometry of
homopolymers was performed as demonstrated in Figure 7.6.
Figure 7.5: HFIP GPC traces of PCys(SO2Et) 6 a and PCys(SO2iPr) 6 b.
The polymer distribution in MALDI-TOF mass spectroscopy is narrow,
displaying dispersities of Ð = 1.11 for poly(S-ethylsulfonyl-L-cysteine)
(PCys(SO2Et)) and Ð = 1.14 for poly(S-isopropylsulfonyl-L-cysteine)
(PCys(SO2iPr)). The degrees of polymerization are in good agreement
with the values from the 1H NMR and gel permeation chromatography
(GPC) experiments. As can be noted from the magnification (Figure 7.6
B), initiation by impurities or termination reactions does not occur.
In addition, each chain is equipped with a terminal primary amine.
Figure 7.6 C compares the simulated peaks of PCys(SO2iPr) with the
measured spectrum revealing an identical isotope distribution due to
the natural occurrence of 32S and 34S. MALDI-TOF experiments, therefore,
clearly confirm the absence of chemical chain termination or other side
reactions due to protective group cleavage and emphasize the highly
controlled polymerization of S-alkylsulfonyl-L-cysteine NCAs.
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Table 7.1: Polymer characteristics of PCys(SO2Et) 6 a and PCys(SO2iPr) 6 b.
No. Xn Ð Mn/kg mol−1
NMR MALDI GPC MALDI GPC MALDI
6 a 13 11 1.13 1.11 6.03 2.19
28 -a 1.15 -a 11.64 -a
6 b 15 13 1.15 1.14 8.07 2.61
23 -a 1.17 -a 9.50 -a
a Longer homopolymers could not be ionized.
... and solid phase
peptide synthesis.
Figure 7.6: MALDI-TOF spectrum of PCys(SO2iPr) 6 b with a Xn, NMR = 15.
The sequential peptide synthesis with Cys(SO2R) using peptide-coup-
ling techniques as Fmoc chemistry and carbodiimide coupling[393] is illus-
trated on the right-hand side of Scheme 7.3. Both protected amino acids
(2 a and b) were converted into the corresponding Fmoc-derivatives 7
and coupled to a C-terminally protected amino acid (in this study OtBu-
alanine) to form a dipeptide 8, illustrating the use of Cys(SO2R) in pep-
tide synthesis. The synthesis in solution was chosen over a solid phase
approach to monitor the peptide coupling itself as well as the individual
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deprotection steps by 1H NMR spectroscopy. The S-alkylsulfonyl group
remained intact during the coupling procedure wit N,N-diisopropyl-
carbodiimide (DIC), the protective group removal and the workup of the
Cys(SO2R)-Ala dipeptide 8 (see Supporting Information). These findings
suggest that Cys(SO2R) is a candidate for solid phase peptide synthesis
(SPPS), although a suitable protocol needs to be established.
7.2.4 Polypeptide Conversion
Concluding, the thiol-reactivity of the S-alkylsulfonyl group in the poly-
meric state was investigated in analogy to the conversions of Cys(SO2R)
with thiols (Scheme 7.2, Figure 7.3, 7.4 and 7.9).
The homopolymer 6 b readily engages in post polymerization modifi-
cation reactions with a thiol (in this study benzylmercaptan), ultimately
resulting in an asymmetric disulfide and the corresponding sulfinate
(Figure 7.7 A). In agreement with the reactivity of the amino acids, quan-
titative conversion was observed already after 60 s. As can be noted in
Figure 7.7 B and C, signals corresponding to the polycysteine backbone
and the end-group signal remain present. Further, signals in Figure 7.7
C originating from the benzyl group as well as the sulfinate appear.
Figure 7.7: A) Scheme of the reaction of PCys(SO2iPr) 6 b with benzylmercaptan.
B) 1H NMR spectrum of 6 b with polymer-associated protective group
signal at 1.34 ppm. C) 1H NMR spectrum after conversion with ben-
zylmercaptan showing a signal at 1.08 ppm corresponding to the
fully converted protective group. D) Enlarged comparison of both
1H NMR spectra emphasizing the quantitative conversion.
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The magnification in Figure 7.7 D reveals the complete disappearance
of the polymer associated signal of the S-isopropylsulfonyl group at
1.34 ppm (e), which is replaced by the signal at 1.08 ppm (5) correspond-
ing to the reacted protective group. Therefore, Cys(SO2R) prove to be the
first reactive amino acids for direct disulfide formation applicable to
NCA polymerization, enabling the synthesis and implementation of a
new class of reactive polypeptides.[21]
7.3 C O N C L U S I O N S
We report a novel class of S-alkylsulfonyl-L-cysteine derivatives
Cys(SO2Et) and Cys(SO2iPr)[364] for chemoselective disulfide formation. The
S-alkylsulfonyl group provides stability towards amine nucleo philes,
as was confirmed experimentally as well as theoretically by DFT calcu-
lations. The Cys(SO2R) were successfully transferred into the correspond-
ing NCAs and Fmoc-derivatives and were implemented in peptide synthe-
sis by ring-opening polymerization and peptide coupling, respectively.
Moreover, instant disulfide formation of the S-alkylsulfonyl group with
thiol nucleophiles was demonstrated with both the protected amino acid
and the well-defined poly(S-alkylsulfonyl-L-cysteines).
Thus, the S-alkylsulfonyl group combines properties of a protective
and activating moiety. It is the first thiol modification that provides sta-
bility during nucleophilic ring-opening polymerization of NCAs and is
compatible with peptide coupling chemistry, while being directly ad-
dressable by thiols yielding asymmetric disulfides without additional
modification steps. Combined with the intrinsically bioreversible char-
acter of disulfides, this straightforward concept offers attractive options
for the conjugation of polypeptides to thiol-containing molecules.
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7.5 E X P E R I M E N TA L S E C T I O N
Protocols for the preparation of all compounds as well as materials, in-
strumentation details and spectra are provided in the Supporting Infor-
mation. Syntheses of compounds 5–8 were performed under an inert
nitrogen atmosphere.
7.5.1 pH Stability
To investigate the stability of the S-thiosulfonyl group, the protected
amino acids 2 a and 2 b were subjected to different pH in D2O at room
temperature and the reactions were monitored by 1H NMR spectroscopy.
Therefore, Cys(SO2Et) (6.40 mg, 30 mmol) or Cys(SO2iPr) (6.82 mg,
30 mmol) were dissolved in D2O (0.7 mL) with varying pH immediately
prior to the measurement. The pH was adjusted with a Na2HPO4)/ KH2PO4
buffer to pH 4, 6, 7, and 8 and with [D1]TFA or NaOD (40 wt % in D2O) to
a pH of 2, 10 and 13, respectively. 1H NMR spectra were recorded after
2, 30 min and 1, 3 and 6 h. The protective group was removed as ethane-
and isopropanesulfinic acid, respectively, as the corresponding anions.
The mechanism of the alkaline hydrolysis of thiosulfonates in general
is rather complex, but subsequently an intermediately formed thiolate
readily reacts with the starting thiosulfonate, resulting is a symmetri-
cal disulfide,[290,391] which was cysteine in this study. Overall hydrolysis
was evaluated relating the integral of protected amino acid signals to
the integral of removed protective group signals and thus giving the
conversion. Since the concentration of the OH– ions is approximately
constant due to the large excess of the buffer, pseudo-first order kinetic
behavior can be assumed. A plot of the logarithmic residual concentra-
tion of Cys(SO2R) (log[M0– conv.×M0])[370] over time gives a straight line
as shown in Figure 7.8 A in the Supporting Information. The apparent
pseudo-first order rate constant −k/s is given as the slope. The rate con-
stants of 2 a and 2 b at different pH are listed in Table 7.2 in the Support-
ing Information and the relation to the pH is illustrated in Figure 7.8
B.
7.5.2 Amine Stability
Stability of 2 a and 2 b was tested towards neopentylamine, hexyl-
methylamine, morpholine and piperidine at different temperatures.
The nucleophiles were present in large excess to ensure that the reaction
followed pseudo-first order kinetics. All reactions were carried out in
absolute [D6]DMSO under inert atmosphere, analyzed by 1H NMR spec-
troscopy and evaluated in the same fashion as the pH stability stud-
ies. Deuterated solvents and amines were dried prior to use. [D6]DMSO
and [D4]MeOD were dried over molecular sieve (3 Å) and filtered di-
rectly before use. Oven-dried Schlenk tubes and NMR tubes with PTFE
valves were used to prevent moisture from entering the reaction vessel.
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Samples were prepared as followed: Cys(SO2Et) (6.93 mg, 32.5 mmol) or
Cys(SO2iPr) (7.39 mg, 32.5 mmol) were dried in vacuo, overnight, and dis-
solved in dry [D6]DMSO (0.7 mL for 20 °C measurements) or a mixture of
dry [D6]DMSO and dry [D4]MeOD (0.6 mL and 0.1 mL for 0 °C and 10 °C
measurements). The NMR tubes were filled in a glove box under an ar-
gon atmosphere. Two equivalents (65.0 mmol) of the particular amine
were added, kept at the given temperature and 1H NMR spectra were
measured at 1, 6, 24 h, followed by every 24 h for one week. The long
time period was chosen for evaluating the stability of the protective
group in regard to NCA polymerizations, which are typically conducted
at low temperatures for several days. The pseudo-first order rate con-
stants were determined as described above and are given in Table 7.3 in
the Supporting Information.
7.5.3 Reactions with Thiols
Aside from the stability of the S-alkylsulfonyl group reactivity against
thiols was also investigated. Cys(SO2R) (1.0 equiv) and 1.1 equiv of a
thiol component (see Scheme 7.2, Figures 7.3, 7.4 and 7.9) were sepa-
rately dissolved in D2O (0.35 mL each). Immediately prior to the mea-
surement both solutions were mixed and the reaction progress was mon-
itored by 1H NMR spectroscopy. Cys(SO2R) (1.0 equiv) was dissolved in
[D6]DMSO (0.70 mL) and butylamine (1.0 equiv) or hexanethiol (1.0 equiv)
were added. In the sample containing hexanethiol a colorless precipi-
tate formed immediately. Adding [D1]TFA dissolved the precipitate and
the 1H NMR spectrum was measured. Complete conversion and pres-
ence of S-(hexylsulfanyl)-L-cysteine (4) could be observed after 1 min
(minimal time for measurement). The sample containing butylamine re-
mained a colorless solution and the reaction was quenched after 15 min
by adding [D1]TFA. 1H NMR spectroscopy revealed fully preserved signals
of 2, thus no reaction with butylamine occurred. Addition of 1.0 equiv
of both butylamine and hexanethiol also immediately resulted in a col-
orless precipitate. The precipitate was identified as S-(hexylsulfanyl)-L-
cysteine (4) by 1H NMR spectroscopy and electrospray ionization mass
spectrometry (ESI-MS). No adduct of the amine was observed.
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7.6 S U P P O R T I N G I N F O R M AT I O N
7.6.1 Materials and Instrumentation
All chemicals were purchased from Sigma Aldrich and used as received
unless otherwise noted. Tetrahydrofurane THF and hexane were distilled
from Na/K and ethyl acetate and dichloromethane (DCM) from CaH2. N,N-
dimethyl formamide (DMF) was purchased dry over molecular sieve. It
was further purified by stirring over molecular sieve (3 Å) and BaO. It
was then distilled and stored at −80 ◦C under exclusion of light. Prior
to use DMF was degassed in vacuo to remove traces of dimethylamine.
Neopentylamine (purchased from TCI Europe) and hexylmethylamine
were dried over NaOH followed by distillation, morpholine was distilled
from Na. Cysteine was purchased from OPREGEN, diphosgene from
Alfa Aesar, hexafluoro 2-propanol (HFIP) was purchased from
Fluorochem and deuterated solvents from Deutero GmbH.
1H and 13C NMR spectra were recorded on a Bruker Avance II HD 400 at
a frequency of 400 and 101 MHz respectively. 1H NMR spectra were also
recorded on a Bruker Avance III HD 300 at 300 MHz. Two-dimensional
NMR spectra as 1H diffusion ordered spectroscopy (DOSY), correlation
spectroscopy (COSY) and heteronuclear single-quantum correlation
spectroscopy (HSQC) were recorded on a Bruker Avance III HD 400 at
400 MHz. All spectra were recorded at room temperature (25 ◦C) and cal-
ibrated on solvent signals.[394] Crystallographic data were collected on
a STOE IPDS 2T diffractometer using graphite monochromated Mo Kα
radiation (λ= 0.710 69 Å). Lorentz and polarisation correction was imple-
mented and the structure was solved by direct methods (SIR-2004)[395]
and refined (SCHELXL-2014).[396] Hydrogen atoms were refined isotrop-
ically assuming riding motion, other atoms were refined anisotropically.
Crystallographic data reported in this publication has been deposited
with the Cambridge Crystallographic Data Centre (CCDC) and are pro-
vided free of charge. Supplementary publication numbers and further
details are given with the characterization data.
Electrospray ionization mass spectrometry (ESI-MS) was performed
on a Micromass Q-TOF-Ultima spectrometer. Melting points were mea-
sured using a Mettler FP62 melting point apparatus at a heating rate of
1 ◦C min−1. Preparative reverse phase-HPLC was performed with a Jasco
LC-4000 series system equipped with a VariTide RPC column (PL1E12-
5A05, 250 x 21.2 mm) run at a flow of 10.0 ml min−1 and loaded with
a 2 ml injection loop. The system was operated and samples analyzed
with ChromNAV FC software (version 2.0). The UV-detector was run at
a wavelength of 214 nm. Gel permeation chromatography (GPC)was per-
formed with HFIP containing 3 g l−1 potassium trifluoroacetate (KTFA) as
eluent at 40 ◦C and a flow rate of 0.8 ml min−1. The columns were packed
with modified silica (PFG columns particle size: 7 µm, porosity: 100 Å
and 1000 Å). Polymethly methacrylate PMMA standards (Polymer Stan-
dards Services GmbH) were used for calibration and toluene was used
as internal standard. A refractive index detector (G1362A RID) and an
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UV/Vis detector (at 230 nm unless otherwise stated; Jasco UV-2075 Plus)
were used for polymer detection.
Matrix assisted laser desorption ionization time of flight (MALDI-TOF)
mass spectra[397] were recorded using a Bruker Reflex II MALDI-TOF
mass spectrometer equipped with a 337 nm N2 laser. Acceleration of
the ions was performed with pulsed ion extraction (PIE, Bruker) at a
voltage of 20 kV. The analyzer was operated in reflection mode and
a microchannel plate detector was used. Mass spectra were processed
by the X-TOF 5.1.0 software (Bruker). A solvent free sample prepa-
ration was performed using trans-2-[3-(4-tertbutylphenyl)-2-methyl-2-
propenylidene]malononitrile (DCTB) as the matrix and sodium trifluo-
roacetate NaTFA as the cationizing salt. Calibration was carried out us-
ing a C60/C70 fullerene mixture. Spectra were analyzed and simulated
using mMass. Density functional calculations were performed with the
ORCA[398] series of programs. The B3LYP[399] formulation of density
functional theory was used employing the Def2-SVP[400] basis set. Sol-
vent modeling were simulated by COSMO[401] and the relative correc-
tion was performed by ZORA.[402,403] For accelerated calculations the
RIJCOSX-approximation[404,405] with the supplementary basis set Def2-
SVP/J[406] was used. Illustration of the frontier orbitals was performed
by the ChemCraft software, isosurface parameters were kept constant at
0.1 a. u.
7.6.2 Synthetic Procedures
Ethanesulfinic acid sodium salt
A solution of sodium sulfite (391.98 g, 3.11 mol) in water (800 mL) was
heated to 80 °C. Ethanesulfonyl chloride (147.40 mL, 199.30 g, 1.55 mol)
and sodium carbonate (329.63 g, 3.11 mol) were added simultaneously
while significant quantities of CO2 evolved. The reaction mixture was
stirred for one hour at 80 °C, afterwards water was removed in vacuo
at 60 °C. The resulting solid was suspended in methanol and filtered.
Evaporation of methanol gave ethanesulfinic acid sodium salt (153.54 g,
1.32 mol, 85 %) as a colorless solid.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 1.79 (q, 3JH,H = 7.6 Hz, 2H, – CH2 – ),
0.90 (t, 3JH,H = 7.6 Hz, 3H, – CH3).
Propane-2-sulfinic acid sodium salt
The synthesis was carried out analogous to the ethanesulfinic acid
sodium salt using sodium sulfite (88.23 g, 700 mmol), propane-2-sulfonyl
chloride (39.29 mL, 49.91 g, 350 mmol) and sodium carbonate (74.19
g, 700 mmol). Purification yielded propane-2-sulfinic acid sodium salt
(40.56 g, 312 mmol, 89 %) as a colorless solid.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 1.59 (hept., 3JH,H = 6.9 Hz, 1H,
–– CH – ), 0.87 (d, 3JH,H = 6.9 Hz, 6H, – (CH3)2).
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S-ethylsulfonyl-L-cysteine (Cys(SO2Et)) 2 a
An ice-cold solution of sodium nitrite (5.94 g, 86 mmol) in degassed
water (45 mL) was slowly added to a stirred solution of L-cysteine hy-
drochloride (13.57 g, 86 mmol) in previously degassed 2 N HCl (90 mL)
at 0 °C. After 1 h, ethanesulfinic acid sodium salt (20.00 g, 172 mmol)
was added to the deep red solution and was stirred for 2 h. Additional
sodium ethanesulfinate (5.00 g, 43 mmol) was added and eventually
a colorless solid precipitated. The reaction mixture was stirred at 0 °C
overnight. The precipitate was filtered off and the pH of the colorless
filtrate was adjusted with 2 N NaOH to pH 4-5, resulting in additional col-
orless solid precipitating. The filtrate was allowed to stand at 4 °C un-
til precipitation was complete. The combined precipitates were washed
with MeOH to remove residual sulfinate and dried in vacuo yielding
Cys(SO2Et) (5.03 g, 24 mmol, 27 %) as a colorless, crystalline solid. Crystal
Structure (CCDC-1440861): colorless platelett from H2O (0.026 × 0.280 ×
0.550 mm), monoclinic space group P 21, refinement: wR2 = 0.1223 (R1 =
0.0467 for observed reflections, 0.0509 for all reflections), flack parame-
ter x = -01(1), crystal structure contains two independent molecules with
slightly different conformations.
1H NMR (400 MHz, DMSO-d6/ TFA-d) δ [ppm] = 4.34 (t, 3JH,H = 6.4 Hz,
3JH,H = 6.0 Hz, 1H, α– H), 3.66 (dd, 2JH,H = 14.4 Hz, 3JH,H = 6.0 Hz, 1H,
– CHH – S), 3.62 (q, JH,H = 7.2 Hz, 2H, – CH2 – SO2), 3.53 (dd, 3JH,H = 14.4 Hz,
3JH,H = 6.4 Hz, 1H, – CHH – S), 1.30 (t, 3JH,H = 7.2 Hz, 3H, – CH3).
13C NMR (101 MHz, DMSO – d6/ TFA – d) δ [ppm] = 168.88 ( – COO), 56.27
( – CH2SO2), 51.84 ( – CHN), 34.79 ( – CH2S), 8.30 ( – CH3).
ESI – MS: m/z = 214.03 [M+H]+, (calc. 213.28 g mol-1); 236.01 [M+Na]+, (calc.
236.15 g mol-1).
S-isopropylsulfonyl-L-cysteine (Cys(SO2iPr)) 2 b
The synthesis was carried out analogous to 2 a using sodium nitrite
(11.60 g, 168 mmol), L-cysteine hydrochloride (26.50 g, 168 mmol) and
propane-2-sulfinic acid sodium salt (43.30 g, 465 mmol). The purification
yielded Cys(SO2iPr) (8.78 g, 39 mmol, 23 %) as a colorless, crystalline solid.
Crystal Structure (CCDC-1440862): colorless needle from H2O (0.060 ×
0.200× 0.630 mm), monoclinic space group C 2, refinement: wR2=0.1794
(R1=0.0639 for observed reflections, 0.0805 for all reflections), flack pa-
rameter x = -014(17), crystal structure contains two independent
molecules with slightly different conformations.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 4.34 (t, 3JH,H = 6.0 Hz, 1H, α– H),
3.76 (hept, JH,H = 6.7 Hz, 1H, –– CH – SO2), 3.65 (dd, 2JH,H = 14.4 Hz,
3JH,H = 6.0 Hz, 1H, – CHH – S), 3.54 (dd, 2JH,H = 14.4 Hz, 3JH,H = 6.2 Hz,
1H, – CHH – S), 1.35 (d, 3JH,H = 6.7 Hz, 6H, – (CH3)2).
13C NMR (101 MHz, DMSO – d6) δ [ppm] = 169.08 ( – COO), 63.04 ( – CHSO2),
52.18 ( – CHN), 35.29 ( – CH2S), 16.39-16.12 (( – CH3)2).
ESI – MS: m/z = 228.04 [M+H]+, (calc. 227.30 g mol-1); 250.01 [M+Na]+, (calc.
249.86 g mol-1).
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S-ethylsulfonyl-L-cysteine N-carboxyanhydride (Cys(SO2Et) NCA) 5 a
Dried Cys(SO2Et) (7.00 g, 32.82 mmol) was suspended in absolute THF
(100 mL) and heated to 70 °C. Diphosgene (3.60 mL, 5.84 g, 29.52 mmol)
was slowly added and the suspension was heated for an additional 4 h.
Dry nitrogen was bubbled through the reaction mixture overnight into
a gas washing bottle with an aqueous KOH solution to remove excess
diphosgene, HCl and most of the solvent. The remaining solvent was re-
moved in vacuo and the residue was dissolved in 100 mLabsolute ethyl
acetate. Any insoluble compounds were removed by filtration avoiding
contact with air and the NCA was precipitated by adding 800 mLabso-
lute hexane. The recrystallization of the product was repeated two more
times yielding Cys(SO2Et) NCA (6.43 g, 26.87 mmol, 82%) as a colorless,
crystalline powder (m.p. 113–115 °C).
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.32 (s, 1H, – NHCO), 4.86 (td,
3JH,H = 6.0 Hz, 3JH,H = 4.8 Hz, 3JH,H = 1.6 Hz, 1H, α– H), 3.64 (dd, 2JH,H
= 14.4 Hz, 3JH,H = 4.8 Hz, 1H, – CHH – S), 3.62 (q, 3JH,H = 7.2 Hz, 2H,
– CH2 – SO2), 3.57 (dd, 2JH,H = 14.4 Hz, 3JH,H = 6.4 Hz, 1H, – CHH – S), 1.29
(t, 3JH,H = 7.2 Hz, 3H, – CH3).
13C NMR (101 MHz, DMSO – d6) δ [ppm] = 169.58 (CNOO), 151.68 ( – COO),
56.99 ( – CHSO2), 56.16 ( – CHN), 36.00 ( – CH2S), 8.24 ( – CH3).
S-isopropylsulfonyl-L-cysteine N-carboxyanhydride (Cys(SO2iPr) NCA) 5 b
The synthesis of Cys(SO2iPr) NCA was carried out under identical condi-
tions as 5 a employing Cys(SO2Et) (6.04 g, 26.57 mmol) and diphosgene
(4.00 mL, 6.56 g, 33.14 mmol). Recrystallization yielded Cys(SO2iPr) NCA
(4.64 g, 18.3 mmol, 69 %) as a colorless, crystalline powder (m.p. 98–
100 °C).
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.33 (s, 1H, – NHCO), 4.84 (td,
3JH,H = 5.4 Hz, 3J = 1.4 Hz, 1H, α– H), 3.75 (hept, JH,H = 6.6 Hz, 1H,
–– CH – SO2), 3.59 (ddd, 2JH,H = 14.4 Hz, 3JH,H = 5.6 Hz, 3JH,H = 5.1 Hz,
2H, – CH2 – S), 1.33 (dd, 3JH,H = 6.6 Hz, 3JH,H = 0.9 Hz, 6H, – (CH3)2).
13C NMR (101 MHz, DMSO – d6) δ [ppm] = 169.52 (CNOO), 151.65 ( – COO),
62.69 ( – CHSO2), 52.12 ( – CHN), 36.18 ( – CH2S), 15.90-15.87 (( – CH3)2).
poly(S-ethylsulfonyl-L-cysteine) (PCys(SO2Et)) 6 a
Cys(SO2Et) NCA (107 mg, 447 µmol) was transferred into a Schlenk tube
under dry nitrogen counter flow. Absolute DMF (3 mL) and absolute
neopentylamine (1.74 µL, 1.30 mg, 15 µmol) were added and the ves-
sel was cooled to -10 °C. A steady flow of dry nitrogen was sustained
during the polymerization, preventing any impurities from entering the
Schlenk tube, while ensuring the escape of produced CO2. The progress
of the polymerization was monitored via IR spectroscopy by the dis-
appearing NCA carbonyl peaks intensities at 1858 cm−1 and 1788 cm−1.
Samples were taken using a nitrogen flushed syringe trough a septum.
The polymer was precipitated after 70 % conversion in a mixture of
cold diethyl ether and tetrahydrofurane (THF) (5:1 v/v) to solubilize
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and remove remaining NCA. The suspension was centrifuged (4500 rpm,
15 min, 0–10 °C) and decanted. This procedure was repeated twice con-
cluding with pure diethyl ether yielding poly(S-ethylsulfonyl-L-cysteine)
(65 mg, 73 %) as a colorless to slightly yellow solid.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 8.76 (m, 1nH, – NHCO),
4.68 (m, 1nH, α– H), 3.63-3.42 (m, 4nH, – CH2 – SSO2 – CH2 – ), 1.30 (t, 3nH,
– CH3), 0.85 (s, 9H, – (CH3)3).
poly(S-isopropylsulfonyl-L-cysteine) (PCys(SO2iPr)) 6 b
Polymerization of PCys(SO2iPr) was conducted under identical conditions
as synthesis of 6 a. Cys(SO2iPr) NCA (146 mg, 576 µmol) was polymerized
using dry neopentylamine (4.50 µL, 3.35 mg, 38 µmol) in absolute DMF
(3 mL) at -10 °C yielding poly(S-isopropylsulfonyl-L-cysteine) (80 mg,
80 %) after purification.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 8.72 (m, 1nH, – NHCO),
4.65 (m, 1nH, α– H), 3.64 (m, 1nH, –– CH – SO2), 3.47-3.33 (m, 2nH, – CH2 – S),
1.33 (d, 6nH, – (CH3)2), 0.84 (s, 9H, – (CH3)3).
N-(9-Fluorenylmethoxycarbonyl)-S-ethylsulfonyl-L-cysteine
(Fmoc-Cys(SO2Et)) 7 a
Dried Cys(SO2Et) (621 mg, 2.91 mmol) were suspended in absolute DCM
(2 mL) and cooled to 0°C. Absolute DIPEA (545 µL, 414 mg, 3.20 mmol)
and Fmoc – OSu (983 mg, 2.91 mmol) were added under dry nitrogen counter
flow. The reaction mixture was stirred at room temperature for 4 h fol-
lowed by removal of the solvent under reduced pressure. The crude
product was purified by flash chromatography (DCM + 10 % MeOH),
dissolved in benzene and lyophilized yielding Fmoc – Cys(SO2Et) (552 mg,
1.27 mmol, 44 %).
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 7.94 (d, 3JH,H = 8.5 Hz, 1H, – NH),
7.90 (d, 3JH,H = 7.5 Hz, 2H, –– CH – ), 7.71 (d, 3JH,H = 7.4 Hz, 2H, –– CH – ), 7.42
(t, 3JH,H = 7.4 Hz, 2H, –– CH – ), 7.33 (t, 3JH,H = 6.9 Hz, 2H, –– CH – ), 4.36–4.21
(m, 4H, α– H, –– CH – , – OCH2 – ), 3.61–3.48 (m, 2H, – CH2 – SO2), 3.41–3.28 (m,
2H, – CH2 – S), 1.25 (t, 3JH,H = 7.2 Hz, 3H, – CH3).
13C NMR (101 MHz, DMSO – d6) δ [ppm] = 171.33 ( – COO), 155.99 (NCOO),
143.77 ( –– CH – ), 140.76 ( –– CH – ), 127.70 ( –– CH – ), 127.12 ( –– CH – ), 125.24
( –– CH – ), 120.19 ( –– CH – ), 65.84 (OCH2 – ), 55.58 ( – CH2SO2 – ), 53.58 ( – CHN),
46.59 ( –– CH – ), 36.57 ( – CH2S – ), 8.29 ( – CH3).
ESI – MS: m/z = 458.09 [M+Na]+, (calc. 458.33 g mol-1); 474.06 [M+K]+, (calc.
474.18 g mol-1).
N-(9-Fluorenylmethoxycarbonyl)-S-isopropylsulfonyl-L-cysteine
(Fmoc-Cys(SO2iPr)) 7 b
The synthesis was carried out analogous to 5 a using Cys(SO2iPr) (3.99 g,
17.55 mmol), Fmoc – OSu (5.92 g, 17.55 mmol) and DIPEA (3.28 mL, 2.50
g, 19.31 mmol). Purification yielded Fmoc – Cys(SO2iPr) (2.70 g, 6.01 mmol,
34 %).
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1H NMR (400 MHz, DMSO-d6) δ [ppm] = 7.92 (d, 3JH,H = 7.0 Hz, 1H, – NH),
7.89 (d, 3JH,H = 7.6 Hz, 2H, –– CH – ), 7.72 (d, 3JH,H = 7.4 Hz, 2H, –– CH – ), 7.42
(t, 3JH,H = 7.4 Hz, 2H, –– CH – ), 7.33 (t, 3JH,H = 6.9 Hz, 2H, –– CH – ), 4.36–4.21
(m, 4H, α– H, –– CH – , – OCH2 – ), 3.69 (hept, JH,H = 6.7 Hz, 1H, –– CH – SO2),
3.55 (dd, 2JH,H = 14.0 Hz, 3JH,H =4.7 Hz, 1H, – CHH – S), 3.36 (dd, 2JH,H =
13.8 Hz, 3JH,H = 9.7 Hz, 1H, – CHH – S), 1.31 (d, 3JH,H = 6.7 Hz, 6H, – (CH3)2).
13C NMR (101 MHz, DMSO – d6) δ [ppm] = 171.27 ( – COO), 155.95 (NCOO),
143.75 ( –– CH – ), 140.74 ( –– CH – ), 127.68 ( –– CH – ), 127.10 ( –– CH – ), 125.22
( –– CH – ), 120.16 ( –– CH – ), 65.84 (OCH2 – ), 62.22 ( – CHSO2 – ), 53.80 ( – CHN),
46.59 ( –– CH – ), 36.82 ( – CH2S – ), 15.98-15.82 (( – CH3)2).
ESI – MS: m/z = 472.10 [M+Na]+, (calc. 472.54 g mol-1); 488.06 [M+K]+, (calc.
488.01 g mol-1).
S-isopropylsulfonyl-L-cysteine-L-alanine (Cys(SO2iPr)-Ala) 8
Dried Fmoc – Cys(SO2iPr) (131.5 mg, 293 µmol) and dried Ala – OtBu
(44.3 mg, 244 µmol) were solved in absolute DCM (2.5 mL) in a Schlenk
tube. N,N-diisopropylcarbodiimide (DIC) (45.0 µL, 36.29 mg, 292 µmol)
were added under dry nitrogen counter flow. The opaque reaction mix-
ture was stirred for 2 h at 20 °C and the solvent was removed in vacuo.
1H NMR revealed a coupling efficiency of 84 %. The Fmoc protective
group removal was conducted at 0 °C with 2 mLof a 20 % solution
of absolute piperidine in absolute DCM for 10 min. The solvent was
evaporated in vacuo, 2 mL absolute DCM were added and removed in
vacuo three times to remove residual piperidine. The tert-butyl protec-
tive group was removed at 0 °C with 2 mL of a 50 % solution of TFA in
DCM for 1 h. The solvent was evaporated in vacuo. The crude product
was purified by preparative reverse phase-HPLC (H2O + 1 % acetoni-
trile + 0.1 % TFA). An overall yield however was not determined due so
numerous samples taken for 1H NMR analytics to evaluate the coupling
efficiency and protective group removal.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 4.22 (t, 3JH,H = 7.2 Hz, 1H,α– H)Cys,
4.12 (m, 1H, α– H)Ala, 3.77 (hept, JH,H = 6.7 Hz, 1H, –– CH – SO2)Cys, 3.52
(ddd, 2JH,H = 13.7 Hz, 3JH,H = 7.7 Hz, 3J = 6.8 Hz, 2H, – CH2 – S)Cys, 1.36
(dd, 3JH,H = 6.7 Hz, 3JH,H = 1.1 Hz, 6H, – (CH3)2)Cys, 1.30 (d, 3JH,H = 7.2
Hz, 3H, – CH3)Ala.
ESI – MS: m/z = 299.05 [M+H]+, (calc. 298.07 g mol-1).
7.6.3 pH Stability
The protective group remained fully intact at pH 2 and 4. Hydrolysis
sets slowly in at pH 6 proceeding with increasing pH. Hydrolysis at
pH 13 was complete before the first time point measurement at 1 min.
The S-isopropylsulfonyl group proved to be slightly more stable towards
hydrolysis in comparison to the S-ethylsulfonyl group . Summarized it
can be stated that long term exposure of the S-alkylsulfonyl group to
neutral to alkaline conditions bears the issue of hydrolysis. However,
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stability of both Cys(SO2Et) and Cys(SO2iPr) under acidic to neutral condi-
tions was confirmed for extended periods of time.
Figure 7.8: pH influence on Cys(SO2R) 2 a and 2 b: A) Plots of the logarithmic
residual concentration of the protected amino acids as monitored
by 1H NMR over time. B) Rate constants of the alkaline hydrolysis in
relation to the pH.
Table 7.2: Apparent rate constants for hydrolysis of Cys(SO2R) at 20 ◦C.
pH kEtOH/s−1 k
iPr
OH/s−1
4 6.1× 10−9 4.2× 10−9
6 7.2× 10−6 4.7× 10−6
7 5.1× 10−5 3.7× 10−5
8 1.1× 10−4 8.9× 10−5
10 1.0× 10−3 7.4× 10−4
7.6.4 Amine Stability
Lowering the temperature results in slower reaction rates for all amines.
Gradual protective group removal was observed for Cys(SO2Et) and
Cys(SO2iPr) when exposed amines at 20 ◦C. At 0 ◦C and −10 ◦C on the
other hand degradation does not occur over time and the protective
groups are stable for more than 7 days.
Table 7.3: Rate constants for reactions of Cys(SO2R) with amines at different tem-
peratures.
amines kEt/s−1 k
iPr/s−1
20 ◦C 0 ◦C −10 ◦C 20 ◦C 0 ◦C −10 ◦C
Neo 2.9× 10−6 1.2× 10−7 1.9× 10−8 5.3× 10−7 1.9× 10−8 5.0× 10−9
Hex 5.3× 10−7 1.0× 10−7 1.3× 10−8 8.3× 10−7 2.2× 10−7 6.5× 10−9
Morph 6.9× 10−7 3.4× 10−8 -a 7.6× 10−7 4.1× 10−8 -a
Pip 6.7× 10−7 1.0× 10−8 -a 6.9× 10−7 3.7× 10−8 -a
a Not determined
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7.6.5 Reactions of Cys(SO2R) with Thiols
Compound 3I-III
Reactivity against thiols was investigated by reaction of Cys(SO2R) (1.0 eq.)
and 1.1 eq. of a thiol component (see Scheme 7.2), which were separately
solved in D2O (0.35 mL each) and combined immediately before the mea-
surement. The specific reaction components for the formation of 3I-III
were as followed:
11.80 mg (55.32 µmol) Cys(SO2Et) and 6.91 mg (60.86 µmol) cysteamine;
11.05 mg (48.61 µmol) Cys(SO2iPr) and 6.08 mg (53.48 µmol) cysteamine;
8.88 mg (41.64 µmol) Cys(SO2Et) and 14.07 mg (45.80 µmol) glutathione;
8.50 mg (37.40 µmol) Cys(SO2iPr) and 12.64 mg (41.14 µmol) glutathione;
8.82 mg (41.35 µmol) Cys(SO2Et) and 6.79 mg (45.49 µmol) D-penicillin-
amine; 9.77 mg (42.98 µmol) Cys(SO2iPr) and 7.05 mg (47.28 µmol) D-
penicillinamine.
ESI-MS: S-(D-penicillinamine)-L-cysteine [3I] (calc. 268.06): 269.06
(3I+H+), 537.11 (2x3I+H+); S-(cysteamine)-L-cysteine [3II] (calc. 196.03):
197.04 (3II+H+), 393.07 (2x3II+H+); S-(glutathione)-L-cysteine [3III] (calc.
426.09): 427.06 (3III+H+), 613.14 (glutathione ox.).
S-(hexylsulfanyl)-L-cysteine (4) in competing reaction with 1-bytylamine
Cys(SO2R) (1.0 eq.) was dissolved in DMSO-d6 (0.70 mL) and butylamine
(1.0 eq.), hexanethiol (1.0 eq.) or both were added. Individual reaction
components were: 4.93 mg (23.12 µmol) Cys(SO2Et) and 2.28 µL (1.69
mg, 23.12 µmol) butylamine; 5.35 mg (25.08 µmol) Cys(SO2Et) and 3.53
µL (2.97 mg, 25.08 µmol) hexanethiol; 6.80 mg (31.88 µmol) Cys(SO2Et)
and 4.49 µL (3.77 mg, 31.88 µmol) hexanethiol and 3.15 µL (2.33 mg,
31.88 µmol) butylamine; 5.45 mg (23.98 µmol) Cys(SO2iPr) and 3.38 µL
(2.84 mg, 23.98 µmol) hexanethiol; 5.41 mg (23.80 µmol) Cys(SO2iPr)
and 3.14 µL (2.41 mg, 23.80 µmol) butylamine; 5.54 mg (25.56 µmol)
Cys(SO2iPr) and 3.60 µL (3.02 mg, 25.56 µmol) hexanethiol and 2.53 µL
(1.87 mg, 25.56 µmol) butylamine.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 4.20 (m, 1H, α– H), 3.20 (dd, 2JH,H
= 14.4, 3J = 4.9 Hz, 2H, – CH2 – ), 3.13 (dd, 2JH,H = 14.4, 3JH,H = 7.1 Hz, 2H,
– CH2 – ), 2.74 (t, 3JH,H = 7.1 Hz, 2H, – CH2 – S), 1.66-1.56 (m, 2H, – CH2 – ),
1.38-1.19 (m, 6H, ( – CH2 – )3), 0.87-0.80 (m, 3H, – CH3).
ESI-MS: S-(hexylsulfanyl)-L-cysteine 4 (calc. 237.09): 238.11 (4+H+), 241.05
(cystine+H+), 259.89 (4+Na+), 263.14 (cystine+Na+), 475.20 (2x4+H+).
102 I N T R O D U C I N G T H E s - A L K Y L S U L F O N Y L P R O T E C T I V E G R O U P
7.6.6 DFT Calculations
The DFT calculated energy levels of the frontier orbitals are given in Ta-
ble 7.4, their visualization and 1H NMR spectra of the conversions are
given in Figure 7.3 and 7.10.
Table 7.4: HOMO/LUMO energy levels of 1-butanamine, 1-hexanethiol and
Cys(SO2R).
HOMO/eV LUMO/eV
Cys(SO2Et) -6.6845 -1.3190
Cys(SO2iPr) -6.6748 -1.3231
1-butanamine -6.2958
1-hexanamine -3.6207
Figure 7.9: A) Detail on 1H NMR spectra of the reaction of Cys(SO2Et) 2 a with
1-butanamine and 1-hexanethiol forming exclusively S-hexane-L-
cysteine 4. B) DFT calculations of HOMO and LUMO of Cys(SO2Et) 2 a
and HOMOs of butylamine (left) and hexanethiol (right).
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7.6.7 Crystallographic Data
Figure 7.10: Crystallographic data of L-Cys(SO2Et) 2 a showing two possible con-
formations.
Figure 7.11: Crystallographic data of L-Cys(SO2iPr) 2 b showing two possible con-
formations.
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7.6.8 NMR Spectra
Figure 7.12: 1H NMR spectrum of 2 a.
Figure 7.13: 13C NMR spectrum of 2 a.
7.6 S U P P O R T I N G I N F O R M AT I O N 105
Figure 7.14: COSY NMR spectrum of 2 a.
Figure 7.15: HSQC NMR spectrum of 2 a.
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Figure 7.16: 1H NMR spectrum of 2 b.
Figure 7.17: 13C NMR spectrum of 2 b.
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Figure 7.18: COSY NMR spectrum of 2 b.
Figure 7.19: HSQC NMR spectrum of 2 b.
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Figure 7.20: 1H NMR spectrum of 5 a.
Figure 7.21: 13C NMR spectrum of 5 a.
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Figure 7.22: 1H NMR spectrum of 5 b.
Figure 7.23: 13C NMR spectrum of 5 b.
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Figure 7.24: 1H NMR spectrum of 6 a.
Figure 7.25: 1H NMR spectrum of 6 b.
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Figure 7.26: 1H NMR spectrum of 7 a.
Figure 7.27: 13C NMR spectrum of 7 a.
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Figure 7.28: COSY NMR spectrum of 7 a.
Figure 7.29: HSQC NMR spectrum of 7 a.
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Figure 7.30: 1H NMR spectrum of 7 b.
Figure 7.31: 13C NMR spectrum of 7 b.
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Figure 7.32: COSY NMR spectrum of 7 b.
Figure 7.33: HSQC NMR spectrum of 7 b.
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Figure 7.34: 1H NMR spectrum of 8.

Part III
O RT H O G O N A L R E A C T I V E
P O LY P E P T ( O ) I D E S

The next part covers controlled polypept(o)ide (polypeptoid-block-poly-
peptide) synthesis by means of ring-opening polymerization of α-amino
acid N-carboxyanhydrides. Correlation between absolute monomer pu-
rity and control over the polymerization was disclosed by X-ray crystal-
lography. Further, analysis of polymerization kinetics investigated opti-
mized conditions of poly(S-alkylsulfonyl-L-cysteine) (PCys(SO2R)) synthe-
sis. Thus, sequential polymerization including the thiol-reactive S-alkyl-
sulfonyl moiety could be performed, to give PSar-block-PCys(SO2R) diblock
copolypept(o)ides, in order to demonstrate three orthogonal functionali-
ties in one polymer. In addition, triblock terpolymers with PSar, PCys(SO2R)
and PLys segments were prepared, to illustrate sequence inversion, while
maintaining constant block length.
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F R O M A B S O L U T E M O N O M E R P U R I T Y T O
C O N T R O L L E D N C A P O LY M E R I Z AT I O N
Olga Schäfer, Dieter Schollmeyer, Alexander Birke, Regina Holm, Ker-
stin Johann, Christian Muhl, Christine Seidl, Benjamin Weber, Matthias
Barz, submitted.
A B S T R A C T : The need for synthetic strategies of not sequence defined
polypeptides on a large scale as biomaterials is met by the ring-opening
polymerization of α-amino acid N-carboxyanhydrides (NCAs). Even
though this polymerization technique appears straight forward, it holds
pitfalls in terms of reproducibility and overall control over the poly-
merization conditions, which depends, beside choice of solvent or ini-
tiator, significantly on reagent purity. Thus, in this work, we describe
the benefits of highly pure monomers in order to control nucleophilic
ring-opening polymerization NCAs. For the first time, monomer purity
is investigated by relating melting points of NCAs with single-crystal and
powder X-ray diffraction crystallography data, which further proves re-
tained stereo-information of NCAs.
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Importance of
NCA purity.
8.1 I N T R O D U C T I O N
The discovery of Leuchs’ anhydrides, also known as α-amino acid N-
carboxyanhydrides (NCAs), in 1906[39] initiated the field of polypeptide
synthesis by nucleophilic ring-opening polymerization (ROP) tech-
niques.[35–37,407] Amine-initiated ROP of NCAs was pioneered by Sig-
mund and Wessely[31] Szwarc,[32] as well as Ballard and Bamford.[33,34]
If sequence control is expendable, it represents now the most com-
monly applied technique for rapid and large-scale synthesis of
polypeptides.[25,38,58,63,313,317] With arising applications of the resulting
poly(amino acid)s as defined therapeutic products in nanomedicine, the
need for precise control over polymer dispersity, molecular architecture
as well as end-group integrity is apparent.[30,59,316,355,408,409] Thus,
manipulation of polymerization conditions evolved into a substantial
element in research topics employing materials obtained by means
of NCA polymerization. The strategies cover various initiators from
rare earth catalysts,[48] to amine hydrochlorides,[49] to organo-nickel
initiators[50] and ammonium salts with tetrafluoroborate anions[51] as
well as hexamethyldisilazane-mediated polymerization approaches.[52]
Further, variation in temperature,[54,55] the introduction of N2 flow[56]
and high purity reagents employed in high vacuum techniques[53] were
evaluated as means to control NCA polymerization.
One of the parameters with tremendous influence on the polymeriza-
tion outcome is the purity of employed solvents, initiators and in par-
ticular NCA monomers. Exclusion of impurities such as solvent traces,
water, residues of amino acid or acid chlorides has been commonly ac-
cepted as mandatory to realize living polymerization. Nucleophilic im-
purities bear the potential to terminate growing electrophilic chain ends,
catalyze side reactions or act as chain-transfer agents, ultimately gener-
ating shorter chains resulting in broad molecular weight distribution of
the material.[410] Hence, considerable emphasis on monomer purifica-
tion is required. NCA crystallization by a slow decrease in solubility, is a
valuable method to achieve pure monomer materials to for high molec-
ular weight polypeptides by NCA ROP polymerization.
In this context, X-ray diffraction (XRD) proves a powerful analytical
technique, granting insights into structural parameters by analysis of
internal lattice properties of crystalline materials. Although external ad-
sorbed impurities, such as solvent traces, may not be detected, XRD of-
fers the means to evaluate NCA crystal purity in terms of co-crystallizing
molecules and elucidate the absolute conformation. The ability of iso-
tactic polypeptides to form secondary structures such as α-helices or
β-sheets will be compromised in an atactic arrangement and result
in a random coil conformation. Thus, loss or conservation of stereo-
information during (multi-step) synthesis of the particular monomer
need to be assured in order to achieve material properties based on sec-
ondary structure formation. In addition, most peptides synthesized by
NCA polymerization originate from L-amino acids. Since D-amino acids
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are uncommon in most organisms, their employment in materials desig-
nated for systemic or local application bears a certain risk regarding the
potential to induce an undesired immune response.[411–413] Ultimately,
validation of NCA purity and structural integrity as an overall qual-
ity control seems highly desirable. Structural characterization multiple
NCAs has been contributed over the past 40 years e. g. by Kanazawa et
al. including NCAs of glycine,[414] L-alanine,[415] L and DL-leucine,[416,417]
γ-benzyl-L-glutamate,[418] L-valine,[419] L and DL-phenylalanine,[420,421]
β-benzyl-L-aspartate,[422] and L-glutamic γ-ethyl ester.[423] Polymeriza-
tion outcome, however, was only evaluated in order to compare poly-
merization rates by IR spectroscopy.
Much so our surprise, a systematic correlation of crystal structure
to the living character of ROP and definition of the resulting polymers
is lacking, although identifying parameters of monomer purity would
help to control the polymerization of NCAs. In this work, we thus corre-
late the high purity of NCA monomers achieved by crystallization and
confirmed by XRD with the readily accessible parameter of melting point
to the control over amine initiated NCA ROP. Definition of polymers is
judged towards completeness of monomer conversion, match of target
chain length as well as narrow molecular weight distribution.
8.2 R E S U LT S A N D D I S C U S S I O N
Most commonly, NCAs are synthesized by the method proposed by
Fuchs in 1922[40] and improved by Farthing.[41,42] It utilizes the respec-
tive amino acid and phosgene (or a phosgene equivalent such as diphos-
gene[424,425] or triphosgene[426,427]) as the cycling agent for a convenient
and fast synthesis upon high atom efficiency as illustrated in Scheme 8.1.
Scheme 8.1: Scheme of α-amino acid N-carboxyanhydride (NCA) synthesis by
the Fuchs-Farthing method.[40,42]
As outlined in the introduction, monomer purity is crucial for a con-
trolled ring-opening polymerization mechanism, since impurities may
act as chain-transfer agents or terminate growing species and catalyze
side reactions. Purification by means of crystallization is a convenient
step which can be included subsequently to the synthesis procedure and
repeated several times to increase purity of the NCA. Exclusion from
air (and thus moisture), as well as use of thoroughly dried, absolute
solvents is necessary to ensure the absence of water.[53,57] Additionally,
sublimation proves a straightforward and effective purification method
N-substituted NCAs as described in detail for sarcosine NCA by Ballard
et al.[33,34] and employed by many groups.[26,44,428]
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NCA
characterization by
X-ray diffraction.
If the NCA is obtained as a single crystal of pure composition and
regular structure (no cracks, twinning or other internal imperfections),
single-crystal X-ray diffraction (XRD) can be performed. This non-de-
structive method is based on on discoveries of Max von Laue and co-
workers[334] who observed how crystalline substances act as three-di-
mensional diffraction gratings for X-rays, which are similar in wave-
length to the spacing of planes in a crystal lattice.[336] Exposure of the
crystalline material results, amongst other events, in diffraction of the
X-rays due to interaction with atomic planes. Ultimately, processing of
scattering information by computational modeling offers insights on
multiple parameters of the crystalline state such as unit cell dimensions,
bond-lengths and -angles as well as details on site-ordering. Single crys-
tal XRD was thus performed for NCAs illustrated in Figure 8.1, revealing
exclusivity L-conformation and absence of co-crystallizing molecules
e. g. solvents.
Figure 8.1: Crystal structure of NCAs evaluated by single-crystal X-ray diffrac-
tion: 1 Asp(OBn) NCA, 2 Cys(SO2Et) NCA, 3 Cys(SO2iPr) NCA, 6 Hcy(SO2Et)
NCA, 8 Lys(Boc) NCA and 10 Sar NCA. Sarcosine NCA single crystals
were obtained by sublimation, all other NCAs by crystallization.
The arrangement of NCAs molecules in the elemental cells was found
to be dominated by hydrogen-bond formation as illustrated in
Section 8.5.4 in the supporting information. In case of Hcy(SO2Et) (6), even
supra molecular stacking in a helical fashion was observed. These in-
sights on the inter-molecular arrangement of NCAs derived from pro-
tected amino acids translate to formation of secondary structures in the
respective polypeptides.[24,37,209] An exception for hydrogen-bond driven
arrangement poses sarcosine NCA (10), N-methylation renders it as an
exclusive hydrogen bond acceptor. As no sites acting as hydrogen-bond
donor are present in the polymer chain, stabilization into secondary
structures is not possible and results in random coil conformation of
polysarcosine.[25,27]
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Melting points as
easily accessible
characterization
parameter.
Other NCAs than in Figure 8.1, yielded too small or fragile crystals for
successful single-crystal XRD, and were thus analyzed by powder XRD.
Although this method does not provide structural information, sharp
peaks characteristic for a crystalline phase confirm the crystalline state
of the NCAs as illustrated in powder diffraction profiles in Section 8.5.5
in the supporting information.
Although XRD is the analytical method of choice to characterize the in-
ternal structure of crystalline substances, adequate instrumentation and
data analysis is far from trivial. A readily accessible parameter for char-
acterization of solid, crystalline substances is the melting point and mea-
surements can be conveniently included in the work-flow e. g. to mon-
itor purification success or to evaluate monomer quality prior to poly-
merization. NCA characterization is commonly performed by 1H NMR
and assignment of the respective proton signals (compare Section 8.5.7
in the supporting information) or by mass spectroscopy. However, sen-
sitivity of those characterization methods towards trace impurities such
as residual solvents or unreacted amino acid is low compared to mea-
surement of the melting point. The presence of any impurities will re-
sult in immediate depression of the melting point compared to of the
pure substance. In addition, single crystals feature a distinct and sharp
melting point, thus crystalline samples will give a narrow melting point
range. Thus, melting point ranges for single crystals of NCAs were mea-
sured by an optical device and are summarized in Table 8.1 in compari-
son with melting points according to literature.
Table 8.1: Melting points of NCAs (alphabetically on the basis of the amino acid).
Crystal melting points were determined at a heating rate of 1°C per
minute, beginning and end of the melting process were recorded
(n = 3). Single crystals were obtained crystallization unless stated oth-
erwise.
No NCA mp. / °C mp. / °C mp. / °C
crystal literature previously
reported
1 Asp(OBn) 124.7 – 124.9 135[45,429,430] -
2 Cys(SO2Et) 100.8 – 101.1 113 – 115[173] 113 – 115[173]
3 Cys(SO2iPr) 92.9 – 93.2 98 – 100[173] 98 – 100[173]
4 Glu(OBn) 91.3 – 91.7 93– 94[45,431,432] 93 – 94[26]
5 Glu(tBu) 99.4 – 100.0 95 – 96[45,433] 100.9[61]
6 Hcy(SO2Et) 94.9 – 95.2 - -
7 Lys(Z) 98.1 – 98.5 101[45,434,435] 100.9[26]
8 Lys(Boc) 136.9 – 137.6 134 – 137[436,437] 138.3[59]
9 Lys(TFA) 94.5 – 95.0 94[45,438] 101[24]
10 Sar 103.0 – 103.7 102 – 105[31,44,45,439] 102 – 104[26]
a Sarcosine NCA single crystals were obtained by sublimation.
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Controlled
ring-opening
polymerization.
Compared to literature, lower melting points were observed for 2, 3,
4 and 9. In this context, automated melting point measurement based
on light transmission from a refracting solid to a clear liquid upon melt-
ing might hold pitfalls. Thermal decomposition and thus evolution of
gaseous fragments, can cause bubbles in the otherwise clear liquid (e. g.
sulfoxides in the case of cysteine and homocysteine based compounds).
Thus, an automated melting point apparatus may not determine the
end of a melting process reliably and indicate too high values due to
refracting bubbles as in case of e. g. 2 (113 – 115 °C) and 3 (98 – 100 °C).
An optical device, however, allows to follow the exact beginning and
completion of the decomposition process and thus measurements of the
correct melting point gave 100.8 – 101.1 °C for 2 and 92.9 – 93.2 °C for 3.
For 5, 7, 8 and 10, melting point ranges were in good agreement with
literature or even surpassing, as in case of 5 with 99.4 – 100.0 °C com-
pared to 95 – 96,°C.[45,433] In summary, measurements of melting points
by a device allowing for optical control is a sensitive and reproducible
method to evaluate NCA purity. Use of crystals devoid of co-crystallizing
molecules, which required confirmation by XRD since melting point mea-
surement is sensitive to trace impurities, gave high and narrow melting
point ranges as reference for characterization of NCAs.
To bridge the gap between findings on NCA monomer purity and suc-
cess of ring-opening polymerization thereof, all presented NCAs were
employed in amine-initiated ROP as illustrated in Scheme 8.2.
Polymerizations following the normal amine mechanism (NAM) are
of living character, as indicated by incorporation of initiator molecules
into every polymer chain and a faster initiation step compared to chain
propagation.[44] In contrast, abstraction of the acidic proton by initiators
with basic character, would lead to the undesired activated monomer
mechanism (AMM) resulting in an overlap of ROP and condensation pro-
cesses and thus broad molecular weight distributions.[45,46] The NAM is
the desired pathway of NCA polymerization, since it provides control
over molecular weights, polymer dispersity and end-group integrity.
Thus, in order to ensure chain propagation by the NAM, exclusion of
nucleophilic impurities has to be ensured since chain termination, side
reactions or chain-transfer will impair the living chain propagation and
thus polymer definition.
Scheme 8.2: Polymerization of NCA by an amine initiator following the normal
amine mechanism.
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Polymers were characterized in terms of conversion rate, agreement
of target block length with experimental findings and molecular weight
distribution as summarized in Table 8.2. The polymerization rate was
determined by infrared (IR) spectroscopy and NCA conversion was fol-
lowed by the decrease of the carbonyl peaks at 1858 cm−1 and 1788 cm−1.
For relation of theoretical and experimental block lengths by 1H NMR ,
the signal of the 9 equivalent protons of the neopentylamine initiator at
0.83 ppm was related to signals of the α-proton of the respective amino
acid. Ultimately, molecular weight distribution and dispersities were
determined by gel permeation chromatography (GPC) in hexafluoro 2-
propanol (HFIP).
Table 8.2: Characterization of polypeptides and polypeptoids obtained by
amine initiated ring-opening polymerization of NCAs with neopenty-
lamine as initiator unless stated otherwise.
polymer NCA M / I % con-
versiona
Xn, NMR Mn, GPCb
/g mol−1
ÐGPCb
PAsp(OBn)c 1 40 100 38 28100 1.19
PCys(SO2Et) 2 15 88 17 8360 1.16
PCys(SO2iPr) 3 30 80 23 13000 1.19
PGlu(OBn) 4 30 100 31 10300 1.08
PGlu(tBu) 5 25 100 27 13300 1.11
PHcy(SO2Et) 6 50 100 37 8320 1.16
PLys(Z) 7 50 100 48 15200 1.08
PLys(Boc) 8 50 100 50 14800 1.18
PLys(TFA) 9 30 100 32 12200 1.12
PSar 10 100 100 104 25000 1.06
a Determined by IR spectroscopy.
b Relative to PMMA standards.
c Diblock copolypept(o)ide initiated by PSar390 as determined by 1H NMR end-group
analysis.
Monomer conversion of 100 % is reached in all cases with good agree-
ment of target and experimental block length, with the exception of 2
and 3 due to physical chain growth termination by secondary structure
formation of β-sheets.[209] High molecular weights and narrow disper-
sities well below 1.2 confirm well-defined polymers. Initiation by wa-
ter or intermediates in the AMM, chain termination or other side reac-
tions, however, would yield poorly defined polypeptides. Thus, the pre-
dominant controlled ring-opening chain propagation follows the nor-
mal amine mechanism as shown in Scheme 8.2.
As illustrated in Figure 8.2, all polymers exhibit monomodal molec-
ular weight distributions as determined by HFIP GPC. To facilitate dis-
tinction of individual elugrams, polymers were grouped in molecular
weights < 10000, 10000–15000 and > 25000 g mol−1.
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Figure 8.2: HFIP GPC traces of polypeptides and polypeptoids obtained
by amine initiated ring-opening polymerization of NCAs: A)
Mn, GPC < 10000, B) Mn, GPC = 10000–15000 and C) Mn, GPC > 25000.
All investigated polymers with the exception of polysarcosine are ca-
pable of hydrogen bond formation.[23,202,440–442] Thus formation of sec-
ondary structures is possible, resulting in different persistence lengths
of the polypeptides and thus variation in elution behavior.[24] Further,
polypeptides evluated in this work feature different side chain chem-
istry and protective groups. As a result, differences in column and sol-
vent interactions are expected based on the chemical variability and
again variation in GPC elution. Thus, elugrams of different polypeptides
obtained by GPC are of qualitative nature and polymer chain length
from 1H NMR should not be related to molecular weight obtained rel-
ative to PMMA standards. The symmetrical GPC elugrams and narrow
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dispersities confirm, however, the synthesis well-defined polymers. In
summary, ring-opening polymerizations of all NCAs proceeded in a con-
trolled fashion, stressing the importance of pure monomers with high
melting points as obtained by crystallization and evaluated by means of
XRD.
8.3 C O N C L U S I O N
We have reported on the benefits of highly pure monomers in regard
to control of nucleophilic ring-opening polymerization α-amino acid N-
carboxyanhydrides (NCAs). Monomer purity was investigated by relat-
ing melting points of NCAs with single-crystal and powder X-ray diffrac-
tion crystallography data. NCA monomers were purified by crystalliza-
tion and preserved stereo-information as well as the absence of any
co-crystallizing impurities was confirmed by XRD. In addition, single
crystal melting points were determined as an easily accessible parame-
ter to monitor monomer purity. Ultimately, well-defined polymers were
synthesized by controlled amine-initiated ring-opening polymerization
of the investigated NCAs. Thus, NCA monomer purity, which can con-
veniently be monitored by evaluation of melting points, was demon-
strated to be essential in oder to achieve control over NCA polymeriza-
tion.
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8.5 S U P P O R T I N G I N F O R M AT I O N
8.5.1 Materials and Instrumentation
All chemicals were purchased from Sigma Aldrich and used as received
unless otherwise noted. Tetrahydrofurane (THF) and hexane were dis-
tilled from Na/K and ethyl acetate and dichloromethane (DCM) from
CaH2. N,N-dimethyl formamide (DMF) was purchased dry over molec-
ular sieve. It was further purified by stirring over molecular sieve (3 Å)
and BaO. It was then distilled and stored at −80 ◦C under exclusion of
light. Prior to use DMF was degassed in vacuo to remove traces of di-
methylamine. Neopentylamine (purchased from TCI Europe) and
hexylmethylamine were dried over NaOH followed by distillation, mor-
pholine was distilled from Na. α-amino acids were purchased from
OPREGEN, sarcosine and diphosgene from Alfa Aesar, HFIP was pur-
chased from Fluorochem and deuterated solvents from Deutero GmbH.
1H NMR spectra were recorded on a Bruker Avance II HD 400 at a fre-
quency of 400 MHz or a Bruker Avance III HD 300 at 300 MHz. All spec-
tra were recorded at room temperature (25 ◦C) and calibrated using the
solvent signals.[394]
Crystallographic data for powder diffraction profiles was collecetd
on a BRUKER D8 Discover diffractometer using monochromated Cu
monochromated Kα radiation (λ= 1.5418 Å) and a High-Star detector.
Crystallographic data for single crstal analysis were collected on a
STOE IPDS 2T diffractometer using graphite monochromated Mo Kα
radiation (λ= 0.7107 Å). Lorentz and polarisation correction was imple-
mented and the structure was solved by direct methods (SIR-2004)[395]
and refined (SCHELXL-2014).[396] Hydrogen atoms were refined isotrop-
ically assuming riding motion, other atoms were refined anisotropically.
Crystallographic data for the structures in this paper have been deposited
with the Cambridge Crystallographic Data Centre as supplementary pub-
lication nos. . Copies of the data can be obtained, free of charge, on ap-
plication to Cambridge Crystallographic Data Centre, 12 Union Road,
Cambridge CB2 1EZ, UK, (fax: +44-(0)1223-336033 or
e-mail: deposit@ccdc.cam.ac.Uk). Publication numbers and further de-
tails are given with individual characterization data. Melting points were
measured using a Mettler FP62 and a Krüss KSP1D melting point appa-
ratus at a heating rate of 1 ◦C min−1.
Gel permeation chromatography (GPC) was performed with HFIP con-
taining 3 g l−1 potassium trifluoroacetate (KTFA) as eluent at 40 ◦C and a
flow rate of 0.8 ml min−1. The columns were packed with modified sil-
ica (PFG columns particle size: 7 µm, porosity: 100 Å and 1000 Å). Poly-
methly methacrylate PMMA standards (Polymer Standards Services
GmbH) were used for calibration and toluene was used as internal stan-
dard. A refractive index detector (G1362A RID) and an UV/Vis detector
(at 230 nm unless otherwise stated; Jasco UV-2075 Plus) were used for
polymer detection.
8.5 S U P P O R T I N G I N F O R M AT I O N 131
8.5.2 Synthetic Procedures
β-benzyl-L-aspartate N-carboxyanhydride (Asp(OBn) NCA) 1
The synthesis was adapted from literature and modified.[424] Into pre-
dried glassware, 8.9 g (40.0 mmol) of benzylester protected asparagine
and 200 mL of absolute THF were added under a steady flow of nitrogen.
The condenser outlet was connected to two gas washing bottles filled
with aqueous NaOH, removing excess HCl and phosgene. Then, 4.1 mL
(33.7 mmol) of diphosgene were added slowly via syringe and the nitro-
gen stream was reduced. The colorless suspension was mildly refluxed
for 1.5 h, yielding a slightly yellow solution. After the last particles were
dissolved, a steady flow of dry nitrogen was lead throw the solution for
3 h. The solvent was evaporated under reduced pressure and absolute
THF was added to completely dissolve the reaction product. Excess of
absolute hexane was added to the solution and kept at 4 °C overnight
to crystallize. The solid was filtered under dry nitrogen atmosphere and
the crude product was recrystallized from THF/hexane twice, washed
with absolute hexane, dried in a dry nitrogen flow, and finally in high
vacuum. A total of 8.7 g of purified product (35.0 mmol, 88 % yield, col-
orless needles, melting point: 124.7 – 124.9 °C) was obtained and stored
in a Schlenk tube at -80 °C. CCDC-1261403.[422]
1H NMR (300 MHz, CDCl3) δ [ppm] = 9.00 (s, 1H, – NHCO), 7.37 (m, 5H,
– C6H5), 5.13 (s, 2H, – CH2 – C6H5), 4.70 (dd, 3JH,H = 7.9 Hz, 3JH,H = 5.4 Hz,
1H, α– H) 3.12–2.87 (dd, 3JH,H = 4.6 Hz, 2H, – CH2 – CH –– ).
S-ethylsulfonyl-L-cysteine N-carboxyanhydride (Cys(SO2Et) NCA)[173] 2
Dried S-ethylsulfonyl-L-cysteine (Cys(SO2Et)) (7.0 g, 32.8 mmol) was sus-
pended in absolute THF (100 mL ) and heated to 70 °C. Diphosgene
(3.6 mL, 5.8 g, 29.5 mmol) was slowly added and the suspension was
heated for an additional 4 h. Dry nitrogen was bubbled through the
reaction mixture overnight into a gas washing bottle with an aqueous
KOH solution to remove excess diphosgene, HCl and most of the sol-
vent. The remaining solvent was removed in vacuo and the residue was
dissolved in 100 mL absolute ethyl acetate. Any insoluble compounds
were removed by filtration avoiding contact with air and the NCA was
precipitated by adding 800 mL absolute hexane. The recrystallization of
the product was repeated two more times. After recrystallization a total
of 6.4 g of purified product (26.9 mmol, 82 % yield, colorless and crys-
talline powder, melting point: 100.8 – 101.1 °C) was obtained and stored
in a Schlenk tube at -80 °C.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.32 (s, 1H, – NHCO), 4.86 (td,
3JH,H = 6.0 Hz, 3JH,H = 4.8 Hz, 3JH,H = 1.6 Hz, 1H, α– H), 3.64 (dd, 2JH,H
= 14.4 Hz, 3JH,H = 4.8 Hz, 1H, – CHH – S), 3.62 (q, 3JH,H = 7.2 Hz, 2H,
– CH2 – SO2), 3.57 (dd, 2JH,H = 14.4 Hz, 3JH,H = 6.4 Hz, 1H, – CHH – S), 1.29
(t, 3JH,H = 7.2 Hz, 3H, – CH3).
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S-isopropylsulfonyl-L-cysteine N-carboxyanhydride (Cys(SO2iPr) NCA)[173] 3
The synthesis of S-isopropylsulfonyl-L-cysteine (Cys(SO2iPr)) NCA was
carried out under identical conditions as Cys(SO2Et) NCA employing
Cys(SO2Et) (6.0 g, 26.6 mmol) and diphosgene (4.0 mL , 6.6 g, 33.1 mmol).
Recrystallization yielded a total of 4.6 g of purified product (18.3 mmol,
69 % yield, colorless and crystalline powder, melting point: 92.9 –
93.2 °C) was obtained and stored in a Schlenk tube at -80 °C.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.33 (s, 1H, – NHCO), 4.84 (td,
3JH,H = 5.4 Hz, 3J = 1.4 Hz, 1H, α– H), 3.75 (hept, JH,H = 6.6 Hz, 1H,
–– CH – SO2), 3.59 (ddd, 2JH,H = 14.4 Hz, 3JH,H = 5.6 Hz, 3JH,H = 5.1 Hz,
2H, – CH2 – S), 1.33 (dd, 3JH,H = 6.6 Hz, 3JH,H = 0.9 Hz, 6H, – (CH3)2).
γ-benzyl-L-glutamate N-carboxyanhydride (Glu(OBn) NCA)[26] 4
The synthesis was adapted from literature and modified.[424] Into pre-
dried glassware, 10.0 g (42.1 mmol) of benzylester protected glutamine
and 200 mL of absolute THF were added under a steady flow of nitrogen.
The condenser outlet was connected to two gas washing bottles filled
with aqueous NaOH, removing excess HCl and phosgene. Then, 4.1 mL
(33.7 mmol) of diphosgene were added slowly via syringe and the nitro-
gen stream was reduced. The colorless suspension was mildly refluxed
for 1.5 h, yielding a slightly yellow solution. After the last particles were
dissolved, a steady flow of dry nitrogen was lead throw the solution for
3 h. The solvent was evaporated under reduced pressure and absolute
THF was added to completely dissolve the reaction product. Excess of
absolute hexane was added to the solution and kept at 4 °C overnight
to crystallize. The solid was filtered under dry nitrogen atmosphere and
the crude product was recrystallized from THF/hexane twice, washed
with absolute hexane, dried in a dry nitrogen flow, and finally in high
vacuum. A total of 10.5 g of purified product (40.0 mmol, 95 % yield, col-
orless needles, melting point: 91.3 – 91.7 °C) was obtained and stored in
a Schlenk tube at -80 °C. CCDC-1102908.[418]
1H NMR (300 MHz, CDCl3) δ [ppm] = 9.11 (s, 1H, – NHCO), 7.42–7.20 (m,
5H, – C6H5), 5.10 (s, 2H, – CH2 – C6H5), 4.52–4.42 (dd, 3JH,H = 7.9 Hz, 3JH,H
= 5.5 Hz, 1H, α– H), 2.52–2.48 (t, 3JH,H = 7.9 Hz, 2H, BnO – CO – CH2 – ), 2.15–
1.85 (m, 2H, – CH2 – CH –– ).
γ-tert-butyloxycarbonyl-L-glutamate N-carboxyanhydride (Glu(tBu) NCA)[61] 5
7.6 g (37.0 mmol) of H – Glu(OtBu) – OH were pestled thoroughly and
weighed into a three-necked round-bottomed flask equipped with a
magnetic stir bar, a condenser, a rubber septum, and a glass stopper and
dried under vacuum. After 30 min, 200 mL absolute THF were used to
suspend the solid under a steady flow of nitrogen. 9.5 mL (8.1 g,
75.0 mmol) of absolute trimethyl-silylchloride were added, dissolving
the amino acid and yielding a clear solution. Immediately afterwards,
10.4 mL (7.6 g, 75.0 mmol) absolute triethylamine TEA were added.
3.6 mL (5.9 g, 30.0 mmol) diphosgene were added slowly via syringe in
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two portions to the reaction mixture at room temperature and heated to
70 °C. After the reaction mixture had cooled down, a stream of nitrogen
was led through the mixture for 3 h to remove HCl. Then, the NEt3H+Cl–
salt was removed by filtration under nitrogen and washed with 30 mL
absolute THF twice. The solution was concentrated in vacuo to a vol-
ume of approx. 40 mL and the product was precipitated by addition of
400 mL absolute hexane with instant sonication. The procedure was re-
peated twice and yielded a colorless precipitate by filtration under ni-
trogen. A total of 5.2 g of purified product (22.7 mmol, 61 % yield, color-
less crystals, melting point: 99.4 – 100.0 °C) was obtained and stored in a
Schlenk tube at -80 °C.
1H NMR (300 MHz, CDCl3) δ [ppm] = 9.06 (s, 1H, – NH – CO – O – CO), 4.45
(ddd, 3JH,H = 6.9 Hz, 5.0 Hz, 0.9 Hz, 1H, α– H), 2.34 (m, 2H, – CH2 – CH2
– CO), 1.76–2.02 (m, 2H, – CH2 – CH2 – CO), 1.40 (s, 9H, – O – C(CH3)3).
S-ethylsulfonyl-L-homocysteine N-carboxyanhydride (Hcy(SO2Et) NCA) 6
2.4 g dried S-ethylsulfonyl-L-homocysteine (10.7 mmol) were sus-
pended in absolute THF (200 mL) at room temperature (25 °C) under ni-
trogen atmosphere. 1.0 mL diphosgene (1.7 g, 8.6 mmol) were added at
once and the suspension became clear after 1 minute. The colorless solu-
tion was stirred for additional 5 minutes bevor THF, excess diphosgene
and HCl were removed in vacuo. The residue was dissolved in 30 mL
absolute ethyl acetate and any insoluble compounds were removed by
filtration while avoiding contact with air. The NCA was precipitated by
adding a mixture of 150 mL absolute n-hexane and 150 mL absolute di-
ethylether. After filtration under nitrogen atmosphere, 1.2 g S-ethyl-
sulfonyl-L-homocysteine NCA (4.7 mmol, 44 % yield, colorless powder,
melting point: 94.9 – 95.2 °C) was obtained and stored in a Schlenk tube
at -80 °C.
1H NMR (300 MHz, DMSO-d6) δ [ppm] = 9.14 (s, 1H, – NH – CO – O – CO),
4.53 (ddd, 3JH,H = 7.77, 5.52, 1.08 Hz, 1H, α– H), 3.57 (q, 3JH,H = 7.26
Hz, 2H, CH3 – CH2 – SO2), 3.29–3-18 (m, 2H, – S – CH2 – ), 2.24–2.07 (m, 2H,
– S – CH2 – CH2 – ), 1.30 (t, 3JH,H = 7.26 Hz, 3H, CH3 – CH2 – SO2).
N-ε-benzyloxycarbonyl-L-lysine N-carboxyanhydride (Lys(Z) NCA)[26] 7
The synthesis was adapted from literature and modified.[424,443]
In a three-necked flask equipped with a reflux condenser
and a septum, 15.0 g (53.5 mmol) Z-protected lysine was
suspended in 300 mL of absolute THF. Afterward, 5.2 mL
(42.8 mmol) of diphosgene were added slowly via syringe
and the nitrogen stream was reduced. The solution was
heated to 70 °C, yielding a slightly yellow clear solution after 2 h
of stirring. Afterward, a steady flow of dry nitrogen was lead through
the solution into two gas washing bottles filled with aqueous NaOH.
The solution was concentrated in vacuo, precipitated with absolute
hexane and stored in the fridge for 1 h. The precipitate was collected by
filtration in dry nitrogen atmosphere and washed with absolute hexane.
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The crude reaction product was recrystallized twice from absolute
THF/hexane. A total of 14.3 g of purified product (46.7 mmol, 87 % yield,
colorless needles, melting point: 98.1 – 98.5 °C) was obtained and stored
in a Schlenk tube at -80 °C.
1H NMR (300 MHz, DMSO-d6) δ [ppm] = 9.09 (s, 1H, – NH – CO – O – CO),
7.40–7.25 (m, 6H, – C6H5, – NH – CH2), 5.01 (s, 2H, – O – CH2 – C6H5), 4.43 (t,
1H, 3JH,H = 6.0 Hz, α– H), 2.99 (q, 2H, 3JH,H = 6.3 Hz, – CH2 – NH – ), 1.74–
1.31 (m, 6H, – CH2 – CH2 – CH2 – NH – ).
N-ε-tert-butyloxycarbonyl-L-lysine N-carboxyanhydride (Lys(Boc) NCA)[367] 8
9.8 g (39.8 mmol) of N-ε-Boc-protected lysine was weighed into a three-
necked flask and dried in vacuo for 1 h. The solid was suspended in
300 mL of absolute THF under a steady flow of dry nitrogen. Afterwards,
9.9 mL (79.6 mmol) of absolute trimethyl-silylchloride and
11.0 mL (79.6 mmol) of absolute triethylamine TEA were added slowly
via syringe. The suspension was stirred for 2 h followed by addition
of 4.8 mL (39.8 mmol) of diphosgene, via syringe. The suspension was
mildly refluxed for another 2 h. Overnight, a steady flow of dry nitro-
gen was lead through the solution into two gas washing bottles filled
with aqueous NaOH solution removing excess phosgene and HCl. The
suspension was filtered under dry nitrogen atmosphere to remove the
salts of TEA and unconverted amino acid. The solid was washed with
absolute THF and the filtrate was evaporated under reduced pressure.
Subsequently, absolute THF was added to completely dissolve the crude
reaction product. The solution was precipitated with absolute hexane
and stored at 4 °C for 1 h. The solid was collected by filtration under dry
nitrogen atmosphere and washed with absolute hexane. The crude re-
action product was then recrystallized twice with absolute THF/hexane.
A total of 6.5 g of purified product (23.9 mmol, 68 % yield, colorless nee-
dles, melting point: 136.9 – 137.6 °C) was obtained and stored in a
Schlenk tube at -80 °C.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.07 (s, 1H, – NH – CO – O – CO),
6.95–6.34 (br, 1H, – NH – CO – O – C(CH3)3), 4.42 (t, 1H, 3JH,H = 6.35 Hz,
– CO – CH – CH2 – ), 2.90 (q, 2H, 3JH,H = 6.03 Hz, – CH2 – NH – CO – O – C(CH3)3),
1.79–1.56 (m, 2H, – CH – CH2 – CH2 – CH2 – Ch2 – NH – ), 1.45–1.12 (m, 13H,
– CH – CH2 – CH2 – CH2 – CH2 – NH – , – NH – CO – O – C(CH3)3).
N-ε-trifluoroacetyl-L-lysine N-carboxyanhydride (Lys(TFA) NCA)[24] 9
10.2 g (41.9 mmol) of Lys(TFA) was dissolved in 150 mL of absolute ethyl
acetate, and the suspension was heated to 70 °C. 6.0 mL (50.3 mmol) of
diphosgene was added via a syringe over 3 h. After an additional 1 h,
in which the solution remained slightly cloudy, a nitrogen stream was
passed through the solution for 1 h, and solution was concentrated in
vacuo. 35 mL of absolute AcOEt was added, and the cloudy solution was
filtered. The product was crystallized by slowly adding 80 mL of abso-
lute hexane to the filtrate over 2.5 h. The product was collected by filtra-
tion, recrystallized two times and dried in vacuo for 1 h. A total of 7.1 g
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of purified product (26.6 mmol, 63 % yield, colorless crystals, melting
point: 84.5 – 85.0°C) was obtained and stored in a Schlenk tube at -80 °C.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.40 (t, 1H, – CONH – CF3), 9.09 (s,
1H, – CONH – CH), 4.43 (t, 3JH,H = 6.3 Hz, 1H, α– H), 3.17 (q, 3JH,H = 6.3 Hz,
2H, CH2 – NH), 1.86–1.58 (m, 2H, CH – CH2), 1.50 (p, 2H,
CH2 – CH2 – CH2 – CH2 – NH), 1.44–1.21 (m, 2H, CH2 – CH2 – CH2 – CH2 – NH).
Sarcosine N-carboxyanhydride (Sar NCA)[26] 10
The synthesis of sarcosine NCA was adapted from literature and
modified.[44] A total of 14.9 g (167.4 mmol) sarcosine, dried in vacuo for
1 h, was weighed into a pre-dried, three-neck, round-bottom flask. A
total of 300 mL of absolute THF was added under a steady flow of ni-
trogen and 16.2 mL (134.0 mmol) of diphosgene were added slowly via
syringe, and the nitrogen stream was reduced. The colorless suspen-
sion was mildly refluxed for 3 h, yielding a clear solution. Afterward,
a steady flow of dry nitrogen was led throw the solution for another
3 h into two gas washing bottles filled with aqueous NaOH solution. The
solvent was evaporated under reduced pressure, yielding a brown oil
as crude reaction product. The oil was heated to 50 °C and dried under
reduced pressure (20 mbar, then < 10-2 mbar for 2 h) to obtain an amor-
phous solid, free of phosgene and HCl, confirmed by testing against sil-
ver nitrate solution. The crude product was dissolved in 40 mL absolute
THF and precipitated with 300 mL absolute hexane. The solution was
cooled to -18 °C overnight for complete precipitation. The solid was fil-
tered under dry nitrogen atmosphere, dried in a stream of dry nitro-
gen for 60–90 min and afterwards under high vacuum for 2 h in a sub-
limation apparatus. The crude product was sublimated at 80–85 °C and
< 10-2 mbar. The product was collected from the sublimation apparatus
in a glovebox on the same day. This procedure yielded 12.6 g of purified
product (110.0 mmol, 65 % yield, colorless crystals, melting point: 103.0 –
103.7 °C) which was stored in a Schlenk tube at -80 °C and only handled
under nitrogen atmosphere.
1H NMR (400 MHz, CDCl3) δ [ppm] = 4.22 (s, 2H, – CH2 – ), 2.86 (s, 3H,
– CH3).
8.5.3 Typical polymerization procedure[26]
A 400 mg aliquot of Glu(OBn) NCA (1.5 mmol) was transferred under ni-
trogen counter flow into a pre-dried Schlenk tube equipped with a stir
bar and dried in high vacuum for 1 h. Then the 400 mg of NCA was
dissolved in 2.8 mL of dry DMF. A total of 5.6 µL of neopentylamine
was added to 2 mL of dry DMF in a glass vial flooded with nitrogen
and mixed. For initiation, 1 mL of the prepared stock solution was di-
rectly added to the Schlenk tube via syringe (yielding a total of 4 mL
with 100 mg/mL in respect to monomer). The solution was stirred at
room temperature and kept at a constant pressure of 1.25 bar of dry
nitrogen via the Schlenk line to prevent impurities from entering the
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reaction vessel while allowing CO2 to escape. Completion of the reac-
tion was confirmed by IR spectroscopy (disappearance of the NCA peaks
(1858 cm−1 and 1788 cm−1). Directly after completion of the reaction, the
polymer was precipitated to cold ether and centrifuged (4500 rpm at 4 °C
for 15 min). After discarding the liquid fraction, new ether was added
and the polymer was resuspended in a sonic bath. The suspension was
centrifuged again and the procedure was repeated. After DMF removal
by the resuspension steps, the polymer was dissolved in dioxane and
lyophilized, obtaining a stiff, porous mass of polymer (65.3 mg from the
1 mL precipitated; yield 70 %).
For different NCA polymerizations the reaction temperature ranges
between -10°C and room temperature (25°C) and work-up conditions
vary as reported in literature.[24,26,61,173,367]
8.5.4 Single-crystal X-ray diffraction of NCAs
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8.5.5 X-ray powder diffraction of NCAs
Figure 8.3: Structure of NCAs evaluated by X-ray powder diffraction: 4 Glu(OBn)
NCA, 5 Glu(tBu) NCA, 7 Lys(Z) NCA and 9 Lys(TFA) NCA.
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8.5.6 Images of NCA single-crystals used for X-ray diffraction
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8.5.7 1H NMR Spectra of NCAs
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Olga Schäfer*, David Huesmann*, Matthias Barz, Macromolecules 2016,
49, 8146-8153. (*authors contributed equally)
A B S T R A C T : The amino acid cysteine possesses a unique role in na-
ture due to its ability to reversibly crosS-link proteins. To transfer this
feature to polypeptides and control the process of disulfide formation, a
protective group needs to provide stability against amines during syn-
thesis, combined with chemoselective reactivity toward thiols. A pro-
tective group providing these unique balance of stability and reactivity
toward different nucleophiles is the S-alkylsulfonyl group . In this work
we report the polymerization of S-ethylsulfonyl-L-cysteine α-amino
acid N-carboxyanhydride (NCA) and kinetic evaluations with respect to
temperature (−10 ◦C, 0 ◦C and 10 ◦C) and monomer concentration. The
polymerization degree of poly(S-ethylsulfonyl-L-cysteine) (PCys(SO2Et))
can be controlled within a range of 10 to 30, yielding well-defined poly-
mers with molecular weights of 6900 g mol−1 to 12 300 g mol−1 with dis-
persity indices of 1.12− 1.19 as determined by gel permeation chro-
matography (GPC) and matrix assisted laser desorption/ionization-time
of flight (MALDI-TOF) analysis. The limitation of chain length is, how-
ever, not related to side reactions during ring-opening polymeriza-
tion, but to physical termination during β-sheet assembly. In the case
of poly(S-ethylsulfonyl-L-cysteine), circular dichroism (CD) as well as
fourier transform infrared (FT-IR) spectroscopy confirm an antiparallel β-
sheet conformation. The reaction of PCys(SO2Et) with thiols is completed
in less than a minute, leading quantitatively to asymmetric disulfide
bond formation in the absence of side reactions. Therefore, poly(S-ethyl-
sulfony-L-cysteines)) are currently the only reactive cysteine derivative
applicable to NCA synthesis and polymerization, which allows efficient
and chemoselective disulfide formation in synthetic polypeptides, by-
passing additional protective group cleavage steps.
149
150 P O LY (s - E T H Y L S U L F O N Y L - L - C Y S T E I N E )
9.1 I N T R O D U C T I O N
The synthesis of polypeptides by ring-opening polymerization of
α-amino acid N-carboxyanhydrides (NCAs) has been the subject of
intensive studies since the early 20th century, when Leuchs discovered
this class of monomers.[37,39,45] From the end of the 20th century,
various techniques to control the polymerization have been explored,
including metal catalysts, different initiators, extremely pure chemi-
cals, and low temperatures.[48–54,56] Achieving control over molecular
architecture and end-group integrity as well as polymer dispersity
seems to be of particular importance for an application of polypeptides
in nanomedicine.[30,355,408,409] A fairly young field of research is NCAs
with side chain functionalities that are stable under polymerization
conditions but directly addressable by post polymerization modifi-
cation reactions.[58,444–446] Bio-orthogonal reactive groups like azides
(copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC)[314]), alkynes
(CuAAC,[447] thiol–yne[313]), double bonds (thiol–ene,[313] oxidations,[448]
Michael addition,[360] olefin metathesis,[449] Suzuki coupling[449]),
thioethers (alkylation[450]), and chlorides (nucleophilic substitution,[451]
ATRP[452]) have been successfully established. However, while all of
these polymers can be modified in one post polymerization step, the
covalent bonds formed (triazines, thioethers, carbon–carbon bonds) are
not reversible, leading to a permanent modification of the polymer. For
biomedical applications a stimuli responsive linkage is often preferred
for the release of cargo or the degradation of carriers.[153] These linkages
can be redox (disulfides) or acid labile (acetals and hydrazones), en-
abling cleavage of the bond in different intracellular compartments. In
contrast to radical polymerizations, acetals and hydrazones are neither
compatible to NCA synthesis and polymerization nor applicable to
chemoselective cross-linking reactions.
Since cysteine is also involved in reversible disulfide bond formation
in natural proteins,[159] it seems to be an ideal candidate for the synthesis
of reactive polypeptides for disulfide formation via post polymerization
reactions. To realize this concept, two requirements have to be fulfilled:
(I) The thiol at the cysteine side chain needs to be activated to react with
other thiols after polymerization under disulfide formation, and (II) the
modified thiol needs to be stable during NCA synthesis and polymeriza-
tion (presence of amine nucleophiles).
Achieving these requirements is not a trivial task because on one
hand a rapid reaction with thiols (soft nucleophiles) is desired, while
on the other hand with amines (hard nucleophiles) need to be strictly
avoided with respect to a controlled polymerization. While a wide
range of cysteine NCAs (S-allylcysteine, S-benzylcysteine, S-benzyloxy-
carbonylcysteine, S-benzyloxycarbonylmethylenecysteine, S-butyl- cys-
teine, S-tert-butylmecaptocysteine, a range of S-alkylcysteines (dode-
cyl, hexyl, methyl, ethyl, prolyl, isopropyl), S-(2- trimethylsilyl ben-
zyl)cysteine, S-(4-trimethylsilylbenzyl)-cysteine, cystine (bisNCA), S-
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thiophenylcysteine) from the early years of NCA polymerization has
been collected,[45] none of them is suitable for activation of the cys-
teine thiol for direct disulfide formation. Recent developments of cys-
teine NCAs were either not focused on post polymerization modifica-
tion at all,[312,357,358,453] have implemented disulfide moieties prior to
NCA formation[454] or have worked with deprotection and subsequent
modification using irreversible thiol–ene chemistry leading to stable
thioethers.[311,359,360] In previous studies, we investigated activated cys-
teine NCAs and their polymerization for post polymerization modifi-
cation. However, all compounds proved to be prone so side reactions
during the polymerization due to high electron deficiency of the side
groups,[321] once again emphasizing the need for a protective group
with a balanced reactivity profile.
In this work we describe the polymerization of the recently devel-
oped S-ethylsulfonyl-L-cysteine (Cys(SO2Et)) NCA[173,364] (Cys(SO2Et) NCA)
and the post polymerization modification these polymers. The S-ethyl-
sulfonyl protective group fulfills all the requirements mentioned above
since it is stable under NCA synthesis and polymerization conditions,
while being highly reactive toward thiols. Detailed analyses of poly-
merization kinetics and polymer properties are presented. In the end,
we report on the stability at different pH values and the reactivity in
post polymerization modifications reactions with thiols, underlining the
enormous potential of this new class of reactive NCAs.
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To obtain the Cys(SO2Et) NCA, first the corresponding protected amino
aicd was received by nitrosation of L-cysteine followed by reaction with
sodium ethanesulfinate (Figure 9.1 A). The NCA was then synthesized by
the Fuchs–Farthing method using diphosgene as the phosgene
source[40–42] and was obtained in high purity (melting point range: 113–
115 °C) after repeated recrystallization. The 1H NMR of the Cys(SO2Et) NCA
is given in Figure 9.1 B and its rather complex spin–spin coupling pat-
tern is discussed in the Supporting Information (Figure 9.8). When solid
state as well as liquid film infrared (IR) spectroscopy (Figure 9.1 C and
9.4 A) is performed, two carbonyl stretching bands can be observed at
frequencies characteristic for mixed anhydrides.[45]-bond formation in
the crystalline, solid state of the Cys(SO2Et) NCA.
The polymerization of the Cys(SO2Et) NCA was initiated by neopenty-
lamine (Figure 9.2 A), since the 9 equiv methyl-protons allow reliable
determination of repeating units by NMR (Figure 9.9). In regard to a
ring-opening polymerization in a controlled fashion, it has to be consid-
ered, that any deprotection reaction at the S-ethylsulfonyl group during
polymerization bears the risk of side reactions. A possible side reaction
would be an attack of the living chain end at the S-ethylsulfonyl site. If
this side reaction was present even at minimal amounts, it would hinder
the polymerization dramatically due to capping of the propagating end
152 P O LY (s - E T H Y L S U L F O N Y L - L - C Y S T E I N E )
Figure 9.1: A) Synthesis of Cys(SO2Et) NCA. B) 1H NMR and C) solid state IR of
Cys(SO2Et) NCA.
group. Furthermore, deprotection reactions may then originate from the
free nucleophilic thiol group, and control over the polymerization pro-
cess would be lost. However, 1H diffusion-ordered NMR experiments
(1H DOSY NMR) of poly(S-ethylsulfonyl-L-cysteine) (PCys(SO2Et)), as well
as further characterization methods such as gel permeation chromatog-
raphy (GPC), matrix assisted laser desorption/ionization-time of flight
(MALDI-TOF), and end-group functionalization, fully eliminates this con-
cern. 1H DOSY NMR reveals only two diffusing species, of which one is
the solvent (DMSO-d6) while all other signals originate from PCys(SO2Et)
(Figure 9.3). Since no other polymeric or small molecular species can be
observed, signals in 1H NMR correspond exclusively to the polymer, and
thus, end group analysis is a valid method to determine the degree of
polymerization.
Figure 9.2: A) Polymerization of Cys(SO2Et) NCA with neopentylamine as initia-
tor. B) HFIP GPC traces of PCys(SO2Et) at various degrees of polymer-
ization (see also Table 9.1).
As can be seen in Table 9.1 and Figure 9.2 B, the polymerization pro-
ceeds in a controlled fashion and yields PCys(SO2Et) well-defined homo-
polymers with narrow, symmetric distributions (Ð< 1.2). Due to the ag-
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gregation ofβ-sheets (as exhibited by most polycysteine derivatives, dis-
cussion below) at degrees of polymerization above 30, no reliable GPC
characterization can be carried out for longer polymers (see Figure 9.11).
Propagating β-sheet formation is also responsible for a change in poly-
merization kinetics, which leads to slower polymerization rates reach-
ing high conversions (see also below). Therefore, PCys(SO2Et) polymer-
izations are usually terminated by precipitation before full conversion
is reached.
Table 9.1: Characterization of PCys(SO2R).
No. M/I % conversion Xn, NMR Mn, GPCa/g mol−1 ÐGPCa
P1 15 80 13 6900 1.12
P2 15 92 15 7000 1.14
P3 20 88 17 8400 1.16
P4 50 39 20 9000 1.15
P5 50 63 27 12300 1.19
a Relative to PMMA standards.
Additionally, the following general aspects regarding S-alkylsulfonyl-
L-cysteine are noteworthy: molecular weights obtained by GPC should
not be interpreted as the real molecular weight. First, as circular dichro-
ism (CD) spectra confirm (Figure 9.3 B), the polymer adapts β-sheet
conformation in solution, thus hydrodynamic volumes will differ
significantly from a polymer in random coil conformation. Second,
the calibration of the GPC is performed with PMMA standards, whose
C – C backbone does not fully correlate to a polypeptide backbone.
Therefore, the Mn, GPC can only serve for comparison between the
polymers, but should not be considered as the real molecular weight.
Further, in order to evaluate handling of the PCys(SO2Et) homopolymers,
their stability in different pH buffers was examined (see Figure 9.12).
The S-ethylsulfonyl group proved to be sensitive to a nucleophilic
OH– attack followed by removal of the protective group. As a result,
precautions have to be taken considering dry solvents and reagents,
whenever bases are present. Acidic to neutral conditions, however, do
not affect the protective group of PCys(SO2Et) at all.
Poly-L-cysteine is known to form β-sheets[37,455] as illustrated in Fig-
ure 9.3 A. This also applies to most of its derivatives[358,453] (although,
equipped with hydrophilic sugar residues[312] or oligo(ethylene glycol)
chains[456] other conformations of varying amounts are possible). Thus,
theβ-sheet conformation of PCys(SO2Et) was evaluated by CD and IR spec-
troscopy. All CD spectra (Figure 9.3 B) show traces shaped typically for
β- sheets and the IR spectrum (Figure 9.3 C) exhibits a strong amide I
band at 1637 cm−1 as well as the amide II band at 1514 cm−1, which are
both characteristic for polypeptides in a β-sheet conformation.[457] The
shoulder at 1690 cm−1 to 1702 cm−1 implies that the polypeptides are ar-
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ranged in an antiparallel direction.[458]
Figure 9.3: A) Schematic illustration of β-sheet formation during growth of
the peptide chain. B) CD spectrum of PCys(SO2Et) in HFIP showing
β-sheets in solution. C) IR spectrum of PCys(SO2Et) in solid state dis-
playing typical absorption bands of antiparallel β-sheets.
Above an Xn of 30, PCys(SO2Et) has the tendency to form β-sheet ag-
gregates, leading to a high molecular weight shoulder in HFIP GPC (Fig-
ure 9.11). Further, increasing turbidity of the polymerization solution
due to aggregation can be observed for higher degrees of polymeriza-
tion (see Figure 9.11 where Xn = 43 shows a significant amount of ag-
gregated polymer chains). However, a length of more than 30 repeating
units is not required for applications like cross-linking; usually, 10–20
repeating units are sufficient as an effective cross-linkable block.
To gain a deeper insight into the kinetic behavior of PCys(SO2Et) poly-
merization, IR spectroscopy was performed during ongoing synthesis
(Figure 9.4 A). The decrease of the carbonyl peaks of the NCA at 1858 cm−1
and 1788 cm−1 is directly related to conversion of the monomer and thus
can be used in kinetic studies to precisely determine monomer conver-
sion. The signals were integrated to calculate the conversion for each
time point. To enhance accuracy and underline reproducibility, the ki-
netic studies were performed for three individual polymerization en-
tries. Standard deviations are included in Figure 9.3 B. It can be observed
that the individual error is negligible for short time points and still mi-
nor for higher conversions.
Figure 9.4: A) IR spectra of a PCys(SO2Et) polymerization at different reaction
times (in DMF, liquid film). B) Kinetic plot of the PCys(SO2Et) poly-
merization with n = 3. C) Kinetic plot of PCys(SO2Et) polymerizations
at varying monomer concentrations (M/I = 50).
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While most NCA polymerizations show pseudo first-order kinetics,
the formation of β-sheets dramatically alters this behavior. Iguchi
adapted the Avrami equation for the kinetics of crystal growth to de-
scribe heterogeneous polymerizations,[459] while Ko¯moto et al.used it in
analyzing NCA polymerizations of aggregating peptide chains.[460,461]
Several assumption are made to suit the heterogeneous polymerization
system: At the beginning of the polymerization the system is homoge-
neous, consisting of the solvent, the monomer and the initiator. It is as-
sumed, that the initiation starts immediately after addition of the initia-
tor. Termination or transfer do not occur chemically. However, oligomers
associate at very early stages of the polymerization. The chains then
propagate at the surface of those soluble nanocrystallites (see Figure 9.3
A). Eventually a physical termination of the “living” chain end can occur,
due to steric restrictions of secondary structures (especially when high
degrees of polymerization are reached). The linear chain growth after ag-
gregation is considered a one-dimensional transformation of the grow-
ing units. This situation attributes to the growth of needle-like crystals.
In fact, most derivatives of poly-L-cysteine exhibit such fibrous struc-
tures at the initial phase of the polymerization.[460,461] The Avrami equa-
tion, adapted for NCA polymerization is given by[459]
δ(x)
δ(t)
= k[I][M0]
(
1−
x
[M0]
)2
(12)
with [M0]= initial monomer concentration, [I]= initiator concentration,
x = [M0] − [Mt]= monomer consumed at time t, and k= rate constant.
It follows that the polymerization rate is proportional to the square of
the residual monomer concentration [Mt]:
δ(x)
δ(t)
= k[I]
[Mt]
2
[M0]
(13)
This signifies, that polymerization rates drop dramatically at high con-
versions. This was also observed experimentally and PCys(SO2Et) poly-
merizations were terminated latest at conversions of 90 % due to stag-
nation of the NCA consumption. From Equation 12 can be derived using
Equation 13:
[M0]
[M0] − x
= k[I]t+ 1 (14)
By plotting
[M0]
[Mt]
− 1 versus the reaction time t, the apparent rate con-
stant kapp = k[I] , and thereby the rate of polymerization k can be cal-
culated. Experimental values obtained from IR spectroscopy following
this kinetic approach are shown in 9.4 B, C and Figure 9.13 A.
According to the kinetic interpretation presented above, the polymer-
ization rates depend on the initial monomer concentration. This behav-
ior can indeed be observed by comparison of the apparent rate con-
stants at varying initial monomer concentrations, while maintaining the
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same monomer to initiator ratio (Figure 9.4 C). Additionally, the proba-
bility for side reactions can be decreased by lowering the reaction tem-
perature,[55,462] ensuring faster polymerization rates and narrow molec-
ular weight distributions (see Figure 9.13).
In terms of polymer characterization, MALDI-TOF mass spec-
troscopy provides an absolute method of determining molecu-
lar weights.[461] However, the transfer of larger cysteine poly-
mers into the gas phase presents a challenge. Since the solu-
bility of PCys(SO2Et) is limited to fringhigh boiling solvents like
DMSO and DMF, a solvent free sample preperation was chosen. P1
(Xn, NMR = 13) was investigated and the results are illustrated in
Figure 9.5 A. The polymer distribution is narrow, yielding calcu-
lated molecular weights of Mn = 2194 g mol−1 and Mw = 2446 g mol−1
(Ð = 1.11). The degree of polymerization derived from Mn, MALDI is
Xn, MALDI = 11 and in good agreement with the value from NMR
Xn, NMR = 13.
Figure 9.5: MALDI-TOF spectrum of PCys(SO2Et) P1 with Xn, NMR = 13.
A magnification of the spectrum (Figure 9.5 B) reveals the individual
signals of PCys(SO2Et) initiated by neopentylamine and each equipped
with a primary amine chain end. Signals indicating initiation by im-
purities or terminations are absent. The most prominent signals corre-
spond to an additional proton (+1). Signals correlating to an addidi-
tonal sodium cation (+23), a potassium cation (+39) and a copper cation
(+64) were also identified. When comparing the calculated masses of
PCys(SO2Et) with the experimental results, the accumulation of heavier
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sulfur atoms has to be taken into account. 32S is the most frequent iso-
tope (95.02 %) followed by 34S (4.21 %).[463] Because of this natural va-
riety of isotopes and the two sulfur atoms per repeating unit, a rather
broad signal is observed. Figure 9.5 C compares the simulated peaks for
PCys(SO2Et) + H+ with Xn = 11 to the measured spectrum, showing the
peaks for individual isotopes, revealing the same isotope distribution
for simulated and experimental data.
In summary, MALDI-TOF experiments clearly reveal the absence of
chemical chain termination when polymer- izations are carried out at
–10 °C in absolute solvents. For different polymerization conditions chain
termination can rapidly occur, which explains the slow polymerization
kinetics and broad molecular weight distributions observed under sub-
optimal conditions (see Supporting Information). To further investigate
the presence of living chain ends and absence of free thiols, labeling of
NH2 groups and potential SH groups was performed.
PCys(SO2Et) was analyzed by means of fluorescent side chain and end
group labeling, evaluating two possible reaction sites. The amine end
group is an important feature of the polypeptides synthesized via NCA
polymerization, since it is a prerequisite for initiation of a second block
leading to diblock copolymers. A second reactive group is a free thiol,
which might be present due to the removal of the protective group by
amine nucleophiles. This presents an undesirable case, since interfer-
ence with the polymerization process can be expected, as well as un-
controlled cross-linking by disulfide bond formation.
First, the absence of free thiol groups was verified, since they might
interfere with labeling of the amine end group. A maleimide dye (fluo-
rescein diacetate 5 maleimide) is a suitable reagent to label thiols (Fig-
ure 9.6 A), but not amines.[464] As can be observed with the bare eye
(Figure 9.6 C), the sample treated with the maleimide dye yielded a col-
orless polymer. Figure 9.6 E displays the ultra violett (UV) signal of the
HFIP GPC traces at the excitation maximum (492 nm) before and after re-
action with the maleimide dye. Only absorption of the free dye, but no
absorption of polymer conjugated dye can be observed. Therefore, it is
apparent that free thiol groups are absent in the polymer and that the S-
ethylsulfonyl group is stable during NCA polymerization. To verify end
group integrity of PCys(SO2Et), labeling of the amine end group was per-
formed with a N-hydroxysuccinimide (NHS) ester dye (Oregon Green
488-X, succinimidyl ester; Figure 9.6 B).[465] This treatment yielded a
bright yellow polymer (Figure 9.6 D). The results are depicted in Fig-
ure 9.6 F comparing the UV signal of the HFIP GPC traces (excitation max-
imum 496 nm) before and after reaction with the succinimidyl ester dye.
In contrast to the labeling with the maleimide dye, the GPC trace shows
a strong absorbance of a polymer–dye conjugate with a narrow molecu-
lar weight distribution in analogy to the parent polymer.
In addition to the findings from MALDI-TOF experiments, this label-
ing reaction also confirms the presence of a functional amine chain end.
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Thus, we clearly state, that the polymerization of PCys(SO2Et) proceeds
in a controlled fashion and in the absence of chemical termination reac-
tions.
Figure 9.6: Labeling reactions of PCys(SO2Et) with a maleimide dye A) and a
NHS ester dye B) respectively. Illustrating photograph of the sam-
ple treated with maleimide dye, which is colorless C), while the one
treated with NHS ester dye D) shows a bright yellow color. HFIP
GPC traces (UV detector signal at excitation maximum of dye) of
PCys(SO2Et) before and after reaction with the maleimide dye E) and
the succinimidyl ester dye respectively F).
Finally, the ability of PCys(SO2Et) to react with thiols in a post polymer-
ization modification reaction was investigated. Therefore, benzylmer-
captan was added immediately prior to the measurement to a solution
of P1 and the reaction progress was monitored by 1H NMR . The thiol was
implemented in sufficient stoichiometric excess relative to the protected
cysteine residues (see Supporting Information), to ensure a complete
conversion of each cysteine side chain into the corresponding disulfide.
The protective group readily engages in a nucleophilic reaction with
the thiol, ultimately resulting in an asymmetric disulfide and the cor-
responding sulfinate (Figure 9.7 A) with quantitative conversion after
60 s. As can be noted in Figure 9.7 B and C, all peaks corresponding to
the poly cysteine backbone and to the end group (a–c, f ) remain present.
Furthermore, signals in Figure 9.7 B originating from the benzyl group
(d’+e’) as well as the free sulfinate (4+5) appear after conversion. Ul-
timately, a magnification in Figure 9.7 D reveals the complete disap-
pearance of the polymer associated triplett of the S-ethylsulfonyl group
(e, 1.30 ppm, being replaced by a triplett (5, 1.08 ppm) corresponding to
the converted protective group.
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Figure 9.7: A) Scheme of the reaction of PCys(SO2Et) with benzylmercaptan.
B) 1H NMR spectrum of PCys(SO2Et) prior to conversion. C) 1H NMR
spectrum after conversion with benzylmercaptan. D) Enlarged com-
parison of both 1H NMR spectra emphasizing the quantitative conver-
sion (disappearance of polymer associated protective group signal
at 1.30 ppm and emerging signal at 1.08 of the fully converted pro-
tective group). E) 1H DOSY NMR spectrum of PCys(SO2Et) prior to con-
version. F) 1H DOSY NMR spectrum after conversion with benzylmer-
captan showing one single diffusing polymeric species without sig-
nals corresponding to the protective group, but including signals of
a benzyl group.
Additionally, the conjunction of the relevant signals to a polymeric
species was confirmed by 1H DOSY NMR experiments. Figure 9.7 E shows
PCys(SO2Et) prior to the reaction. All signals annotated to PCys(SO2Et) ex-
hibit identical diffusion traces (b–f ). Signals corresponding to low molec-
ular weight compounds (such as solvents) diffuse cumulated above.
Once the reaction with the thiol is conducted (Figure 9.7 F), signals an-
notated the protective group at the polymer are absent, being replaced
by a low molecular weight species corresponding to the reacted protec-
tive group (4, 5). Signals corresponding to a benzyl group (d’, e’) are
present in line with those from the backbone (b, c) and the end group
(f ), confirming a single diffusing, polymeric species. Therefore, poly(S-
ethylsulfonyl-L-cysteine) proved to be capable of direct disulfide forma-
tion providing access to a novel class of reactive polypeptides
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9.3 C O N C L U S I O N
We have presented the ring-opening polymerization of the novel S-ethyl-
sulfonyl-L-cysteine NCA which is, under optimized polymerization con-
ditions, a well-controlled process without side reactions. At –10 °C the
polymerization proceeds faster in comparison to higher temperatures,
with rate constants at k= 10-11× 10−4 L mol−1 s−1. The S-ethylsulfonyl-L-
cysteine homo- polymers exhibit a β-sheet conformation in solid phase
as well as in solution, thus they tend to form aggregates at degrees
of polymerization above 30. The polymers are fully stable at neutral
and acidic pH and react directly with thiols in one simple post poly-
merization modification reaction, leading to disulfide-modified poly-L-
cysteines.This new class of activated cysteine polymers possesses high
potential for biomedical applications, since the generated disulfides are
cleavable in the reductive intracellular environment. Exploiting this pro-
cess will allow the reversible conjugation of drugs as well as reversible
cross-linking of nanostructures. Combined with a hydrophilic block, for
example polypept(o)ides,[26,59,70] poly(S-ethylsulfonyl-L-cysteine)) is ex-
pected to lead to a new, promising class of polypeptidic nanomaterials.
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9.5 S U P P O R T I N G I N F O R M AT I O N
9.5.1 Materials and Instrumentation
n-Hexane was distilled from Na/K and ethyl acetate from CaH2. DMF was
purchased from Acros and dried over BaO and molecular sieve (3 Å),
fractionally distilled in vacuo at 20 °C and stored at -80 °C under ex-
clusion of light. Prior to use, N,N-dimethyl formamide (DMF) was de-
gassed in vacuo to remove traces of dimethylamine. Millipore water was
prepared by a MILLI-Q® Reference A+ System. Neopentylamine was
purchased from TCI Europe and was dried over NaOH and fractionally
distilled before use. Cysteine was purchased from OPREGEN and used
as received and diphosgene was purchased from Alfa Aesar. Deuter-
ated solvents were purchased from Deutero GmbH and hexafluoro 2-
propanol (HFIP) from Fluorochem. Other chemicals were purchased from
Sigma-Aldrich and used as received unless otherwise stated.
1H, 19F and 13C nuclear magnetic resonance (NMR) spectra were
recorded on a Bruker AC 400 at a frequency of 400, 376 and 101 MHz,
respectively. 1H and 19F NMR spectra were also recorded on a Bruker
Avance III HD 300 at 300 and 282 MHz, respectively. Two-dimensional
NMR spectra as 1H diffusion ordered spectroscopy (DOSY), correlation
spectroscopy (COSY) and heteronuclear single-quantum correlation
spectroscopy (HSQC) were recorded on a Bruker Avance III HD 400
at 400 MHz. All spectra were recorded at room temperature (25 ◦C)
and calibrated using the solvent signals.[376] Melting points were mea-
sured using a Mettler FP62 melting point apparatus at a heating rate
of 5 ◦C min−1. Electrospray ionization mass spectrometry (ESI-MS) was
performed on a Micromass Q-TOF-Ultima spectrometer and gel perme-
ation chromatography (GPC) was performed with HFIP containing 3 g l−1
potassium trifluoroacetate (KTFA) as eluent at 40 ◦C and a flow rate of
0.8 ml min−1. The columns were packed with modified silica (PFG
columns particle size: 7 µm, porosity: 100 Å and 1000 Å). Polymethly
methacrylate PMMA standards (Polymer Standards Services GmbH)
were used for calibration and toluene was used as internal standard.
A refractive index detector (G1362A RID) and an UV/Vis detector (at
230 nm unless otherwise stated; Jasco UV-2075 Plus) were used for poly-
mer detection.
Matrix assisted laser desorption ionization time of flight (MALDI-TOF)
mass spectra[397] were recorded using a Bruker Reflex II MALDI-TOF
mass spectrometer equipped with a 337 nm N2 laser. Acceleration of
the ions was performed with pulsed ion extraction (PIE, Bruker) at a
voltage of 20 kV. The analyzer was operated in reflection mode and
a microchannel plate detector was used. Mass spectra were processed
by the X-TOF 5.1.0 software (Bruker). A solvent free sample prepa-
ration was performed using tranS-2-[3-(4-tertbutylphenyl)-2-methyl-2-
propenylidene]malononitrile DCTB as the matrix and sodium trifluoroac-
etate NaTFA as the cationizing salt. Calibration was carried out using a
C60/C70 fullerene mixture. Spectra were analyzed and simulated using
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mMass. IR spectroscopy was performed on a Jasco FT/IR- 4100 with an
ATR sampling accessory (MIRacle, Pike Technologies) and Spectra Man-
ager 2.0 (Jasco) was used for integration.
Circular dichroism (CD) spectroscopy was performed on a Jasco J-815
spectrometer at room temperature and Spectra Manager 2.0 (Jasco) was
used to analyze the spectra. A cell with a path length of 1 mm was
used. Spectra were recorded at a concentration of 0.5 mg ml−1 polymer
in HFIP containing 3 g l−1 KTFA. θ was calculated using Equation 15 with
MRepeating Unit = 195.00 g mol−1, cM = 0.1 g l−1 and l = 0.1 cm for Cys(SO2Et).
θMR =
θ ·MRepeatingUnit
10 · cM · l deg cm
2 dmol−1 (15)
9.5.2 Synthetic Procedures
Synthesis of ethanesulfinic acid sodium salt
A solution of sodium sulfite (391.98 g, 3.11 mol) in water (800 mL) was
heated to 80 °C. Ethanesulfonyl chloride (147.40 mL, 199.30 g, 1.55 mol)
and sodium carbonate (329.63 g, 3.11 mol) were added simultaneously
while significant quantities of CO2 evolved. The reaction mixture was
stirred for one hour at 80 °C, afterwards water was removed in vacuo
at 60 °C. The resulting solid was suspended in methanol and filtered.
Evaporation of methanol gave ethanesulfinic acid sodium salt (153.54 g,
1.32 mol, 85 %) as a colorless solid.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 1.79 (q, 3JH,H = 7.6 Hz, 2H, – CH2 – ),
0.90 (t, 3JH,H = 7.6 Hz, 3H, – CH3).
Synthesis of S-ethylsulfonyl-L-cysteine (Cys(SO2Et))[173]
An ice-cold solution of sodium nitrite (5.94 g, 86 mmol) in degassed
water (45 mL) was slowly added to a stirred solution of L-cysteine hy-
drochloride (13.57 g, 86 mmol) in previously degassed 2 N HCl (90 mL)
at 0 °C. After 1 h, ethanesulfinic acid sodium salt (20.00 g, 172 mmol)
was added to the deep red solution and was stirred for 2 h. Additional
sodium ethanesulfinate (5.00 g, 43 mmol) was added and eventually
a colorless solid precipitated. The reaction mixture was stirred at 0 °C
overnight. The precipitate was filtered off and the pH of the colorless
filtrate was adjusted with 2 N NaOH to pH 4-5, resulting in additional col-
orless solid precipitating. The filtrate was allowed to stand at 4 °C un-
til precipitation was complete. The combined precipitates were washed
with MeOH to remove residual sulfinate and dried in vacuo yielding
Cys(SO2Et) (5.03 g, 24 mmol, 27 %) as a colorless, crystalline solid.
Crystal Structure (CCDC-1440861): colorless platelett from H2O
(0.026 × 0.280 × 0.550 mm), monoclinic space group P 21, refinement:
wR2 = 0.1223 (R1 = 0.0467 for observed reflections, 0.0509 for all reflec-
tions), flack parameter x = -01(1), crystal structure contains two indepen-
dent molecules with slightly different conformations.
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1H NMR (400 MHz, DMSO-d6/ TFA-d) δ [ppm] = 4.34 (t, 3JH,H = 6.4 Hz,
3JH,H = 6.0 Hz, 1H, α– H), 3.66 (dd, 2JH,H = 14.4 Hz, 3JH,H = 6.0 Hz, 1H,
– CHH – S), 3.62 (q, JH,H = 7.2 Hz, 2H, – CH2 – SO2), 3.53 (dd, 3JH,H = 14.4 Hz,
3JH,H = 6.4 Hz, 1H, – CHH – S), 1.30 (t, 3JH,H = 7.2 Hz, 3H, – CH3).
13C NMR (101 MHz, DMSO – d6/ TFA – d) δ [ppm] = 168.88 ( – COO), 56.27
( – CH2SO2), 51.84 ( – CHN), 34.79 ( – CH2S), 8.30 ( – CH3).
ESI – MS: m/z = 214.03 [M+H]+, (calc. 213.28 g mol-1); 236.01 [M+Na]+, (calc.
236.15 g mol-1).
Synthesis of S-ethylsulfonyl-L-cysteine N-carboxyanhydride
(Cys(SO2Et) NCA)[173]
Dried Cys(SO2Et) (7.00 g, 32.82 mmol) was suspended in absolute THF
(100 mL) and heated to 70 °C. Diphosgene (3.60 mL, 5.84 g, 29.52 mmol)
was slowly added and the suspension was heated for an additional 4 h.
Dry nitrogen was bubbled through the reaction mixture overnight into
a gas washing bottle with an aqueous KOH solution to remove excess
diphosgene, HCl and most of the solvent. The remaining solvent was re-
moved in vacuo and the residue was dissolved in 100 mLabsolute ethyl
acetate. Any insoluble compounds were removed by filtration avoiding
contact with air and the NCA was precipitated by adding 800 mL abso-
lute hexane. The recrystallization of the product was repeated two more
times yielding Cys(SO2Et) NCA (6.43 g, 26.87 mmol, 82%) as a colorless,
crystalline powder (m.p. 113-115 °C).
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.32 (s, 1H, – NHCO), 4.86 (td,
3JH,H = 6.0 Hz, 3JH,H = 4.8 Hz, 3JH,H = 1.6 Hz, 1H, α– H), 3.64 (dd, 2JH,H
= 14.4 Hz, 3JH,H = 4.8 Hz, 1H, – CHH – S), 3.62 (q, 3JH,H = 7.2 Hz, 2H,
– CH2 – SO2), 3.57 (dd, 2JH,H = 14.4 Hz, 3JH,H = 6.4 Hz, 1H, – CHH – S), 1.29
(t, 3JH,H = 7.2 Hz, 3H, – CH3).
13C NMR (101 MHz, DMSO – d6) δ [ppm] = 169.58 (CNOO), 151.68 ( – COO),
56.99 ( – CHSO2), 56.16 ( – CHN), 36.00 ( – CH2S), 8.24 ( – CH3).
Ring-Opening Polymerization of poly(S-ethylsulfonyl-L-cysteine) (PCys(SO2Et))
Cys(SO2Et) NCA (107 mg, 447 µmol) was transferred into a Schlenk tube
under dry nitrogen counter flow. Absolute DMF (3 mL) and absolute
neopentylamine (1.74 µL, 1.30 mg, 15 µmol) were added and the ves-
sel was cooled to -10 °C. A steady flow of dry nitrogen was sustained
during the polymerization, preventing any impurities from entering the
Schlenk tube, while ensuring the escape of produced CO2. The progress
of the polymerization was monitored via IR spectroscopy by the dis-
appearing NCA carbonyl peaks intensities at 1858 cm−1 and 1788 cm−1.
Samples were taken using a nitrogen flushed syringe trough a septum.
The polymer was precipitated after 70 % conversion in a mixture of
cold diethyl ether and tetrahydrofurane (THF) (5:1 v/v) to solubilize
and remove remaining NCA. The suspension was centrifuged (4500 rpm,
15 min, 0–10 °C) and decanted. This procedure was repeated twice con-
cluding with pure diethyl ether yielding poly(S-ethylsulfonyl-L-cysteine)
(65 mg, 73 %) as a colorless to slightly yellow solid.
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1H NMR (400 MHz, DMSO-d6) δ [ppm] = 8.76 (m, 1nH, – NHCO),
4.68 (m, 1nH, α– H), 3.63-3.42 (m, 4nH, – CH2 – SSO2 – CH2 – ), 1.30 (t, 3nH,
– CH3), 0.85 (s, 9H, – (CH3)3).
Labeling with Fluorescein Diacetate 5-Maleimide
PCys(SO2Et)) was dissolved in HFIP (1 mL) containing potassium triflu-
oroacetate (3 g l−1 KTFA) . One equivalent (for each cysteine side chain)
of fluorescein diacetate-5-maleimide was added and the mixture was
stirred at room temperature for 1 day under exclusion of light. Char-
acterization was carried out by HFIP GPC at with the UV detector set at
λ= 492 nm. The UV signals were normalized using the RI signal, to ex-
clude signal strength variation due to differences in concentration.
Labeling with Oregon Green 488-X, Succinimidyl Ester
PCys(SO2Et)13 (1.10 mg) was dissolved in dry DMF 450 (µL). Oregon Green
488-X succinimidylester (2.09 mg, 7.7 eq. per NH2 end group) in dry DMF
(50 µL) was added. The dye solution was added under nitrogen and the
reaction was stirred for 3 days at room temperature under exclusion of
light. The polymer was then precipitated in cold diethyl ether followed
by the usual work-up yielding a yellow solid. Free dye was removed by
collecting fractions at the GPC outlet. The polymer was characterized by
HFIP GPC at with the UV detector set at λ= 496 nm. The UV signals were
normalized using the RI signal, to exclude signal strength variation due
to differences in concentration.
Thiol-Reactivity
To investigate the ability of PCys(SO2Et)) to react with thiols in a post poly-
merization modification reaction, a mixture of PCys(SO2Et)) and
benzylmercaptan in DMSO-d6 were observed by 1H NMR . Therefore
PCys(SO2Et)13 (P1, 7.30 mg, 1.0 eq.) was dissolved in DMSO-d6 (0.7 mL)
and benzylmercaptan (4.94 mg, 1.1 eq. in respect to Xn Cys) was added
immediately prior to the measurement. The disappearance of the CH3
Signal from the SO2Et group was used to monitor the conversion. Addi-
tionally, the conjunction of the relevant signals to a polymeric species
was confirmed by 1H DOSY NMR experiments.
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9.5.3 NMR Analysis of Cys(SO2Et) NCA
Figure 9.8: 1H NMR of Cys(SO2Et) NCA with assignments and coupling constants.
Due to the rather complex 1H NMR spin-spin coupling pattern of the
Cys(SO2Et) NCA the signals overlap strongly. The assignment of the pro-
tons is given in Figure 9.8. The two methylene protons of the cysteine
side chain (green) exhibit a large geminal proton-proton coupling con-
stant of 2JH,H = 14.4 Hz and two different coupling constants to the α-
proton (3JH,H = 4.8 Hz and 3JH,H = 6.0 Hz). For the α-proton a long dis-
tance interaction between and the two protons of the methylene of the
protective group can be observed. Thus, the signal of the α-proton (or-
ange) results in a doublet of doublets of doublets with the two coupling
constants (3JH,H = 4.8 Hz and 3JH,H = 6.0 Hz) to the methylene protons
of the cysteine side chain (green) and a coupling constant of 6JH,H = 1.6
Hz to the methylene protons of the protective group (pink). The signal
of the methyl group (blue) shows a triplett with a coupling constant of
3JH,H = 7.2 Hz which can again be found in the coupling pattern of the
methylene protons of the protective group (pink).
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9.5.4 NMR Analysis of PCys(SO2Et)
Figure 9.9: 1H NMR of PCys(SO2Et) with assignments (in DMSO-d6).
Figure 9.10: hoch1H DOSY NMR of PCys(SO2Et) with assignments (in DMSO-d6)
showing a single diffusing polymeric species.
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9.5.5 GPC Analysis of PCys(SO2Et)
Upon higher molecular weight a complication in the analysis by
HFIP GPC related to β-sheet formation can be observed, as illustrated in
??. Above a Xn of 30 aggregation processes occur, as detected in HFIP GPC,
thus no reliable GPC characterization can be carried out for these poly-
mers. However, a length of 30 repeating units of PCys(SO2Et) is sufficient
for the desired applications as discussed.
Figure 9.11: HFIP GPC of PCys(SO2Et) with different chain lengths below and
above Xn of 30.
9.5.6 pH Stability
The stability of PCys(SO2Et) in acidic and alkaline media was evaluated
with 1H NMR . Therefore PCys(SO2Et) (7 mg) were dissolved in DMSO-d6
(0.7 mL) and ceTFA-d or NaOD (40 wt% in D2O) were added to reach a
pH of 4 or 10 respectively. Spectra were recorded after 10 min and 24 h
and compared to a spectrum in pure in DMSO-d6.
As illustrated in Figure 9.12, the S-ethylsulfonyl group is removed
when exposed to alkaline conditions. After 10 min PCys(SO2Et) associ-
ated signals (a-f ) decreased significantly. Signals corresponding to the
removed protective group in form of EtSO2 – (I and II) emerge. After 24 h
no polymer signals can be detected. The free thiol group results in cross-
linking, which caused precipitation and is responsible for the vanished
polymer signals. Acidic to neutral conditions however do not affect the
protective group of PCys(SO2Et). All polymer-associated signals remain
intact and no free protective group can be seen. The only notable dif-
ference is the disappearance of the amide proton (a) after 24 h due to
hydrogen-deuterium exchange.
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Figure 9.12: pH-Influence on PCys(SO2Et) as monitored by 1H NMR in DMSO-d6
(pH4: +TFA-d, pH10: +NaOD).
9.5.7 Kinetic Measurements
Polymerizations were analyzed over a period of 7 days while samples
were taken using a nitrogen flushed syringe trough a septum. The de-
creasing NCA carbonyl peaks at 1858 cm−1 and 1788 cm−1 were moni-
tored and the integrals were correlated with the NCA concentration for
kinetic evaluations. Polymerizations carried out at higher initial mon-
omer concentrations exhibit the fastest rate constant (see Figure 9.4
C). However, aggregation of the growing chains is observed upon
monomer concentrations above 0.80 mol/L resulting in gelation and
thus termination. Derived from those findings, polymerizations of
PCys(SO2Et) are conveniently conducted at concentrations around 0.40 -
0.60 mol/L without the issue of premature gelation. Further investiga-
tion of the kinetic behavior of the PCys(SO2Et) polymerization revealed,
that lowering the reaction temperature resulted in faster polymeriza-
tion. The rate constants increase from 2.62× 10−4 L mol−1 s−1 (10 °C) to
4.53× 10−4 L mol−1 s−1 (0 °C) and ultimately to 10.95× 10−4 L mol−1 s−1 (-
10 °C) (Figure 9.13 A). Thus, higher conversions were realized at low
temperatures, indicating chain termination reactions at higher tempera-
tures.
NCA polymerizations are known to be sensitive to side reactions and
lowering the temperature results in a decrease of end group
termination.[54,55] In the case of PCys(SO2Et), the controlled fashion of
polymerizations at -10 °C is lost at 0 °C or above. To underline this find-
ing, the polymerizations of PCys(SO2Et) carried out at different tempera-
tures were compared using HFIP GPC (?? B). Having the same monomer
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Figure 9.13: A Kinetic plots and B HFIP GPC traces of PCys(SO2Et) polymerizations
at different temperatures (M/I = 50).
to initiator ratio, the polymer synthesized at -10 °C reached the highest
degree of polymerization (P5, Xn of 27), while exhibiting a narrow, sym-
metrical distribution (Ð = 1.19). The distribution broadens upon higher
polymerization temperature. At 0 °C a low molecular weight shoulder
can be observed, at 10 °C even a bimodal distribution. Thus, in order
to maintain chain propagation in a controlled fashion and yielding well-
defined polymers, polymerization at -10 °C is essential.
9.5.8 Supplementary NMR Spectra of Cys(SO2Et) NCA
Figure 9.14: 1H NMR spectrum of Cys(SO2Et) NCA
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Figure 9.15: 13C NMR spectrum of Cys(SO2Et) NCA
Figure 9.16: COSY NMR spectrum of Cys(SO2Et) NCA
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Figure 9.17: HSQC NMR spectrum of Cys(SO2Et) NCA
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A B S T R A C T : We report on the synthesis of polysarcosine-block-poly-
(S-alkylsulfonyl-L-cysteine) block copolymers, which combine three or-
thogonal addressable groups enabling site specific conversion of all re-
active entities in a single step. The polymers are readily obtained by
ring-opening polymerization (ROP) of corresponding α-amino acid N-
carboxyanhydrides (NCAs) combining azide and amine chain ends, with
thiol-reactive S-alkylsulfonyl-L-cysteine side chains. Functional group
interconversion of chain ends using strain–promoted azide–alkyne cyclo-
additionn (SPAAC) and activated ester chemistry with NHS and DBCO-
containing fluorescent dyes could be readily performed without affect-
ing the cross-linking reaction between thiols and S-alkylsulfonyl pro-
tective groups. Eventually, all three functionalities can be combined in
the formation of multifunctional disulfide core cross-linked nanopar-
ticles bearing spatially separated functionalities. The simultaneous at-
tachment of dyes in core and corona during the formation of core-cross-
linked nanostructures with controlled morphology is confirmed by
fluorescence cross-correlation spectroscopy (FCCS).
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10.1 I N T R O D U C T I O N
Polymers bearing one or several different reactive functional
groups are of great interest to create multifunctional polymeric
architectures.[466–468] Telechelic polymers, i. e. , polymer chains with
either the same (homotelechelic),[469–472] one (semitelechelic),[60,473–475]
or two different functional end groups (heterotelechelic)[253,476–478]
provide access to (multi)-block copolymers,[479] graft polymers,[480,481]
miktoarm star polymers,[482] polymer–peptide[210,483–485] and polymer
drug conjugates,[486] and functional building blocks for supramolecular
chemistry.[487] They are accessible by a variety of different controlled
polymerization methods like controlled radical polymerization (RAFT,
ATRP) or ring-opening polymerization (ROMP, anionic and NCA ROP).[229]
Additional reactive functional groups can be introduced through the
copolymerization of functionalized monomers, but the incompatibility
of many of these groups with a variety of polymerization conditions
remains a considerable synthetic challenge. As building blocks in
core-shell micellar aggregates, amphiphilic block copolymers that
combine two or several spatially separated and orthogonally address-
able reactive functional groups are highly valuable because spatial
separation of functional groups in the core and corona is achieved.[488]
While chain end functionalities can be used to introduce targeting
moieties or fluorophores in a site-specific manner, side chain function-
alities in the hydrophobic segment are relevant for drug attachment
or core cross-linking of polymeric micelles. In this respect, reactive
functional groups enabling bioreversible modifications are highly
attractive.[153] By incorporating three orthogonally reactive functional
groups into one block copolymer, multifunctional nanoparticles are
accessible in a chemically very elegant manner.[489,490]
Polypept(o)ides (polypeptide-block-polysarcosine block copolymers)
have emerged as promising materials for nanomedicines and are read-
ily synthesized by controlled ring-opening polymerization (ROP) of the
corresponding α-amino acid N-carboxyanhydrides (NCAs). While the
corona-forming PSar block provides stealth-like properties, the poly-
peptide segment creates a functional compartment for the drug or
biomolecule encapsulation or attachment. Polypeptides represent par-
ticularly interesting core-forming blocks because of their high propen-
sity to form secondary structures and their intrinsic side-chain-related
stimuli responsiveness (pH, redox).[22,25] While side-chain reactivity
of the functional polypeptide block is so far mostly limited to irre-
versible modifications, such as thiol–ene, CuAAC, or alkylation,[21,320]
the recently developed S-alkylsulfonyl group for cysteine enables
NCA synthesis and controlled polymerization, enabling thiol-selective
asymmetric disulfide formation as a postpolymerization modification
method.[173,209,321] In addition, the tendency for β-sheet formation of S-
alkylsulfonylcysteine blocks enables morphology control by secondary
structure-directed self-assembly.[22]
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In the present study, we have investigated the orthogonality of the thiol-
reactive S-alkylsulfonyl group toward SPAAC and activated ester- me-
diated amidation to create multifunctional building blocks, which al-
low for the formation and functionalization for core-shell nanostruc-
tures in one step. For this purpose, we have synthesized trifunctional
polysarcosine-block-poly(S-alkylsulfonyl-L-cysteine) (PSar-b-PCys(SO2R))
block copolymers bearing three orthogonally reactive groups by a
macroinitiator approach.[61] They are incorporated as reactive chain ends
either in the hydrophilic segment or result from the polymerization in
the hydrophobic block. Incorporated in the latter, the S-alkylsulfonyl
side chain provides an additional terminal functionality in the polycys-
teine segment. The synthesis of PSarn-b-PCys(SO2R)m block copolymers can
in principle be accomplished by pursuing two different synthetic routes
(see Scheme 10.1).
Scheme 10.1: Reaction scheme of PSarn-b-PCys(SO2R)m block copolymer synthesis
using sequential polymerization (route A) or a bifunctional initia-
tor (route B).
Route A involves standard sequential polymerization of sarcosine
NCA (Sar NCA) using neopentylamine or propargylamine as initia-
tor. S-ethylsulfonyl-L-cysteine or S-isopropylsulfonyl-L-cysteine NCAs
(Cys(SO2Et) or Cys(SO2iPr) NCAs) are then subsequently polymerized us-
ing PSar as macroinitiator. On the other hand, route B exploits N-boc-
ethylenediamine as a bifunctional initiator. After polymerization of
Sar NCA, resulting macroinitiators can be functionally capped using, e. g.
azide-containing capping agents (see Figure 10.4) before liberating the
primary amine for polymerization upon deprotection using TFA/H2O
(see Figure 10.5). The fundamental difference of the presented syn-
thetic routes constitutes the chemical nature of the initiating species. For
route A, a secondary amine initiates polymerization of Cys(SO2R) NCAs,
whereas for route B, the initiating species is a primary amine. Since the
S-alkylsulfonyl group exhibits reduced stability toward species with en-
hanced basic character, the temperature during initiation needs to be
meticulously controlled. At –10 °C, this is the case, and well-defined
block copolymers result for both synthetic approaches as summarized
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for different monomer-to-initiator (M/I) ratios and monomer combina-
tions (Cys(SO2Et) or Cys(SO2iPr) NCA in Table 10.1) (see Figure 10.6-10.9 for
1H NMR characterization). Block copolymers with comparably low dis-
persities (Ð= 1.2–1.3) and monomodal molecular weight distributions
are obtained by hexafluoro 2-propanol (HFIP) gel permeation chromatog-
raphy (GPC), considering the presence of polypeptides in different sec-
ondary structures (random coil and β-sheet).[24] Figure 10.1 A exemplar-
ily displays the GPC elugram of P3 and its precursor bifunctional PSar
macroinitiator. The shift toward lower elution volumes indicates suc-
cessful chain extension upon block copolymerization. Moreover, the ob-
servation of only one diffusing species in 1H DOSY NMR further supports
the results obtained by GPC (see Figure 10.1 B).
Table 10.1: Characterization of block copolymers.
No. macro-
initiator
2nd NCA n : ma Mnb /
g mol−1
Ðb end
groups
P1 PSar Cys(SO2Et) 104/8 27260 1.2 NAc /NH2
P2 PSar Cys(SO2iPr) 104/8 30480 1.3 NAc /NH2
P3 bi PSar Cys(SO2Et) 320/21 32170 1.3 Ac/NH2
P4 bi PSar Cys(SO2iPr) 425/23 32550 1.3 Ac/NH2
P5 bi PSar Cys(SO2Et) 69/8 22480 1.2 N3/NH2
P6 bi PSar Cys(SO2Et) 382/12 32900 1.3 Ac/NH2
P7 bi PSar Cys(SO2Et) 310/12 32230 1.2 N3/NH2
a Determined by 1H NMR in DMSO-d6.
b Determined by GPC in HFIP relative to PMMA standards.
c NA = neopentylamine
While under controlled polymerization conditions, sequential poly-
merization seems straightforward from a synthesis point of view, the ap-
proach is not as modular and, therefore, as versatile as the bifunctional
initiator approach. During the capping step, not only azide-containing
but also other functionalities (here shown with simple acetylation to re-
inforce the “stealth” character of PSar) can be introduced into the PSar
macroinitiator without the need of synthesizing a new functional macro-
initiator each time. Certainly, route A does also offer the possibility to
use functional initiators instead of neopentylamine, and initiator func-
tionalities have been shown to be incorporated with high end group
integrity.[25] Unfortunately, polymer chain lengths cannot always be re-
liably determined due to a lack of distinct chain end group signals de-
tectable in 1H NMR . Accordingly, trifunctional block copolymers with
an azide and a primary amine end group as well as S-alkylsulfonyl side
chains were obtained by following synthetic route B (bifunctional initia-
tor) and employing azide-containing capping agents.
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Figure 10.1: Characterization of P3: A) GPC elugrams in HFIP of the macroinitia-
tor and the resulting block copolypept(o)ide P3 after polymeriza-
tion with Cys(SO2Et) NCA and B) 1H NMR and 1H DOSY NMR spectrum
in DMSO-d6 of P3, indicating only one diffusing species with a uni-
form diffusion coefficient.
To verify if the incorporated functional groups were indeed orthogo-
nal to each other, their reactivity was separately addressed using their re-
spective reactive counterparts (see Figure 10.2 A). While azide function-
ality readily undergoes cycloaddition reactions with alkynes in the pres-
ence of copper(I) (copper–catalyzed alkine azide cyloaddition (CuAAC))
or cyclooctynes (SPAAC), the primary amine readily forms amide bonds
using activated ester derivatives. The S-ethylsulfonyl group is reactive
toward thiols (see Scheme 10.2). Polymer P5 was chosen as a model sys-
tem, and labeling was performed with either DBCO-carboxyrhodamine
110 (DBCO-CR110) or Alexa Fluor 647-NHS ester (AF647-NHS), and the re-
sulting labeled block copolymers were analyzed by GPC in HFIP (see
Figure 10.2 B). UV detection at 495 nm (CR110) and 600 nm (AF647), re-
spectively, confirmed qualitatively covalent fluorophore attachment. De-
tection at 230 nm was performed to ensure that the detected peak was
indeed of polymer origin. Furthermore, the S-ethylsulfonyl group re-
mained stable under the applied labeling condition. Cross-linking was
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not observed, which would result in an additional peak at lower elution
volumes, and 1H NMR measurements confirmed the presence of the in-
tact protective group (see Figure 10.10 and 10.11). The presence of the
respective dyes was further confirmed using UV – Vis spectroscopy (see
Figure 10.12).
Figure 10.2: A) Synthetic scheme of PSarn-b-PCys(SO2R)m end group conversion
with NHS-AF647 and DBCO-CR110 fluorophores, respectively, and
thiol-reactivity of the S-ethylsulfonyl group in the side chain. B)
GPC elugrams in HFIP after conversion and purification, indicating
successful fluorophore labeling (UV detection at 230 nm (gray), 495
nm (green), and 600 nm (red), respectively). C) Thiol conversion as
monitored by 1H NMR showing full conversion of the protective
group to the asymmetric disulfide.
To ascertain that the S-alkylsulfonyl group is, however, still reactive
toward thiols, block copolymers were reacted with benzylmercaptan in
DMSO-d6, and the reaction was monitored by 1H NMR (see Figure 10.2
C and Figure 10.14 and 10.15). Fast and selective conversion of thi-
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ols with the S-alkylsulfonyl group was observed, identical to the
reports on the protected amino acid and on neopentylamine-initiated
homopolymers.[173,209] It can be concluded from these results that
both chain end functionalities can be selectively addressed using their
reactive counterparts without affecting the S-alkylsulfonyl group under
the experimental conditions applied. This marks these trifunctional
block copolymers as ideal building blocks to create functional core-shell
nanostructures in one step.
Consequently, we exploited the tendency for microphase separation
of amphiphilic PSar-b-PCys(SO2R) block copolymers to evaluate the three
functionalities in a combined approach. We have recently reported on
the self-assembly behavior of these reactive block copolymers, which
can be deliberately manipulated by exploiting secondary structure for-
mation of the polycysteine segment, thus controlling size and
morphology.[22] The thiol-reactivity of the S-alkylsulfonyl group further
enables bioreversible core cross-linking and complete decoupling of ag-
gregate formation from function. With respect to the present approach,
the azide functionality is located at the end of the PSar block and thus
will be presented on the corona of core-shell nanoparticles. The amine
end group of the PCys(SO2Et) segment on the other hand will be situated
in the nanoparticles core. This spatial separation is highly attractive for
the formation of multifunctional core-shell systems. It is of great value
to be able to selectively address functionalities on the outside, e. g. for
active targeting purposes, as well as on the inside of the particle, e. g. for
fluorescent labeling for detection in in vitro and in vivo experiments.
For simplified analysis reasons, azide and amine block copolymer end
groups were labeled with spectroscopically different dyes for detection
in fluorescence cross-correlation spectroscopy (FCCS). PSar-b-PCys(SO2Et)
block copolymers were self-assembled under controlled conditions us-
ing a solvent switch procedure in the presence of thiourea to suppress
β-sheet formation of the polycysteine block as previously reported and
core cross-linked using the dithiol triethylenetetramineα,ω-di(cysteine)-
diamide (TETA), thus addressing side chain functionality (see SI).[22] Re-
sulting core cross-linked micelles were labeled with DBCO-carboxy-
rhodamine 110 (DBCO-CR110) and Cy5-NHS at respective polymer end
groups as schematically illustrated in Figure 10.3 A. Labeling reactions
were performed in phosphate buffered saline (PBS) (pH 8) for Cy5-NHS
and H2O for DBCO-CR110. It should be noted here that we employed Cy5-
NHS for functional particle modification instead of AF647-NHS, which is
spectroscopically similar but bears the advantage of being less hydro-
philic. This facilitates purification and is also more transferable for use
in core crosslinked polymeric micelles with hydrophobic cores. The syn-
thesis of functional nanoparticles was followed by repetitive spin filtra-
tion with ethanol and H2O to remove excess dye and cross-linker from
the particles (see SI for particle preparation). Although labeling of poly-
mer end groups can in principle be performed prior to self-assembly
and cross-linking, it is preferential to form core cross-linked particles
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first and accomplish the modification in one step to avoid any influence
of the, e. g. dye polarity or steric demands on the self-assembly process.
After particle labeling with both dyes in a consecutive manner, sam-
ples were analyzed by dynamic light scattering (DLS). Figure 10.3 B shows
intensity-weighted size distributions of polymeric micelles after cross-
linking (unlabeled) and after sequential reaction with both dyes as well
as single-labeled particles. As can be deduced from the very similar
intensity-weighted size distributions obtained in all cases, hydro-
dynamic diameters (Dh) and size distributions were not significantly
affected by the labeling reaction. Moreover, the obtained results indi-
cate that the labeling step is not significantly influenced by the order
of dye addition, although a slight broadening of the size distribution is
observed for CR110 first.
Figure 10.3: A) Amphiphilic trifunctional block copolymers are self-assembled
into micelles, and orthogonal end groups as well as side-chain
functionalities can be addressed subsequently by cross-linking
with dithiol cross-linkers and labeling with DBCO-CR110/NHS-Cy5.
B) DLS of cross-linked particles prior to and after labeling with one
dye or both dyes, respectively. C) FCCS) auto- and cross-correlation
curves of dual labeled particles (1) Cy5 and (2) CR110, showing
strong cross-correlation that confirms dual labeling.
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To verify if the respective functionalization was effective for the two
dyes in both the PSar corona (CR110) and the PCys(SO2Et) core (Cy5), dual la-
beled particles were analyzed by FCCS. Typical auto- and cross-
correlation curves are shown in Figure 10.3 C. The large amplitude of
the cross-correlation curve G(0) is comparable to that of the autocorrela-
tion curves, which implies that both dyes are attached to the core cross-
linked particles (see Figure 10.3 C).[491] Interestingly, a slight dependence
on the order of labeling was also noticed in FCCS. Cross-correlation was
not as strong when particles were labeled with Cy5-NHS first (see Fig-
ure 10.13), which is presumably due to the fact that Cy5-NHS reacts with
the primary amine functionality localized in the core of the micelle,
whereas DBCO-CR110 converts with the azide attached to the corona-
forming block. As a consequence, core labeling might be partially im-
peded, when CR110 is incorporated first.
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In conclusion, we have presented a versatile synthetic concept toward
trifunctional PSar-b-PCys(SO2R) block copolymers with independently ad-
dressable functional groups that are spatially separated from each other.
Notably, the S-alkylsulfonyl group remains intact during functional
group conversion of azide and amine chain end under the applied reac-
tion conditions. These amphiphilic trifunctional block copolymers pro-
vide the basis to form functional core-shell nanostructures in a clean,
simple, and versatile manner. While the S-alkylsulfonyl group provides
stability by bioreversible core cross-linking, distinct reactive groups at
polymer chain ends empower simultaneous introduction of functional
moieties in the core and corona, e. g. pilot molecules for active targeting
and fluorophores for detection, in one step.
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10.5.1 Materials and Instrumentation
DMF was purchased from Acros and dried over BaO and molecular sieve
(3 Å), fractionally distilled in vacuo at 20 °C and stored at -80 °C under
exclusion of light. Prior to use, N,N-dimethyl formamide (DMF) was de-
gassed in vacuo to remove residing traces of dimethylamine. tetrahydro-
furane (THF) and hexane were distilled from Na/K and ethyl acetate
from CaH2. Neopentylamine was purchased from TCI Europe and was
dried over NaOH followed by distillation. Cysteine was purchased from
OPREGEN, sarcosine and diphosgene from Alfa Aesar. Hexafluoro-2-
propanol (HFIP) and N-Boc-1,2-diaminoethane were purchased from Flu-
orochem. Millipore water was prepared by a MILLI-Q® Reference A+
System and used at a resistivity of 18.2 MΩ cm-1 and total organic car-
bon < 5 ppm. Deuterated solvents were obtained from Deutero GmbH.
CR 110 DBCO was purchased from Jena Bioscience, AF647-NHS ester from
Invitrogen, Cy5-NHS ester from Lumiprobe and Sephadex® LH 20 from
Sigma Aldrich.
1H NMR spectra were recorded on a Bruker Avance II HD 400 at a fre-
quency of 400 MHz or a Bruker Avance III HD 300 at 300 MHz. Two-
dimensional nuclear magnetic resonance (NMR) spectra (1H diffusion
ordered spectroscopy (DOSY)) were recorded on a Bruker Avance III HD
400 at 400 MHz. All spectra were recorded at room temperature (25 °C)
and calibrated using the solvent signals.[394] Melting points were mea-
sured using a Mettler FP62 melting point apparatus at a heating rate of
1 °C min-1.
Gel permeation chromatography (GPC) was performed with HFIP con-
taining 3 g l−1 potassium trifluoroacetate (KTFA) as eluent at 40 ◦C and a
flow rate of 0.8 ml min−1. GPC columns were packed with modified sil-
ica (PFG columns particle size: 7 µm, porosity: 100 Å and 1000 Å). Poly-
methly methacrylate PMMA standards (Polymer Standards Services
GmbH) were used for calibration and toluene was used as internal stan-
dard. A refractive index detector (G1362A RID) and an UV/Vis detector
(at 230 nm or as indicated; Jasco UV-2075 Plus) were used for polymer
detection.
Infrared IR spectroscopy was performed on a Jasco FT/IR-4100 with
an ATR sampling accessory (MIRacle, Pike Technologies) using Spec-
tra Manager 2.0 (Jasco) for integration and data processing. UV – Vis ab-
sorbance spectra were recorded using a Jasco spectrophotometer V-630
and Spectra Manager 2.0 (Jasco) for data processing.
Single-angle dynamic light scattering (DLS) measurements were per-
formed with a ZetaSizer Nano ZS instrument (Malvern Instruments Ltd.,
Worcestershire, UK) equipped with a He – Ne laser (λ= 633 nm) as the in-
cident beam. All measurements were conducted at 25 °C and a detection
angle of 173 °C. Disposable polystyrene or PMMA cuvettes (VWR, Darm-
stadt, Germany) were used for DLS measurements. Cumulant size, poly-
dispersity index (PDI), and size distribution (intensity-weighted) his-
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tograms were calculated based on the autocorrelation function of sam-
ples, with automated attenuator adjustment and multiple scans (typi-
cally 10 – 15 scans) for optimal accuracy.
Dual color fluorescence cross-correlation spectroscopy (DC FCCS) ex-
periments were performed on an LSM 880 (Carl Zeiss, Jena, Germany).
For simultaneous excitation of the CR110 and Cy5 fluorophores the laser
beams of an argon-ion laser (488 nm) and a helium-neon laser (633 nm)
were made collinear and focused through a Zeiss C-Apochromat 40x/1.2
W water immersion objective into the sample solutions. Emitted fluo-
rescence light was collected with the same objective, passed through
a confocal pinhole and directed to a spectral detection unit (Quasar,
Carl Zeiss). In this unit emission is spectrally separated by a grating
element on a 32 channel array of GaAsP detectors operating in a single
photon counting mode. The emission of CR110 was detected in the spec-
tral range 500 – 562 nm and that of Cy5 in the range 642 – 696 nm. The
observations volumes were calibrated using AlexaFluor488 and Alex-
aFluor647 as reference dyes with known diffusion coefficients. An eight-
well polystyrene, chambered cover glass (Laboratory-Tek, Nalge Nunc
International) was used as a sample cell. For each sample, 30 measure-
ments (5 seconds each) were performed.
10.5.2 Synthetic Procedures
Synthesis of ethanesulfinic acid sodium salt
A solution of sodium sulfite (391.98 g, 3.11 mol) in water (800 mL) was
heated to 80 °C. Ethanesulfonyl chloride (147.40 mL, 199.30 g, 1.55 mol)
and sodium carbonate (329.63 g, 3.11 mol) were added simultaneously
while significant quantities of CO2 evolved. The reaction mixture was
stirred for one hour at 80 °C, afterwards water was removed in vacuo
at 60 °C. The resulting solid was suspended in methanol and filtered.
Evaporation of methanol gave ethanesulfinic acid sodium salt (153.54 g,
1.32 mol, 85 %) as a colorless solid.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 1.79 (q, 3JH,H = 7.6 Hz, 2H, – CH2 – ),
0.90 (t, 3JH,H = 7.6 Hz, 3H, – CH3).
Synthesis of S-ethylsulfonyl-L-cysteine (Cys(SO2Et))[173]
An ice-cold solution of sodium nitrite (5.94 g, 86 mmol) in degassed
water (45 mL) was slowly added to a stirred solution of L-cysteine hy-
drochloride (13.57 g, 86 mmol) in previously degassed 2 N HCl (90 mL)
at 0 °C. After 1 h, ethanesulfinic acid sodium salt (20.00 g, 172 mmol)
was added to the deep red solution and was stirred for 2 h. Additional
sodium ethanesulfinate (5.00 g, 43 mmol) was added and eventually
a colorless solid precipitated. The reaction mixture was stirred at 0 °C
overnight. The precipitate was filtered off and the pH of the colorless
filtrate was adjusted with 2 N NaOH to pH 4-5, resulting in additional col-
orless solid precipitating. The filtrate was allowed to stand at 4 °C un-
til precipitation was complete. The combined precipitates were washed
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with MeOH to remove residual sulfinate and dried in vacuo yielding
Cys(SO2Et) (5.03 g, 24 mmol, 27 %) as a colorless, crystalline solid.
1H NMR (400 MHz, DMSO-d6/ TFA-d) δ [ppm] = 4.34 (t, 3JH,H = 6.4 Hz,
3JH,H = 6.0 Hz, 1H, α– H), 3.66 (dd, 2JH,H = 14.4 Hz, 3JH,H = 6.0 Hz, 1H,
– CHH – S), 3.62 (q, JH,H = 7.2 Hz, 2H, – CH2 – SO2), 3.53 (dd, 3JH,H = 14.4 Hz,
3JH,H = 6.4 Hz, 1H, – CHH – S), 1.30 (t, 3JH,H = 7.2 Hz, 3H, – CH3).
Synthesis of S-ethylsulfonyl-L-cysteine N-carboxyanhydride
(Cys(SO2Et) NCA)[173]
Dried Cys(SO2Et) (7.00 g, 32.82 mmol) was suspended in absolute THF
(100 mL) and heated to 70 °C. Diphosgene (3.60 mL, 5.84 g, 29.52 mmol)
was slowly added and the suspension was heated for an additional 4 h.
Dry nitrogen was bubbled through the reaction mixture overnight into
a gas washing bottle with an aqueous KOH solution to remove excess
diphosgene, HCl and most of the solvent. The remaining solvent was re-
moved in vacuo and the residue was dissolved in 100 mLabsolute ethyl
acetate. Any insoluble compounds were removed by filtration avoiding
contact with air and the NCA was precipitated by adding 800 mL abso-
lute hexane. The recrystallization of the product was repeated two more
times yielding Cys(SO2Et) NCA (6.43 g, 26.87 mmol, 82 %) as a colorless,
crystalline powder (m.p. 113–115 °C).
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.32 (s, 1H, – NHCO), 4.86 (td,
3JH,H = 6.0 Hz, 3JH,H = 4.8 Hz, 3JH,H = 1.6 Hz, 1H, α– H), 3.64 (dd, 2JH,H
= 14.4 Hz, 3JH,H = 4.8 Hz, 1H, – CHH – S), 3.62 (q, 3JH,H = 7.2 Hz, 2H,
– CH2 – SO2), 3.57 (dd, 2JH,H = 14.4 Hz, 3JH,H = 6.4 Hz, 1H, – CHH – S), 1.29
(t, 3JH,H = 7.2 Hz, 3H, – CH3).
Propane-2-sulfinic acid sodium salt
The synthesis was carried out analogous to the ethanesulfinic acid
sodium salt using sodium sulfite (88.23 g, 700 mmol), propane-2-sulfonyl
chloride (39.29 mL, 49.91 g, 350 mmol) and sodium carbonate (74.19
g, 700 mmol). Purification yielded propane-2-sulfinic acid sodium salt
(40.56 g, 312 mmol, 89 %) as a colorless solid.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 1.59 (hept., 3JH,H = 6.9 Hz, 1H,
–– CH – ), 0.87 (d, 3JH,H = 6.9 Hz, 6H, – (CH3)2).
Synthesis of S-isopropylsulfonyl-L-cysteine (Cys(SO2iPr))[173]
The synthesis was carried out analogous to Cys(SO2Et) using sodium ni-
trite (11.60 g, 168 mmol), L-cysteine hydrochloride (26.50 g, 168 mmol)
and propane-2-sulfinic acid sodium salt (43.30 g, 465 mmol). The purifi-
cation yielded Cys(SO2iPr) (8.78 g, 39 mmol, 23 %) as a colorless, crys-
talline solid. Crystal Structure (CCDC-1440862): colorless needle from
H2O (0.060 × 0.200 × 0.630 mm), monoclinic space group C 2, refine-
ment: wR2=0.1794 (R1=0.0639 for observed reflections, 0.0805 for all re-
flections), flack parameter x = -014(17), crystal structure contains two
independent molecules with slightly different conformations.
10.5 S U P P O R T I N G I N F O R M AT I O N 185
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 4.34 (t, 3JH,H = 6.0 Hz, 1H, α– H),
3.76 (hept, JH,H = 6.7 Hz, 1H, –– CH – SO2), 3.65 (dd, 2JH,H = 14.4 Hz,
3JH,H = 6.0 Hz, 1H, – CHH – S), 3.54 (dd, 2JH,H = 14.4 Hz, 3JH,H = 6.2 Hz,
1H, – CHH – S), 1.35 (d, 3JH,H = 6.7 Hz, 6H, – (CH3)2).
Synthesis of S-isopropylsulfonyl-L-cysteine N-carboxyanhydride
(Cys(SO2iPr) NCA)[173]
The synthesis of Cys(SO2iPr) NCA was carried out under identical con-
ditions as Cys(SO2Et) NCA employing Cys(SO2Et) (6.04 g, 26.57 mmol) and
diphosgene (4.00 mL, 6.56 g, 33.14 mmol). Recrystallization yielded
Cys(SO2iPr) NCA (4.64 g, 18.3 mmol, 69 %) as a colorless, crystalline pow-
der (m.p. 98–100 °C).
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.33 (s, 1H, – NHCO), 4.84 (td,
3JH,H = 5.4 Hz, 3J = 1.4 Hz, 1H, α– H), 3.75 (hept, JH,H = 6.6 Hz, 1H,
–– CH – SO2), 3.59 (ddd, 2JH,H = 14.4 Hz, 3JH,H = 5.6 Hz, 3JH,H = 5.1 Hz,
2H, – CH2 – S), 1.33 (dd, 3JH,H = 6.6 Hz, 3JH,H = 0.9 Hz, 6H, – (CH3)2).
Synthesis of sarcosine N-carboxyanhydride (Sar NCA)[26]
The synthesis of sarcosine NCA was adapted from literature and
modified.[44] A total of 14.92 g (167.4 mmol) sarcosine, dried in vacuo for
1 h, was weighed into a pre-dried, three-neck, round-bottom flask. A
total of 300 mL of absolute THF was added under a steady flow of ni-
trogen and 16.2 mL (134 mmol) of diphosgene were added slowly via
syringe, and the nitrogen stream was reduced. The colorless suspen-
sion was mildly refluxed for 3 h, yielding a clear solution. Afterward,
a steady flow of dry nitrogen was led throw the solution for another
3 h into two gas washing bottles filled with aqueous NaOH solution. The
solvent was evaporated under reduced pressure, yielding a brown oil
as crude reaction product. The oil was heated to 50 °C and dried under
reduced pressure (20 mbar, then < 10-2 mbar for 2 h) to obtain an amor-
phous solid, free of phosgene and HCl, confirmed by testing against sil-
ver nitrate solution. The crude product was dissolved in 40 mL absolute
THF and precipitated with 300 mL absolute hexane. The solution was
cooled to -18 °C overnight for complete precipitation. The solid was fil-
tered under dry nitrogen atmosphere, dried in a stream of dry nitro-
gen for 60–90 min and afterwards under high vacuum for 2 h in a sub-
limation apparatus. The crude product was sublimated at 80–85 °C and
< 10-2 mbar. The product was collected from the sublimation apparatus
in a glovebox on the same day. This procedure yielded 12.64 g of puri-
fied product (110 mmol, 65 % yield, colorless crystals, which was stored
in a Schlenk tube at -80 °C and only handled under nitrogen atmosphere;
mp 102–104 °C.
1H NMR (400 MHz, CDCl3) δ [ppm] = 4.22 (s, 2H, – CH2 – ), 2.86 (s, 3H,
– CH3).
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Synthesis of polysarcosine using neopentylamine (route A)
1.02 g (8.9 mmol) sarcosine NCA were dried in vacuo and dissolved in
5 mL dry DMF. To the monomer solution 10.4 µL absolute neopenty-
lamine (7.7 mg, 89 µmol) were added. The clear, colorless solution was
stirred at room temperature under a steady flow of dry nitrogen. The re-
action was completed after 2 days (monitored by IR-spectroscopy). Pre-
cipitation in diethyl ether yielded 559 mg (55 %) of a colorless solid.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 4.34–3.92 (m, 2nH, – CH2 – ), 2.93–
2.73 (m, 3nH, – CH3), 0.82 (s, 9H, – (CH3)3).
Synthesis of polysarcosine using N-Boc-1,2-diaminoethane (route B)
1.6 g (13.8 mmol) sarcosine NCA were dried in vacuo and dissolved in
7 mL dry DMF and 5.5 µL (5.5 mg, 34.5 µmol) N-Boc-1,2-diaminoethane
were added. The clear, colorless solution was stirred at room tempera-
ture under a steady flow of dry nitrogen. The reaction was completed
after 3 days (monitored by IR-spectroscopy). The sarcosine amino termi-
nus was quenched by addition of 96 µL (691 µmol) triethylamine and
32.6 µL (345 µmol) acetic anhydride. The clear solution was allowed to
stir for an additional day at room temperature. Precipitation in
diethylether yielded 823 mg (52 %) of a colorless solid.
The Boc protective group was removed in a mixture of H2O/TFA 1:1 for
2 h. The clear yellow solution was stirred under an argon atmosphere at
room temperature for 1 hour under the exclusion of light. Precipitation
in diethyl ether yielded a colorless solid, which was dialyzed against
Millipore water (MWCO 3.5 kDa), saturated with NaHCO3 for 2 days. Af-
terwards, dialysis in pure Millipore water was carried out for additional
2 days. The polymer was lyophilized from water and 689 mg (43 %) of a
colorless solid were obtained.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 4.35–3.94 (m, 2nH, – CH2 – ), 2.97–
2.73 (m, 3nH, – CH3), 2.01–1.99 (m, 3H, – OCCH3). Additionally 1.37 (m,
9H, – OC(CH3)3) for Boc-terminated.
Synthesis of polysarcosine-block-poly(S-ethylsulfonyl-L-cysteine)
(routes A and B)
144 mg (19.3 µmol) polysarcosine macroinitiator were dried in vacuo and
dissolved in 3 mL dry DMF. The pale yellow monomer solution of 92 mg
(383 µmol) Cys(SO2Et) NCA in 1 mL dry DMF was added. The polymeriza-
tion was carried out at -10 °C under a steady flow of dry nitrogen and
monitored via IR spectroscopy. After 2 days (conversion rate of 47 %),
the reaction was stopped by precipitation in THF/diethyl ether 1:5. The
work-up by precipitation and centrifugation was repeated two times in
THF/diethyl ether 1:5 and then once in pure diethyl ether. After exten-
sive drying in vacuo, 114 mg (52 %) of a colorless solid were obtained.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 8.76 (m, 1mH, – NHCO)Cys, 4.69
(m, 1mH, α– H)Cys, 4.34–3.92 (m, 2nH, – CH2 – )Sar, 3.57–3.47 (m, 4mH,
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– CH2 – SSO2 – CH2 – )Cys, 2.93–2.72 (m, 3nH, – CH3)Sar, 1.29 (t, 3mH, – CH3)Cys.;
additionally 0.82 (s, 9H, – (CH3)3) for route A.
Synthesis of polysarcosine-block-poly(S-isopropylsulfonyl-L-cysteine)
(routes A and B)
143 mg (19.1 µmol) polysarcosine macroinitiator were dried in vacuo and
dissolved in 3 mL dry DMF. The pale yellow monomer solution of 97 mg
(382 µmol) Cys(SO2iPr) NCA in 1 mL dry DMF was added. The polymeriza-
tion was carried out at -10 °C under a steady flow of dry nitrogen and
monitored via IR spectroscopy. After 2 days (conversion rate of 42 %),
the reaction was stopped by precipitation in THF/diethyl ether 1:5. The
work-up by precipitation and centrifugation was repeated two times in
THF/diethyl ether 1:5 and then once in pure diethyl ether. After exten-
sive drying in vacuo, 135 mg (62 %) of a colorless solid were obtained.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 8.72 (m, 1mH, – NHCO)Cys,
4.66 (m, 1mH, α– H)Cys, 4.34–3.93 (m, 2nH, – CH2 – )Sar, 3.64 (hept,
1mH, –– CH – SO2)Cys, 3.48–3.36 (m, 2mH, – CH2 – S)Cys, 2.94–2.72 (m, 3nH,
– CH3)Sar, 1.33 (d, 6n H, – (CH3)2).; additionally 0.82 (s, 9H, – (CH3)3) for
route A.
Labeling of polysarcosine-block-poly(S-ethylsulfonyl-L-cysteine) Block Copoly-
mers with Fluorophores
1.0 eq. of P5 (PSar69-b-PCys(SO2Et)10) (0.6 mg) were dissolved in ac-
etate buffer (2 g L-1) and 1.2 eq. dibenzylcyclooctyne-PEG4-5/6-carboxy-
rhodamine 110 (CR110) (90 µL, 1 g L-1 in DMF) were added, respec-
tively 1.0 eq. of P5 (PSar69-b-PCys(SO2Et)10) (1.0 mg) were dissolved
in PBS buffer (pH 8.18, 2 g L-1) and 1.2 eq. Alexa Fluor® 647 N-
hydroxysuccinimidyl ester (AF647) (213µL, 1 g L-1 in DMF) were added.
The labeling reactions were carried out at room temperature overnight
followed by purification using column chromatography (Sephadex LH
20 and DMSO).
Conversion of polysarcosine-block-poly(S-ethylsulfonyl-L-cysteine) Block Copoly-
mers with Benzylmercaptan in DMSO-d6
1.0 eq. of P3 (PSar320-b-PCys(SO2Et)21)(7.30 mg) were dissolved in 700 µL
DMSO-d6 and 1.1 eq. of benzyl mercaptan (4.94 mg) were added immedi-
ately prior to the 1H NMR measurement. The disappearance of the signal
originating from – CH3 of the S-ethylsulfonyl group was used to monitor
the conversion. Additionally, the conjunction of the relevant signals to
a polymeric species was confirmed by 1H diffusion-ordered NMR experi-
ments (1H DOSY NMR).
188 O R T H O G O N A L R E A K T I V I T Y O F D I B L O C K C O P O LY P E P T ( O ) I D E S
Particle Preparation[22]
Amphiphilic block copolymers were self-assembled and core cross-
linked using a protocol reported previously.[22] Briefly, the polymer was
dissolved in N,N-dimethyl acetamide (DMAc), containing 1 M thiourea
to prevent β-sheet formation of the polycysteine segment, at a concen-
tration of 7.5 g L-1 for 2 h. 1 mM acetate buffer (pH = 4.7, 10 mM thiourea)
was added to adjust the concentration to 6.4 g L. The solution was left to
equilibrate for 3 h and was then dialyzed against 1 mM acetate buffer
(pH = 4.7, 10 mM thiourea). The solution was filtered using a 200 nm sy-
ringe filter (GHP) and the cross-linker TETA was added with SH-groups
equimolar to the number of cysteines as a 100 g L-1 stock solution in wa-
ter. The synthesis of TETA has been reported previously.[22] The reaction
mixture was shaken and allowed to stand for 18 h. Subsequently, the
solution was diluted with 1 mM acetate buffer (pH 4.7), filtered via a
200 nm syringe filter (GHP), and purified by repetitive spin filtration
(MWCO 100 kDa) and dilution steps followed by lyophilization.
Labeling of Nanohydrogels with Fluorophores
After the preparation steps described above, nanohydrogels were dis-
solved at a concentration of 2 g L-1 in the particular solvents and an
equimolar amount of fluorophore in DMF (1 g L-1) was added. The label-
ing reactions were carried out at room temperature overnight followed
by repetitive spin filtration (MWCO 100 kDa) diluting at least 10 times
with EtOH/H2O followed by 10 times H2O. The second labeling step fol-
lowed in analogy subsequently after the first work-up and GPC and DLS
characterization.
The exact procedure was as followed: 0.1 mg of nanohydrogel were
dissolved in water and 4.6 µL dibenzylcyclooctyne-PEG4-5/6-carboxy-
rhodamine 110 (CR110) solution were added. The second labeling step
was carried out with 0.05 mg of nanohydrogel and included the addi-
tion of 10-fold concentrated PBS to adjust the pH to 8 and 1.6 µL cyanin
5 N-hydroxysuccinimidyl ester (Cy5) solution. The inverted procedure
was carried out with 6.74 mg of nanohydrogel in PBS buffer (pH 8.18)
and 217.8 µL Cy5 solution followed by double labeling of 1 mg of nano-
hydrogel in water with 40 µL of CR 110 solution.
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Figure 10.4: FT-IR spectrum of PSar100-N3 confirming the incorporation of the
azide moiety into the macroinitiator during capping at 2100 cm-1.
Figure 10.5: PSar215 macroinitiator before (PSar215-N-Boc) and after (PSar215-NH2) de-
protection in TFA/H2O.
190 O R T H O G O N A L R E A K T I V I T Y O F D I B L O C K C O P O LY P E P T ( O ) I D E S
Figure 10.6: 1H NMR spectrum (400 MHz) of P1 in DMSO-d6.
Figure 10.7: 1H NMR spectrum (400 MHz) of P2 in DMSO-d6.
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Figure 10.8: 1H NMR spectrum (400 MHz) of P4 in DMSO-d6.
Figure 10.9: 1H NMR spectrum (400 MHz) of P5 in DMSO-d6.
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Figure 10.10: 1H NMR spectrum (400 MHz) after conversion of P5 with CR110-
DBCO in DMSO-d6.
Figure 10.11: 1H NMR spectrum (400 MHz) after conversion of P5 with AF647-NHS
in DMSO-d6.
Scheme 10.2: Functional group conversion by subsequently addressing poly-
mer chain end functionalities and thiol-reactive side chain func-
tionality.
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Figure 10.12: UV-Vis absorbance spectra of PSar-b-PCys(SO2Et) P5 labeled with
CR110, AF647 or both dyes.
Figure 10.13: Auto- and cross-correlation curves measured for dual labeled par-
ticles (1) CR110 and (2) Cy5 showing strong cross-correlation that
confirms dual labeling.
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Figure 10.14: Asymmetric disulfide formation upon conversion of benzylmer-
captane with P1 S-(ethylsulfonyl)-L-cysteine in PSar-b-PCys(SO2Et)
block copolymers synthesized by route A using neopentylamine
as initiator.
Figure 10.15: Asymmetric disulfide formation upon conversion of ben-
zylmercaptane with P2 S-(isopropylsulfonyl)-L-cysteine in
PSar-b-PCys(SO2iPr) block copolymers synthesized by route A using
neopentylamine as initiator.
11
S E Q U E N C E A LT E R AT I O N O F T R I B L O C K
C O P O LY P E P T ( O ) I D E S W I T H I N N AT E
T H I O L - R E A C T I V I T Y
RNA interference (RNAi) therapeutics faces several challenges in systemic
application e. g. enzymatic degradation by ribonucleases, short circula-
tion times and entrapment in cellular compartments.[80,83,84] These deliv-
ery barriers can be addressed by nanodimensional delivery strategies,
in which ideal polymeric materials should combine a shielding segment
with a cross-linkable one as well as a cationic block for efficient siRNA
complexation. These demanding structural requirements are met e. g.
by ABC-type amphiphilic cationic triblock terpolymers.[492] Up to now,
the influence of block sequence of triblock copolymers on nanoparticle
properties and systemic delivery properties has not been investigated.
However, there is a broad consensus that the properties of nanoparti-
cles formed by triblock copolymers are governed by the microstructure
of the employed block copolymer,[493–498]
To derive first structure-property relationships, we synthesized
triblock copolymers, which contain a polysarcosine (PSar), a poly(S-
ethylsulfonyl-L-cysteine) (PCys(SO2Et)) and a polylysine (PLys) block by
sequential ring-opening polymerization of the corresponding α-amino
acid N-carboxyanhydrides, but upon alteration of block sequence. In
polymer P1 the sequence is PSar-block-PCys(SO2Et)-block-PLys (A-B-C) and in
P2 PSar-block-PLys-block-PCys(SO2Et) (A-C-B) while the overall block length
of PCys(SO2Et) and PLys are kept constant. The PCys(SO2Et) block was
introduced for bioreversible cross-linking by chemoselective disulfide
formation, which provides stability in circulation and degradability
upon cellular uptake.[158] Our group recently demonstrated modifica-
tion of PLys in triblock copolypept(o)ides (polypeptoid-block-peptide-
block-peptide) with N-succinimidyl 3-(2-pyridyl-dithio)propionate
(SPDP) and by dithiol cross-linking, a library of polypept(o)ide-based
pDNA polyplexes was created.[154] However, this strategy involved
three post polymerization modification steps to achieve thiol-reactivity,
while the presented S-alkylsulfonyl group introduces directed disulfide
formation in polypept(o)ides, bypassing all post polymerization modi-
fication and activation steps.[173,327]
Thus, we report on the synthesis of triblock copolypept(o)ides differ-
ing in block sequence of cross-linkable and complexing segments to in-
vestigate the role of block sequence alteration on nanocarrier formation
and efficacy as small interfering RNA (siRNA) delivery vectors (compare
Chapter 16 for nanoparticle formation and biological investigation). The
functional elements are a hydrophilic, non-ionic shielding block based
on PSar,[27,143] combined with a polycationic PLys block for complexa-
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Synthesis of A-B-C
and A-C-B triblock
copolypept(o)ides.
Polymer
characteritaion.
tion of siRNA, as well as a hydrophobic PCys(SO2Et) segment mediating
chemoselective disulfide stabilization without the need of post polymer-
ization modification steps.[22,173]
The synthesis of triblock copolypept(o)ides was performed by sequen-
tial ring-opening polymerization (ROP) of α-amino acid N-carboxyan-
hydrides (NCAs), enabling precise control over block length and block
sequence according to Birke et al.[26] Polysarcosine (PSar) was chosen
as the starting block A with a degree of polymerization of 85 units to
mediate sufficient shielding of the resulting carrier systems (see sup-
porting information for polymerization procedures).[70] For the hydro-
phobic PCys(SO2R) B block, 25-30 repeating units were chosen, in order
to provide sufficient carrier stability upon disulfide cross-linking.[154]
The polycationic PLys block C was set to 12-13 repeating units to be able
to form polyplexes by electrostatic interactions with negatively charged
nucleic acids as shown by Heller et al.[70,367] For complexation of small
siRNA molecules, a relatively short cationic segment is sufficient, particu-
larly in combination with a cationic cross-linker.[22,154] For the synthesis
oft the A-B-C block copolymer the bifunctional initiator approach was
chosen as reported by Schäfer et al.[327] while for the A-C-B block copoly-
mer sequential polymerization provided best control over block length
(see Figure 11.1 A and B).
Figure 11.1: Polymerization scheme of triblock copolypept(o)ides by sequen-
tial ring-opening polymerization of NCAs: A) A-C-B triblock co-
polypept(o)ide (P1) with A: PSarn, B: PCys(SO2Et)m and C: PLysl as well
as B) A-C-B triblock copolypept(o)ide (P2) upon inversed sequence
of the cross-linking and polycationic block.
Characterization of triblock copolypept(o)ides was performed by
1H NMR as well as gel permeation chromatography (GPC) as summarized
in Figure 11.2 and 11.3, indicating well-defined block copolymers with
narrow size distribution. Successful chain extension into triblock copoly-
mers and the absence of homopolymers or diblock copolymer impuri-
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ties was confirmed by GPC and diffusion ordered 1H NMR spectroscopy
(DOSY) as illustrated in Figure 11.2 A (see additionally 16.6 and 16.9 in
Chapter 16). Block lengths of PSar macroinitiators were determined by
GPC relative to PSar standards[47] and were in good agreement with 1H
NMR experiments. Repeating units of PCys(SO2Et) and PLys(Boc) were de-
termined by 1H NMR by evaluation of the α-proton signal at 4.70 ppm
and ε-amide proton signal at 6.3–6.7 ppm, respectively (compare Fig-
ure 16.5 and 16.8 in Chapter 16).
Table 11.1: Characterization data of of triblock polymers.
No polypept(o)ide
architecturea, b
Mn, GPCc
/g mol−1
Mn, GPCd
/g mol−1
ÐGPCd
P1 PSar71-b-PCys(SO2Et)29-b-
PLys13
9050 26200 1.14
P2 PSar104-b-PLys12-b-
PCys(SO2Et)26
9190 26500 1.27
a Xn PSar relative to PSar standards.[47]
b Xm and Xl from 1H NMR relative to Xn, GPC PSar.
c Relative to PSar standards.
d Relative to PMMA standards.
Figure 11.2: 1H NMR and 1H DOSY NMR characterization in DMSO-d6 of A-B-C tri-
block P1-Boc, indicating only one diffusing species with a uniform
diffusion coefficient.
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Conclusion.
Quantitative removal of the Boc protective group was accomplished
by cleavage with a 1:1 mixture of H2O / TFA as reported previously[367]
and verified by disappearance of the characteristic Boc signal at 1.3–
1.5 ppm (compare Figure 16.7 and 16.10 in Chapter 16). As illustrated
in Figure 11.3, both triblock copolypept(o)ides P1 and P2 exhibit
monomodal molecular weight distributions in HFIP GPC. Moreover,
virtually identical molecular weights and distributions are obtained
for both polymers, independent from A-B-C or A-C-B block sequence
alteration. The higher dispersity of 1.27 for A-C-B polymer P2, in con-
trast to a PDI of 1.14 for A-B-C polymer P1, may arise from the inverted
block sequence, as P2 features a terminal hydrophobic B segment in
contrast to terminal hydrophilic A and C blocks in P1. Since 1H DOSY
NMR confirms equivalent diffusion coefficients (see Figure 11.2), the
observed dispersity of P2 may be attributed to secondary effects, e. g.
interactions with the column material in GPC.
Figure 11.3: GPC characterization in HFIP of triblock polypept(o)ides P 1 and P2
after deprotection of the PLys segment.
In summary, we prepared A-B-C and A-C-B triblock copoly-
pept(o)ides in order to evaluate the impact of block sequence alterations
on formation and in vivo performance of siRNA delivery systems. As
functional elements, a PSar-based shielding block, a hydrophobic
PCys(SO2R) segment for bioreversible disulfide stabilization and a poly-
cationic PLys block for complexation of siRNA were combined in triblock
copolymers. Synthesis was performed by sequential ring-opening poly-
merization of α-amino acid N-carboxyanhydride yielding well defined
triblock copolypept(o)ides with permuted block sequence but identi-
cal individual block lengths and effective hydrodynamic volume. The
influence of triblock copolymer microstructure and block sequence on
nanoparticle properties and RNAi in vivo are investigated in Chapter 16.
Part IV
S E L F - A S S E M B LY O F
B L O C K C O P O LY P E P T ( O ) I D E S

The secondary structure-driven self-assembly of amphiphilic PSar-block-
PCys(SO2R) block copolypept(o)ides into disulfide stabilized core-shell
nanoparticles was investigated in the following part. Parameters of the
self-assembly process were systematically screened and offered precise
control over the resulting core-shell structures, especially by manipula-
tion of secondary structure stabilization of the PCys(SO2R) segment. In
addition to control over size and morphology, complete decoupling
of function from particle preparation was achieved by dithiol cross-
linkers. Thus, hydrophobic core cross-linked polymeric micelles for, e. g.
chemotherapeutic agents and cationic nanohydrogels for complexation
of negatively charged nucleic acids, e. g. siRNA could be realized upon
variation in size and shape. Concluding, near-infrared fluorescence cor-
relation spectroscopy in flowing human blood demonstrated the signif-
icance of covalent modification (cross-linking, covalent attachment of
cargo or fluorescent probes) in nanocarriers aiming for systemic admin-
istration.
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A B S T R A C T : Achieving precise control over the morphology and
function of polymeric nanostructures during self-assembly remains a
challenge in materials as well as biomedical science, especially when in-
dependent control over particle properties is desired. Herein, we report
on nanostructures derived from amphiphilic block copolypept(o)ides by
secondary structure-directed self-assembly, presenting a strategy to ad-
just core polarity and function separately from particle preparation in a
bioreversible manner. The peptide-inherent process of secondary struc-
ture formation allows for the synthesis of spherical and worm-like core-
cross-linked architectures from the same block copolymer, introducing
a simple yet powerful approach to versatile peptide-based core-shell
nanostructures.
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12.1 I N T R O D U C T I O N
Controlling the self-assembly of block copolymers in solution offers a
versatile and powerful method to create nanometer-sized particles with
defined and controllable geometry, size, and functionality.[441,499–501] The
size, shape, and internal structure of nanosized objects that are obtained
by the aggregation of amphiphilic coil–coil block copolymers in a block-
selective solvent in thermodynamic equilibrium are mainly dictated by
the volume ratio of the solvophilic and the solvophobic block.[495] The
self-assembly of rod–coil block copolymers is additionally driven by the
aggregation of the rod segment and the formation of orientational or-
der, which may lead to morphologies that are different from those ob-
tained from typical coil–coil polymers.[502–505] In crystallization-driven
self-assembly, different types of polymers have been described as rod
segments throughout the literature, among them polyferrocenylsilane
(PFS) block copolymers with polydimethylsiloxane (PDMS), polyisoprene
(PI), and poly(lactic acid).[506–508] In contrast to this type of organization,
anisotropic nanomaterials can also be obtained by the controlled aggre-
gation of peptide amphiphiles (PAs), a concept that is well-established
in supramolecular chemistry.[503,509–511] In these systems, self-assembly
is predominantly driven by the formation of secondary structures in the
peptide segment.
It is noteworthy that β-sheet-driven polypeptide self-assembly is thus
far mostly limited to sequence-defined peptides.[512–515] Approaches
based on ring-opening polymerizations of α-amino acid N-carboxyan-
hydrides (NCAs) to create the peptidic rod-like segment have also been
used to stabilize micellar aggregates in vivo,[516] to induce oligomer
aggregation, or to create smart materials that can be switched from rod–
coil to coil–coil with external stimuli, such as a change in temperature
or pH or the addition of chaotropic agents.[517,518] However, approaches
utilizing synthetic polypeptides derived from NCA polymerization are
mostly restricted to α-helical motifs as the synthesis of β-sheet-forming
polymers is not trivial.[37] Therefore, directing the morphology of poly-
meric micelles by β-sheet formation of the hydrophobic core-forming
synthetic polypeptide has not yet been realized.
Cysteine is a particularly interesting amino acid because of its thiol
side chain with its potential bioreversible modification and its propen-
sity to form β-sheets in solution.[453] Our group has recently intro-
duced S-ethylsulfonyl-L-cysteine NCAs,[364] which enabled controlled
ring-opening polymerization to yield well-defined polymers with av-
erage chain lengths of up to 30 repeat units and intrinsic antiparallel
β-sheet conformations.[209] When this amino acid was used as a build-
ing block in polypept(o)ides, a unique material was obtained that com-
bines the functionality, stimuli responsiveness, and secondary structure
formation of polypeptides with the stealth-like properties of the coil-
forming polypeptoid polysarcosine (PSar).[25]
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Keeping in mind that the secondary structure of proteins can be dena-
tured by different external stimuli,[333] the self-assembly of these block
copolypept(o)ides should be controllable by switching from rod–coil
block copolymers (intact β-sheet conformation, Figure 12.1 A) to coil–
coil polymers with a chaotropic agent (disturbed β-sheet conformation,
Figure 12.1 B).
Figure 12.1: A) Formation of antiparallel β-sheets and B) suppressed forma-
tion of secondary structures by chaotropic agents (e. g. thiourea). C)
Proposed platform featuring the following phases: I) Self-assembly
of amphiphilic PSar-b-PCys(SO2Et) block copolymers into different mi-
cellar morphologies directed by secondary structure alignment; II)
subsequent core cross-linking by disulfides of choice, yielding core
cross-linked polymeric micelles (CCPMs) or nanohydrogels (NHGs);
III) disintegration of the system upon a reductive stimulus.
Apart from constituting the driving force for self-assembly (Fig-
ure 12.1 C I), the S-alkylsulfonyl cysteine block also remains highly
reactive towards thiols after polymerization.[173] This chemoselec-
tive reactivity enables core cross-linking through the formation of
asymmetric disulfides (Figure 12.1 C II), which seems to be a suitable
approach to preserve the morphologies of the formed nanoparticles.
PSar-b-PCys(SO2Et) block copolymers can be obtained by NCA poly-
merization with a bifunctional initiator as reported previously (see
the supporting Information, Scheme 12.1).[61] Block copolymers with
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differing block length ratios and total block lengths were prepared with
dispersity indices (Ð) between 1.2 and 1.4 (Table 12.3 and Figure 12.5).
The self-assembly of PSar-b-PCys(SO2Et) block copolymers was investi-
gated methodically by varying two major factors contributing to the
overall morphology, namely the composition of the amphiphile as well
as favoring/suppressing the formation of the secondary structure in the
absence/presence of the chaotropic agent thiourea. The amount of the
hydrophobic cysteine block was kept at 15wt. % (P1 Xn/Xm= 407:28 and
P2 Xn/Xm = 265:17, determined by 1H NMR spectroscopy) or 30 wt. % (P3
Xn/Xm = 97:15, determined by 1H NMR spectroscopy).
To obtain well-defined micelles, the block copolymers were first dis-
solved in N,N-dimethyl acetamide (DMAc), aggregated in the presence of
20 vol. % 1 mM acetate buffer (Figure 12.6), and subsequently dialyzed
against 1 mM acetate buffer to allow for the formation of thermodynam-
ically favored structures. For β-sheet suppression (Figure 12.1 C II), thio-
urea (1M in DMAc and 10 mM in the buffer) was used. Upon solvent
exchange, the micelle cores were cross-linked by disulfide formation to
stabilize the formed aggregates (triethylenetetramine α,ω-di(cysteine)-
diamide (TETA) c2 was used throughout Figure 12.2 yielding nanohydro-
gels (NHG), see also Table 12.2) for characterization. As the obtained mor-
phologies were fixated by cross-linking while the size distributions were
fully preserved (Figure 12.3 B I), thus enabling detailed particle char-
acterization by dynamic light scattering (DLS), circular dichroism (CD),
transmission electron microscopy (TEM), and atomic force microscopy
(AFM).
As determined by cumulant analysis of DLS, P1 formed structures with
a hydrodynamic diameter of Dh = 77 nm (wNHG1) in the absence of thio-
urea and considerably smaller structures with Dh = 51 nm (sNHG2) in
the presence of thiourea (Figure 12.2 A II and Table 12.1). From a the-
oretical point of view, block copolymers with a 15 wt. % hydrophobic
block are expected to form spherical micelles.[495] As briefly outlined
above, the self-assembly behavior of rod–coil polymers differs consider-
ably from that of coil–coil polymers. In the case of β-sheet rods, inter-
molecular interactions between rod chains dominate, and an enhanced
packing of the crystallizing chains can lead to the formation of shape-
anisotropic/ elongated objects. Moreover, β-sheets tend to arrange in
twisted structures,[519] which is also typical for natural peptides, such
as β-sheet barrels (Figure 12.2 A I).[520] Coil–coil polymers, on the other
hand, favor rounded interfaces to minimize contact between the less sol-
uble block and the solvent (Figure 12.2 A III). TEM and AFM were sub-
sequently used to elucidate the morphology of core-cross-linked self-
assembly structures (Figure 12.2 B and 12.7). TEM images were recorded
after staining with uranyl acetate to visualize the polycysteine core,[521]
whereas AFM showed the dimensions of the whole particle. Both meth-
ods demonstrate the formation of worm-like structures wNHG1 in the
rod–coil case (without thiourea) and of spherical ones sNHG2 in the coil–
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coil case (with thiourea). The larger Dh of wNHG1 observed by DLS can
thus be explained by the one-dimensional growth of twisted antiparal-
lel β-sheet alignments into worm-like nanohydrogels. The retained in-
ternal β-sheet structure was further confirmed by CD analysis before
and after core cross-linking and purification (Figure 12.8). Worm-like mi-
celles show a negative Cotton effect at λ≈ 220 nm, confirming the pres-
ence of β-sheets throughout the particle preparation. Reliable CD data of
micelles in the presence of thiourea could not be obtained owing to the
high UV absorption of thiourea at relevant concentrations (10 mM–1M).
Table 12.1: Particle characterization of NHGs and CCPMs.
particle polymer thiourea morphology cross-linker
wNHG1 P1 - worm-like cationic (c2)
sNHG2 P1 + spherical cationic (c2)
swNHG3 P2 - mixed cationic (c2)
sNHG4 P2 + spherical cationic (c2)
wNHG5 P3 - worm-like cationic (c2)
wNHG6 P3 + worm-like cationic (c2)
sCCPM8 P2 + spherical hydrophobic (c1)
sCCPM10 P2 + spherical hydrophobic (c1)
wNHG11 P1 - worm-like cationic (c2)
Polymer P2, with the same block-to-block ratio (15 wt. %) but a shorter
total chain length, gave rise to a mixture of spherical and worm-like
nanohydrogels swNHG3 in the absence of thiourea and small spherical
nanohydrogels sNHG4 (Dh = 29 nm; (Figure 12.2 A II, 12.2 C and 12.9) in
the presence of thiourea. This coexistence of morphologies most likely
originates from the fact that synthetic block copolymers bear a certain
polydispersity, indicating that not all polymer chain have attained the
critical length to successfully participate in theβ-sheet alignments neces-
sary to exclusively form elongated structures. Hence multi-angle DLS re-
vealed angle-dependent scattering for swNHG3, indicating non-spherical
and/or polydisperse samples, with a µ2 value of 0.17, whereas sNHG4
showed no angular dependence, as is typical for spherical and uniform
particles, with a µ2 value of 0.06 indicating low polydispersity (Fig-
ure 12.10. Increasing the percentage of the hydrophobic block to 30 wt. %
in polymer P3 resulted in the formation of worm-like nanohydrogels
wNHG5 and wNHG6 both in the presence and in the absence of thio-
urea, which differ only slightly in the hydrodynamic diameter (Dh = 62
and 50 nm, respectively; Figure 12.2 D, 12.9 C and 12.11). This behav-
ior was anticipated for coil–coil polymers with a 30 wt. % hydrophobic
block.[495]
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Figure 12.2: A I) Core framework of worm-like particles with twisted β-
sheets in the absence of a chaotropic agent. II) Size range of the
obtained core-cross-linked nanohydrogels wNHG1, sNHG2, and
sNHG4 (DLS). III) Core framework of the spherical particles with
intertwined polymer chains in random coil conformation in the
presence of a chaotropic agent. B) Shape control of nanohydrogels
wNHG1 and sNHG2 (visualized by AFM/TEM), modulated by the
presence or absence of secondary structure stabilization (from P1,
hydrophobic segment: 15 wt.%). C) Nanohydrogels from a shorter
block copolymer (P2, 15 wt. %) exhibit either a mixed morphol-
ogy in the presence of secondary structures swNHG3 or small-scale
spheres sNHG4 (AFM). D) Worm-like nanohydrogels wNHG5 and
wNHG6 (AFM) are obtained independently from secondary struc-
ture stabilization, due to higher weight percentage of the hydro-
phobic segment in P3 (30 wt.%).
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Our findings underline the fact that β-sheet formation of the poly-
cysteine block in block copolypept(o)ides substantially influences the
self-assembly behavior as it leads to a rigid rod segment by intermolec-
ular interactions that can be transformed into a coil conformation by
the chaotropic agent thiourea. Consequently, a PSar-b-PCys(SO2Et) block
copolymer with a hydrophobic ratio known to lead to spherical micelles
and a certain critical total length will form elongated structures when
undisturbed (rod–coil) and spherical structures when transformed into
a coil–coil polymer in the presence of thiourea.
Figure 12.3: A) Cross-linking of self-assembled nanostructures by using the
thiol-reactivity of the S-ethylsulfonyl group with various dithiols
and thus introducing bioreversible disulfide bonds in core cross-
linked polymeric micelles (CCPMs, yellow core) and nanohydrogels
(NHGs, blue core). B I) The particle size remains constant in the
presence of various cross-linkers II) while the core functionality is
changed. C I) Adjusting the core polarity of CCPMs with lipoic acid
derived cross-linkers with various side chains II)without affecting
the particle size.
In addition to morphology control and covalent core cross-linking, the
S-alkylsulfonyl group in the PSar-b-PCys(SO2Et) block copolymers is par-
ticular attractive for the construction of drug delivery systems. This ap-
proach can not only be used to incorporate functionality into the core of
micelles, but also leads to bioreversible disulfide bonds (Figure 12.3 A
and 12.12). Micelles with disulfide cross-linkages and polyplexes are
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known to be stable in the blood (10 µM glutathione (GSH)) but are rapidly
cleaved inside cells (10 mM GSH).[19,159] Therefore, this type of cross-
linking appears to be ideal to stabilize nanoparticles while they are in
circulation, but makes them responsive to a change in redox potential
once they enter cells in order to disintegrate and release their cargo
specifically.[522] In contrast to the disulfide cross-linking frequently re-
ported in the literature, for example, by oxidation in the presence of
oxygen[164] or DMSO,[274] the cross-linking reaction of Cys(SO2Et) is thiol-
selective, proceeds rapidly, and yields asymmetric disulfides in aqueous
solution.[173,209]
Having established that core crosslinking does not alter the size
distribution under optimized cross-linking conditions (Figure 12.3 B I
and Table 12.2), it seemed highly interesting to investigate whether
the core polarity could be adjusted or even inverted. In this case,
the desired function of the carrier system can be introduced in one
single step by the cross-linker itself, enabling the rapid production of
nanoparticle libraries from one precursor micelle. Whereas hydrophobic
cross-linkers (e. g. hexanedithiol c1) form core cross-linked polymeric
micelles (CCPMs)[153], cationic cross-linkers (e. g. TETA c2) invert the
core polarity and thus lead to the formation of cationic nanohydro-
gels (NHGs)[104] (Figure 12.3 B II). Successful core cross-linking was
confirmed by gel permeation chromatography in hexafluoro 2-propanol
(HFIP), which is a good solvent for both blocks (Figure 12.13). With
core-cross-linked polymeric micelles and nanohydrogels as the core
polarity extremes, a library of lipoic acid based cross-linkers c4 a–k was
synthesized to finetune the core polarity (Figure 12.3 C I and Table 12.4).
In addition to simply altering polarity, the residues R of the cross-linker
c4 can be readily adjusted to match, for example, a certain cargo to
covalently attach drugs or imaging probes.[523,524] As shown earlier, the
cross-linking reaction (for c3 and c4a–k after equimolar reduction with
tris(2-carboxyethyl)phosphine (TCEP); Scheme 12.2) is independent of
the chemical nature of the cross-linker and results in particles sCCPM9a-g
with comparable size distributions (Figure 12.3 C II and Table 12.2).
These findings underline that nanostructure formation is completely
separated from chemical functionality in this approach, which is a very
desirable characteristic in a new material.
Furthermore, the function of the core-cross-linked polymeric micelles
on the one hand and the nanohydrogels on the other hand was in-
vestigated. Spherical sCCPM8 was formulated with the hydrophobic
chemotherapeutic agent paclitaxel (PTX), yielding sCCPM10 with
Dh = 39 nm. The hydrodynamic diameter did not change significantly
upon loading with paclitaxel (Figure 12.4 A and Table 12.2). Success-
ful loading and release was confirmed indirectly by in vitro cell experi-
ments using human breast cancer cells (TD47 cells). Whereas PTX-loaded
CCPMs led to substantially decreased cell viability, comparable to that
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achieved with free paclitaxel, empty CCPMs were non-toxic (Figure 12.4
A II).
Figure 12.4: A) sCCPM8 with cross-linker c1 was loaded with Paclitaxel (PTX) to
give sCCPM10 and shows I) uniform sizes prior to and after load-
ing as well as II) pronounced in vitro efficacy on TD47 cells. B)
Cationic nanohydrogels with cross-linker c2 prior to (wNHG1) and
after complexation of siRNA (wNHG11) I) exhibit near-neutral ζ-
potential and II) enable stimuli-responsive release at intracellular
glutathione levels (10 mM).
On the other hand, worm-like nanohydrogels wNHG1 enabled the
complexation of chol-siRNA at N/P ratios of 8 (Figure 12.14), resulting in
wNHG11 with Dh = 81 nm, once again upon unchanged size distributions
(Figure 12.15 and Table 12.22). In addition, nanohydrogels exhibited
near-neutral ζ-potentials before and after loading (surface ζ= 0.4 mV
and 0.5 mV, respectively; Figure 12.4 B I), which is due to the effective
shielding of the PSar segment. The bioreversible nature of the siRNA
complexation was evaluated by agarose gel electrophoresis using extra-
and intracellularly relevant GSH concentrations (Figure 12.4 B II). In the
absence of GSH and with 10µM GSH (extracellular), chol-siRNA-loaded
nanohydrogels remained stable whereas the siRNA was released at
10 mM GSH (intracellular). The successful loading of the respective core-
functionalized particles as well as cargo release upon a reductive stimu-
lus portray the last phase of the proposed platform (Figure 12.1 C III).
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In summary, our findings highlight the potential of secondary structure-
driven self-assembly to control the size and shape of polymeric nanos-
tructures in combination with adjustable core functionality by
bioreversible core cross-linking in a separate, single post-polymerization
step. The S-alkylsulfonyl group for cysteine enables the controlled NCA
ring-opening polymerization, which was exploited here for the synthe-
sis of amphiphilic PSar-b-PCys(SO2Et) block copolypept(o)ides. Their self-
assembly behavior can be directed by switching the conformation of
the polycysteine segment from rod to coil, and the polymer association
can be tuned by manipulating the secondary structures. In addition to
size and shape control, this approach enables the complete decoupling
of function from the self-assembly process as the polarity of the mi-
cellar core is introduced only after particle formation by using dithiol-
containing cross-linkers. This novel polypept(o)ide-based nanoparticle
platform can be used to generate nanoparticle libraries for various bio-
medical applications, ranging from nucleic acid delivery (RNAi) over
drug delivery to imaging, and may help to further elucidate the size and
shape dependence of circulation, biodistribution, and cellular response.
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12.5.1 Materials and Instrumentation
Tetrahydrofurane (THF) and n-hexane were distilled from Na/K,
ethyl acetate from CaH2 prior to use. N,N-dimethyl formamide (DMF)
was purchased from Acros and dried over BaO and molecular sieve (3 Å),
fractionally distilled in vacuo at 20 °C and stored at -80 °C under exclu-
sion of light. Prior to use, DMF was degassed in vacuo to remove residing
traces of dimethylamine. N-Boc-1,2-diaminoethane and HFIP)were pur-
chased from Fluorochem. Millipore water was prepared by a MILLI-Q®
Reference A+ System used at a resistivity of 18.2Ω cm and total organic
carbon < 5 ppm. Cysteine and sarcosine were purchased from OPRE-
GEN and Alfa Aesar, respectively and used as received. Diphosgene
was purchased from Alfa Aesar, deuterated solvents were obtained from
Deutero GmbH. 1,6-Hexanedithiol was purchased from Sigma Aldrich,
DL-lipoic acid was purchased from TCI Europe. Paclitaxel was obtained
from Biotrend or used as Taxol formulation (pharmacy) as stated in the
experimental section. siRNA sequences were purchased from Hokkaido
System Science Co., Ltd. (Hokkaido, Japan) and used as follows: (1) Fire-
fly chol-GL3-luciferase siRNA: sense strand: 5’-CUUACGCUGAGUAC
UUCGAdTdT-3’-chol; antisense strand: 3’-dTdTGAAUGCGACUCAU
GAAGCU-5’. Other chemicals were purchased from Sigma-Aldrich and
used as received unless otherwise stated.
1H, 19F and 13C nuclear magnetic resonance (NMR) spectra were re-
corded on a Bruker AC 400 or a Bruker AC 300. All spectra were recorded
at room temperature (25 °C) and calibrated using the solvent signals.[394]
Melting points were measured using a Mettler FP62 melting point appa-
ratus at a heating rate of 5 °C min-1. Gel permeation chromatography
(GPC) was performed with HFIP containing 3 g l−1 potassium trifluoroac-
etate (KTFA) as eluent at 40 °C and a flow rate of 0.8 mL min-1. GPC
columns were packed with modified silica (PFG columns, particle size:
7µm porosity: 100 Åand 1000 Å, respectively). Polymethyl methacrylate
standards (PMMA, Polymer Standards Services GmbH) were used for
calibration and toluene was used as the internal standard. A refractive
index detector (G1362A RID) and an UV/Vis detector (230 nm; Jasco UV-
2075 Plus) were used for polymer detection. Infrared IR spectroscopy
was performed on a Jasco FT/IR-4100 with an ATR sampling accessory
(MIRacle, Pike Technologies) using Spectra Manager 2.0 (Jasco) for inte-
gration. Circular dichroism (CD) spectroscopy was performed on a Jasco
J-815 spectrometer at 20 °C and Spectra Manager 2.0 (Jasco) was used to
analyze the spectra. A cell with a path length of 2 mm was employed.
Spectra were recorded at varying concentrations in HFIP, 3 g L-1 KTFA or
1 mM acetate buffer as indicated.
Atomic force microscopy AFM was measured on mica using a
Cypher®AFM (Asylum Research) using tapping mode at a scan rate of
1 Hz. Samples were prepared by spin-casting a drop of particle solu-
tion (0.1 g L-1 in water) onto freshly cleaned mica. The sample was dried
214 S E C O N D A R Y S T R U C T U R E - D R I V E N S E L F - A S S E M B LY
overnight at room temperature. Images were evaluated and apparent
height profiles were extracted using Gwyddion. The core morphology
of polymeric micelles was characterized by TEM imaging on a H-7000
electron microscope (Hitachi Ltd., Tokyo, Japan) according to a previ-
ous report.[525] Briefly, a glow-discharged carbon-coated collodion mem-
brane containing copper TEM grid (Nisshin EM Co., Ltd., Japan) was
dipped into the polymeric micelle solution, which was pre-treated with
an equivalent volume of uranyl acetate (UA) (2% (w/v)) for 30 s to obtain
effective deposition of the samples onto the grid. The sample-deposited
grids were blotted onto a filter paper to remove excess sample solution,
air-dried for 30 min at room temperature, and then transferred to the
TEM machine for imaging. Images were captured at an acceleration volt-
age of 75 kV. Polymeric micelles size distributions were obtained by mea-
suring the diameter of the core from the TEM images using Image J 1.48v
software (National Institutes of Health, USA).
Single-angle dynamic light scattering (DLS) measurements were per-
formed with a ZetaSizer Nano ZS instrument (Malvern Instruments Ltd.,
Worcestershire, UK) equipped with a He-Ne laser (λ= 633 nm) as the
incident beam. All measurements were conducted at 25 °C and a de-
tection angle of 173 rˇ unless otherwise stated. Disposable polystyrene
or PMMA cuvettes (VWR, Darmstadt, Germany) were used for |acDLS
measurements, for zeta potential measurements disposable folded cap-
illary cells (Malvern Instruments Ltd., Worcestershire, UK) were em-
ployed. Cumulant size, polydispersity index (PDI), and size distribution
(intensity-weighted) histograms were calculated based on the autocorre-
lation function of samples, with automated attenuator adjustment and
multiple scans (typically 10 – 15 scans) for optimal accuracy. Aggrega-
tion and Dissociation experiments were performed at fixed attenuator
of 8 and 9, respectively at concentrations as indicated.
For multi-angle DLS, cylindrical quartz cuvettes (Hellma, Mühlheim,
Germany) were cleaned by dust-free distilled acetone. Particle solutions
were filtered into these cuvettes through Millex GHP filters, 0.2 µm pore-
size (Millipore). DLS measurements were performed on a He – Ne Laser
(25 mW output power at λ= 632.8 nm) and on an ALV-CGS 8F SLS/DLS
5022F goniometer with eight simultaneously working ALV 7004 correla-
tors and eight QEAPD avalanche photodiode detectors. The correlation
functions of the particles were fitted using a sum of two exponentials.
The z-average diffusion coefficient Dz was calculated by extrapolating
Dapp for q = 0. By formal application of Stokes law, the inverse z-average
hydrodynamic radius is Rh = 〈R−1h 〉−1z .
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12.5.2 Experimental Procedures
Ethanesulfinic acid sodium salt
A solution of sodium sulfite (391.98 g, 3.11 mol) in water (800 mL) was
heated to 80 °C. Ethanesulfonyl chloride (147.40 mL, 199.30 g, 1.55 mol)
and sodium carbonate (329.63 g, 3.11 mol) were added simultaneously
while significant quantities of CO2 evolved. The reaction mixture was
stirred for one hour at 80 °C, afterwards water was removed in vacuo
at 60 °C. The resulting solid was suspended in methanol and filtered.
Evaporation of methanol gave ethanesulfinic acid sodium salt (153.54 g,
1.32 mol, 85 %) as a colorless solid.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 1.79 (q, 3JH,H = 7.6 Hz, 2H, – CH2 – ),
0.90 (t, 3JH,H = 7.6 Hz, 3H, – CH3).
Synthesis of S-ethylsulfonyl-L-cysteine (Cys(SO2Et))[173]
An ice-cold solution of sodium nitrite (5.94 g, 86 mmol) in degassed
water (45 mL) was slowly added to a stirred solution of L-cysteine hy-
drochloride (13.57 g, 86 mmol) in previously degassed 2 N HCl (90 mL)
at 0 °C. After 1 h, ethanesulfinic acid sodium salt (20.00 g, 172 mmol)
was added to the deep red solution and was stirred for 2 h. Additional
sodium ethanesulfinate (5.00 g, 43 mmol) was added and eventually
a colorless solid precipitated. The reaction mixture was stirred at 0 °C
overnight. The precipitate was filtered off and the pH of the colorless
filtrate was adjusted with 2 N NaOH to pH 4-5, resulting in additional col-
orless solid precipitating. The filtrate was allowed to stand at 4 °C un-
til precipitation was complete. The combined precipitates were washed
with MeOH to remove residual sulfinate and dried in vacuo yielding
Cys(SO2Et) (5.03 g, 24 mmol, 27 %) as a colorless, crystalline solid.
1H NMR (400 MHz, DMSO-d6/ TFA-d) δ [ppm] = 4.34 (t, 3JH,H = 6.4 Hz,
3JH,H = 6.0 Hz, 1H, α– H), 3.66 (dd, 2JH,H = 14.4 Hz, 3JH,H = 6.0 Hz, 1H,
– CHH – S), 3.62 (q, JH,H = 7.2 Hz, 2H, – CH2 – SO2), 3.53 (dd, 3JH,H = 14.4 Hz,
3JH,H = 6.4 Hz, 1H, – CHH – S), 1.30 (t, 3JH,H = 7.2 Hz, 3H, – CH3).
Synthesis of S-ethylsulfonyl-L-cysteine N-carboxyanhydride
(Cys(SO2Et) NCA)[173]
Dried Cys(SO2Et) (7.00 g, 32.82 mmol) was suspended in absolute THF
(100 mL) and heated to 70 °C. Diphosgene (3.60 mL, 5.84 g, 29.52 mmol)
was slowly added and the suspension was heated for an additional 4 h.
Dry nitrogen was bubbled through the reaction mixture overnight into
a gas washing bottle with an aqueous KOH solution to remove excess
diphosgene, HCl and most of the solvent. The remaining solvent was re-
moved in vacuo and the residue was dissolved in 100 mLabsolute ethyl
acetate. Any insoluble compounds were removed by filtration avoiding
contact with air and the NCA was precipitated by adding 800 mLabso-
lute hexane. The recrystallization of the product was repeated two more
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times yielding Cys(SO2Et) NCA (6.43 g, 26.87 mmol, 82 %) as a colorless,
crystalline powder (m.p. 113–115 °C).
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.32 (s, 1H, – NHCO), 4.86 (td,
3JH,H = 6.0 Hz, 3JH,H = 4.8 Hz, 3JH,H = 1.6 Hz, 1H, α– H), 3.64 (dd, 2JH,H
= 14.4 Hz, 3JH,H = 4.8 Hz, 1H, – CHH – S), 3.62 (q, 3JH,H = 7.2 Hz, 2H,
– CH2 – SO2), 3.57 (dd, 2JH,H = 14.4 Hz, 3JH,H = 6.4 Hz, 1H, – CHH – S), 1.29
(t, 3JH,H = 7.2 Hz, 3H, – CH3).
Synthesis of sarcosine N-carboxyanhydride (Sar NCA)[26]
The synthesis of sarcosine NCA was adapted from literature and
modified.[44] A total of 14.92 g (167.4 mmol) sarcosine, dried in vacuo for
1 h, was weighed into a pre-dried, three-neck, round-bottom flask. A
total of 300 mL of absolute THF was added under a steady flow of ni-
trogen and 16.2 mL (134 mmol) of diphosgene were added slowly via
syringe, and the nitrogen stream was reduced. The colorless suspen-
sion was mildly refluxed for 3 h, yielding a clear solution. Afterward,
a steady flow of dry nitrogen was led throw the solution for another
3 h into two gas washing bottles filled with aqueous NaOH solution. The
solvent was evaporated under reduced pressure, yielding a brown oil
as crude reaction product. The oil was heated to 50 °C and dried under
reduced pressure (20 mbar, then < 10-2 mbar for 2 h) to obtain an amor-
phous solid, free of phosgene and HCl, confirmed by testing against sil-
ver nitrate solution. The crude product was dissolved in 40 mL absolute
THF and precipitated with 300 mL absolute hexane. The solution was
cooled to -18 °C overnight for complete precipitation. The solid was fil-
tered under dry nitrogen atmosphere, dried in a stream of dry nitro-
gen for 60–90 min and afterwards under high vacuum for 2 h in a sub-
limation apparatus. The crude product was sublimated at 80–85 °C and
< 10-2 mbar. The product was collected from the sublimation apparatus
in a glovebox on the same day. This procedure yielded 12.64 g of puri-
fied product (110 mmol, 65 % yield, colorless crystals, which was stored
in a Schlenk tube at -80 °C and only handled under nitrogen atmosphere;
mp 102–104 °C.
1H NMR (400 MHz, CDCl3) δ [ppm] = 4.22 (s, 2H, – CH2 – ), 2.86 (s, 3H,
– CH3).
Synthesis of polysarcosine (PSar)[327]
2.21 g (192 mmol) sarcosine NCA, was dissolved in 10 mL dry DMF and
7.6µL (4.19µg, 48.1µmol) N-boc-1,2-diaminoethane were added. The
clear, colorless solution was stirred at room temperature and the reac-
tion was completed after three days (monitored by IR spectroscopy).
The sarcosine amino terminus was quenched by addition of 133.4µL
(0.96 mmol) triethylamine and 45.5µL (0.48 mmol) acetic anhydride. The
clear solution was allowed to stir for an additional day at room temper-
ature. Precipitation in diethyl ether yielded 1.44 g (64%) of a colorless
solid.
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The Boc protective group was removed in a mixture of H2O/TFA 1:1 for
2 h. The clear yellow solution was stirred under an argon atmosphere at
room temperature for 1 hour under the exclusion of light. Precipitation
in diethyl ether yielded a colorless solid, which was dialyzed against
Millipore water (MWCO = 3.5 kDa), saturated with NaHCO3 for 2 days.
Afterwards, dialysis in pure Millipore water was carried out for addi-
tional 2 days. The polymer was lyophilized from water and 479 mg (22
%) of a colorless solid were obtained.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 4.35–3.94 (m, 2nH, – CH2 – ), 2.97–
2.73 (m, 3nH, – CH3), 2.01–1.99 (m, 3H, – OCCH3). Additionally 1.37 (m,
9H, – OC(CH3)3) for Boc-terminated.
Synthesis of polysarcosinen-block-poly(S-ethylsulfonyl-L-cysteine)m block copoly-
mers (PSarn-b-PCys(SO2Et)m)[327]
200 mg (6.9µmol) polysarcosine macroinitiator were dried in vacuo and
dissolved in 3 mL dry DMF. The pale yellow monomer solution of 83 mg
(345µmol) Cys(SO2Et) NCA in 1 mL dry DMF was added. The polymer-
ization was carried out at -10 °C and monitored via IR spectroscopy. After
3 days (conversion rate of 47%), the reaction was stopped by precipita-
tion in THF/diethyl ether 1:5. The work-up by precipitation and centrifu-
gation was repeated two times in THF/diethyl ether 1:5 and then once
in pure diethyl ether. After extensive drying in vacuo, 183 mg (69%) of a
colorless solid were obtained.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 8.76 (m, 1mH, – NHCO)Cys, 4.69
(m, 1mH, α– H)Cys, 4.34–3.92 (m, 2nH, – CH2 – )Sar, 3.57–3.47 (m, 4mH,
– CH2 – SSO2 – CH2 – )Cys, 2.93–2.72 (m, 3nH, – CH3)Sar, 1.29 (t, 3mH, – CH3)Cys.
Triethylenetetramine α,ω-di((S-Trt-N-Boc)cysteine)diamide
1.20 g (2.60 mmol) Cys(S-Trt)N-Boc and 472 mg (3.50 mmol) HOBt (12 %
water) were dissolved in 10 mL DMF and 589 mg (3.12 mmol) EDC·HCl
were added. The solution was stirred for 1 h at rt. 193µL triethylenete-
tramine were added and the solution was stirred for 30 more minutes.
The solvent was removed in vacuo and the product purified by flash
chromatography (AcOEt:MeOH (3:5) +2 % NEt3).
1H NMR (300 MHz, CDCl3) δ [ppm] = 7.45–7.33 (m, 12H, m-HAr), 7.29–7.21
(m,12H, o-HAr), 7.22–7.13 (m, 6H, p-HAr), 6.62 (s, 2H, – CO – NH – ), 5.05 (s,
br, 2H, α– H), 3.92 (s, 2H, – NH), 3.39–3.09 (m, 4H, – CH2 – S – ), 2.68 - 2.60
(m, 8H, - – CO – NH – CH2 – CH2 – ), 2.58 (s, 4H, – NH – CH2 – CH2 – NH – ), 1.39 (s,
18H, – O – C(CH3)3).
ESI – MS: m/z = 1038.7 [M+H]+, (calc. 1037.5 g mol-1); 1059.6 [M+Na]+, (calc.
1059.5 g mol-1).
Triethylenetetramine α,ω-di(cysteine)diamide
442 mg (0.426 mmol) triethylenetetramine α,ω-di((S-Trt-N-Boc)cyste-
ine)diamide and 263 mg (1.7 mmol) dithiothreitol (DTT) were dissolved
in 18 mL DCM. 0.7 mL (3.4 mmol) triisopropylsilane followed by 2 mL
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TFA. The solution was stirred under argon for 3 h and and precipitated
in diethyl ether. The crude product was dissolved in 4 mL water/ace-
tonitrile (97:3 + 0.1% TFA), 130 mg DTT were added and the mixture was
purified by HPLC. Lyophilization yielded 287 mg triethylenetetramine
α,ω-di(cysteine) diamide tetratriflouroacetate.
1H NMR (400 MHz, D2O) δ [ppm] = 4.24 (dd, 3JH,H = 6.3, 5.2 Hz, 2H, α– H),
3.79–3.66 (m, 2H, – CH2 – S – ), 3.65–3.54 (m, 2H, – CH2 – S – ), 3.52 (s, 4H,
– NH – CH2 – CH2 – NH – ), 3.33 (q, 3JH,H = 5.8 Hz, 4H, – CO – NH – CH2), 3.17–
3.02 (dq, 3JH,H = 5.8, 14.1 Hz, 4H, – CH2 – NH – ).
ESI – MS: m/z = 353.2 [M+H]+, (calc. 353.2 g mol-1).
Synthesis of perfluorophenyl 5-(1,2-dithiolan-3-yl)pentanoate
2.00 g (9.69 mmol) of DL-lipoic acid were weighed into a pre-dried
Schlenk-flask and dissolved in 5.0 mL of absolute THF. Next, DIPEA
(1.98 mL, 11.6 mmol, 1.2 eq.) and pentafluorophenyl trifluoroacetate
(2.0 mL, 11.6 mmol, 1.2 eq.) were added. The solution was stirred in the
absence of light in a dry nitrogen atmosphere for 24 h at room tempera-
ture. Subsequently, the solvent was removed in high vacuum, yielding
a yellow oil. Upon purification by column chromatography (cyclohex-
ane/ethyl acetate, 9/1–6/1), 3.21 g of perfluorophenyl 5-(1,2-dithiolan-
3-yl)pentanoate (8.62 mmol, 89 % yield) were obtained as a yellow solid.
The product was stored at -20 °C in the absence of light.
1H NMR (300 MHz, CDCl3) δ [ppm] = 3.57 (1H, dq, 3JH,H = 8.3 Hz, 6.4 Hz,
– CHS), 3.15 (2H, m, – CH2S), 2.69 (2H, t, 3JH,H = 7.4 Hz, – CH2CO), 2.48
(1H, dtd, 2JH,H = 13.1 Hz, 3JH,H = 6.6 Hz, 5.4 Hz, -CH’HCH2S), 1.93 (1H, dq,
2JH,H = 12.7 Hz, 3JH,H = 6.9 Hz, -CH”HCH2S), 1.78 (4H, m, – CH2CHS,
– CH2CH2CO), 1.57 (2H, m, – CH2CH2CH2CO).
13C NMR (101 MHz, CDCl3) δ [ppm] = 169.40, 142.41, 140.81, 139.91, 139.25,
138.29, 136.72,110.12, 56.28, 40.33, 38.66, 34.64, 33.25, 28.60, 24.62.
19F NMR (282 MHz, CDCl3) δ/ppm = -154.0, -159.2, -163.5.
FD – MS: m/z = 372.4, [M]+, (calc. 372.4 g mol-1).
Synthesis of liponamides (c4a-4k)
250 mg (0.671 mmol, 1 eq.) of perfluorophenyl 5-(1,2-dithiolan-3-yl)
pentanoate were weighed into a pre-dried Schlenk-flask and dissolved
in 5.0 mL of absolute DMF. Next, DIPEA (685µL, 4.03 mmol, 6.0 eq.) and
the respective amine (0.739 mmol, 1.1 eq.) were added and the solution
was stirred for 18 h in a dry nitrogen atmosphere at room temperature.
Upon full conversion as monitored by thin layer chromatography (TLC),
the solvent was removed under reduced pressure and the crude reaction
product was purified by column chromatography (cyclohexane/ethyl
acetate or dichloromethane/methanol).
N-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethyl)-5-(1,2-dithiolan-3-yl)
pentanamide (c4a)
Yield: 53 %, logP = 1.41.
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1H NMR (300 MHz, CDCl3) δ [ppm] = 6.18 (1H, s, – CONH), 3.68
(10H, m, – O(CH2CH2O)2CH2), 3.55 (3H, m, – CHS, – CONHCH2CH2),
3.46 (2H, m, – CONHCH2), 3.40 (2H, m, – CH2N3), 3.14 (2H, m,
– CH2S), 2.46 (1H, dtd, 2JH,H = 13.1 Hz, 3JH,H = 6.6 Hz,5.4 Hz, -CH’HCH2S),
2.20 (2H, t, 3JH,H = 7.4 Hz, – CH2CO), 1.91 (1H, dq, 2JH,H = 12.7 Hz,
3JH,H = 6.9 Hz, -CH”HCH2S), 1.68 (4H, m, – CH2CHS, – CH2CH2CO), 1.46 (2H,
m, – CH2CH2CH2CO).
13C nmR (101 MHz, CDCl3) δ [ppm] = 174.05, 70.80, 70.74, 70.65, 70.35,
70.17, 69.81, 56.53, 50.82, 40.37, 39.58, 38.61, 36.43, 34.71, 28.97, 25.54.
FD – MS: m/z = 429.2, [M+Na]+, (calc. 406.2 g mol-1).
5-(1,2-Dithiolan-3-yl)-N-(2-methoxyethyl)pentanamide (c4b)
Yield: 85 %, logP = 1.48.
1H NMR (300 MHz, CDCl3) δ [ppm] = 5.91 (1H, s, – CONH), 3.56 (1H,
dq, 3JH,H = 8.5, 6.4 Hz, – CHS), 3.46 (4H, m, – NHCH2CH2O), 3.37 (3H, s,
– OCH3), 3.13 (2H, m, – CH2S), 2.46 (1H, dtd, 2JH,H = 13.1 Hz, 3JH,H = 6.6 Hz,
5.4 Hz, -CH’HCH2S), 2.22 (2H, t, 3JH,H = 7.2 Hz, – CH2CO), 1.91 (1H,
dq, 2JH,H = 12.7 Hz, 2JH,H = 6.9 Hz, -CH”HCH2S), 1.68 (4H, m, – CH2CHS,
– CH2CH2CO), 1.46 (2H, m, – CH2CH2CH2CO).
13C nmR (101 MHz, CDCl3) δ [ppm] = 173.39, 71.24, 58.95, 56.54, 40.38,
39.38, 38.62, 36.57, 34.75, 28.99, 25.52.
FD – MS m/z = 263.3, [M]+, (calc. 263.4 g mol-1).
5-(1,2-Dithiolan-3-yl)-N-(prop-2-yn-1-yl)pentanamide (c4c)
Yield: 95 %, logP = 1.76.
1H NMR (300 MHz, CDCl3) δ [ppm]= 5.71 (1H, s, – CONH), 4.05 (2H, dd,
3JH,H = 5.3 Hz, 4JH,H = 2.6 Hz, – CONHCH), 3.57 (1H, dq, 3JH,H = 8.6 Hz,
6.4 Hz, – CHS), 3.14 (2H, m, – CH2S), 2.46 (1H, dtd, 2JH,H = 13.1 Hz,
3JH,H = 6.6 Hz, 5.4 Hz, -CH’HCH2S), 2.22 (3H, m, – CCH, – CH2CO), 1.91 (1H,
dq, 2JH,H = 12.6 Hz, 3JH,H = 6.9 Hz, -CH”HCH2S), 1.68 (4H, m, – CH2CHS,
– CH2CH2CO), 1.47 (2H, m, – CH2CH2CH2CO).
13C nmR (101 MHz, CDCl3) δ [ppm] = 172.69, 79.55, 71.86, 56.50, 40.38,
38.62, 36.26, 34.71, 29.38, 28.95, 25.32.
FD – MS m/z = 243.3, [M]+, (calc. 243.4 g mol-1).
N-Butyl-5-(1,2-dithiolan-3-yl)pentanamide (c4d)
Yield: 51 %, logP = 2.85.
1H NMR (300 MHz, CDCl3) δ [ppm] = 5.44 (1H, s, – CONH), 3.57
(1H, dq, 3JH,H = 8.5 Hz, 6.4 Hz, – CHS), 3.24 (2H, td, 3JH,H = 7.1 Hz,
5.7 Hz, – CONHCH2), 3.13 (2H, m, – CH2S), 2.45 (1H, dtd, 2JH,H = 13.0 Hz,
3JH,H = 6.6 Hz, 5.4 Hz, -CH’HCH2S), 2.16 (2H, t, 3JH,H = 7.3 Hz, – CH2CO),
1.90 (1H, dq, 3JH,H = 12.7 Hz,3JH,H = 6.9 Hz, -CH”HCH2S), 1.68 (4H, m,
– CH2CHS, – CH2CH2CO), 1.46 (4H, m, – CH2CH2CO, – CONHCH2CH2), 1.34
(2H, m, – CH2CH3), 0.93 (3H, m, – CH3).
13C nmR (101 MHz, CDCl3) δ [ppm] = 172.74, 56.57, 40.38, 39.38, 38.61,
36.71, 34.77, 31.88, 29.04, 25.59, 20.21, 13.90.
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FD – MS: m/z = 261.4, [M]+, (calc. 261.5 g mol-1).
5-(1,2-Dithiolan-3-yl)-N-neopentylpentanamide (c4e)
Yield: 35 %, logP = 3.15.
1H NMR (300 MHz, CDCl3) δ [ppm] = 5.48 (1H, s, – CONH), 3.57 (1H,
dq, 3JH,H = 8.5 Hz, 6.4 Hz, – CHS), 3.12 (4H, m, – CH2S, – CONHCH2),
2.45 (1H, dtd,2JH,H = 13.0 Hz, 3JH,H = 6.6 Hz, 5.4 Hz, -CH’HCH2S), 2.20
(2H, t, 3JH,H = 7.4 Hz, – CH2CO), 1.90 (1H, dq, 2JH,H = 12.7 Hz,
3JH,H = 7.0 Hz, -CH”HCH2S), 1.68 (4H, m, – CH2CHS, – CH2CH2CO), 1.48 (2H,
m, – CH2CH2CH2CO), 1.34 (9H, s, – CH3).
13C nmR (101 MHz, CDCl3) δ [ppm] = 172.84, 77.16, 56.55, 50.62, 40.37,
38.61, 36.87, 34.78, 31.95, 29.07, 27.35, 25.70.
FD – MS: m/z = 275.4, [M]+, (calc. 275.5 g mol-1).
N-Benzyl-5-(1,2-dithiolan-3-yl)pentanamide (c4f)
Yield: 56 %, logP = 3.25.
1H NMR (300 MHz, CDCl3) δ [ppm] = 7.40–7.15 (5H, m, HAr), 5.72 (1H, s,
– CONH), 4.44 (1H, d, 3JH,H = 5.7 Hz, – CONHCH2), 3.57 (1H, dq, 3JH,H
= 8.4 Hz, 6.4 Hz, – CHS), 3.14 (2H, m, – CH2S), 2.46 (1H, dtd, 2JH,H =
13.0 Hz, 3JH,H = 6.6 Hz, 5.4 Hz, -CH’HCH2S), 2.23 (2H, t, 3JH,H = 7.7 Hz,
– CH2CO), 1.91 (1H, dq, 2JH,H = 12.7 Hz, 3JH,H = 6.9 Hz, -CH”HCH2S), 1.68
(4H, m, – CH2CHS, – CH2CH2CO), 1.48 (2H, m, – CH2CH2CH2CO).
FD – MS: m/z = 295.3, [M]+, (calc. 295.3 g mol-1).
5-(1,2-Dithiolan-3-yl)-N-phenylpentanamide (c4g)
Yield: 53 %, logP = 3.55.
1H NMR (300 MHz, CDCl3) δ [ppm] = 7.51 (2H, d, 3JH,H = 8.3 Hz, o-
HAr), 7.31 (2H, t, 3JH,H = 8.0 Hz, m-HAr), 7.10 (1H, t, 3JH,H = 7.4 Hz,
p-HAr), 3.57 (1H, dq, 3JH,H = 8.4 Hz, 6.4 Hz, – CHS), 3.14 (2H, m,
– CH2S), 2.46 (1H, dtd, 2JH,H = 13.1 Hz, 3JH,H = 6.6 Hz, 5.4 Hz, -CH’HCH2S),
2.37 (2H, t, 3JH,H = 7.4 Hz, – CH2CO), 1.91 (1H, dq, 2JH,H = 12.8 Hz,
3JH,H = 6.9 Hz, -CH”HCH2S), 1.74 (4H, m, – CH2CHS, – CH2CH2CO), 1.52 (2H,
m, – CH2CH2CH2CO).
FD – MS: m/z = 281.3, [M]+, (calc. 281.4 g mol-1).
5-(1,2-Dithiolan-3-yl)-N-hexylpentanamide (c4h)
Yield: 59 %, logP = 3.74.
1H NMR (300 MHz, CDCl3) δ [ppm] = 5.49 (1H, s, – CONH), 3.57
(1H, dq, 3JH,H = 8.4, 6.4 Hz, – CHS), 3.24 (2H, td, 3JH,H = 7.2 Hz, 5.6 Hz,
– CONHCH2), 3.13 (2H, m, d), 2.46 (1H, dtd, 2JH,H = 13.0 Hz, 3JH,H =6.6,
5.3 Hz, -CH’HCH2S, 2.17 (2H, t, 3JH,H = 7.5 Hz, – CH2CO), 1.91 (1H,
dq, 2JH,H = 12.7 Hz, 3JH,H = 6.9 Hz, -CH”HCH2S), 1.68 (4H, m, – CH2CHS,
– CH2CH2CO), 1.47 (4H, m, – CH2CH2CO, – CONHCH2CH2), 1.29 (6H, m,
– CONHCH2CH2CH2CH2), 0.84 (6H, m, – CH3).
FD – MS: m/z = 289.2, [M]+, (calc. 289.3 g mol-1).
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5-(1,2-Dithiolan-3-yl)-N-(naphthalen-1-yl)pentanamide (c4i)
Yield: 65 %, logP = 4.54.
1H NMR (300 MHz, CDCl3) δ [ppm] = 7.89–7.45 (7H, m, HAr, – CONH),
3.61 (1H, m, – CHS), 3.16 (2H, m, – CH2S), 2.51 (3H, m, – CH2CO – ,
CH’HCH2S), 1.86 (5H, m, -CH”HCH2S, – CH2CHS, – CH2CH2CO), 1.60 (2H, m,
– CH2CH2CH2CO).
13C nmR (101 MHz, CDCl3) δ [ppm] = 171.76, 134.21, 132.30, 128.88, 127.42,
126.43, 126.12,126.06, 125.83, 121.40, 120.82, 56.53, 40.39, 38.63, 37.39, 34.80,
29.08, 25.60.
ESI – MS: m/z = 332.1, [M]+, (calc. 331.5 g mol-1).
5-(1,2-Dithiolan-3-yl)-N-(2-ethylhexyl)pentanamide (c4j)
Yield: 90 %, logP = 4.55.
1H NMR (300 MHz, DMSO-d6) δ [ppm] = 7.67 (1H, t, 3JH,H = 5.8 Hz,
– CONH), 3.59 (1H, dq, 3JH,H = 8.6 Hz, 6.2 Hz, – CHS), 3.13 (2H, m,
– CH2S), 2.96 (2H, t, 3JH,H = 6.0 Hz, – CONHCH2), 2.41 (1H, m, -CH’HCH2S),
2.06 (2H, t, 3JH,H = 7.2 Hz, – CH2CO), 1.90 (1H, dq, 2JH,H = 12.8 Hz,
3JH,H = 6.8 Hz, -CH”HCH2S), 1.56 (4H, m, – CH2CHS, – CH2CH2CO), 1.25
(11H, m, CH2CH2CH2CO, – CH2CH2CH2CH3, – CHCH2
ce-CH3), 0.84 (6H, m, – CH3, – CH3).
13C nmR (101 MHz, DMSO-d6) δ [ppm] = 173.00, 56.56, 42.47, 40.38, 39.51,
38.61, 36.79, 34.78, 31.15, 29.04, 29.01, 25.64, 24.38, 23.16, 14.22, 11.02.
FD – MS: m/z = 317.4, [M]+, (calc. 317.6 g mol-1).
5-(1,2-Dithiolan-3-yl)-N-tetradecylpentanamide (c4k)
Yield: 70 %, logP = 7.30.
1H NMR (300 MHz, DMSO-d6) δ [ppm] = 5.41 (1H, s, – CONH), 3.57 (1H,
m, – CHS), 3.17 (4H, m, – CH2S, – CONHCH2), 2.45 (1H, m, -CH’HCH2S),
2.17 (2H, t, 3JH,H = 7.2 Hz, – CH2CO), 1.90 (1H, dq, 2JH,H = 12.6 Hz, 3JH,H
= 6.9 Hz, -CH”HCH2S), 1.67 (4H, m, – CH2CHS, – CH2CH2CO), 1.48 (4H,
m, – CH2CH2CH2CO, – CONHCH2CH2), 1.25 (22H, – (CH2)11-), 0.93 (3H, m,
– CH3).
13C nmR (101 MHz, DMSO-d6) δ [ppm] = 172.78, 110.13, 56.59, 40.40, 39.74,
38.62, 36.72, 34.78, 32.07, 29.84, 29.82, 29.81, 29.75, 29.71, 29.51, 29.46,
29.06, 27.09, 25.62, 22.85, 14.28.
FD – MS: m/z = 401.6, [M]+, (calc. 401.7 g mol-1).
Particle Preparation
The polymer was dissolved in DMAc at a concentration of 7.5 g L-1 for
1.5 h. 1 mM acetate buffer (pH = 4.7) was added to adjust the concen-
tration to 6 g L-1. The solution was left to equilibrate for 3 h and then
dialyzed against 1 mM acetate buffer. The solution was filtered using a
200 nm filter (GHP) and concentrated to 6 g L-1 using a spin filter (Ami-
con MWCO: 3 kDa). The cross-linker was added with SH-groups equimo-
lar to the number of cysteines (c1 in EtOH/DMAc and c2 as a 50 g/L
stock solution in 1 mM acetate buffer). Liponamide-based cross-linkers
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(c3 and c4a-k) were dissolved in DMAc, EtOH or iPrOH at a concentration
of c = 25 mmol L-1 and one equivalent of concentrated aqueous TCEP so-
lution (c = 50 g L-1) was added per disulfide. After 18 h, the cross-linker
solution was added to the micelle solution. The reaction mixture was
shaken and allowed to stand for 18 h. Subsequently, the solution was
diluted with 1 mM acetate buffer (pH = 4.7), filtered via GHP 200 nm sy-
ringe filter, and purified by repetitive spin filtration (MWCO = 100 kDa)
and dilution steps. In cases, where β-sheet suppression was desired,
thiourea was added. The concentrations were 1 M and 10 mM thiourea
in DMAc and acetate buffer, respectively.
Table 12.2: Characterization of CCPMs (cross-linker c1, c3 or c4a-k) and NHGs
(cross-linker c2).
particle thiourea cross-linker Dh, DLS PDIDLS polymer
wNHG1 - c2 77 0.162 P1
sNHG2 + c2 51 0.156 P1
swNHG3 - c2 78 0.199 P2
sNHG4 + c2 29 0.127 P2
wNHG5 - c2 62 0.132 P3
wNHG6 + c2 50 0.144 P3
sPM7 + -a 29 0.140 P2
sCCPM8 + c1 32 0.185 P2
sCCPM9 + c3 44 0.181 P4
sCCPM9a + c4a 40 0.168 P4
sCCPM9b + c4b 41 0.152 P4
sCCPM9c + c4c 44 0.193 P4
sCCPM9d + c4d 43 0.161 P4
sCCPM9e + c4e 41 0.184 P4
sCCPM9f + c4f 43 0.162 P4
sCCPM9g + c4g 51 0.219 P4
sCCPM9h + c4h 45 0.194 P4
sCCPM9i + c4i 50 0.201 P4
sCCPM9j + c4j 45 0.194 P4
sCCPM9k + c4k 48 0.145 P4
sCCPM10 + c1 39 0.242 P4
wNHG11 - c2 81 0.153 P1
a Micelle prior to cross-linking.
Agarose Gel Electrophoresis
Agarose gels were prepared by adding agarose (1.5 g) to a Tris-acetate-
EDTA buffer (TAE) buffer (150 mL, pH = 7.4). The mixture was heated
to dissolve the agarose powder and then allowed to cool down before
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preparing the gels. Samples were loaded into the gel and electrophoresed
(100 V, 20 min) in TAE running buffer. After electrophoresis, siRNA was
stained by CYBRGreen and gel images were captured by a Typhoon
9410 instrument equipped with a 532 nm laser.
PTX Loading
750µL of CCPMs (1 g L-1 in MilliQ-water) were mixed with 2.8 mL of DMSO
and 150µL Paclitaxel (1 g L-1) (attempted loading 17 wt.%) was added.
The solution was incubated for 1.5 h and subsequently dialyzed against
MilliQ-water (MWCO = 6 – 8 kDa). Paclitaxel-loaded CCPMs were filtered
using a GHP 200 nm filter and lyophilized.
In vitro Effect of Paclitaxel-loaded Core Cross-linked Polymeric Micelles
5x105 human breast cancer cells (T47D) were cultured in 24 well plates
for 48 h. The cells were treated with either 10µg paclitaxel or 10 µg
paclitaxel stabilized in the particles (53.4µg). Untreated cells and cells
treated with the empty particles (53.4µg) served as controls. T47D cells
were stained with a fixable viability dye (eFluor 780) and cell viability
was determined by Flow Cytometry. The mean of three independent
experiments (±SD) is shown (two-tailed unpaired t-test).∗∗∗6P 0.001,
∗∗∗∗6P 0.0001, ns = not significant. Paclitaxel: concentrate for solution
for infusion (Taxol®), diluted in phosphate buffered saline (PBS) (2 g L-1),
paclitaxel stabilized in the particle: dissolved in PBS (1 g L-1), particle: dis-
solved in PBS (0.1 g L-1).
12.5.3 Supporting Results
Scheme 12.1: Polymerization scheme of PSarn-b-PCys(SO2Et)m highlighting
chemoselective reactivity of the S-ethylsulfonyl group .
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Table 12.3: Characterization of PSarn-b-PCys(SO2Et)m.
polymer Xna Xma wt.% Mnb/ g mol−1 / g mol-1 Ðb
P1 407 28 15 32100 1.38
P2 265 17 15 30600 1.29
P3 94 15 30 31200 1.25
P4 373 13 9 31200 1.26
a Determined by 1H NMR in DMSO-d6.
b Determined by GPC in HFIP relative to PMMA standards.
Figure 12.5: HFIP GPC traces of P1-4 (see also Table 12.3). Note that secondary
structures are present in the eluent (HFIP containing 3 g L-1 KTFA,
Figure 12.8 A), thus elution volumes may be influenced not only
by the total polymer length, but also by the length and degree of
secondary structure formation of the PCys(SO2Et) block.
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Figure 12.6: Aggregation behavior of P2 in DMAc observed with respect to
added vol.% buffer via DLS. The attenuator was fixed and the nor-
malized count rate is plotted as a function of vol.% buffer added.
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Figure 12.7: Size range of A) worm-like nanohydrogels (wNHG1) and B) spher-
ical nanohydrogels (sNHG2) as derived from statistical analysis of
AFM and TEM data presented in Figure 12.2 B). Characterization of
the core was derived from TEM (due to the selective uranyl acetate
staining of the peptidic core-building block) and overall apparent
particle dimensions from AFM.
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Figure 12.8: CD spectra of A) P2 in HFIP (+3 g L-1 KTFA) and B) of micelles (PM)
and core cross-linked micelles (CCPM) from P2 in 1 mM acetate
buffer.
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Figure 12.9: Extracted apparent height profiles of nanohydrogels swNHG3,
sNHG4, wNHG5 and wNHG6 corresponding to AFM micrographs
shown in Figure 12.2 C) and D).
Figure 12.10: Multi-angle dynamic light scattering (DLS) of nanohydrogels from
P2: A) swNHG3 with Rh = 59.4 nm and µ2 = 0.17 in the absence and
B) sNHG4 with Rh = 17.2 nm and µ2 = 0.06 in the presence of thio-
urea.
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Figure 12.11: Multi-angle DLS of nanohydrogels from P3: A) wNHG5 with
Rh = 35.6 nm and µ2 = 0.19 in the absence and B) wNHG6 with
Rh = 35.2 nm and µ2 = 0.15 in the presence of thiourea.
Figure 12.12: Degradation of NHGs and CCPMs depending on glutathione con-
centration observed at different time points via DLS. All reactions
were carried out under physiological relevant conditions (PBS
buffer at pH 7.1 and 37 °C). The attenuator remained fixed and
the normalized countrate is plotted as a function of time. Degra-
dation of nanohydrogels A) in absence or B) presence of thiourea
and C) degradation of cross-linked polymeric micelles in pres-
ence of thiourea.
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Figure 12.13: HFIP GPC traces of P2 and sNHG4 after cross-linking with c2 and
sCCPM8 after cross-linking with c1 both after purification using
spin filters (MWCO = 100 kDa).
Table 12.4: LogP values for cross-linkers c1, c3 and c4a-k as calculated from
MarvinSketch V16.718.0.
cross-linker logP cross-linker logP
c1 2.76 c4f 3.25
c3 2.11a c4g 3.55
c4a 1.41 c4h 3.74
c4b 1.48 c4i 4.54
c4c 1.76 c4j 4.55
c4d 2.85 c4k 7.30
a for the sodium salt logP = -1.4.
Scheme 12.2: Mechanism of cross-linking using pre-reduced lipoic acid-based
cross-linkers c4a-k.
12.5 S U P P O R T I N G I N F O R M AT I O N 231
Figure 12.14: Agarose gel electrophoresis of chol-siRNA loaded wNHG1 at dif-
ferent N/P ratios. Complete complexation can be obtained at
N/p= 8.
Figure 12.15: DLS of nanohydrogel from polymer P1 before (wNHG1) and after
loading with siRNA (wNHG11).
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12.5.4 1H NMR Spectra
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Self-assembly of amphiphiles is typically influenced by parameters such
as block length ratio and solvent composition.[495] In addition, as demon-
strated in Chapter 12, the choice whether chaotropic agents are em-
ployed or not, will have a distinct influence on self-assembly on poly-
pept(o)ides exhibiting secondary structures, as micellar structures were
found to vary in size and shape. Thus, to provide a better under-
standing of underlying principles, conditions of self-assembly of poly-
sarcosine-block-poly(S-alkylsulfonyl-L-cysteine) (PSar-b-PCys(SO2R)) block
copolypept(o)ides were screened methodically in this chapter. The pos-
sible modes of the self-assembly of PSar-b-PCys(SO2R) in respect to sec-
ondary structure formation are illustrated in Figure 13.1.
Figure 13.1: Self-assembly of amphiphilic PSar-b-PCys(SO2R) block copolymers by
the solvent switch method. A) PCys(SO2R) (orange)exhibits anti par-
allel β-sheets in an organic solvent (right) which are suppressed
by addition of a chaotropic agent (left). B) Self-assembly of coil-coil
polymers in the case of suppressed secondary structures (left) or
self-assembly of rod-coil polymers (right) into C) predominantly
spherical structures in presence of chaotropic agents (left) or elon-
gated structures stabilized by β-sheets in the particle core (right).
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The PCys(SO2R) segment exhibits β-sheets in aqueous solution as well
as in organic solvents.[209] In contrast, addition of chaotropic agents such
as thiourea will disrupt intra molecular hydrogen-bond formation (Fig-
ure 13.1 A). During the solvent-switch, amphiphilic macromolecules ar-
range in accordance to the volume ratio of the hydrophobic and hydro-
philic segment.[495] In the absence of β-sheets, the resulting polymer is
in a coil-coil conformation and follows solely those parameters.
However, if β-sheet formation is enabled, the self-assembly of result-
ing rod-coil polymers does not necessarily follow the anticipated prin-
ciples directed by blocklength ratios (depicted in Figure 13.1 B).[503,504]
A one-dimensional growth by the controlled aggregation of peptide am-
phiphiles in e. g. filamentous aggregates is a well established concept
in supramolecular chemistry.[502,509–511] Further, β-sheets are known to
form β-sheet barrels in natural peptides.[520] Thus, a one-dimensional ar-
rangement of PSar-b-PCys(SO2R) into elongated structures as illustrated in
Figure 13.1 C is proposed. In extreme cases, the same polymer can then
yield elongated structures if β-sheet formation is enabled, and spherical
structures when prepared in presence of chaotropic agents.[22]
13.1 R E S U LT S A N D D I S C U S S I O N
The parameters, by which self assembly of polysarcosine-block-poly-
(S-ethylsulfonyl-L-cysteine) (PSar-b-PCys(SO2Et)) block copolypept(o)ides
can be controlled are the ratio of hydrophobic-hydrophilic segment and
the use of chaotropic agents. First, block copolypept(o)ides of varying
hydrophobic-hydrophilic ratio were prepared, which is expressed by
weight percentage (wt. %) of the PCys(SO2Et) segment on the total molec-
ular weight. Figure 13.2 gives an overview on the investigated polymer
compositions and shows the possible relations which can be compared.
Figure 13.2: PSar-b-PCys(SO2Et) diblock copoylpept(o)ides of varying composi-
tions for evaluation of self-assembly conditions: from top left to
bottom right increasing hydrophobic block ratio upon constant S-
ethylsulfonyl-cysteine block length (constant PCys(SO2Et) in or-
ange) and from bottom left to top right increasing hydrophobic block
ratio upon constant polysarcosine block length (constant PSar in
blue).
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Hydrophobic volume
ratio dictates the
overall aggregation
behavior.
Polymers P1-3 maintain a comparable total length of the hydrophobic
PCys(SO2Et) block (in orange), while the relative hydrophobic fraction in-
creases due to the shorter polysarcosine chain length (from top left to
bottom right). In contrast, P4, P2 and P5 maintain the same length of the
hydrophilic polysarcosine (in blue), again while the relative hydrophobic
fraction increases due to the longer PCys(SO2Et) chain length (from bottom
left to top right).
The mechanism of self-assembly is based on microphase separation
of two immiscible blocks, which is driven by a decrease in free energy
due to hydrophobic interactions.[441,526] Upon variation of the solvent
composition, polymer-polymer interactions slowly override polymer-
solvent interactions of the hydrophobic block. Ultimately, an amphiphilic
system arranges a local thermodynamic equilibrium structure character-
istic for this particular block copolymer under the specific conditions.
Thus, at a certain solvent composition, a block copolymer will arrange
in a thermodynamic stable fashion. Since all micellar aggregation pro-
cesses are of dynamic nature, micelles exist in equilibrium with block
copolymer unimers above their critical aggregation concentration
CMC.[527] In terms of micelle stability, this thermodynamic regime fa-
vored to a kinetically obtained structure, which are always prone to dis-
assembly without further stabilization.[153]
The structures discussed in Chapter 12 in Figure 12.6) were prepared
in a local thermodynamic equilibrium for the particular system. In the
present study, the self-assembly process was tightly screened to cover
all possible self-assembly structures. Thus, solvent compositions ranged
from 10 vol. % of block-selective solvent to 30 vol. % in increments of
2.5 vol. %. Micelles were prepared under identical conditions, chang-
ing only the solvent composition, and the particle size was analyzed
by dynamic light scattering (DLS) after workup. Figure 13.3 summarizes
the results divided in four cohorts for comparison: (top) self-assembly of
P1-3 with same length of the hydrophobic block in absence (A) or pres-
ence (B) of β-sheets and (bottom) self-assembly of P4, P2 and P5 with same
length of the hydrophilic block, also in absence (C) or presence (D) of β-
sheets.
A first inspection shows, how polymers with similar wt. % hydro-
phobic block behave alike, as can be seen from comparing general
trends of data sets from the top to the bottom row. Detailed informa-
tion on self-assembly of individual polymers with respect to size and
distribution is given in Figure 13.4-13.8. Polymers with highest wt. %
hydrophobic block ratios (P3 and P5) yield small, well defined particles
above 20 vol. % of block-selective solvent. Upon hydrodynamic diame-
ters of 30-40 nm, micelle distributions range around PDI. 0.1 indepen-
dently of chaotropic agent (compare Figure 13.6 and 13.8). This finding
is consistent with the general concept of solvent-solute interaction: a
larger hydrophobic block collapses at lower vol. % of block-selective sol-
vent, favoring chain-chain instead chain-solvent interactions. Thus, self-
assembly at hight vol. % of block-selective solvent will yield kinetically
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Figure 13.3: Evaluation of self-assembly behavior of diblock copoylpept(o)ides:
(top) constant S-ethylsulfonyl-cysteine block length and self-
assembly A) without and B) in the presence of thiourea as chao-
tropic agent, (bottom) constant polysarcosine block length and self-
assembly C) without and D) in the presence of thiourea as chao-
tropic agent.
driven structures instead of a slow, thermodynamicly driven aggrega-
tion of polymer chains.
In contrast, P1 and P4 with lowest wt. % hydrophobic block ratios
yield large structures upon higher vol. % of block-selective solvent. Es-
pecially for self-assembly with chaotropic agent above 25 vol. %, parti-
cles are poorly defined. In this case, micelles exhibit poor distributions
with PDIs & 0.2 for micellar aggregates of hydrodynamic diameters well
above 50 nm (compare Figure 13.4 and 13.7). With loss of the ability to
form intra molecular hydrogen bonds, stabilization depends solely on
hydrophobic chain-chain interactions. As a consequence, definition of
structures derived from polymers with short PCys(SO2Et) blocks suffers
considerably from self-assembly in a kinetically driven regime and will
profit from the possibility of β-sheet stabilization. Thus, self-assembly
in presence of chaotropic agents upon polymers with short PCys(SO2Et)
block should be avoided.
As can be derived from comparing self-assembly in absence of chao-
tropic agents (left) to their presence (right), larger micellar structures
were obtained without a chaotropic agent. The cooperative effect of β-
sheet stabilization will presumably allow for aggregation of more poly-
mer chains in one structure. β-sheets are known to form β-sheet barrels
in natural peptides,[520] thus a one-dimensional growth into elongated
structures is plausible. During a slow self-assembly in the regime below
20 vol. % of block-selective solvent, the driving force for this one dimen-
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Influence of
secondary structures
on self-assembly
outcome.
sional aggregation is higher than in the large vol. % regime. Again, this
effect is more pronounced for P3 and P5 with highest ratio of the β-sheet
forming PCys(SO2Et) block. From the findings stated above, it can be con-
cluded that the hydrophobic block ratio dictates the overall aggregation
behavior in block selective solvent mixtures, mostly independently from
overall polymer length. Further, no notable change in particle size of the
non cross-linked micelles was observed upon extended storage (over
1 year) in respective buffer at 4 °C (Figure 13.4 to 13.8 in the support-
ing information). In addition, stable and well defined micelles exhibit-
ing distributions approximately below a PDI. 0.15 maintained this good
distribution over 1 year. As a consequence, the pronounced stability of
the obtained PSar-b-PCys(SO2Et) based micelles stresses the importance of
self-assembly in a thermodynamic equilibrium.
Additionally, valuable implications are accessible from the display of
self-assembly of the same polymer in presence or absence of a chao-
tropic agent. Conditions which give comparable results independently
from chaotropic agents, are most likely driven by the hydrophobic-
hydrophilic volume ratio. This can be either due to self-assembly in a
kinetic regime (compare P3 in Figure 13.6 or P5 in Figure 13.8 above 20
vol. %) or due to low influence of secondary structure stabilization of
short chains in a thermodynamic regime (compare P1 in Figure 13.4 or
P4 in Figure 13.7 below 20 vol. %). The most intriguing conditions were
found for P2 in Figure 13.5: The opposing trends in size for presence
or absence of a chaotropic agent indicate considerable influence of sec-
ondary structure stabilization on the resulting self-assembled structures.
Thus, deviating morphology as proposed in Figure 13.1 and demon-
strated in Chapter 12 may be achieved when self-assembly is performed
under those conditions.
13.2 C O N C L U S I O N
The presented study enables orientation on self-assembly conditions
for amphiphilic PSar-b-PCys(SO2Et) diblock copolypept(o)ides. A broad
range of nanodimensional core-shell carrier systems were evaluated
based on secondary structure modulated self-assembly of amphiphilic
PSar-b-PCys(SO2Et) diblock copolypept(o)ides. Upon variation of parame-
ters such as hydrophobic to hydrophilic block length ratio and/or block
selective solvent composition, size and shape of the resulting micelles
can be modulated as follows:
• Self-assembly of polymers with low wt. % hydrophobic block in
presence of chaotropic agents should be avoided, due to insuffi-
cient control without secondary structure stabilization.
• Polymers with high wt. % hydrophobic block have a tendency to
aggregate faster compared to polymers with low wt. %. As a re-
sult, small, well defined structures are obtained above 20 vol. % of
block-selective solvent independent of secondary structures.
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• Elongated structures are expected for polymers with high wt. %
hydrophobic block in a slow, thermodynamically controlled ag-
gregation. This can be achieved below 20 vol. % of block-selective
solvent independent of secondary structures.
• However, overall larger structures can be obtained in absence of
chaotropic agents, indicating a one dimensional growth mediated
by β-sheet stabilization.
• Polymers with intermediate wt. % hydrophobic block (15-20 wt. %)
follow opposing trends for self-assembly with and without chao-
tropic agents in a thermodynamic regime below 20 vol. % of block-
selective solvent.
– In presence of chaotropic agents, small micelles of presum-
ably spherical morphology are obtained.
– In absence of chaotropic agents, large micelles of presumably
elongated morphology are obtained due to one dimensional
growth by β-sheet stabilization.
• Well-defined PSar-b-PCys(SO2Et) based micelles will maintain overall
dimensions as well as particle distribution upon extended storage
in solution.
In conclusion, a prediction on micellar dimensions and shape prior to
self-assembly of new batches of block copolypept(o)ides can be made
based on principles outlined above. The parameters of interest are the
block-length ratio, deviation of self-assembly behavior from presence to
absence of chaotropic agents and the amount of block selective solvent
during self-assembly.
13.3 S U P P O R T I N G I N F O R M AT I O N
13.3.1 Self-Assembly of Amphiphilic Micelles
For preparation of polysarcosine-block-poly(S-ethylsulfonyl-L-cysteine)
(PSar-b-PCys(SO2Et)) block copolymers see Chapter 12 or 10.[22,327] The re-
sulting amphiphilic block copolymers were self-assembled using a pro-
tocol reported previously.[22] Briefly, the polymer was dissolved in N,N-
dimethyl acetamide (DMAc) at a concentration of 7.5 g L-1 for 2 h. Various
volume percentages of 1 mM acetate buffer (pH = 4.7) were added as the
block-selective solvent. Self-assembly was carried out in the presence or
absence of thiourea as chaotropic agent with 10-30 volume % of block
selective solvent. For self-assembly processes with suppression of the
β-sheet formation of the polycysteine segment the DMAc contained 1 M
and the 1 mM acetate buffer contained 10 mM thiourea as chaotropic
agent. The solutions were left to equilibrate for 3 h, dialyzed against
the respective buffer (3.5 kDa) and filtered using a 200 nm filter (GHP).
Micelles were stored in the respective buffer at 4°C. The size range of
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micelles prepared from P1-5 was evaluated by DLS at 25°C. DLS experi-
ments were performed immediately after self-assembly and work-up as
well as after 1 year storage in the respective aqueous buffer at 4°C.
Table 13.1: Characterization of PSarn-b-PCys(SO2Et)m diblock copoly-
pept(o)ides.
No Xn, GPCa Xm, NMRb Mn, GPCc/g mol−1 ÐGPCc
P1 375 15 32000 1.24
P2 186 17 27900 1.21
P3 94 15 22500 1.17
P4 186 9 25300 1.23
P5 186 37 31200 1.25
a Xn PSar relative to PSar standards.[47]
b Xm from 1H NMR relative to Xn, GPC PSar.
c Relative to PMMA standards.
13.3.2 Size Range and Distribution of Micelles (immediately after prepara-
tion / 1 year storage)
Figure 13.4: Size range and PDI of micelles prepared from P1(determined by
DLS).
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Figure 13.5: Size range and PDI of micelles prepared from P2 (determined by
DLS).
Figure 13.6: Size range and PDI of micelles prepared from P3 (determined by
DLS).
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Figure 13.7: Size range and PDI of micelles prepared from P4 (determined by
DLS).
Figure 13.8: Size range and PDI of micelles prepared from P5 (determined by
DLS).
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The polymeric micelles presented in Chapter 13 proved remarkable sta-
bility in terms of size and definition when stored in aqueous media.
Without covalent stabilization e. g. by disulfide bridges (Figure 14.1 A),
however, the introduction of micellar nanocarriers in biological relevant
environments such as the blood stream, will considerably destabilize
the self-assembled system. Dilution, shear forces in flowing blood as
well as presence of surfaces for adsorption such as proteins, will result
in leakage of the amphiphilic unimers from a non-stabilized micelle (Fig-
ure 14.1 B) and demonstrate poor systemic circulation.
Figure 14.1: Illustration of the fate of covalently or non-covalently modified
nanocarriers in the blood stream: A) Covalent modifications in
the compartment such as disulfide core cross-linking and covalent
labeling with amine-reactive IRDye® 800CW NHS-ester. B) With-
out covalent stabilization of micellar nanocarriers, amphiphilic
unimers may diffuse from the micelle. C) Nanocarriers loaded non-
covalently with IRDye® 800CW are prone to loss of cargo (adsorp-
tion to biological surfaces). Thus, observed fluorescence signal is
no longer associated with the carrier system. D) Covalent attach-
ment ensures co-localization of observed fluorescence with the car-
rier system, as far as cellular internalization occurs followed by
a stimuli-responsive breakdown of the disulfide core-stabilization
and release of cargo/fluorescence.
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Further, non-covalently loaded or labeled nanocarriers are prone to
loss of cargo due to a surfaces available for adsorption upon introduc-
tion into biological environments.[151] As a consequence, co-localization
of the monitored label with the carrier system is no longer guaranteed
(Figure 14.1 C). Thus, the rational design of well defined and reliable car-
rier systems has to ensure stabilization of the nanocarrier itself as well
as consider covalent attachment of the encapsulated cargo.
Loading stability of core cross-linked micelles, can be demonstrated
by near-infrared fluorescence correlation spectroscopy (NIR – FCS) al-
lowing for evaluation of drug nanocarriers in blood. Furthermore,
fluorescence correlation spectroscopy (FCS) measurements offer com-
plementary to light scattering access to nanocarrier dimensions in
solution (compare Section 5.2.3 for theoretical background). Especially
the resemblance of hydrodynamic radii in aqueous media (as present
during particle preparation and characterization) to biological relevant
media such as serum, plasma or full blood is a desirable feature
validating stability of the particles as well as low protein adsorption.
To demonstrate how the NIR – FCS method can be used to monitor the
behavior of drug nanocarriers in blood spherical core cross-linked
polymeric micelles (CCPMs) were employed. Polymeric micelles were
prepared by means of self assembly in the presence of thiourea from
PSar203-b-PCys(SO2Et)11 (13 wt % of the hydrophobic block) at 23 vol. %
block selective solvent (see micelle preparation and labeling). Subse-
quent core cross-linking by hexanedithiol and fluorescent labeling of
the N-terminus of the PCys(SO2Et) segment in the core-compartment (as
introduced in Chapter 10) yielded a covalently modified particle, as
illustrated in Figure 14.1 D.
The following passages and results are reproduced with permission
from: Inka Negwer, Andreas Best, Meike Schinnerer, Olga Schäfer,
Manfred Schmidt, Volker Mailänder, Mark Helm, Matthias Barz,
Hans-Jürgen Butt, Kaloian Koynov, "Monitoring Drug Nanocarriers in
Human Blood by Near-Infrared Fluorescence Correlation Spectroscopy"
Nature Communications 2018, under revision, NCOMMS-18-12754-T.
CCPMs were loaded with IRDye® 800CW, which was used as a model
for a small drug molecule. IRDye® 800CW was either covalently (PM 1)
or non-covalently (PM 2) attached to the nanocarriers (see supporting
information). A first NIR – FCS characterization in water revealed hy-
drodynamic radii for PM 1 and PM 2 of 51 nm and 44 nm, respec-
tively (Figure 14.2 A). These values were in accordance with the multi-
angle dynamic light scattering data obtained for the unloaded micelles
(Rh, PM = 45 nm) and indicated that the IRDye® 800CW molecules were in-
deed loaded to the micelles. Nevertheless, the FCS fits also indicated the
presence of a second type of fluorescent species with Rh 1 nm, which
was identified as free dye with apparent fractions of 6 % for PM 1 and
23 % for PM 2. After 30 h of incubation in blood, the micelles were sub-
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Conclusion.
jected to NIR – FCS measurements in flowing blood. The processed auto-
correlation curves devoid of cell contributions are shown together with
the corresponding fits in Figure 14.2 B.
Figure 14.2: NIR-FCS studies of the loading stability of core cross-linked nanocar-
riers in blood. Normalized autocorrelation curves (symbols) and
the corresponding fits (lines) are shown for micelles that were ei-
ther covalently (PM 1, blue) or non-covalently (PM 2, green) loaded
with IRDye® 800CW. A) Measurements in water. The dye is mainly
loaded to the micelles and only a small fraction of free dye was
detected for both systems. B) Measurements in the blood flow (ve-
locity of 50 µL h-1) upon incubation with blood for 30 h (at 4°C).
The dye is fully released from PM 2, but still loaded to PM 1.
As in water, two fluorescent species with different hydrodynamic radii
of 55 nm and 2.9 nm were observed for PM 1. The larger species corre-
sponded to dye loaded micelles and the smaller one to free dye molecules
that have formed one-to-one complexes with plasma pro-
teins.[528] Furthermore, the apparent fraction of free dye had increased
to 18 %. This increase could be a result of a partial degradation of the
peptide-dye bond and/or the presence of a small fraction of dyes that
were non-covalently attached and thus dissociated from the micelles in
blood. The dominant fraction of the dye cargo, however, was still loaded
on the micelles which were intact and did not change their size e. g.
due to decomposition or aggregation even after 30 h in blood. The fit
to the autocorrelation curve measured for PM 2 in blood (Figure 14.2 B)
revealed the presence of only one type of fluorescent species with Rh
of 3.4 nm. This indicates a complete loss of the non-covalently attached
dye cargo from the nanocarrier, which is in line with observations on
the loss of encapsulated dexamethasone from CCPMs in vivo.[151]
Near-infrared fluorescence correlation spectroscopy (NIR – FCS) stud-
ies in flowing blood, provided quantitative understanding of the in vivo
behavior of nanocarrier-based therapeutics. Upon covalent stabilization
by disulfides, properties of a core-cross-linked polymeric micelle were
not altered when transferred from aqueous solution and exposed to full
blood for 30 h. Hence, decomposition, aggregation or extensive protein
adsorption can be plausibly ruled out. Further, covalent attachment of
fluorescent probes clearly performed superior to non-covalent loading
with regard to loss of cargo. Thus, by means of the NIR – FCS technique
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implemented in full blood, the significance of covalent modification of
nanocarriers evaluated in vivo is stressed.
A PSar203-b-PCys(SO2Et)11 block copolymer[22] was dissolved in N,N-
dimethyl acetamide (DMAc) with 1 M thiourea at a concentration of
7.5 g L-1 for 1.5 h to prevent β-sheet formation of the polycysteine seg-
ment. For self-assembly, 1 mM acetate buffer with 10 mM thiourea
(pH = 4.7) was added to adjust the concentration to 6 g L-1. The solution
was left to equilibrate for 3 h and then dialyzed against 1 mM acetate
buffer. The cross-linker hexanedithiol was added as a DMAc solution to
the micelle solution in 1 mM acetate buffer with 10 mM thiourea with SH-
groups equimolar to the number of cysteines. The reaction mixture was
shaken and allowed to stand for 18 h. Subsequently, the solution was di-
alyzed against water, filtered via GHP200 syringe filter, and purified by
repetitive spin filtration (MWCO 100 kDa) and dilution steps. After the
preparation steps described above, the particle solution was divided for
covalent and non-covalent labeling with an equimolar amount of fluo-
rophore in N,N-dimethyl formamide (DMF) (5 mM).[327] The labeling re-
actions were carried out at room temperature overnight followed by pu-
rification. For covalent labeling, 10-fold concentrated PBS was added to
adjust the pH to 8 and followed by 14.1 µL IRDye® 800CW succinimidyl
ester (LI-COR Biotechnology) solution. Purification was performed by
repetitive spin filtration (MWCO 100 kDa) diluting at least 10 times with
EtOH/H2O followed by 10 times H2O. For non-covalent labeling, 14.1 µL
IRDye® 800CW dibenzocyclooctyne (DBCO) solution were added to the
aqueous particle solution followed by purification using column chro-
matography (Sephadex LH 20 in H2O).
Part V
C O R E - S H E L L S Y S T E M S I N
S Y S T E M I C A P P L I C AT I O N

This last part combined the gathered knowledge on chemoselective
disulfide formation of the S-alkylsulfonyl group, controlled sequential
ring-opening polymerization of (multi)block copolypept(o)ides and self
assembly thereof into cross-linked core-shell systems. In vivo studies
were composed, evaluating blood circulation, biodistribution and tu-
mor accumulation of fluorescently labeled cross-linked polymeric mi-
celles and cationic nanohydrogels, varying in size and morphology.
Promising findings from this investigation led to the latest stage of
polypept(o)ide-based core-shell carrier systems for systemic application.
Cross-linked core-shell system for systemic siRNA delivery were pre-
pared from triblock copolypept(o)ides, which combined cationic PLys
for efficient siRNA complexation, a PCys(SO2R) segment for chemoselec-
tive disulfide stabilization and a stealth-like PSar block in a single poly-
mer. In a comparative study, the connection was drawn between block
sequence alteration and physicochemical properties of cross-linked core-
shell nanoparticles, which were successfully applied in intratumoral
RNAi mediated gene scilencing in vivo.
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P O LY P E P T ( O ) I D E - B A S E D N A N O PA RT I C L E S
A B S T R A C T : Self-assembly of polysarcosine-block-poly(S-ethylsulf-
onyl-L-cysteine) (PSar-b-PCys(SO2Et)) diblock copolypept(o)ides offers ac-
cess to a broad range of core-shell structures with control over parti-
cle size and morphology. Disulfide core cross-linking of the PCys(SO2R)
segment ensures bioreversible stabilization of the resulting structures,
combined with the possibility to adjust core polarity and functional-
ity by choice of the cross-linker. Thus, available carrier functionalities
range from hydrohpobic core cross-linked polymeric micelles for e. g.
hydrophobic chemotherapeutic agents, to cationic nanohydrogels for
complexation of negatively charged nucleic acids e. g. small interfering
RNA (siRNA). In order to evaluate PSar-b-PCys(SO2Et)-based carrier systems
in systemic applications, core cross-linked structures with spherical or
worm-like morphology, varying hydrodynamic dimensions and core-
polarities were prepared, covalently labeled and evaluated in vivo. By
means of intravital real-time confocal microscopy and in vivo as well as
ex vivo imaging by an in vivo imaging system, blood circulation as well
as biodistribution was evaluated by observation up to 24 h in systemic
circulation.
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On the in vivo fate
of nanocarriers in
systemic application.
15.1 I N T R O D U C T I O N
Self-assembly of polysarcosine-block-poly(S-ethylsulfonyl-L-cysteine)
(PSar-b-PCys(SO2Et)) diblock copolypept(o)ides offers the means to pre-
pare a broad range of core-shell structures with control over particle
size and morphology as demonstrated in Chapter 13. The self-assembly
process is regulated by varying parameters such as hydrophobic to
hydrophilic block length ratio,[495] composition of the block selective
solvent and whether self assembly is directed by secondary structure
formation of the β-sheets forming PCys(SO2R) segment.[22] For systemic
applications, covalent cross-linking significantly improves carrier
stability[153,529], thus stabilization was ensured by disulfide formation
in the core compartment.[22,209] Bioreversible stabilization by disulfides
proves am attractive option, since carriers are typically exposed to
different redox potentials when in systemic circulation in contrast to
intracellular compartments.[158] Further, core polarity and thus function-
ality of PSar-b-PCys(SO2Et)-based carriers can be conveniently adjusted
by the choice of the dithiol cross-linker as demonstrated in Chapter 12.
The core-compartment can hence be devised to suit various therapeutic
cargoes. A broad range of core polarities is available from hydrophobic
cross-linkers for accommodation of hydrophobic chemotherapeutic
agents e. g. paclitaxel to polycationic moieties for complexation of
negatively charged nucleic acids e. g. small interfering RNA (siRNA).[22]
non-covalent In addition, PSar-b-PCys(SO2Et) block copolypept(o)ides
mediate end-group functionality[327] for further modification of the re-
sulting carrier systems as presented in Chapter 10. Since non-covalently
loaded or labeled nanocarriers are prone to loss of (hydrophobic)
cargo upon introduction into biological environments,[151] covalent
modification is key to ensure carrier integrity in vivo. As demonstrated
in Chapter 14, fluorescently labeled core cross-linked polymeric mi-
celles in full human blood (30 h exposure) maintained their size and
definition upon covalent attachment of the fluorescent probe in contrast
to a non-covalently loaded micelle. Covalent modification is thus a
crucial factor for carriers in systemic application, since co-localization
of the monitored label with the carrier system has to be guaranteed for
reliable tracking as well as successful delivery of therapeutic cargo.
Blood circulation and tissue distribution of a nanocarrier in systemic
application depends on several factors such as morphology, overall hy-
drodynamic dimensions and surface properties. Particle size serves as a
first parameter to estimate the biodistribution in vivo. Large particles of
several microns are commonly retained in the lung capillaries upon first
passage after intravenous administration and small-sized nanoparticles
(<5 nm) are subject to rapid renal filtration.[110] Under pathophysiologi-
cal conditions in cancerous or inflamed tissue, accumulation of particles
sized roughly between several tens to 100 nm is observed.[122,123] Upon
prolonged blood circulation, extravasation of nanoparticles trough irreg-
ular fenestrated vasculature and retention due to defective lymphatic
15.2 B L O O D C I R C U L AT I O N O F C R O S S - L I N K E D M I C E L L E S 257
drainage is exploited for passive tumor accumulation mediated by the
enhanced permeability and retention (EPR) effect[122]. Accumulation and
tumor penetration profits from a decrease in size, as demonstrated by
Cabral at al. for of 30-100 nm sized systems.[124] Upon increasing size be-
yond 150 nm, however, particles accumulate progressively in the liver
and spleen.[115] In context of prolonged blood circulation, shielding prop-
erties of the particle corona are crucial, since opsinization by plasma pro-
teins accelerates blood clearance by the mononuclear phagocyte system
(MPS) in the liver, the lymph nodes and the spleen.[109,112] High surface
charge promotes blood clearance and especially positive surface charge
is associated with poor systemic circulation and toxicity.[109,120] Neutral
or slightly negatively charged nanoparticles, on the other hand, show re-
duced adsorption of serum proteins leading to longer circulation times
as demonstrated by Kataoka and co-workers.[121] In addition, particle
morphology can have an effect on the biodistribution, as differences in
flow-characteristics affect blood circulation time, cell membrane inter-
actions and macrophage uptake.[115] Effects of shape-anisotropy on sys-
temic circulation are mediated by physical forces in flowing blood and
may not applicable for particularly rigid or short elongated structures
with approximate spherical hydrodynamic dimensions due to rotation.
However, for strong shape anisotropic filament-like micelles on the size
scale of micrometers, prolonged circulation in comparison to spherical
counterparts was observed due to alignment in the blood flow, as shown
by Discher and co-workers.[116] Further, rigidity of the carrier promotes
retention in the lungs, the liver as well as in the spleen.[110]
In light of the manifold parameters affecting in vivo performance of
nanocarriers, this work focuses on PSar-b-PCys(SO2Et)-based carrier sys-
tems in systemic application. Blood circulation as well as biodistribution
is monitored and evaluated with respect to particle morphology, hydro-
dynamic dimensions and chemical properties. For this purpose, cova-
lently labeled core cross-linked polymeric micelles with hydrophobic
cores and cationic nanohydrogels with spherical and worm-like mor-
phologies were investigated in vivo. Biological experiments in this chap-
ter were conducted in cooperation with Prof. Horacio Cabral (University
of Tokyo, Japan).
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C O R E C R O S S - L I N K E D P O LY M E R I C M I C E L L E S ( C C P M s) .
The technique of intravital real-time confocal laser scanning microscopy
(IVRT-CLSM) allows for instantaneous observation of intravenously in-
jected substances in the blood stream of a living organism by observa-
tion of multicolor fluorescence in the ear-lobe of mice.[530,531] Thus, fluo-
rescently labeled hydrophobic core cross-linked micelles could be eval-
uated with regard to blood circulation continuously over an extended
period of time (15 h). In analogy to near-infrared fluorescence correla-
tion spectroscopy (NIR – FCS) studies of core cross-linked polymeric mi-
celles in full blood in Chapter 14, samples were prepared from PSar203-b-
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PCys(SO2Et)11 (P1, see Table 15.3 for characterization). Self-assembly was
performed under identical conditions with variation whether a chao-
tropic agent was present or not, yielding micelles differing in morphol-
ogy as illustrated in Figure 15.1 A and Table 15.1.
Table 15.1: Characterization of covalently labeled core cross-linked polymeric
micelles (CCPMs) employed in intravital microscopy.
No Dh, DLSa
/ nm
polymer Xn/Xmb thiourea morphologyc dye
wCCPM 80 P1 203/11 - worm-like Cy5
sCCPM 90 P1 203/11 + spherical Cy3
a Particle sizes rounded for simplification, accurate values are given in Table 15.4.
b Xn PSar relative to PSar standards,[47] Xm from 1H NMR relative to Xn, GPC.
c Morphology determined by AFM.
Figure 15.1: Particles evaluated by intravital real-time confocal laser scanning
microscopy: A) Self-assembly of PSar-b-PCys(SO2Et) into micelles
varying in morphology. Core cross-linking with hexanedithiol as
hydrophobic disulfide cross-linker gives core cross-linked poly-
meric micelles with worm-like (wCCPM) and spherical mor-
phology (sCCPM), which were labeling covalently in the core-
compartment (Cy5 and Cy3, respectively). B) Summary of sizes and
morphologies of CCPMs and characterization by C) AFM imaging
(performed by Dr. Kristina Klinker) as well as D) dynamic light
scattering.
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Subsequent core cross-linking of the polymeric micelles by hexane-
dithiol yielded core cross-linked polymeric micelles designated as
wCCPM with worm-like and sCCPM with spherical morphology (see
Table 15.1 and Table 15.4 for characterization). NIR – FCS experiments
in Chapter 14 emphasized the significance of covalent modification
for in vivo applications of polymeric nanocarriers. Thus, labeling was
performed in analogy by covalent modification at the amine end-group
in the core with amine-reactive NHS-ester derivatives of fluorescent
dyes.[327] One of the remarkable features of IVRT-CLSM, is the possibility
to follow simultaneously two species with distinct spectral proper-
ties. Thus, to ensure sufficient spectral separation, Cy3 and Cy5 were
chosen as fluorophores. Ultimately, the difference in morphology was
confirmed by atomic force microscopy (AFM), while comparable hy-
drodynamic diameters of 83 nm for wCCPM and 89 nm for sCCPM were
determined by dynamic light scattering (DLS) as shown in Figure 15.1 D.
Both fluorescently labeled CCPMs were co-administered by intra-
venous injection of a healthy BALB/c mouse and fluorescence intensity
was observed in a confocal volume of a vein in the ear-lobe. Figure 15.2
shows exemplary frames of the consecutive recording at different time
points of 3 min, 3 h and 15 h of consecutive recording. The rows repre-
sent the channels for separate observation of wCCPM (top) and sCCPM
(middle) fluorescence as well as a merged display (bottom).
Figure 15.2: Co-injected wCCPM and sCCPM as observed by IVRT-CLSM in
frames at different time points.
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Throughout the measurement fluorescence was detected in the blood
stream even in smaller blood vessels, indicating circulating particles. In
consistency with findings from Chapter 14 by exposure of CCPMs to full
blood, no aggregation with blood components is observed in vivo. In ad-
dition to the qualitative character of the recorded images, the confocal
setup of the intravital real-time confocal laser scanning microscopy al-
lows for quantification of fluorescence intensity. Covalent attachment of
dye molecules ensures co-localization of observed fluorescence with the
circulating particle, thus monitored fluorescence intensity is directly pro-
portional to the particle fraction circulating in the blood stream. Quan-
tification of blood circulation of worm-like wCCPM and spherical sCCPM
given in Figure 15.3 as the normalized fluorescence intensity over time.
Figure 15.3: Quantification of Cy5 (wCCPM) and Cy3 (sCCPM) fluorescence in
the blood vessel.
Both particles achieve stable systemic circulation over 15 h, indicating
good shielding of the PSar particle shell, which is a desirable property
in terms of passive accumulation. Worm-like wCCPM shows an initial
drop in fluorescence intensity followed by constant circulation around
20-25 %, while spherical sCCPM maintains constant fluorescence inten-
sity of 90-100 %. The fraction of free dye was determined by fluorescence
correlation spectroscopy (FCS) prior to in vivo tracking (< 10 %), thus
different content of free fluorescent molecules and consequently differ-
ences in clearance e. g. by renal filtration, can be ruled out. Further,
wCCPM and sCCPM exhibit very similar hydrodynamic diameters (83 nm
and 89 nm, respectively), thus sole morphology related effects on circula-
tion seem unlikely. In addition, polypept(o)ide-based cylindrical
brushes of varying aspect ratios employed in our group show contrast-
ing in vivo circulation (close to 100 %) without initial drop. Thus, the
systemic circulation observed for wCCPM and sCCPM may be attributed
to chemical properties, rather than variation in physical flow-dynamics
of worm-like and spherical shapes. This interpretation will be discussed
subsequently in the next section, upon in vivo evaluation of particles of
inversed core-polarity.
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15.3 B I O D I S T R I B U T I O N O F C O R E C R O S S - L I N K E D
C AT I O N I C N A N O H Y D R O G E L S ( N H G s) .
Introduction of charge in nanoparticles for systemic administration is
known to pose challenges in terms of blood circulation[109,115] and es-
pecially carrier systems featuring polycationic moieties for delivery of
negatively charged nucleic acids suffer rapid blood clearance within few
hours.[101,135] In this context, PSar-b-PCys(SO2Et)-based systems offer the
possibility of variation in core polarity by dithiol cross-linkers without
affecting particle size and morphology.[22] Hence, on account of the sta-
ble systemic circulation of hydrophobic core cross-linked polymeric mi-
celles shown by intravital microscopy for over 15 h, other carrier types
were investigated in vivo. Core cross-linking by a dithiol cross-linker
with cationic moieties yielded nanohydrogels as suitable carriers for nu-
cleic acid delivery of e. g. siRNA. And in order to evaluate biodistribution
as well as potential accumulation sites for siRNA based therapeutics, tu-
mor bearing mice were injected with core cross-linked cationic nanohy-
drogels varying in size and morphology and blood circulation was mon-
itored as well as organ distribution.
Thus, block copolypept(o)ides P1-4 (see Table 15.3 for characteriza-
tion) were employed in self-assembly to give worm-like or spherical
structures upon variation of secondary structure stabilization as illus-
trated in Figure 15.4 A. Core cross-linking was performed by a cationic
triethylenetetramine α,ω-di(cysteine)diamide (TETA) cross-linker yield-
ing cationic nanohydrogels (NHGs). The replacement of the hydrophobic
S-ethylsulfonyl group with the poly(ethyleneimine)-based side chain
modification resulted in inverted core-polarity (as illustrated by the tran-
sition of the core compartment from yellow to dark blue).
Ultimately, two cationic nanohydrogels with worm-like morphology
(wNHG1 and 2) and three of spherical morphology (sNHG1-3) were ob-
tained as illustrated in Figure 15.4 B. In addition, a non cross-linked,
spherical polymeric micelle (sPM) was employed as a control to demon-
strate the positive effect on circulation by core cross-linking stabilization
in vivo. A near-infrared (NIR) dye was chosen as the reporting fluores-
cent agent due to the favorable in vivo signal to background ratio of
dyes with excitation and emission maxima in the region between 650
and 900 nm.[350] In addition, covalent attachment of the dye is essential
to ensure co-localization of the monitored fluorescence signal with the
actual nanoparticle as discussed in Chapter 14. Thus, covalent labeling
was performed in analogy to CCPMs in the core compartment using an
amine reactive IRDye® 800CW succinimidyl ester.[327] The resulting parti-
cles employed in the evaluation of biodistribution are summarized in Ta-
ble 15.2. Characterization of hydrodynamic dimensions was performed
by DLS (see Figure 15.4 C and 15.5) and the morphology was deduced
from imaging by cryogenic transmission electron microscopy (cryoTEM)
and atomic force microscopy (AFM) as illustrated in Figure 15.5.
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Figure 15.4: Particles evaluated in vivo in terms of biodistribution: A) Prepara-
tion of particles by self-assembly of PSar-b-PCys(SO2Et) into structures
varying in morphology. Core cross-linking with TETA as a cationic
disulfide cross-linker yields nanohydrogels (NHGs), followed by
covalent labeling in the core-compartment (IRDye® 800CW). B)
Summary of particle sizes and morphologies evaluated in vivo. C)
Size of core cross-linked NHGs and control micelle (DLS).
Table 15.2: Characterization of core cross-linked nanohydrogels (NHGs) and
control micelle evaluated in terms of biodistribution. Covalent la-
beling was performed with an IRDye® 800CW dye for all particles.
No Dh, DLSa/nm polymer Xn/Xmb thiourea morphologyc
wNHG1 70 P2 186/17 - worm-like
wNHG2 120 P3 203/20 - worm-like
sNHG1 40 P4 94/15 + spherical
sNHG2 50 P2 186/17 + spherical
sNHG3 80 P1 203/11 + spherical
sPMd 50 P2 186/17 + spherical
a Sizes rounded for simplification, accurate values are given in Table 15.4.
b Xn PSar relative to PSar standards,[47] Xm from 1H NMR relative to Xn, GPC.
c Morphology determined by cryoTEM.
d Non cross-linked polymeric micelle.
Visualization by means of cryoTEM is based on transmitted electrons
from a vitrified sample, allowing particle imaging in aqueous solution.
As staining or fixation are not necessary, contrast results solely from the
electron density of the specimen. Visualization by means of AFM is based
on the measurement of forces between a cantilever tip and the specimen
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Figure 15.5: Size and shape of particles evaluated in vivo as characterized by
DLS and visualized by cryoTEM (performed by Benjamin Weber), as
well as AFM (performed by Tobias Bauer) for nanohydrogels with
worm-like (A and B) and spherical morphology (C - E) as well as a
spherical, non cross-linked micelle (F).
surface. Thus, in case of PSar-b-PCys(SO2Et) based systems, cryoTEM imag-
ing shows predominantly electron density in the particle core due to the
sulfur content of the core-forming PCys(SO2Et) block in contrast to the
PSar corona, while AFM height micrographs depict the overall particle
surface. wNHG1 and wNHG2 were found to exhibit elongated morpholo-
gies (as depicted in Figure 15.5 A and B) with hydrodynamic diameters
around 70 nm and 120 nm, respectively as determined by DLS. In con-
trast, sNHG1-3 and sPM were prepared in presence of thiourea as a chao-
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nanohydrogels.
tropic agent and exhibit thus a spherical morphology (Figure 15.5 C - F,
with equal results in AFM imaging). Hydrodynamic diameters of 40, 50
and 80 were determined by DLS for sNHG1, sNHG2 and sNHG3, respec-
tively, as well as 50 nm for the non cross-linked micelle sPM.
Ultimately, the covalently labeled nanohydrogels were investigated
in systemic application in a tumor bearing animal model towards blood
circulation as well as biodistribution. Therefore, as illustrated in Fig-
ure 15.6 A, BALB/c mice bearing 4T1-luc mammary tumors (n = 3) were
injected intravenously with the respective nanohydrogel or the non
cross-linked control. Blood samples were collected from tail incision at
time point of 1 h, 4 h and 24 h post injection. After 24 h, tumor accumu-
lation was evaluated in vivo by fluorescence imaging by an in vivo imag-
ing system (IVIS). As outlined in Section 5.3.3 on methodology of IVIS,
imaging of deep tissues as well as the use of hairy mice is challenging
in terms of accuracy and does not allow for quantification of the tissue
distribution. Thus, ex vivo biodistribution was performed. Animals were
sacrificed 24 h post injection and fluorescence imaging of the tumor tis-
sue, spleen, kidney, liver and lung as well as the collected blood samples
was performed. Figure 15.6 B summarizes findings on blood circulation
of nanohydrogels and the non cross-linked control micelle (data is pro-
vided in Table 15.5 in the supporting information).
Figure 15.6: A) Experimental setup of in vivo evaluation of core cross-linked
NHGs: BALB/c mice bearing 4T1-luc mammary tumors were in-
jected with covalently fluorescent labeled particles via tail-vein in-
jection (n=3); after 1h, 4h and 24 h blood samples were collected
and preserved with heparin; 24 h post injection imaging of blood
samples as well as an ex vivo organ-distribution was performed by
IVIS. B) Blood circulation profiles of IR-labeled particles expressed
as percentage of initial fluorescence intensity over time. Data are
expressed as mean; bars ± SE.
The non cross-linked micelle sPM was cleared rapidly and already 4 h
post injection fluorescence intensity in the blood is barely detectable.
These findings are in line with rapid systemic clearance commonly
observed for amphiphilic micelles without further stabilization,[115,153]
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stressing the importance of covalent stabilization e. g. by core cross-
linking. The circulation of nanohydrogels with worm-like morphology
wNHG is similar to blood circulation observed by intravital microscopy
for hydrophobic worm-like wCCPM (compare Figure 15.3). Both worm-
like nanohydrogels show an initial decrease of blood fluorescence to
5 % and 7 % fluorescence intensity after 24 h in systemic circulation
for wNHG1 and wNHG2, respectively. Spherical nanohydrogels sNHG, in
contrast, exhibit a slow decrease in blood fluorescence over time with
a residual fluorescence 24 h post injection of 43 %, 32 % and 22 % for
sNHG1, sNHG2 and sNHG3, respectively.
The observed prolonged systemic blood circulation of polymeric
core-shell nanoparticles featuring cationic moieties, especially without
any charge compensating nucleic acid cargo, is remarkable. Unmodi-
fied cationic particles (e. g. poly(L-lysine)-pDNA complexes) are fully
degraded within 10 min in blood.[532] In contrast, systemic circulation
of approximately 30-60 min is achieved for plasmid DNA carriers
upon shielding with poly(ethylene glycol) (PEG) as demonstrated for
poly(ethyleneimine) (PEI) based carriers[533,534] or poly(L-lysine) based
systems.[521,535] In addition, stabilization by cross-linking has a positive
effect on carrier circulation.[535,536] However, blood clearance below
10 % of initial dose is commonly observed within 1-2 h for systemic
administration.[537] Thus, extension of systemic circulation up to 24 h
for nanoparticles with a cationic core compartment is a substantial
progress in light of prolonged blood circulation necessary for passive
tumor accumulation.
As mentioned in the previous section, differences in circulation ob-
served for worm-like morphologies from spherical ones (CCPM and NHG
alike) may originate from differences in chemical properties, rather than
physical flow-dynamics based on aspect ratio. The obvious contrast be-
tween preparation of worm-like and spherical particles is the presence
or absence of secondary structure of the PCys(SO2R) segment.[209] Since
β-sheets tend to arrange in twisted structures,[519] (resulting in e. g. β-
sheet barrels in natural peptides),[520] the polymer density in the core of
worm-like and spherical micelles is expected to be unequal.
Twisted and rigid β-sheets are present in the absence of a chaotropic
agent and result in elongated morphologies as exploited for formation
of wCCPM and wNHG1-2.[22] Thus, disulfide stabilization is sterically more
challenging and leads most likely to intra-molecular cross-linking and
hence a loosely cross-linked core and impaired stabilization. In addition,
differences in the effective shielding have to be considered. Cylindrical
polysarcosine-block-poly(L-lysine) brushes employed in our group show
stable systemic circulation on the time scale of days. In comparison,
grafting density of shielding PSar chains in worm-like PSar-b-PCys(SO2Et)
micelles is presumably lower, as it is dictated by arrangement of the
PCys(SO2R) segments in the core. And in comparison to spherical mi-
celles, the overall higher surface to volume ratio of elongated cores of
worm-like micelles obstruct effective shielding. Another effect is the po-
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sitioning of a N-terminally attached fluorescent probe. The placement
onto the rigid β-sheet segment may be different in worm-like particles
compared to the positioning on a flexible random-coil segment in spher-
ical particles. Since most fluorescent dye molecules are of hydrophobic
nature, their placement outside of the hydrophobic core, for instance,
protruding in the hydrophilic sarcosine corona, may cause deviating
overall chemical surface properties of the particle. Ultimately, sterically
challenging secondary structures constitute the core of worm-like struc-
tures and can result in decreased disulfide cross-linking density and
thus lesser stabilization along with diminished shielding by the PSar
corona. Those chemical factors increase the possibility of interaction with
proteins or other particles and thus accelerate clearance.
Systemic circulation of worm-like structures was thus found to be
lower compared to spherical particles with 20-25 % for sCCPM after 15 h
and below 10 % for wNHG1-2 after 24 h. In contrast, random coil confor-
mation upon suppression of β-sheets for formation of spherical mor-
phologies allows for densely packed PCys(SO2R) chains in the core dur-
ing phase separation by self-assembly. Thus, a greater inter-molecular
cross-linking density of polymer chains can be achieved upon introduc-
tion of dithiol cross-linkers. As a result, better stabilization of spherical
CCPMs and NHGs is achieved resulting in stable systemic circulation of
90-100 % for sCCPM after 15 h and 20-40 % for sNHG1-3 after 24 h.
The findings on pronounced blood circulation of cationic nanohydro-
gels after 24 h are highly encouraging, since systemic circulation of
cationic nanoparticles beyond several hours is not reported so far. Fur-
ther evaluation included ex vivo biodistribution 24 h post injection. Tu-
mor tissue and relevant filter organs for intravenously administered
nanoparticles (spleen, kidney, liver and lung)[110,115] were examined ex
vivo by IVIS imaging. The relative fluorescence intensities were normal-
ized on individual tissue weight and results are given in Table 15.5 and
depicted in Figure 15.7.
Figure 15.7: Tissue distribution of IR-labeled NHGs 24 h after systemic adminis-
tration as percentage of initial fluorescence intensity normalized
on individual tissue mass. Data are expressed as mean; bars ± SE.
For non cross-linked micelle sPM, no fluorescence above background
levels was detected in the examined tissues ex vivo. This observation is in
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line with the rapid blood clearance of sPM and reinforces the importance
of covalent carrier stabilization in vivo.
All nanohydrogels, however, show pronounced tumor associated
fluorescence (up to 4 % 24 h post injection) in comparison to signals
from the spleen, kidneys, the liver as well as the lung. Passive tumor
accumulation mediated by the EPR effect is thus likely for long cir-
culating nanohydrogels. In general, organ accumulation is low with
maximum 2 %, which is desirable in order to achieve long systemic
circulation for passive tumor accumulation and reduce off target effects
of therapeutic cargoes. Aggregates of several microns would lead
to sequestration in the lung. As only minor fluorescence below 1 %
was co-localized with the lung tissue for all nanohydrogels, particle
aggregation or pronounced interaction with blood components can
be ruled out.[109,110] Accumulation of fluorescence in the kidney due
to renal filtration of <5 nm species[110] e. g. dissociated dye molecules
or free polymer chains, was also not observed. Further, the spleen
and the liver as the main phagocytotic active organs exhibit also very
low fluorescence intensities of 1-1.5 %. Thus, nanohydrogels success-
fully avoided opsinization by plasma proteins and blood clearance
by the mononuclear phagocyte system (MPS) in the liver and the
spleen[109,112] due to PSar mediated shielding. This observation is very
promising in light of tumor targeting strategies, since passive targeting
of cationic polyplexes or nanohydrogels is predominantly employed for
applications based on their pronounced liver accumulation.[107,534,537]
As discussed for systemic circulation, variances of worm-like and
spherical particles may be attributed to differences in chemical proper-
ties. Due to presence of β-sheets in worm-like wNHG1-2, carrier stability
by core cross-linking as well as shielding efficiency may be impaired, re-
sulting in faster blood clearance and thus lower accumulation. Further,
spherical nanohydrogels sNHG1-3 are still in systemic circulation after
24 h, thus progressing passive tumor accumulation can be anticipated.
Due this prolonged circulation, later time points of 48 h and 72 h need
to be evaluated in the future to complete the biodistribution profile.
Ultimately, the importance of covalent stabilization in vivo by core
cross-linking was demonstrated, as the non cross-linked amphiphilic mi-
celle was fully cleared from blood within hours and showed no tissue
accumulation. Further, exceptional long blood circulation in combina-
tion with pronounced tumor accumulation and low systemic distribu-
tion, identified PSar-b-PCys(SO2Et)-based cationic nanohydrogels as attrac-
tive carriers for intravenous delivery of nucleic acids e. g. siRNA.
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In order to deduce generally valid information on in vivo performance
of PSar-b-PCys(SO2Et)-based core-shell nanoparticles a range of factors re-
quire throughout evaluation. Future biodistribution studies need to in-
vestigate the influence of chemical core-variation by appropriate dithiol
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cross-linkers (at least 4 core-types: hydrophilic, hydrophobic as well as
positively and negatively charged). Further, both morphologies (2 varia-
tions: elongated and spherical ) are required, as well as particle sizes be-
tween of 30 nm and 150 nm to cover the range relevant in passive tumor
accumulation (5 sufficiently distinct sizes e. g. 30, 50, 70, 100, 150 nm).
Thus, already 40 particles need to be synthesized and characterized. Ad-
ditionally, in-depth in vivo studies should use larger cohort sizes to re-
duce intergroup variation (n> 5), resulting in 200 laboratory animals
(excluding potential control groups). And as demonstrated in this work,
long systemic circulation needs to be considered in order to evaluate
biodistribution based on passive accumulation (at least 5 time points:
< 5 min as value for 100 %, several hours as intermediate and 24, 48 and
72 h as long term range). Considering ex vivo tissue distribution for long
circulating particles at more than the last time point, doubled or even
tripled amounts of animals would be necessary. A study even closely re-
sembling this extensive design was beyond the scope of this work, thus
presented in vivo results are unpublished.
However, first advances were made in order to elucidate on blood cir-
culation, biodistribution and tumor accumulation of PSar-b-PCys(SO2Et)-
based core-shell nanoparticles in vivo. Worm-like and spherical particles
of varying sizes were prepared by self-assembly and subsequent core
cross-linking yielded hydrophobic core cross-linked polymeric micelles
and allowed to introduce cationic moieties for formation of nanohydro-
gels. Covalent fluorescent labeling was performed in the core compart-
ment for in vivo evaluation. Intravital microscopy revealed stable sys-
temic circulation of hydrophobic core cross-linked polymeric micelles
over 15 h with 20-25 % and 90-100 % for worm-like and spherical mor-
phology, respectively. Spherical cationic nanohydrogels prepared under
chaotropic conditions were found to circulate at 20-40 % after 24 h as
determined by blood sampling and IVIS imaging. This stable systemic
circulation of cationic systems is singular in the flied of cationic gene
delivery vectors has great potential with regard to passive tumor ac-
cumulation. Thus, the ex vivo biodistribution of cationic nanohydrogels
was evaluated and revealed pronounced tumor accumulation combined
with low systemic organ burden. In conclusion, prolonged systemic cir-
culation of cationic nanocarriers in combination with tumor specificity
characterizes PSar-b-PCys(SO2Et)-based core cross-linked cationic nanohy-
drogels as excellent carriers for systemic gene delivery e. g. siRNA.
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Preparation of Core Cross-Linked Polymeric Micelles and Nanohydrogels
For preparation of polysarcosine-block-poly(S-ethylsulfonyl-L-cysteine)
(PSar-b-PCys(SO2Et)) block copolypept(o)ides and the cationic cross-linker
triethylenetetramine α,ω-di(cysteine)diamide (TETA), see Chapter 12.[22]
Characterization of polymers employed in nanoparticle preparation for
in vivo studies is summarized in Table 15.3.
Table 15.3: Characterization of PSarn-b-PCys(SO2Et)m diblock copoly-
pept(o)ides.
No Xn, GPCa Xm, NMRb Mn, GPCc/g mol−1 ÐGPCc
P1 203 11 28700 1.31
P2 186 17 27900 1.21
P3 203 20 29800 1.31
P4 94 15 22500 1.17
a Xn PSar relative to PSar standards.[47]
b Xm from 1H NMR relative to Xn, GPC PSar.
c Relative to PMMA standards.
Self-assembly of amphiphilic block copolypept(o)ides and core cross-
linking was performed using a protocol reported previously.[22] The re-
sulting core cross-linked polymeric micelles (CCPMs) and nanohydro-
gels (NHGs) evaluated in vivo are summarized in Table 15.4. Briefly, the
respective polymer was dissolved in N,N-dimethyl acetamide (DMAc) at
a concentration of 7.5 g L-1 for 2 h. 1 mM acetate buffer (pH = 4.7) was
then added as the block-selective solvent. For self-assembly processes
with suppression of the β-sheet formation of the polycysteine segment,
DMAc contained 1 M and the 1 mM acetate buffer contained 10 mM thio-
urea as chaotropic agent. The solutions were left to equilibrate for 3 h,
dialyzed against the respective buffer and filtered using a 200 nm filter
(GHP). Micelles were stored in the respective buffer at 4°C.
Hydrophobic CCPMs were prepared as followed: The cross-linker hex-
anedithiol was added as a DMAc solution to the micelle solution in 1 mM
acetate buffer with 10 mM thiourea with SH-groups equimolar to the
number of cysteines. The reaction mixture was shaken and allowed to
stand for 18 h and dialyzed against water. Core cross-linking for cationic
NHGs was achieved by addition of the cross-linker TETA with SH-groups
equimolar to the number of cysteines as a 100 g L-1 stock solution in wa-
ter. The reaction mixture was shaken and allowed to stand for 18 h. Pu-
rification for both systems was performed by repetitive spin filtration
(MWCO 100 kDa) and dilution steps concluding in H2O followed by fil-
tration via a 200 nm syringe filter (GHP).
Covalent labeling was performed for all particles with equimolar
amount of fluorophore in DMF (5 mM).[327] The labeling reactions were
carried out at room temperature overnight followed by purification. For
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covalent labeling, 10-fold concentrated phosphate buffered saline (PBS)
was added to adjust the pH to 8 and followed exemplary by 14.1 µL
IRDye®800CW succinimidyl ester (NHS ester, LI-COR Biotechnology) so-
lution. Purification was performed by repetitive spin filtration (MWCO
100 kDa) diluting at least 10 times with EtOH/H2O followed by 10 times
with H2O.
Table 15.4: Characterization of PSar-b-PCys(SO2Et)-based particles in vivo.
No thiourea Dh, DLS / nm PDIDLS polymer Xn/Xma
wCCPM - 83.1 ± 0.3 0.127 ± 0.012 P1 203/11
sCCPM + 89.4 ± 0.7 0.161 ± 0.007 P1 203/11
wNHG1 - 66.9 ± 0.5 0.127 ± 0.015 P2 186/17
wNHG2 - 122.2 ± 2.4 0.161 ± 0.007 P3 203/20
sNHG1 + 42.6 ± 1.6 0.195 ± 0.029 P4 94/15
sNHG2 + 50.7 ± 1.7 0.109 ± 0.037 P2 186/17
sNHG3 + 81.7 ± 0.5 0.125 ± 0.014 P1 203/11
sPMa + 52.1 ± 0.4 0.229 ± 0.019 P2 186/17
a Xn PSar relative to PSar standards,[47] Xm from 1H NMR relative to Xn, GPC.
b Non cross-linked polymeric micelle.
In vivo Evaluation of PSar-b-PCys(SO2Et)-based Core-Shell Structures
Female BALB/c mice were purchased from Charles River Co. (Tokyo,
Japan). All animal experiments were conducted in accordance with
the Guidelines for the Care and Use of Laboratory Animals as stated
by the University of Tokyo. For intravital microscopy[531] of core cross-
linked polymeric micelles, a healthy BALB/c mouse was co-injected
intravenously with samples labeled CCPM as listed in Table 15.4. The
mouse was anesthetized by 1-3 % isoflurane (Abbot Laboratories) and
placed onto a temperature-controlled microscope stage. The ear lobe
was attached beneath the cover slip with a single drop of immersion oil.
Core cross-linked polymeric micelles in millipore water were filtered
via GHP200 syringe filter and co-administered by tail vein injection.
Consecutive video acquisition of the dermis tissue was performed for
15 h. All picture and movie acquisitions were performed using a Nikon
A1R confocal laser scanning microscope system attached to an upright
ECLIPSE FN1 machine equipped with a CFI Apo 40x WI λS objective
lens (Nikon, Tokyo, Japan). Acquired data was further processed using
Nikon NIS Elements software for a region of interest (ROI), which was
manually defined in the vein.
For biodistribution of core cross-linked nanohydrogels, BALB/c mice
bearing orthotropic 4T1-luc mammary tumors (n = 3) were injected in-
travenously with samples labeled NHG for nanohydrogel and PM for the
non cross-linked controll as listed in Table 15.4. Female mice were inocu-
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lated subcutaneously in the mammary gland with 1 × 106 4T1-luc cells to
prepare the orthotropic 4T1-luc mammary tumors model. After the pri-
mary tumors were sufficiently developed, fluorescently labeled nanohy-
drogels and the control micelle in H2O were filtered via a GHP200 sy-
ringe filter and administered by tail vein injection. Blood samples (10 µL)
were collected from tail incision at time point of 1 h, 4 h and 24 h post in-
jection upon heparin addition to prevent coagulation. In vivo and ex vivo
fluorescent imaging was performed with an in vivo imaging system (IVIS)
(Xenogen Corporation) comprised of a highly sensitive, S2 cooled CCD
camera mounted in a light-tight specimen box. The animals were anes-
thetized using 1-3 % isoflurane (Abbot Laboratories). 24 h post injection,
in vivo fluorescence imaging was performed using an IVIS spectrum to
confirm tumor accumulation in vivo. Animals were subsequently sacri-
ficed and tumors, spleen, kidney, liver and lung were harvested. Fluo-
rescence imaging of tissue samples as well as blood samples was per-
formed using the IVIS setup. The regions of interest (ROIs) were selected
by an automated grid to measure the fluorescence intensity from indi-
vidual tissues as well as the the background. Photons emitted from ROIs
were quantified using Living Image software (ver. 4.5.5). Fluorescence
was detected as radiant efficiency (photons/sec/cm2/sr per µW/cm2).
Blood circulation over time was obtained from comparison of initial flu-
orescence from the nanoparticle sample with the residual fluorescence
intensity of the blood samples. Fluorescence intensity of blank blood
was subtracted as background from blood samples and normalized on
the actual injected fluorescence intensity to give a relative percentage
of the initial fluorescence intensity. For evaluation of ex vivo biodistribu-
tion, fluorescence intensity devoid of background was normalized on
mass of the individual tissue and initial fluorescence intensity of the
respective sample. Results from the biodistribution as well as blood cir-
culation of nanohydrogels and the micelle control are summarized in
Table 15.5.
Table 15.5: Blood circulation and ex vivo tumor accumulation of nanohydrogels
24 h post injection.
No Dh, DLSa
/ nm
morphologyb fluorescence per g
tumor tissue / %
fluorescence per
mL blood / %
wNHG1 70 worm-like 1.29 ± 0.15 5.25 ± 2.66
wNHG2 120 worm-like 2.41 ± 0.59 7.15 ± 4.68
sNHG1 40 spherical 2.68 ± 0.60 43.32 ± 5.43
sNHG2 50 spherical 4.04 ± 0.61 31.69 ± 3.08
sNHG3 80 spherical 4.22 ± 0.12 22.23 ± 4.92
sPMc 50 spherical - d 1.26± 0.54
a Sizes rounded for simplification, accurate values are given in Table 15.4.
b Morphology determined by cryoTEM.
c Non cross-linked polymeric micelle.
d No fluorescence was detected.
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A B S T R A C T : The fundamental cellular mechanism of RNA inter-
ference enables the silencing of gene expression and thus, provides enor-
mous therapeutic potential. A systemic application of therapeutic small
interfering RNA (siRNA) requires a delivery system for transport to the
site of action in the cytosol of targeted cells, e. g. in a solid tumor. To ful-
fill this task, a carrier need to combine bioreversible entrapment of siRNA
to avoid degradation with stability in the blood stream for prolonged cir-
culation. In this work, we report on the synthesis of triblock terpolymers,
which combine a cationic polylysine block for efficient siRNA complexa-
tion, a PCys(SO2Et) segment for chemoselective disulfide formation and a
stealth-like polysarcosine in a single polymer. The triblock copolymers
can be realized by straightforward sequential ring-opening polymeriza-
tion of the corresponding α-amino acid N-carboxyanhydride, allowing
control over polymer microstructure. Since the sequential polymeriza-
tion allows permutation of block sequence, we report the influence of
triblock copolymer microstructure and block sequence on nanoparticle
carrier properties and RNA interference (RNAi) in vivo.
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16.1 I N T R O D U C T I O N
The mechanism of RNA interference (RNAi) is one of the recent ad-
ditions to the repertoire of nucleic acid-based therapies and shows
great potential for treatment of multiple diseases including cancer.[79,86]
By base-pairing of small interfering RNA (siRNA) with messenger RNA
(mRNA) of complementary sequence, enzymatic degradation of mRNA
is induced, resulting in silencing of gene expression relevant in the
underlying pathologies.[77,89] However, several challenges prevail for
systemic application of RNAi therapeutics e. g. enzymatic degradation
by ribonucleases, short circulation times and entrapment in cellular
compartments.[80,83,84] These delivery barriers can be addressed by nano
dimensional delivery strategies based on lipid[538–541] or polymer-based
formulation,[542–544] showing promising results in preclinical studies as
well as in translation to the clinic.[72,76] While local application or de-
livery to the liver or lung can take profit on multiple delivery systems,
current strategies in siRNA delivery to solid tumors are gravitating to-
wards polymer based core-shell systems such as nanohydrogels[104–106]
or polyplex systems.[101,122,135] On the structural level, these systems
share a polycationic core for complexation of negatively charged siRNA
and a shielding corona to ensure prolonged systemic circulation for
passive tumor accumulation. Further, covalent cross-linking of carriers
was shown to improve stability,[153,529,545] which is substantial for small
siRNA molecules.[546]
As a consequence, ideal polymeric materials should combine a shield-
ing segment with a cross-linkable one as well as a cationic block for ef-
ficient siRNA complexation. These demanding structural requirements
are met by ABC-type amphiphilic cationic triblock terpolymers.[492]
The outer A block is constituted by a hydrophilic polymer with
shielding properties.[27,138–140,144,145] The B block can serve either as
a protective layer, e. g. employing poly(-caprolactone)[139,547,548] or
poly(propylene sulfide)[549] as well as a biodegradable[550,551], pH or
redox responsive one.[552,553] Although Kataoka and coworkers em-
ployed poly(L-lysine) as the B segment in combination with a hydro-
phobic core forming block C, ultimately creating a carrier with siRNA
loading capacity in the intermediate layer,[554] most commonly seg-
ment C is of cationic nature to efficiently complex siRNA e. g. linear
poly(ethyleneimine) (lPEI),[139] poly(2-(dimethylamino)ethyl methacry-
late) (PDMA),[548] poly(2-aminoethylethylene phosphate) (PPEEA),[547]
cationic peptides,[549] poly(L-arginine)[555] or poly(L-lysine).[550] Stim-
uli responsive moieties can also be incorporated in the C block of
siRNA delivery vectors e. g. for hypoxia targeting[556] or mediating pH
sensitivity.[557,558]
Interestingly, up to now the influence of block sequence on nanopar-
ticle as well as delivery properties has not been investigated in such
systems. In contrast, there is a broad consensus that the properties of
nanoparticles formed by triblock copolymers are governed by the mi-
crostructure of the employed terpolymer[493–498] To derive first structure-
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Synthesis of A-B-C
and A-C-B triblock
copolypept(o)ides.
property relationships, we synthesized triblock copolymers, which
all contain a polysarcosine (PSar), a poly(S-ethylsulfonyl-L-cysteine)
(PCys(SO2Et)) and a polylysine (PLys) block by sequential ring-opening
polymerization of the corresponding α-amino acid N-carboxyanhy-
drides, but upon alteration of block sequence. In polymer P1 the se-
quence is PSar-block-PCys(SO2Et)-block-PLys (A-B-C) and in P2 PSar-block-PLys-
block-PCys(SO2Et) (A-C-B) while the overall block length of PCys(SO2Et)
and PLys are kept constant. The PCys(SO2Et) block was introduced
for bioreversible cross-linking by chemoselective disulfide formation,
which provides stability in circulation and degradability upon cellu-
lar uptake.[158] Our group recently demonstrated modification of PLys
in triblock copolypept(o)ides (polypeptoid-block-peptide-block-peptide)
with N-succinimidyl 3-(2-pyridyl-dithio)propionate (SPDP) and subse-
quent dithiol cross-linking, creating a library of polypept(o)ide-based
pDNA polyplexes.[154] However, this strategy involved three post poly-
merization modification steps to achieve thiol-reactivity, while the pre-
sented S-alkylsulfonyl group introduces thiol-reactive moieties in poly-
pept(o)ides, bypassing all post polymerization modification and activa-
tion steps.[173,327]
Thus, in the present study we report on the synthesis of triblock co-
polypept(o)ides differing in block sequence of cross-linkable and com-
plexing segments to investigate the role of block sequence alteration on
nanocarrier formation and efficacy as siRNA delivery vectors. The func-
tional elements are a hydrophilic, non-ionic shielding block based on
PSar,[27,143] combined with a polycationic PLys block for complexation of
siRNA, as well as a hydrophobic PCys(SO2Et) segment mediating chemos-
elective disulfide stabilization without the need of post polymerization
modification steps.[22,173]
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The synthesis of triblock copolypept(o)ides was performed by sequen-
tial ring-opening polymerization (ROP) of α-amino acid N-carboxyan-
hydrides (NCAs), enabling precise control over block length and block
sequence according to Birke et al.[26] Polysarcosine (PSar) was chosen
as the starting block A with a degree of polymerization of 85 units to
mediate sufficient shielding of the resulting carrier systems (see sup-
porting information for polymerization procedures).[70] For the hydro-
phobic PCys(SO2R) B block, 25-30 repeating units were chosen, in order
to provide sufficient carrier stability upon disulfide cross-linking.[154]
The polycationic PLys block C was set to 12-13 repeating units to be able
to form polyplexes by electrostatic interactions with negatively charged
nucleic acids as shown by Heller et al.[70,367] For complexation of small
siRNA molecules, a relatively short cationic segment is sufficient, particu-
larly in combination with a cationic cross-linker.[22,154] For the synthesis
oft the A-B-C block copolymer the bifunctional initiator approach was
chosen as reported by Schäfer et al.[327] while for the A-C-B block copoly-
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mer sequential polymerization provided best control over block length
(see Figure 16.1 A and B).
Figure 16.1: Polymerization scheme of triblock copolypept(o)ides by sequen-
tial ring-opening polymerization of NCAs: A) A-C-B triblock co-
polypept(o)ide (P1) with A: PSarn, B: PCys(SO2Et)m and C: PLysl as well
as B) A-C-B triblock copolypept(o)ide (P2) upon inversed sequence
of the cross-linking and polycationic block.
Characterization of triblock copolypept(o)ides was performed by
1H NMR as well as gel permeation chromatography (GPC) as summa-
rized in Table 16.1, indicating well-defined block copolymers with nar-
row size distribution. Successful chain extension into triblock copoly-
mers and the absence of homopolymers or diblock copolymer impuri-
ties was confirmed by GPC and diffusion ordered 1H NMR spectroscopy
(DOSY) as illustrated in Figure 16.2 A, 16.6 and 16.9. Block lengths of PSar
macroinitiators were determined by GPC relative to PSar standards[47]
and were in good agreement with 1H NMR experiments. Repeating units
of PCys(SO2Et) and PLys(Boc) were determined by 1H NMR by evaluation
of the α-proton signal at 4.70 ppm and ε-amide proton signal at 6.3–
6.7 ppm, respectively (compare Figure 16.5 and 16.8 in the supporting
information).
Table 16.1: Characterization of triblock copolypept(o)ides.
No polypept(o)ide
architecturea, b
Mn, GPCc
/g mol−1
Mn, GPCd
/g mol−1
ÐGPCd
P1 PSar71-b-PCys(SO2Et)29-b-
PLys13
9050 26200 1.14
P2 PSar104-b-PLys12-b-
PCys(SO2Et)26
9190 26500 1.27
a Xn PSar relative to PSar standards.[47]
b Xm and Xl from 1H NMR relative to Xn, GPC PSar.
c Relative to PSar standards.
d Relative to PMMA standards.
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Figure 16.2: Characterization of triblock polypept(o)ides: A) 1H NMR and 1H
DOSY NMR spectrum in DMSO-d6 of A-B-C triblock P1-Boc, indicat-
ing only one diffusing species with a uniform diffusion coefficient
and B) GPC elugrams in HFIP of P 1 and P2 after deprotection of the
PLys segment.
Quantitative removal of the Boc protective group was accomplished
by cleavage with a 1:1 mixture of H2O / TFA as reported previously[367]
and verified by disappearance of the characteristic Boc signal at 1.3–
1.5 ppm (compare Figure 16.7 and 16.10 in the supporting information).
As illustrated in Figure 16.2 B, both triblock copolypept(o)ides P1 and P2
exhibit monomodal molecular weight distributions in HFIP GPC. More-
over, virtually identical molecular weights and distributions are obtained
for both polymers, independent from A-B-C or A-C-B block sequence al-
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teration. The higher dispersity of 1.27 for A-C-B polymer P2, in contrast
to a PDI of 1.14 for A-B-C polymer P1, may arise from the inverted block
sequence, as P2 features a terminal hydrophobic B segment in contrast to
terminal hydrophilic A and C blocks in P1. Since 1H DOSY NMR confirms
equivalent diffusion coefficients, the observed dispersity of P2 may be
attributed to secondary effects, e. g. interactions with the column mate-
rial in GPC.
In order to investigate the influence of block-microstructure on result-
ing gene delivery vectors, both triblock copolypept(o)ides were utilized
in two strategies to construct siRNA carrier systems, namely nanohydro-
gel (NH) or polyplex (PP) (Figure 16.3 A and B). While polyplexes are
formed in the presence of siRNA followed by cross-linking resulting in
entrapment of siRNA, nanohydrogels are initially formed in the absence
of siRNA (see supporting information for details on particle preparation)
and loaded afterwards with the oligonucleotide.
Thus, starting from 2 polymers, 2 polyplexes and 2 nanohydrogels
are generated (see Figure 16.3). The 2 polyplexes PP1 and PP2 differ in
the location of the siRNA. While the PSar-block-PCys(SO2Et)-block-PLys triblock
copolymer P1 can form core-shell polyplexes in which the siRNA is
trapped in the core, polyplexes based on P2 have a hydrophobic core due
to the terminal PCys(SO2R) block. Although this block will be cationic by
core cross-linking with the dithiol triethylenetetramineα,ω-di(cysteine)-
diamide (TETA) (transition from yellow to dark blue compartments), siRNA
may remain in the PLys segment and is thus less likely located in the
inner core. The same differences in microstructure are valid for nanohy-
drogels. NH1 features the PLys part in the inner core, while TETA shapes
the outer part of the core and will thus mostly contribute to the complex-
ation of siRNA. In the case of NH2 the situation is inversed and the PLys
side chains of the triblock copolymer complexate the oligonucleotide.
Most importantly, in all 4 cases the microstructure of the triblock co-
polypept(o)ides dictates the inner structure of the carrier and compart-
mentalizes the nanoparticle[559] and the hydrophilic PSar segment forms
in all cases a hydrophilic corona (light blue).
The loading capacities with siRNA of all four different structures was
evaluated first by gel electrophoresis (see Figure 16.11 and 16.12) and
later confirmed by fluorescence correlation spectroscopy (FCS) using a
fluorescently labeled ATTO647 siRNA[344,345] For correlation of freely diffus-
ing siRNA a hydrodynamic diameter of 4-5 nm is derived, while complex-
ation by a cationic nanocarrier shifts the autocorrelation function consid-
erably to prolonged diffusion times (compare Figure 16.13). Further, the
fraction of free siRNA can be determined by application of a bimodal fit
of the autocorrelation function, thus quantifying complexation efficacy.
Successful siRNA loading was confirmed for both nanohydrogels NH1
and NH2 as well as for polyplex PP1 (compare Figure 16.13). In contrast,
PP2 based on A-C-B triblock copolypept(o)ide P2 did not yield uniform
fluorescent species and a large fraction of free siRNA was observed (46 %
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Figure 16.3: Particle platform derived from triblock polypept(o)ides by self-
assembly into nanohydrogels (NH) or polyplex formation (PP).
Block A constitutes the hydrophilic PSar corona (light blue). Subse-
quent cross-linking by a cationic cross-linker (triethylenetetramine
α,ω-di(cysteine)diamide (TETA), light gray) inverts polarity of the
hydrophobic S-ethylsulfonyl-cysteine segment (illustrated by tran-
sition from yellow to dark blue). A) A-B-C triblock polypept(o)ide P1
gives systems with a a cationic lysine-core (red) and a cross-linked
cysteine-layer (NH1 and PP1) and B) A-C-B triblock polypept(o)ide
P2 yields systems with an inversed functionality upon a cationic
lysine-layer (red) and a cross-linked cysteine-core (NH2 and PP2).
C) ζ-potential of triblock copolypept(o)ides, empty and loaded
cross-linked nanohydrogels and cross-linked polyplexes. D) Size
range of particles evaluated in vivo as determined by DLS: non
cross-linked polymeric micelle as control, layer cross-linked nano-
hydrogel NH1 and polyplex PP1 derived from A-B-C triblock poly-
pept(o)ide P1.
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free siRNA). This drastic difference seem to originate solely from the vari-
ation in microstructure between A-B-C and A-C-B polymers, since all
other parameters are identical, indicating that a terminal hydrophobic
PCys(SO2R) block in P2 hinders efficient complexation of siRNA. In con-
trast, the terminal cationic C block in P1 is readily available for interac-
tion with siRNA molecules compared to an intermediate cationic layer
in P2. Preformed nanohydrogels, in contrast, compensate the poor tem-
plate effect of small siRNA molecules, resulting in stable complexation by
NH1 and NH2 independently from block sequence.
Table 16.2: Characterization of cross-linked nanohydrogels and polyplexes
based on triblock copolypept(o)ides P1 and P2 as determined by DLS
(in 10 mM HEPES buffer).
No mircostructure Dh / nm ζ-potential
/ mV
net
charge
triblock copolypept(o)ides
P1 A-B-C – 35 positive
P2 A-C-B – 26 positive
cross-linked nanohydrogels
NH1 (empty) Lys - core 42 27 positive
NH1 (siRNA) Lys - core 52 0.2 neutral
NH2 (empty) Lys - layer 52 15 positive
NH2 (siRNA) Lys - layer 68 –20 negative
cross-linked polyplexes
PP1 (siRNA) Lys - core 100 0.5 neutral
PP2 (siRNA) Lys - layer 109 –0.9 neutral
ζ-potential naked siRNA = –27.7 mV.
As expected from the proposed model, the triblock copolymer
sequence governs particle properties, such as size and surface charge
as determined by measurement of the ζ-potential (Table 16.2 and
Figure 16.3 C). Nanohydrogels increased slightly in size upon siRNA
loading, while maintaining their size distribution (42 nm to 52 nm for
NH1 and 52 nm to 68 nm for NH2). Polyplexes were considerably larger
upon hydrodynamic diameters around 100 nm due to reduced contri-
bution of small siRNA molecules to a polyplex compaction process. As
discussed for FCS experiments, only the terminal cationic PLys segment
in P1 yields well defined polyplexes (PP1), while polyplexes PP2 based
on P2 are polydisperse (PDI above 0.7). The ζ-potential of P1 and P2
with 26.1 and 35.3 mV, respectively, is strongly cationic independent of
block sequence and both nanohydrogel architectures remain positively
charged when empty, although the PSar block reduces the observed
ζ-potential. Upon introduction of negatively charged siRNA (-27.7 mV),
however, NH1 based on A-B-C triblock achieves full charge compensa-
tion (from 26.9 mV to 0.2 mV) in contrast to NH2 based on A-C-B triblock
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(from 15.4 mV to -19.8 mV) which indicates insufficient shielding. Both
polyplexes mediate full charge compensation (0.5 mV and -0.9 mV for
PP1 and PP2, respectively), however, PP2 proved insufficiently defined.
On the way to in vivo studies, this choice was further reinforced by
investigation of cellular toxicity of the carrier systems as intermediate
step (see Figure 16.14 in the supporting information). No cytotoxic
effect for siRNA loaded carriers derived from A-B-C-type polymer P1
was observed in agreement with their neutral surface potential, in
contrast to charge-imbalanced structures based on P2, which showed
concentration dependent toxicity. Based on these findings, the selection
of siRNA carrier systems was reduced to NH1 and PP1.
Ultimately, NH1 and PP1, both derived from the A-B-C-type triblock
P1, were investigated in terms of RNAi efficacy in vivo. Knockdown ef-
ficacy was evaluated upon systemic administration in an orthotropic
mammary carcinoma model expressing luciferase (4T1-luc).[560] The tar-
get in the 4T1-luc cell line is the mRNA transcribed from genes encod-
ing for the luciferase enzyme which catalyzes an oxidative decarboxyla-
tion and bioluminescence (λ= 480 nm) upon administration of the sub-
strate D-luciferin. Bioluminescence intensity is thus directly correlated
to luciferase expression levels and the readout directly monitors enzy-
matic activity. Therefore, BALB/c mice bearing 4T1-luc mammary tu-
mors were threated with 450 µM antiGL3 siRNA as the therapeutic cargo
in NH1 and PP1. As specificity control, a nonfunctional scramble siRNA
was employed. Further, a polymeric micelle derived from AB diblock
copolypept(o)ide was employed as additional control to exclude effects
of PSar or PCys(SO2R) blocks. NH1 and PP1 were both loaded with func-
tional or nonfunctional siRNA, without variation in size between control
groups and upon neutral surface charge of –0.6 mV to 0.9 mV (see Ta-
ble 16.4 and Figure 16.3 D for characterization). Administration was per-
formed by tail vein injection and after 24 h, D-luciferin was administered
intravenously as substrate for luciferase in bioluminescence imaging by
an in vivo imaging system (IVIS) (see Figure 16.15).
Representative IVIS images (Figure 16.4 A) clearly visualize a reduced
luciferase activity from the group threated with antiGL3 siRNA loaded in
PP1 (right panel) in comparison to the empty AB micelle and nonfunc-
tional scramble siRNA (left and middle, respectively) indicating intratu-
moral RNAi in vivo. This observation was confirmed by quantification
of the bioluminescence data, where we observed a reduction of the lu-
ciferase signal of more than 60 % compared to control for antiGL3 siRNA
loaded PP1, while scr. siRNA showed no effect on luciferase activity (see
Figure 16.4 C). For NH1, however, an unspecific decrease in enzymatic
activity was observed (42 % and 52 % reduction of the luciferase signal
for antiGL3 and scr. siRNA, respectively). This lack of specificity is an indi-
cation for toxicity related effects and does not support successful intratu-
moral RNAi. In contrast, PP1 showed no concentration dependent toxicity
with siRNA concentrations ranging as high as 800 nM (see Figure 16.4 B)
and potent intratumoral RNAi.
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Figure 16.4: Effects of A-B-C triblock copolypept(o)ide based nanocarriers for
systemic delivery of therapeutic siRNA in orthotropic 4T1-luc mam-
mary tumor model (n = 3). NH1 and PP1 were each loaded with
scr. siRNA as well as antiGL3 siRNA (450 µMol per mouse) and an
unloaded AB polymeric micelle was used as the control. BALB/c
mice were injected intravenously and knock-down efficacy was
evaluated 24 h post injection in vivo by bioluminescence imaging.
A) Representative bioluminescence images of control and PP1 with
scr. siRNA and antiGL3 siRNA. B) Cytotoxicity of NH1 as well as PP1
loaded with gradually increasing siRNA concentrations (CCK8 cell
viability assay, 6.25 to 800 nM siRNA). C) Relative luminescence in-
tensity (RLU) by IVIS imaging after 10 min of luciferin injection (RLU
determined by IVIS and normalized on individual weight of tumor
tissue; data are expressed as mean; bars ± SE.).
Since both carrier systems, PP1 and NH1, are derived from the same
A-B-C triblock copolypept(o)ide P1, deviation of in vivo performance
can be attributed solely to the process of carrier formation. While siRNA
molecules are complexed in the core during polyplex formation of PP1,
loading of a nanohydrogel requires diffusion into inner compartments.
Thus, upon exposure to biological fluids, dissociation of siRNA and car-
rier is more likely for the performed particle in contrast to the polyplex.
Loss of cargo, however, can lead to charge-mediated cytotoxicity as ob-
served along with unspecific decrease of enzymatic activity in vivo for
NH1. Ultimately, the polyplex PP1 derived from an A-B-C triblock co-
polypept(o)ide allowed for specific in vivo siRNA mediated silencing of
luciferase expression in 4T1-luc tumors based on the favorable compo-
sition of the polymer microstructure of A: a shielding block, B: an in-
termediate hydrophobic segment combined with bioreversible disulfide
stabilization and C: a terminal cationic block for polyplex formation.
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In summary, we prepared A-B-C and A-C-B triblock copolypept(o)ides
in order to evaluate the impact of block sequence alterations on for-
mation and in vivo performance of siRNA delivery systems. As func-
tional elements, a PSar-based shielding block, a hydrophobic PCys(SO2R)
segment for bioreversible disulfide stabilization and a polycationic PLys
block for complexation of siRNA were combined in triblock copolymers.
Synthesis was performed by sequential ring-opening polymerization
of α-amino acid N-carboxyanhydride yielding well defined triblock co-
polypept(o)ides with permuted block sequence but identical individual
block lengths and effective hydrodynamic volume. Both triblock copoly-
pept(o)ide architectures were employed in the formation of nanohydro-
gels as well as polyplexes and characterized in light of their structure-
property relationship based on sequence alteration. While A-C-B type
triblock copolymers did only form polydisperse polyplexes and nano-
hydrogels with enhanced toxicity, polyplexes (PP1) and nanohydrogels
(NH1) derived from an A-B-C polymer provide stable siRNA complexa-
tion, charge-shielding properties and low cytotoxicity. In vivo, however,
only the polyplex PP1 achieved specific siRNA mediated knockdown of
intratumoral luciferase expression. These findings underline the signifi-
cance of block sequence in multifunctional triblock polymers employed
in formation of gene delivery vectors for systemic applications.
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16.5.1 Materials and Instrumentation
DMF was purchased from Acros and dried over BaO and molecular sieve
(3 Å), fractionally distilled in vacuo at 20 °C and stored at -80 °C under
exclusion of light. Prior to use, N,N-dimethyl formamide (DMF) was de-
gassed in vacuo to remove residing traces of dimethylamine. tetrahydro-
furane (THF) and hexane were distilled from Na/K and ethyl acetate from
CaH2. Neopentylamine was purchased from TCI Europe and was dried
over NaOH followed by distillation. Cysteine and lysine were purchased
from OPREGEN, sarcosine from Sigma-Aldrich and diphosgene from
Alfa Aesar. Hexafluoro-2-propanol (HFIP) and N-Boc-1,2-diaminoethane
were purchased from Fluorochem and deuterated solvents were
obtained from Deutero GmbH. Millipore water was prepared by a
MILLI-Q® Reference A+ System used at a resistivity of 18.2 MΩ cm-1
and total organic carbon < 5 ppm.
1H NMR spectra were recorded on a Bruker Avance II HD 400 at a fre-
quency of 400 MHz or a Bruker Avance III HD 300 at 300 MHz. Two-
dimensional nuclear magnetic resonance (NMR) spectra (1H diffusion
ordered spectroscopy (DOSY)) were recorded on a Bruker Avance III HD
400 at 400 MHz. All spectra were recorded at room temperature (25 °C)
and calibrated using the solvent signals.[394] Melting points were mea-
sured using a Mettler FP62 melting point apparatus at a heating rate of
1 °C min-1.
Gel permeation chromatography (GPC) was performed with HFIP con-
taining 3 g l−1 potassium trifluoroacetate (KTFA) as eluent at 40 ◦C and a
flow rate of 0.8 ml min−1. GPC columns were packed with modified sil-
ica (PFG columns particle size: 7 µm, porosity: 100 Å and 1000 Å). Poly-
methly methacrylate PMMA standards (Polymer Standards Services
GmbH) were used for calibration and toluene was used as internal stan-
dard. A refractive index detector (G1362A RID) and an UV/Vis detector
(at 230 nm or as indicated; Jasco UV-2075 Plus) were used for polymer
detection.
Single-angle dynamic light scattering (DLS) measurements and ζ-po-
tential measurements were performed with a ZetaSizer Nano ZS instru-
ment (Malvern Instruments Ltd., Worcestershire, UK) equipped with a
He – Ne laser (λ= 633 nm) as the incident beam. All measurements were
conducted at 25 °C and a detection angle of 173 °C. The particle mean
diameter (z-ave.), size distribution (intensity-weighted) histograms, the
width of the fitted Gaussian distribution, which is displayed as the poly-
dispersity index (PDI), as well as the average ζ-potential values were
calculated based on the autocorrelation function of samples, with auto-
mated attenuator adjustment and multiple scans (typically 10 – 15 scans)
for optimal accuracy. Data are displayed as the mean value of at least
three measurements ± standard deviation. Agarose gel electrophoresis
was performed using a 0.5 w % agarose gel prepared with TBE buffer and
GelRed for staining. Electrophoresis was carrier out at 120 V for 30 min.
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Visualization was performed in a dark hood under UV light (365 nm)
and documented by a conventional digital camera. Fluorescence cor-
relation spectroscopy (FCS) experiments were performed using a com-
mercial setup (Zeiss, Germany), consisting of a ConfCor2 module and
an inverted microscope (Axiovert200). For excitation of ATTO647-labeled
siRNA, a helium-neon laser (633 nm) was used and focused through a
Zeiss C-Apochromat 40x/1.2 W water immersion objective into the sam-
ple solutions. The emission of the ATTO647 fluorophore was detected in
the spectral range 642 – 696 nm and the observations volumes were cali-
brated using AlexaFluor647 as reference dye with known diffusion coef-
ficient. An eight-well polystyrene, chambered cover glass (Laboratory-
Tek, Nalge Nunc International) was used as a sample cell. For each sam-
ple, a series of ten measurements with (10 seconds each) was performed.
siRNA sequences were purchased from Hokkaido System Science Co.,
Ltd. (Hokkaido, Japan) and used as follows: Firefly GL3 luciferase siRNA
(antiGL3 siRNA) sense strand with sequence 5’–CUUACGCUGAGUACUUC-
GAdTdT–3’ and antisense strand 3’–dTdTGAAUGCGACUCAUGAAGCU–5’.
Scramble luciferase (scr. siRNA) sense strand 5’–UUCUCCGAACGUGUCA-
CGUdTdT–3’ and antisense strand 3’–dTdTAAGAGGCUUGCACUGAGCA–5’.
Murine breast adenocarnicoma 4T1 cells expressing luciferase (4T1-luc)
were purchased from Japanese Collection of Research Bioresources Cell
Bank (Osaka, Japan). The cells were cultured in Dulbecco’s Modified Ea-
gle Medium (DMEM) with 10 % fetal bovine serum FBS and 1 % strepto-
mycin/ penicillin and maintained at 37 °C and 5% CO2. The Cell Count-
ing Kit-8 (CCK8) was purchased from Dojindo Laboratories, absorbance
of the cell viability assay was measured by a microplate reader (Tecan
Trading AG, Switzerland) and evaluated by a Spark Controll Method
editor (ver. 2.1) software.
Female BALB/c mice were purchased from Charles River Co. (Tokyo,
Japan). All the experiments were conducted in accordance with the
Guidelines for the Care and Use of Laboratory Animals as stated by
the University of Tokyo. The mice were inoculated subcutaneously with
1 × 106 4T1-luc cells to prepare the orthotropic 4T1-luc mammary tu-
mors model. In vivo bioluminescent imaging was performed with an IVIS
Imaging System (Xenogen Corporation) comprised of a highly sensitive,
S2 cooled CCD camera mounted in a light-tight specimen box. Images
and measurements of bioluminescent signals were acquired and ana-
lyzed using Living Image Software (Xenogen, ver. 4.5.5). The animals
were anesthetized using 1-3 % isoflurane (Abbot Laboratories). 10 min-
utes prior to in vivo imaging, animals received D-luciferin (Promega) as
the luciferase substrate at 150 mg/kg in PBS by intravenous injection.
Mice were placed on a warmed stage inside the camera box and re-
ceived continuous exposure to 1-2 % isoflurane to sustain sedation dur-
ing imaging. Imaging times ranged from 10 to 60 s, depending on mag-
nitude of the bioluminescence of the metastatic lesions.
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16.5.2 Synthetic Procedures
M O N O M E R S Y N T H E S I S
Ethanesulfinic acid sodium salt
A solution of sodium sulfite (391.98 g, 3.11 mol) in water (800 mL) was
heated to 80 °C. Ethanesulfonyl chloride (147.40 mL, 199.30 g, 1.55 mol)
and sodium carbonate (329.63 g, 3.11 mol) were added simultaneously
while significant quantities of CO2 evolved. The reaction mixture was
stirred for one hour at 80 °C, afterwards water was removed in vacuo
at 60 °C. The resulting solid was suspended in methanol and filtered.
Evaporation of methanol gave ethanesulfinic acid sodium salt (153.54 g,
1.32 mol, 85 % yield) as a colorless solid.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 1.79 (q, 3JH,H = 7.6 Hz, 2H, – CH2 – ),
0.90 (t, 3JH,H = 7.6 Hz, 3H, – CH3).
S-ethylsulfonyl-L-cysteine (Cys(SO2Et))[173]
An ice-cold solution of sodium nitrite (5.94 g, 86 mmol) in degassed wa-
ter (45 mL) was slowly added to a stirred solution of L-cysteine hydrochlo-
ride (13.57 g, 86 mmol) in previously degassed 2 N HCl (90 mL) at 0 °C. Af-
ter 1 h, ethanesulfinic acid sodium salt (20.00 g, 172 mmol) was added to
the deep red solution and was stirred for 2 h. Additional sodium ethane-
sulfinate (5.00 g, 43 mmol) was added and eventually a colorless solid
precipitated. The reaction mixture was stirred at 0 °C overnight. The
precipitate was filtered off and the pH of the colorless filtrate was ad-
justed with 2 N NaOH to pH 4-5, resulting in additional colorless solid
precipitating. The filtrate was allowed to stand at 4 °C until precipita-
tion was complete. The combined precipitates were washed with MeOH
to remove residual sulfinate and dried in vacuo yielding Cys(SO2Et) (5.03
g, 24 mmol, 27 %) as a colorless, crystalline solid.
1H NMR (400 MHz, DMSO-d6/ TFA-d) δ [ppm] = 4.34 (t, 3JH,H = 6.4 Hz,
3JH,H = 6.0 Hz, 1H, α– H), 3.66 (dd, 2JH,H = 14.4 Hz, 3JH,H = 6.0 Hz, 1H,
– CHH – S), 3.62 (q, JH,H = 7.2 Hz, 2H, – CH2 – SO2), 3.53 (dd, 3JH,H = 14.4 Hz,
3JH,H = 6.4 Hz, 1H, – CHH – S), 1.30 (t, 3JH,H = 7.2 Hz, 3H, – CH3).
S-ethylsulfonyl-L-cysteine N-carboxyanhydride (Cys(SO2Et) NCA)[173]
Dried Cys(SO2Et) (7.00 g, 32.82 mmol) was suspended in absolute THF
(100 mL) and heated to 70 °C. Diphosgene (3.60 mL, 5.84 g, 29.52 mmol)
was slowly added and the suspension was heated for an additional 4 h.
Dry nitrogen was bubbled through the reaction mixture overnight into
a gas washing bottle with an aqueous KOH solution to remove excess
diphosgene, HCl and most of the solvent. The remaining solvent was re-
moved in vacuo and the residue was dissolved in 100 mL absolute ethyl
acetate. Any insoluble compounds were removed by filtration avoiding
contact with air and the NCA was precipitated by adding 800 mL abso-
lute hexane. After recrystallization a total of 6.43 g of purified product
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(26.87 mmol, 82 %yield, colorless and crystalline powder, melting point:
113–115 °C) was obtained and stored in a Schlenk tube at -80 °C.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.32 (s, 1H, – NHCO), 4.86 (td,
3JH,H = 6.0 Hz, 3JH,H = 4.8 Hz, 3JH,H = 1.6 Hz, 1H, α– H), 3.64 (dd, 2JH,H
= 14.4 Hz, 3JH,H = 4.8 Hz, 1H, – CHH – S), 3.62 (q, 3JH,H = 7.2 Hz, 2H,
– CH2 – SO2), 3.57 (dd, 2JH,H = 14.4 Hz, 3JH,H = 6.4 Hz, 1H, – CHH – S), 1.29
(t, 3JH,H = 7.2 Hz, 3H, – CH3).
N-ε-tert-butyloxycarbonyl-L-lysine N-carboxyanhydride (Lys(Boc) NCA)[59]
9.8 g (39.8 mmol) of N-ε-Boc-protected lysine was weighed into a three-
necked flask and dried in vacuo for 1 h. The solid was suspended in
300 mL of absolute THF under a steady flow of dry nitrogen. Afterward,
9.9 mL (79.6 mmol) of absolute trimethyl-silylchloride and 11.0 mL
(79.6 mmol) of absolute triethylamine TEA were added slowly via sy-
ringe. The suspension was stirred for 2 h followed by addition of 4.8 mL
(39.8 mmol) of diphosgene, via syringe. The suspension was mildly re-
fluxed for another 2 h. Overnight, a steady flow of dry nitrogen was
lead through the solution into two gas washing bottles filled with aque-
ous NaOH solution removing excess phosgene and HCl. The suspension
was filtered under dry nitrogen atmosphere to remove the salts of TEA
and unconverted amino acid. The solid was washed with absolute THF
and the filtrate was evaporated under reduced pressure. Subsequently,
absolute THF was added to completely dissolve the crude reaction prod-
uct. The solution was precipitated with absolute hexane and stored at
4 °C for 1 h. The solid was collected by filtration under dry nitrogen
atmosphere and washed with absolute hexane. The crude reaction prod-
uct was then recrystallized twice with absolute THF/hexane. A total of
6.52 g of purified product (23.9 mmol, 68 % yield, colorless needles, melt-
ing point: 138.3 °C) was obtained and stored in a Schlenk tube at -80 °C.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 9.07 (s, 1H, – NH – CO – O – CO),
6.95–6.34 (br, 1H, – NH – CO – O – C(CH3)3), 4.42 (t, 1H, 3JH,H = 6.35 Hz, – CO –
CH – CH2 – ), 2.90 (q, 2H, 3JH,H = 6.03 Hz, – CH2 – NH – CO – O – C(CH3)3), 1.79–
1.56 (m, 2H, – CH – CH2 – CH2 – CH2 – CH2 – NH – ), 1.45–1.12 (m, 13H, – CH –
CH2 – CH2 – CH2 – CH2 – NH– , – NH – CO – O – C(CH3)3).
Sarcosine N-carboxyanhydride (Sar NCA)[26]
The synthesis of sarcosine NCA was adapted from literature and
modified.[44] A total of 14.92 g (167.4 mmol) sarcosine, dried in vacuo for
1 h, was weighed into a pre-dried, three-neck, round-bottom flask. A
total of 300 mL of absolute THF was added under a steady flow of ni-
trogen and 16.2 mL (134 mmol) of diphosgene were added slowly via
syringe, and the nitrogen stream was reduced. The colorless suspen-
sion was mildly refluxed for 3 h, yielding a clear solution. Afterward,
a steady flow of dry nitrogen was led throw the solution for another
3 h into two gas washing bottles filled with aqueous NaOH solution. The
solvent was evaporated under reduced pressure, yielding a brown oil
as crude reaction product. The oil was heated to 50 °C and dried under
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reduced pressure (20 mbar, then < 10-2 mbar for 2 h) to obtain an amor-
phous solid, free of phosgene and HCl, confirmed by testing against sil-
ver nitrate solution. The crude product was dissolved in 40 mL absolute
THF and precipitated with 300 mL absolute hexane. The solution was
cooled to -18 °C overnight for complete precipitation. The solid was fil-
tered under dry nitrogen atmosphere, dried in a stream of dry nitro-
gen for 60–90 min and afterwards under high vacuum for 2 h in a sub-
limation apparatus. The crude product was sublimated at 80–85 °C and
< 10-2 mbar. The product was collected from the sublimation apparatus
in a glovebox on the same day. This procedure yielded 12.64 g of purified
product (110 mmol, 65 % yield, colorless crystals, melting point: 102–104
°C) which was stored in a Schlenk tube at -80 °C and only handled under
nitrogen atmosphere.
1H NMR (400 MHz, CDCl3) δ [ppm] = 4.22 (s, 2H, – CH2 – ), 2.86 (s, 3H,
– CH3).
S Y N T H E S I S O F A - B - C T R I B L O C K C O P O LY P E P T ( O ) I D E ( P 1 )
Polysarcosine initiated by N-Boc-1,2-diaminoethane[327]
1.5 g (13.1 mmol) sarcosine NCA were dried in vacuo and dissolved in
9.5 mL dry DMF and 41.5 µL (262 µmol) N-Boc-1,2-diaminoethane in
0.5 mL dry DMF were added. The clear, colorless solution was stirred
at room temperature under a steady flow of dry nitrogen for 2 days
(complete conversion was monitored by IR-spectroscopy). The sarcosine
amino terminus was quenched by addition of 726 µL (0.52 mmol) tri-
ethylamine and 248 µL (0.26 mmol) acetic anhydride. The clear solution
was allowed to stir for an additional day at room temperature. Precipi-
tation in diethylether yielded 980 mg (95 %) of a colorless solid. The Boc
protective group was removed in a mixture of H2O/TFA 1:1 for 2 h. The
clear yellow solution was stirred under an argon atmosphere at room
temperature for 1 hour under the exclusion of light. Precipitation in di-
ethyl ether yielded a colorless solid, which was dialyzed against Milli-
pore water (MWCO 3.5 kDa), saturated with NaHCO3 for 2 days followed
by dialysis in pure Millipore water for additional 2 days. The polymer
was lyophilized from water and 450 mg (46 %) of a colorless solid were
obtained.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 4.35–3.94 (m, 2nH, – CH2 – ), 2.97–
2.73 (m, 3nH, – CH3), 2.01–1.99 (m, 3H, – OCCH3). Additionally 1.37 (m,
9H, – OC(CH3)3) for Boc-terminated.
Polysarcosine-block-poly(S-ethylsulfonyl-L-cysteine) (PSar-b-PCys(SO2Et))[327]
208 mg (40.5 µmol) amine terminated polysarcosine macroinitiator were
dried in vacuo and dissolved in 5 mL dry DMF. The pale yellow mono-
mer solution of 485 mg (2.0 mmol) Cys(SO2Et) NCA in 4 mL dry DMF
was added. The polymerization was carried out at -10 °C under a steady
flow of dry nitrogen and monitored via IR spectroscopy. After 2 days
(conversion rate of 51%), the reaction was stopped by precipitation in
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THF/diethyl ether 1:5. The work-up by precipitation and centrifugation
was repeated two times in THF/diethyl ether 1:5 and then once in pure
diethyl ether. After extensive drying in vacuo, 252 mg (42%) of a colorless
solid were obtained.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 8.76 (m, 1mH, – NHCO)Cys,
4.69 (m, 1mH, α– H)Cys, 4.34–3.92 (m, 2nH, – CH2 – )Sar, 3.57–3.47 (m,
4mH, – CH2 – SSO2 – CH2 – )Cys, 2.93–2.72 (m, 3nH, – CH3)Sar, 1.29 (t, 3mH,
– CH3)Cys.
Polysarcosine-block-poly(S-ethylsulfonyl-L-cysteine)-block-poly-L-lysine
(PSar-b-PCys(SO2Et)-b-PLys P2)
252 mg (23.7 µmol) PSar-b-PCys(SO2Et) macroinitiator were dried in vacuo
and dissolved in 2.5 mL dry DMF. 4.0 µL (23.7 µmol) dry N,N-diiso-
propylethylamine (DIPEA) were added and the macroinitiator solution
was stirred at 0 °C for 0.5 h. A monomer solution of 258 mg (0.95 mmol)
Lys(Boc) NCA in 2.5 mL dry DMF was added. The polymerization was car-
ried out at 0 °C under a steady flow of dry nitrogen and monitored via
IR spectroscopy. After 2 days (conversion rate of 46%), the reaction was
stopped by precipitation in THF/diethyl ether 1:5. The work-up by pre-
cipitation and centrifugation was repeated two times in THF/diethyl
ether 1:5 and once in pure diethyl ether, yielding 375 mg (88 %) Boc-
protected A-B-C triblock copolymer as a colorless solid. The Boc protec-
tive group of 158 mg Boc-protected triblock copolymer was removed in
a mixture of H2O/TFA 1:1 for 2 h. The clear yellow solution was stirred
under an argon atmosphere at room temperature for 1 hour under the
exclusion of light. Precipitation in diethyl ether yielded a colorless solid,
which was dialyzed against 2 vol% acetic acid in Millipore water
(MWCO 3.5 kDa) for 3 days. Lyophilisation yielded 129 mg (82 %) PSar-b-
PCys(SO2Et)-b-PLys as a colorless solid.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 8.78 (m, 1lH, – NHCO)Cys, 8.12
(m, 1mH, – NH – CO – O – CO)Lys, 4.68 (m, 1lH, α– H)Cys, 4.35–3.94 (m, 2nH
– CH2 – Sar, 1mH – CO – CH – CH2 – Lys), 3.56 (m, 4lH, – CH2 – SSO2 – CH2 – )Cys,
3.31 (m, 2mH, – CH2 – NH – CO – O – C(CH3)3)Lys, 2.94–2.73 (m, 3nH,
– CH3)Sar, 1.51 (m, 6mH, – CH – CH2 – CH2 – CH2 – CH2 – NH – )Lys, 1.30 (t, 3lH,
– CH3)Cys.
S Y N T H E S I S O F A - C - B T R I B L O C K C O P O LY P E P T ( O ) I D E ( P 2 )
Polysarcosine initiated by neopentylamine[26]
1. g (8.9 mmol) sarcosine NCA were dried in vacuo and dissolved in 5 mL
dry DMF. To the monomer solution 10.4 µL absolute neopentylamine
(7.7 mg, 89 µmol) were added. The clear, colorless solution was stirred
at room temperature under a steady flow of dry nitrogen. The reaction
was completed after 2 days (monitored by IR-spectroscopy). Precipita-
tion in diethyl ether yielded 559 mg (55 %) of a colorless solid.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 4.34–3.92 (m, 2nH, – CH2 – ), 2.93–
2.73 (m, 3nH, – CH3), 0.82 (s, 9H, – (CH3)3).
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Polysarcosine-block-poly(N-ε-tert-butyloxycarbonyl-L-lysine)
(PSar-b-PLys(Boc))
172 mg (23.1 µmol) polysarcosine macroinitiator were dried in vacuo and
dissolved in 1.7 mL dry DMF. 3.9 µL (23.1 µmol) dry N,N-diisopropyl-
ethylamine (DIPEA) were added and the macroinitiator solution was
stirred at 0 °C for 0.5 h. The monomer solution of 314 mg (1,15 mmol)
Lys(Boc) NCA in 3 mL dry DMF was added. The polymerization was car-
ried out at 0 °C under a steady flow of dry nitrogen and monitored via
IR spectroscopy. After 24h full conversion was reached and the reaction
was terminated by precipitation in diethyl ether. The work-up by pre-
cipitation and centrifugation was repeated two times and 300 mg (69%)
of a colorless solid were obtained.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 8.16 (m, 1mH, – NH – CO – O –
CO)Lys, 6.67–6.63 (m, 1mH, – NH – CO – O – C(CH3)3)Lys, 4.35–3.94 (m, 2nH
– CH2 – Sar, 1mH – CO – CH – CH2 – Lys), 3.32 (m, 2mH, – CH2 – NH – CO – O –
C(CH3)3)Lys, 2.96–2.73 (m, 3nH, – CH3)Sar, 1.52 (m, 6mH, – CH – CH2 – CH2 –
CH2 – CH2 – NH – )Lys, 1.35 (m, 9mH, – NH – CO – O – C(CH3)3)Lys, 0.82 (m, 9H,
– (CH3)3)Neo.
Polysarcosine-block-poly-L-lysine-block-poly(S-ethylsulfonyl-L-cysteine)
(PSar-b-PLys-b-PCys(SO2Et) P1)
221 mg (21.1 µmol) PSar-b-PLys(Boc) macroinitiator were dried in vacuo and
dissolved in 3 mL dry DMF. 3.6 µL (21.1 µmol) dry DIPEA were added the
macroinitiator solution was stirred at -10 °C for 0.5 h. The pale yellow
monomer solution of 253 mg (1.1 mmol) Cys(SO2Et) NCA in 3.5 mL dry
DMF was added. The polymerization was carried out at -10 °C under a
steady flow of dry nitrogen and monitored via IR spectroscopy. After
2 days (conversion rate of 43%), the reaction was stopped by precipi-
tation in THF/diethyl ether 1:5. The work-up by precipitation and cen-
trifugation was repeated two times in THF/diethyl ether 1:5 and then
once in pure diethyl ether, yielding 328 mg (75 %) Boc-protected tri-
block copolymer as a colorless solid. The Boc protective group of 151 mg
Boc-protected A-C-B triblock copolymer was removed in a mixture of
H2O/TFA 1:1 for 2 h. The clear yellow solution was stirred under an ar-
gon atmosphere at room temperature for 1 hour under the exclusion of
light. Precipitation in diethyl ether yielded a colorless solid, which was
dialyzed against 2 vol% acetic acid in Millipore water (MWCO 3.5 kDa)
for 3 days. Lyophilisation yielded 124 mg (82 %) PSar-b-PLys-b-PCys(SO2Et)
as a colorless solid.
1H NMR (400 MHz, DMSO-d6) δ [ppm] = 8.79 (m, 1lH, – NHCO)Cys,
8.16 (m, 1mH, – NH – CO – O – CO)Lys, 4.68 (m, 1lH, α– H)Cys, 4.35–3.94 (m,
2nH – CH2 – Sar, 1mH – CO – CH – CH2 – Lys), 3.56 (m, 4lH, – CH2 – SSO2 –
CH2 – )Cys, 3.32 (m, 2mH, – CH2 – NH – CO – O – C(CH3)3)Lys, 2.96–2.73 (m,
3nH, – CH3)Sar, 1.52 (m, 6mH, – CH – CH2 – CH2 – CH2 – CH2 – NH – )Lys, 1.30 (t,
3lH, – CH3)Cys, 0.82 (m, 9H, – (CH3)3)Neo.
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S Y N T H E S I S O F C AT I O N I C C R O S S - L I N K E R T E TA
Triethylenetetramine α,ω-di((S-Trt-N-Boc)cysteine)diamide
1.20 g (2.60 mmol) Cys(S-Trt)N-Boc and 472 mg (3.50 mmol) HOBt (12 %
water) were dissolved in 10 mL DMF and 589 mg (3.12 mmol) EDC·HCl
were added. The solution was stirred for 1 h at rt. 193µL triethylenete-
tramine were added and the solution was stirred for 30 more minutes.
The solvent was removed in vacuo and the product purified by flash
chromatography (AcOEt:MeOH (3:5) +2 % NEt3).
1H NMR (300 MHz, CDCl3) δ [ppm] = 7.45–7.33 (m, 12H, m-HAr), 7.29–7.21
(m,12H, o-HAr), 7.22–7.13 (m, 6H, p-HAr), 6.62 (s, 2H, – CO – NH – ), 5.05 (s,
br, 2H, α– H), 3.92 (s, 2H, – NH), 3.39–3.09 (m, 4H, – CH2 – S – ), 2.68 - 2.60
(m, 8H, - – CO – NH – CH2 – CH2 – ), 2.58 (s, 4H, – NH – CH2 – CH2 – NH – ), 1.39 (s,
18H, – O – C(CH3)3).
ESI – MS: m/z = 1038.7 [M+H]+, (calc. 1037.5 g mol-1); 1059.6 [M+Na]+, (calc.
1059.5 g mol-1).
Triethylenetetramine α,ω-di(cysteine)diamide
442 mg (0.426 mmol) triethylenetetramine α,ω-di((S-Trt-N-Boc)cyste-
ine)diamide and 263 mg (1.7 mmol) dithiothreitol (DTT) were dissolved
in 18 mL DCM. 0.7 mL (3.4 mmol) triisopropylsilane followed by 2 mL
TFA. The solution was stirred under argon for 3 h and and precipitated
in diethyl ether. The crude product was dissolved in 4 mL water/ace-
tonitrile (97:3 + 0.1% TFA), 130 mg DTT were added and the mixture was
purified by HPLC. Lyophilization yielded 287 mg triethylenetetramine
α,ω-di(cysteine) diamide tetratriflouroacetate.
1H NMR (400 MHz, D2O) δ [ppm] = 4.24 (dd, 3JH,H = 6.3, 5.2 Hz, 2H, α– H),
3.79–3.66 (m, 2H, – CH2 – S – ), 3.65–3.54 (m, 2H, – CH2 – S – ), 3.52 (s, 4H,
– NH – CH2 – CH2 – NH – ), 3.33 (q, 3JH,H = 5.8 Hz, 4H, – CO – NH – CH2), 3.17–
3.02 (dq, 3JH,H = 5.8, 14.1 Hz, 4H, – CH2 – NH – ).
ESI – MS: m/z = 353.2 [M+H]+, (calc. 353.2 g mol-1).
16.5.3 Particle Preparation
For preparation of cross-linked cationic nanohydrogels, P1 or P2 was dis-
solved in N,N-dimethyl acetamide (DMAc) at a concentration of
7.5 g L-1 overnight. 25 vol. % of 1 mM acetate buffer (pH = 4.7) were then
added as the block-selective solvent. The solutions were left to equili-
brate for 4 h, dialyzed against 1 mM acetate buffer (MWCO = 3.5 kDa).
Cross-linking was performed by addition of the cationic cross-linker
TETA with SH-groups equimolar to the number of cysteines as a 50 g L-1
stock solution in water. The reaction mixtures were vortexed and al-
lowed to stand overnight. Subsequently, the solutions were diluted with
1 mM acetate buffer (pH 4.7), purified by repetitive spin filtration
(MWCO 100 kDa) and dilution steps concluding in 10 mM HEPES buffer
and filtered via a 200 nm syringe filter (GHP). Loading with siRNA was
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performed as follows: The desired amount of siRNA in sterile water
(70 µM for antiGL3 siRNA and 76.9 µM for scr. siRNA) was diluted with a
solution of the respective nanohydrogel (3.5 g L-1 in 10 mM HEPES) at a
mass ratio of 20:1 and vortexed for 10 s. The solutions were incubated
for 1 h at room temperature and the final concentration was adjusted
with 10 mM HEPES buffer prior to use.
For the formation of cross-linked polyplexes, P1 or P2 was dissolved in
10 mM HEPES buffer at a concentration of 10 g L-1. The desired amount of
siRNA in sterile water (70 µM for antiGL3 siRNA and 76.9 µM for scr. siRNA)
was diluted with the respective polymer solution at a N:P ratio of 15:1
(corresponding mass ratio of 18:1) and vortexed for 10 s. The solutions
were incubated for 30 min at room temperature. Cross-linking was per-
formed with the cationic cross-linker TETA with SH-groups equimolar to
the number of cysteines as a 50 g L-1 stock solution in water. The cross-
linker was added and the solution was vortexed immediately for 10 s.
The solutions were incubated for 1-2 h at room temperature and the fi-
nal concentration was adjusted with 10 mM HEPES buffer prior to use.
Table 16.3: Characterization of cross-linked nanohydrogels and polyplexes
based on triblock copolypept(o)ides P1 and P2 as determined by DLS
(in 10 mM HEPES buffer).
No Dh / nm PDI ζ-potential / mV
triblock copolypept(o)ides
P1 – – 35.3 ± 1.2
P2 – – 26.1 ± 1.1
cross-linked nanohydrogels
NH1 (empty) 41.7 ± 0.9 0.224 ± 0.024 26.9 ± 0.5
NH1 (siRNA) 52.4± 1.7 0.223 ± 0.015 0.2 ± 0.2
NH2 (empty) 52.2 ± 0.5 0.230 ± 0.024 15.4 ± 0.6
NH2 (siRNA) 68.1 ± 5.7 0.237 ± 0.019 –19.8 ± 1.3
cross-linked polyplexes
PP1 (siRNA) 100.4 ± 0.2 0.237 ± 0.006 0.5 ± 0.2
PP2 (siRNA) 109.3 ± 12.6 0.759 ± 0.074 –0.9 ± 0.5
ζ-potential naked siRNA = –27.7 mV.
16.5.4 Biological Evaluation
In Vitro Cytotoxicity Assay
The cytotoxicity of triblock copolypept(o)ides and the derived delivery
systems were evaluated in 4T1-luc cells using the Cell Counting Kit-8.
The cells (10000 cells/100 µL) were cultured for 24 h at 37 °C in DMEM
containing 10 % FBS in a 96-well multiplate. The cells were then exposed
to the respective samples for additioinal 24 h at 37 °C. The medium was
discarded, replaced with 100 µL fresh medium and followed by addition
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of the manufacturer’s reagent (10 µL). After 1 h incubation at 37 °C the
absorbance was measured at 450 nm using a microplate reader. For data
shown in Figure 16.14, siRNA concentrations were 100, 200 and 400 nM,
respectively. For detailed evaluation of cytotoxicity prior to in vivo ap-
plication (data shown in Figure 16.4 B), siRNA concentrations were 6.25,
12.5, 25, 50, 100, 200, 400 and 800 nM for loaded NH1 and PP1, or an equiv-
alent amount of 10 mM HEPES for empty NH1 and free polymer P2.
In Vivo Bioluminescence Assay
In order to evaluate the knock-down efficacy of siRNA delivery vectors
based on triblock copolypept(o)ides, female BALB/c mice bearing or-
thotropic 4T1-luc mammary tumors (n = 3) were treated intravenously
with 450 µM antiGL3 siRNA or scr. siRNA as a control, encapsulated in NH1
or PP1, respectively (200 µL injected volume, siRNA concentration of
2.25 µM prior to injection). The control group was treated with an un-
loaded, non stabilized polymeric micelle derived from PSar-b-PCys(SO2Et)
diblock copolypept(o)ide (see Table 16.4 for characterization of individ-
ual samples). Female BALB/c mice were inoculated with 1 × 106 cell sub-
cutaneously in the mammary gland. After the primary tumors were suf-
ficiently developed, samples were administered via tail vein injection
and 24 h post injection, in vivo bioluminescence imaging was performed
using an IVIS spectrum. The mice were anesthesized with isoflurane and
injected intravenously with luciferin as a substrate for luciferase. At
10 min after luciferin injection, the mice were imaged for 10-60 s. The
regions of interest (ROIs) were selected to measure the tumor volume
and background. Photons emitted from ROIs were quantified using Liv-
ing Image software (ver. 4.5.5). The in vivo luciferase activity was ex-
pressed as relative luminescence units and normalized on individual
tumor weight as determined after excision.
Table 16.4: Characterization of nanocarriers evaluated in vivo.
No + siRNA Dh / nm PDI ζ-potential / mV
control (empty micelle) 52.1 ± 0.4 0.229 ± 0.019 0.8 ± 0.3
NH1 + scr. siRNA 53.0 ± 1.8 0.240 ± 0.005 –0.6 ± 0.2
NH1 + antiGL3 siRNA 50.7 ± 0.2 0.232 ± 0.009 0.2 ± 0.2
PP1 + scr. siRNA 103.7 ± 1.9 0.252 ± 0.005 0.9 ± 0.1
PP1 + antiGL3 siRNA 101.8 ± 0.8 0.261 ± 0.028 0.5 ± 0.2
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16.5.5 1H NMR Characterization of Triblock Copolymers
Figure 16.5: 1H NMR spectrum (400 MHz) of P1-Boc in DMSO-d6.
Figure 16.6: DOSY 1H NMR spectrum (400 MHz) of P1-Boc in DMSO-d6.
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Figure 16.7: 1H NMR spectrum (400 MHz) of P1 in DMSO-d6.
Figure 16.8: 1H NMR spectrum (400 MHz) of P2-Boc in DMSO-d6.
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Figure 16.9: DOSY 1H NMR spectrum (400 MHz) of P2-Boc in DMSO-d6.
Figure 16.10: 1H NMR spectrum (400 MHz) of P2 in DMSO-d6.
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16.5.6 Additional Results
Figure 16.11: Agarose gel electrophoresis of siRNA loaded cross-linked nanohy-
drogels: NH1 derived from A-B-C polymer P1 and NH2 derived
from A-C-B polymer P2.
Figure 16.12: Agarose gel electrophoresis of siRNA loaded cross-linked poly-
plexes: PP1 derived from A-B-C polymer P1 and PP2 derived from
A-C-B polymer P2.
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Figure 16.13: Auto-correlation curves measured for free ATTO647-siRNA, ATTO488-
siRNA loaded cross-linked nanohydrogels NH1, NH2 and cross-
linked polyplex PP1.
Figure 16.14: Cell viability assay (CCK8) of 4T1-luc cells exposed to triblock co-
polypept(o)ides (P1, P2) as well as derived cross-linked nanohy-
drogels (NH1, NH2) and cross-linked polyplexes (PP1, PP2) loaded
with varying concentrations of scr. siRNA.
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Figure 16.15: In vivo bioluminescence imaging 24 h post injection of female
BALB/c mice bearing orthotropic 4T1-luc mammary tumors
(n = 3). Groups were divided as follows: not cross-linked poly-
meric micelle as the control, cross-linked nanohydrogel NH1
and cross-linked polyplex PP1 derived from PSar71-b-PCys(SO2Et)29-
b-PLys13 (P1) loaded with 450 µM scr. siRNA or antiGL3 siRNA per
mouse.

Part VI
S U M M A RY A N D O U T L O O K

17
S U M M A RY
The goal of this thesis was the development of stabilized polypept(o)ide-
based core-shell carrier systems for systemic application as nanomedi-
cines e. g. for gene delivery. Bioreversible chemoselective disulfide sta-
bilization was mediated by S-alkylsulfonyl-L-cysteines, which were em-
ployed as building blocks in synthesis of (multi)block copolypept(o)ides
by controlled ring-opening polymerization of α-amino acid N-carboxy-
anhydrides (NCAs). Preparation of core-shell nanoparticles by secondary
structure-modulated self-assembly of the resulting polypept(o)ides of-
fered control over size, morphology and functionality in combination
with disulfide stabilization by cross-linking. The resulting core-shell sys-
tems were evaluated in vivo and showed exceeding stable systemic cir-
culation for hydrophobic core cross-linked polymeric micelles and, re-
markably, for cationic nanohydrogels. Ultimately, RNA interference
(RNAi) in solid tumors was demonstrated upon systemic delivery by
cationic, cross-linked polypept(o)ide-based systems.
Polypept(o)ides were chosen as the platform for nanoparticle prepa-
ration and the impact of absolute monomer purity promoting on control
over the polymerization was demonstrated by correlating crystal struc-
ture and melting point of NCAs to the quality of resulting polypeptides.
Based on the importance of bioreversible nanoparticle stabilization in
systemic applications, options for disulfide-mediated stabilization were
evaluated with focus on the amino acid cysteine. Since moieties for di-
rected disulfide formation that are compatible with polypept(o)ide syn-
thesis by nucleophilic ring-opening polymerization of NCAs were com-
pletely lacking, protective and activating groups for thiols were synthe-
sized and investigated towards stability against N-nucleophiles and re-
activity towards S-nucleophiles.
S-alkylsulfonyl-L-cysteines met these demanding criteria by balanc-
ing the electrophilic character of the cysteine sulfur atom with steric hin-
drance of the protective group, which ultimately allowed for sequential
polymerization by ring-opening polymerization of the respective NCAs.
In addition, the resulting poly(S-alkylsulfonyl-L-cysteines) (PCys(SO2R))
segment showed pronounced tendency to form secondary structures, as
antiparallel β-sheets conformation was confirmed in aqueous solution
as well as in organic solvents. Thorough kinetic evaluation on PCys(SO2R)
polymerization characteristics laid the groundwork for synthesis of di-
and triblock polypept(o)ides by sequential polymerization. Trifunctional
PSar-b-PCys(SO2R) diblock copolymers were obtained with independently
addressable functional groups in spatial separation upon nanoparticle
preparation. The S-alkylsulfonyl group remained intact during conver-
303
304 S U M M A R Y
sion of azide and amine polymer chain ends and was readily address-
able by thiols for bioreversible disulfide formation.
Amphiphilic PSar-b-PCys(SO2Et) block copolypept(o)ides were imple-
mented in secondary structure-driven self-assembly to control the size
and shape of polymeric core-shell nanostructures. In addition, core func-
tionality was adjusted by bioreversible core cross-linking in an inde-
pendent, single post-polymerization step. The self-assembly behavior
of PSar-b-PCys(SO2Et) was systematically screened by varying the block-
length ratio of the polymer, solvent composition during self-assembly
and, most importantly, by modulating secondary structure formation in
order to switch the conformation of the polycysteine segment from rod
to coil. Ultimately a versatile platform of disulfide stabilized nanoparti-
cles was available with adjustable hydrodynamic dimensions between
approximately 30 nm and 150 nm. Variation was achieved between elon-
gated or spherical morphology and functionalities can be included
ranging from hydrophobic core cross-linked polymeric micelles for e. g.
hydrophobic chemotherapeutic agents, to cationic nanohydrogels for
complexation of negatively charged nucleic acids e. g. small interfering
RNA (siRNA). Near-infrared fluorescence correlation spectroscopy per-
formed in flowing human blood, demonstrated the importance of co-
valent modification of nanocarriers in biological relevant environment.
Thus covalent labeling and cross-linking of PSar-b-PCys(SO2Et)-based core-
shell nanoparticles was self-evident for in vivo applications.
Blood circulation, biodistribution and tumor accumulation of cross-
linked polymeric micelles and cationic nanohydrogels was elucidated,
revealing stable systemic circulation of hydrophobic core cross-linked
polymeric micelles over 15 h and, astonishingly, of cationic nanohydro-
gels 24 h post injection as determined by blood sampling and in vivo
imaging system (IVIS). This stable systemic circulation of cationic sys-
tems is singular for polycationic gene delivery vectors and has great
potential regarding passive tumor accumulation. Thus, ex vivo biodis-
tribution of cationic nanohydrogels was evaluated and revealed pro-
nounced tumor accumulation in combination with low accumulation
in the lungs, kidneys, the spleen and the liver. These promising result
on circulation and biodistribution of cross-linked polypept(o)ide based
nanoparticles prompted the investigation of polypept(o)ide-based car-
riers for systemic delivery of siRNA. As carrier systems, amphiphilic
cationic triblock copolypept(o)ides were sequentially polymerized fea-
turing PSar as a shielding block, a hydrophobic PCys(SO2Et) segment for
bioreversible disulfide stabilization and a polycationic PLys block for
complexation of siRNA, all in one polymer. The triblock copolypept(o)ides
were employed in the formation of nanohydrogels and polyplexes as
siRNA delivery systems and characterized in light of their structure-
property relationship based on sequence alteration. Ultimately, lead can-
didates were identified and upon systemic delivery by a cross-linked
PSar-b-PCys(SO2R)-b- PLys polyplex, a specific RNAi mediated knockdown
in mammary tumors was demonstrated.
18
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This thesis provided a vital contribution towards polypept(o)ide-based
core-shell carrier systems as gene delivery vectors in systemic appli-
cation. A versatile nanoparticle platform was presented regarding sec-
ondary structure-directed self-assembly of nanocarriers, (multi)block co-
polypept(o)ide structure and bioreversible disulfide stabilization.
This modular approach enables stepwise adjustment of individual pa-
rameters to further optimize these polypept(o)ide-based carrier systems.
The influence of other secondary structures can be evaluated, for exam-
ple α-helical arrangement of recently developed poly(L-homocysteine)
derivatives. In conjunction with the S-alkylsulfonyl group they present
an appealing option for synthesis of larger segments for chemoselective
disulfide stabilization, as nanoprecipitation does not occur in contrast
to β-sheet forming polypeptides. In addition to disulfide stabilization,
the S-alkylsulfonyl group can be exploited for covalent attachment of
therapeutic cargoes by pro-drug cross-linkers based on e. g. lipoic acid.
Bioreversible covalent attachment is expected to increase stability dur-
ing systemic circulation and improve the therapeutic effect in compari-
son to free drug and non-covalent loading.
Further in vivo studies in terms of blood circulation and biodistribu-
tion of cross-linked polypept(o)ide-based nanoparticles are necessary.
Systematic variations in core polarity, size and morphology should be
considered and, due to the long systemic circulation, evaluation over
several days to ensure complete tumor accumulation. Additionally, site-
specific modification of the PSar corona e. g. by azide moieties is an at-
tractive strategy for selective targeting achieved by appropriate ligands
such as peptide sequences, sugars, antibodies or their fragments.
The location of siRNA in the presented multicompartment gene de-
livery vectors based on triblock copolypept(o)ides, can be determined
using fluorescently labeled siRNA molecules and evaluation by super re-
selotion fluorescence microscopy. In addition, covalent fluorescent label-
ing of the polypept(o)ide carrier and siRNA with dyes of a spectroscop-
ically independent range will allow to elaborate on co-localization of
carrier and cargo in systemic delivery. The introduction of functional
cross-linkers in gene delivery vectors can be readily realized by reaction
of the S-alkylsulfonyl group with thiol bearing molecules, preferably
with endosomolytic properties such as pH buffering capacities or intro-
duction of fusogenic peptides. As demonstrated recently in the prepa-
ration of functional polyplex libraries, this approach provides a screen-
ing strategy towards lead candidates in transfection efficacy. Ultimately,
a therapeutic in vivo readout towards antitumor efficacy mediated by
polypept(o)ide-based core-shell siRNA delivery systems is appealing and
should be evaluated on the level of mRNA.
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ATRP atom transfer radical polymerization
CCDC Cambridge Crystallographic Data Centre
CCPM core cross-linked polymeric micelle
CD circular dichroism
Cys(SO2R) S-alkylsulfonyl-L-cysteine
Cys(SO2Et) S-ethylsulfonyl-L-cysteine
Cys(SO2iPr) S-isopropylsulfonyl-L-cysteine
COSY correlation spectroscopy
CRP controlled radical polymerization
cryoTEM cryogenic transmission electron microscopy
CuAAC copper–catalyzed alkine azide cyloaddition
Cys cysteine
DCM dichloromethane
DFT density functional theory
DIPEA N,N-diisopropylethylamine
DLS dynamic light scattering
DMAc N,N-dimethyl acetamide
DMF N,N-dimethyl formamide
DMSO dimethylsulfoxide
DOSY 1H diffusion ordered spectroscopy
DTT dithiothreitol
EPR enhanced permeability and retention
ESI-MS electrospray ionization mass spectrometry
EWG electron-withdrawing group
FCCS fluorescence cross-correlation spectroscopy
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IVIS in vivo imaging system
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Pyr 2- or 4-pyridyl
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RNAi RNA interference
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siRNA small interfering RNA
SLS static light scattering
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SPPS solid phase peptide synthesis
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TEM transmission electron microscopy
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XRD X-ray diffraction
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FT-IR fourier transform infrared
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Ich habe mich mein Leben lang
dagegen gewehrt, das zu werden, was man
heutzutage einen richtigen Erwachsenen nennt:
nämlich jenes entzauberte, banale, aufgeklärte Krüppelwesen,
das in einer entzauberten, banalen, aufgeklärten Welt
sogenannter Tatsachen existiert.
— Michael Ende
Zettelkasten. Skizzen und Notizen (1994)
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